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Abstract 
Bioavailability and clinical effectiveness of a poorly soluble drug can be highly affected by its 
formulation design. In this respect, research on solid dispersion of hydrophilic carrier has 
commenced a decade ago to resolve the problem of poorly soluble drug. However, the 
availability of solid dispersion is commercially limited due to the concerns of its physical 
instability, unpredictability and inconsistency formulation performance. This is attributed to the 
lack of fundamental understanding on the processing method, physicochemical properties of the 
obtained solid dispersion. Therefore, better understanding on the processing methods and 
factors underlying the performance of solid dispersion may be required to maximize the use of 
solid dispersion.  
Hot melt extrusion (HME) method was introduced in formulating solid dispersion. The use of 
this production method offers many advantages such as environmental friendly, cost sparing 
and readily scalable production as compared to conventional methods. On the other hand, the 
hydrophilic polyvinylpyrrolidone (PVP) polymer with its good stabilising ability in the solid 
dispersion is less applied in HME process due to its possible degradation at high temperature. 
However, rejection on the use of PVP without thorough understanding of its potential might 
lead to underuse of this polymer in HME solid dispersion.  
This project explores the feasibility of using PVP and its derivative in HME manufacturing 
method. It offers an in-depth study on the hot melt processing, physical stability and dissolution 
behaviour of HME PVP-based solid dispersion. Factors affecting the production of fully 
amorphous solid dispersion and its physical stability are discussed, taking into account the 
influence of the composition and characteristic of the drug, drug-polymer interaction and the 
molecular weight of the polymer.  In parallel, HME poorly soluble drug in PVP based solid 
dispersion were produced and investigated for their dissolution performances in order to 
understand the mechanism underlying the dissolution process of the HME PVP-based solid 
dispersion system.  
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Chapter 1. Introduction 
 
1.1. General Introduction 
For any oral administered product, absorption of the active pharmaceutical ingredients (API) is 
depending on its aqueous solubility and gastrointestinal permeability (Abrahamsson and 
Lennernäs, 2009). In this context, Biopharmaceutics Classification System (BCS) provided by U.S. 
Food and Drug Administration has classified APIs into 4 classes according to their aqueous 
solubility and gastrointestinal permeability (Kasim et al., 2003). Table 1.1 illustrated the 4 different 
classes of BCS classification system. This system is a guide in understanding the intestinal 
absorption of an API. 
 
Table 1.1:  Biopharmaceutical classification system of API adapted from Kolter 2012 
 High solubility Low solubility 
High permeability Class I Class II 
Low permeability Class III Class IV 
 
Low membrane permeability of class III and IV substances will usually revert to its structural 
optimization phase to obtain the desired physicochemical properties. High solubility properties of 
class I is not a concern in the therapeutic achievement as sufficient doses of these API will be 
obtained after oral administration. In contrary, low solubility of class II substances is often deemed 
to be a concern in inadequate drug absorption. This is due to the limited drug release (of BCS class 
II substance) in the gastrointestinal area despite its high permeability.  
Today, formulation scientists are facing significant challenges due to the increasing number of 
poorly soluble API. It has been reported that more than 40% of the newly discovered APIs are 
poorly soluble (Fahr and Liu, 2007). These APIs are often classified as BCS class II or IV, based 
on their solubility and permeability properties. Poor solubility characteristic of BCS class II API 
during the dissolution process is the rate limiting step to drug absorption into the bloodstream. 
Thus, the key to establish successful oral formulation for BCS class II API is through proper 
formulation which is the main interest of this thesis.  
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The common strategies in the formulation of BCS class II APIs are the physical addition of 
hydrophilic or surface active excipients, micronisation of drug particles, formation of inclusion 
complexes, emulsion/ micro emulsion and production of amorphous solid dispersion (SD).  
Amongst the aforementioned strategies, amorphous solid dispersions (SDs) have been one of the 
most promising dosage forms due to their promising dissolution enhancement of BCS class II 
APIs. However, this type of dosage form is not widely commercialized due to their inherent 
thermodynamic instability that might alter the therapeutic effect of the API upon long-term storage. 
Therefore, there is a great need to improve amorphous SD system in order to bring about the 
maximum benefit of this formulation approach.  
The subsequent section of this chapter will cover the basic nature of a typical amorphous 
pharmaceutical system with emphasis on the application of SD systems as a means of overcoming 
the difficulties associated with formulating an amorphous API. In addition, various processing 
methods of SD will be introduced with the emphasis on the use of hot melt extrusion (HME) as this 
is the main manufacturing method employed in this study. Subsequently, a review on the stability 
and dissolution performance of SD is presented.   
 
1.2. Amorphous pharmaceutical and its advantages 
Amorphous pharmaceutical can be obtained under three main sets of circumstances (Craig et al., 
1999, Hancock and Zografi, 1997). Firstly, some materials exist naturally as an amorphous form 
which is stable at room temperature. These materials include polymers such as 
polyvinylpyrrolidone, polyethylene glycol and D/L polylactic acid. Secondly, amorphous materials 
can be generated unintentionally during manufacturing processes such as milling, drying or 
compression. Thirdly, amorphous material may be prepared deliberately for its high apparent 
solubility or dissolution rate. The conversion of crystalline APIs into their amorphous form has 
been shown to increase the dissolution rate of API by enhancing apparent solubility of the 
compound; hence, amorphous APIs have gained considerable attention in the field of 
pharmaceutics for dosage form design.  
Amorphous materials have excess free energy, enthalpy, entropy, higher specific volume, lower 
density and higher molecular mobility as compared to the crystalline structure. This has led to 
mechanical properties (viscosity and elastic modulus) that resemble those of a liquid rather than 
those of a solid and hence these systems can be visualized as supercooled liquids (Hancock et al., 
2002, Hancock and Zografi, 1997). The absence of long range order and crystalline bonds in the 
structure of amorphous systems has resulted in ready dissolution as less activation energy is needed 
for dissolution in relation to the structurally ordered crystalline form (Elamin et al., 1994). This has 
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also given rise to several fold solubility enhancement (Hancock and Parks, 2000, Hancock and 
Zografi, 1997) and subsequently enhanced bioavailability of the compound (Craig et al., 1999, 
Graeser et al., 2009a). Therefore amorphous systems have been seen as a means of overcoming the 
issue of poorly soluble APIs. 
Although amorphous systems are reported to be a reliable way of solving the problem of poorly 
soluble APIs, there are only limited amorphous products in the market such as Kaletra® (ritonavir 
and lopinavir), a sustained release formulation of verapamil (Isoptin SRE), Sporanox® 
(itraconazole) and Prograf® (tacrolimus) (Graeser et al., 2009a). This is mainly due to the inherent 
physical instability of the amorphous state that could lead to reversion to its crystalline counterpart 
over a period of time, causing sub-therapeutic effects of the amorphous product due to lowered 
dissolution and hence absorption. Thus, the behaviour of an amorphous system should be well 
understood before one can effectively design a successful pharmaceutical dosage form with 
consistent product performance and desired therapeutic effect. 
 
1.2.1. Behavioural features of amorphous materials 
The most significant features of amorphous material include the glass transition temperature (Tg), 
fragility, molecular mobility and relaxation, plasticization, annealing and aging. These features are 
discussed in detail with accompanying theoretical background in the subsequent sections. 
 
1.2.1.1. Glass transition temperature 
The glass transition temperature (Tg) is a temperature at which a material transforms from its liquid 
/ rubbery state to its corresponding glassy state. It is associated with a change in molecular mobility 
rather than a change of state as such, as there is no significant change in ordering through this 
temperature. Figure 1.1 illustrates the pathway of generating an amorphous material begins from 
the cooling of a melt and the correlation to the glass transition temperature of the material (Craig et 
al., 1999).  
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Figure 1.1: The change in volume or enthalpy with temperature for a material undergoing crystallization or glass 
transition. Tm is melting temperature of the crystalline material. Tg1 is the point at which there is a discontinuity 
in volume and enthalpy. The dashed line between Tg1 and Tk representing the profile of volume and enthalpy 
change when a melt is slow-cooled. Tg 2 is the glass transition temperature when the slow cooling is performed. Tk 
is Kauzman temperature (Craig et al., 1999, Pinal, 2008). 
 
From Figure 1.1, an API will exist in the liquid state at temperatures above the melting temperature 
(Tm). Decreasing the temperature of the melted API to a temperature lower than its melting point 
will result in the transition of the melt to its crystalline form via a recrystallization process. It is an 
exothermic process that leads to sudden contraction of the system (shown by the long downward 
arrow in Figure 1.1) which is caused by the decrease in its free volume (a volume in which the 
molecules are free to move) at Tm. Consequently, both enthalpy and volume of the system 
decrease at Tm. The solid line at the bottom of the graph represents the crystalline state, as shown 
in Figure 1.1.  
When the decrease in temperature of the API is too fast for the crystallization process to take place, 
an amorphous material may be obtained. This is because the fast cooling process may cause 
unfavourable molecular shape, size and configuration that is important for a crystallization process.  
In the fast cooling process, no discontinuity in enthalpy of the melted API is seen at temperature 
below Tm. At this point, a super-cooled liquid is formed and it exists in “rubbery state” (Figure 
1.1). In this state, the average time range for its molecular motion is approximately 100 seconds 
with a typical viscosity of between 10
-3
 and 10
12
 Pa.s (Hancock and Zografi, 1997).   
Enthalpy / 
Volume 
Supercooled Liquid 
Glass 
Liquid 
Crystal 
Tg 2 Tg 1 
Tm Tk (
o
C) 
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Upon continual cooling, the material is unable to attain its equilibrium kinetically in the time scale 
of the cooling rate and then it reaches a frozen state at Tg 1. In this state (at Tg 1), the translational 
and rotational motions of the molecules are dramatically reduced. Finally, glassy material is formed 
at temperature lower than Tg 1 whereby only molecular vibrations are taking place. The Tg value of 
an amorphous material is highly dependent on the cooling rate of the melt. Slower cooling rates 
resulted a lower Tg value that is represented by the dashed line in Figure 1.1 with a value of Tg 2, 
where Tg 2 is < Tg 1. 
The glass transition temperature of a material can be obtained using various methods as outlined in 
the literature (Hancock and Zografi, 1997, Craig et al., 1999). Commonly, it is detected by using 
Differential Scanning Calorimetry (DSC) (Craig et al., 1999, Hancock and Zografi, 1994). The 
detail of the DSC instrument is presented in Chapter 2. In brief, the sample is heated or cooled 
alongside a reference whereby the differential heat flow between the sample and reference as a 
function of temperature is measured. This provides the data regarding the heat capacity of the 
sample and reference. Figure 1.2 shows the measurement of Tg using DSC method.  
 
Figure 1.2: Measurement of Tg using DSC thermogram. Tb is the beginning of the transition and the extrapolated 
onset of the transition point is T1. Tg is taken as half height of the transition event. Similarly the extrapolated end 
point is T2 and the transition process end at Te. 
 
Tg is specified by the half height of the transition event on cooling, i.e. the temperature at which 
the heat capacity is in the middle of that of glassy and rubbery state. It is a kinetic event and 
therefore the detected value is highly constrained by the timescale of the experiments i.e. heating or 
cooling rate during manufacturing as measured with DSC. At Tg, a transition of heat capacity, ΔCp, 
is noted due to the change of molecular mobility before and after the glass transition temperature. 
Viscosity of the material at Tg temperature is in the region of 10 
12 
-10 
14
 Pa.s which is the main 
parameter used in deriving the fragility concept of an amorphous system that will be covered in the 
next section. 
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1.2.1.2. Fragility 
Temperature dependency of the viscosity of a melt may be described by the well-known Arrhenius 
Equation (1.1).   
    
   
                                                                                
where η is viscosity, K is a constant, Ea is the activation energy of melt flow, R is universal gas 
constant and T is temperature (DiNunzio et al., 2009). According to Equation (1.1), higher 
temperature of the melt will give rise to low viscosity of the melt.  
In defining Fragility, Angell plotted the relationship of melt viscosity and the melt temperature 
scaling with Tg by taking the natural logarithm of Arrhenius Equation (1.1), i.e. plotting log (η) 
versus (Tg/T) (Angell, 1995). Based on the plot of variety of liquids, it was found that some liquid 
exhibited a linear relationship and some deviated from linearity of Arrhenius equation (Angell, 
1995). Angell (1995) suggested that system that showed linear relation in the Arrhenius plot is 
designated as a strong melt and those that deviated from linearity of the Arrhenius plot could be 
designated as fragile liquids (Angell, 1995). Figure 1.3 shows the Arrhenius plot of fragility of 
strong and fragile glass former which is also known as Angell plot.  
 
Figure 1.3: The simplified schematic of Angell Fragility concept (Angell, 1995) 
 
According to Figure 1.3, the fragility index of a material is described by the degree of non-
Arrhenius behaviour of the material. A fragile system possesses higher density of configurationally 
state which leads to rapid thermal excitations and a higher increase in heat capacity (Ojovan and 
Lee, 2005). Thus, the activation energy of a fragile system would be greatly influenced by the 
temperature. Conversely, strong glasses like SiO2, GeO2 B2O3 are structured with covalent bond, in 
which their activation energies are slightly influenced by the change of temperature.  
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The fragility of an amorphous material is usually described by the fragility index, m. This 
parameter, m is evaluated from the Tg values from different heating/cooling rate of DSC scan by 
using Equations (1.2) & (1.3), 
 
  
     
       
                                                                           
  
    
         
                                                                        
 
where   indicates derivative function of Equation (1.2),       is the activation energy for structural 
relaxation at Tg,   is relaxation time and R is universal gas constant.     can be obtained from 
heating/cooling rate dependent of calorimetric Tg as described in Equation (1.4) (Moynihan et al., 
1976), 
      
   
 
  
 
 
     
 
                                                                     
 
By obtaining the magnitude of the fragility index, an amorphous material could be classified into 
strong liquid when m < 40, and fragile liquid when m > 75, and those lie in between this range is 
known as intermediate fragile liquid (Yu, 2001). With that, the value of fragility index, m can be 
used to reflect the physical stability of an amorphous system upon annealing (described in more 
detail in Chapter 4.3.2).  
 
1.2.1.3. Structural relaxation and molecular mobility  
Despite the use of Tg in representing a sudden decrease in mobility, molecular mobility of an 
amorphous system at temperatures well below Tg has been reported (Hancock and Zografi, 1997, 
Nagapudi and Jona, 2008). Thus, together with Tg, molecular mobility has also been correlated to 
the structural relaxation time, whereby the structural relaxation time of an amorphous system is the 
time taken for the relaxation of the amorphous structure toward the thermodynamic equilibrium 
that originally exists in its non-equilibrium state. This parameter could be evaluated by noticing the 
loss of enthalpy accompanied by the relaxation event of the amorphous structure overtime. 
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The lost enthalpy value can be obtained from DSC measurement where the enthalpy is inferred by 
the endothermic relaxation peaks which accompany the glass transition events. These relaxation 
events and Tg could be separated by using modulated mode of DSC which is further presented in 
Chapter 2. With the recovery of the enthalpy, the relaxation time, τ could be estimated by using the 
enthalpy of recovery over time using the empirical Kohlrausch-William-Watts (KWW) Equation 
(1.5). 
 
          [ (
 
 
)
 
]    
       
   
                                                     
 
where β is the stretch parameter which could be obtained by fitting the value of enthalpy recovery 
to Equation (1.5).         is the measured endotherm peak accompanied the Tg event and     
represents the maximum enthalpy that could be recovered, this value could be obtained by using 
Equation (1.6) with the values of heat capacity changes between the liquid and glassy state of the 
sample,    ,  
 
       (    )                                                               
 
where T is the intended storage temperature. The main assumption of this model is that the 
relaxation time did not change during the experiment time scale (Graeser et al., 2009a).  Due to the 
limitations of KWW approach, Adam-Gibbs Equation (1.7) has been suggested as another 
prediction of the relaxation time, 
 
       [
   
 (      ⁄ )
]                                                            
 
 where τ0 is a constant which is taken as the lifetime of atomic vibration, 10
-14
 s. Tf is fictive 
temperature which can be obtained by extrapolation of the linear part of the enthalpy line above 
and below the Tg of a system as shown by T1 in in Figure 1.2 (Lacey et al., 2006). D is Angell’s 
strength parameter and T0 is the temperature where no structural mobility occurred. Both D and the 
T0 can be obtained by solving Equation (1.8) and Equation (1.9), respectively. 
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In Equation (1.9), m is predefined in Equation (1.2) or (1.3) and mmin is the minimum possible 
fragility value which has been calculated as 16 (Aso et al., 2004, Graeser et al., 2009a).  
Besides the relaxation associated with the glass transition temperature (alpha relaxation), beta 
relaxation has also been reported (Nagapudi and Jona, 2008). Beta relaxation is related to the 
molecular motions in small length-scale such as rotations of methyl group and ring flips in benzene 
group (Van Krevelen and Te Nijenhuis, 2009). These minor motions are thought to promote the 
spontaneous formation of small nuclei thereby causes physical instability of the amorphous phase. 
It was suggested that at temperature < 40 
o
C of Tg, the beta relaxation is the dominant relaxation 
process which would be the main factor for physical stability at T < Tg-40 
o
C (Nagapudi and Jona, 
2008). 
 
1.2.1.4. Plasticization 
Amorphous materials are highly affected by the presence of moisture and additive materials. This 
is because the small molecule size of the additive materials may introduce a considerable excess 
free volume in the system which will cause plasticization of the system (Hancock and Zografi, 
1997). Due to the hygroscopic nature of amorphous systems (Hancock and Zografi, 1994, Hancock 
and Zografi, 1997), amorphous materials tends to absorb considerable amounts of water which can 
potentially cause plasticization of the amorphous system. The presence of water could change Tg 
of the system significantly due to the difference in the size of water molecule and drug molecule. 
Since Tg is an important parameter for consideration in physical stability of an amorphous API, it 
is imperative to understand the influence of water molecules on the amorphous API which often 
causes plasticization. In this case, the Gordon – Taylor (1952) equation may be employed to predict 
the final Tg of the blend system.  Detail calculation of this approach will be presented in Chapter 
3.3.3.2.1. 
 In the pharmaceutical field, blended systems are commonly used, where the addition of excipients 
to an amorphous API might plasticize or anti-plasticize (raise the Tg of the amorphous API) the 
system. In consideration of physical stability, anti-plasticizing agents are often preferred depending 
on the manufacturing process.  
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1.3. Solid dispersion 
The use of SDs in pharmaceutical formulation was first discovered by Sekiguchi and Obi in 1961, 
whereby the authors found that an eutectics mixture could dramatically improve drug release rate, 
and hence bioavailability of the active ingredients (Sekiguchi and Obi, 1961).  
Literally, SD refers to the dispersion of one or more ingredients in a solid form of continuous 
matrix/carrier. SD could be classified based on physical state. These include eutectics, amorphous 
precipitates in crystalline matrix, solid solutions, glass suspension and glass solution. Table 1.2 
provides the definition of different types of solid dispersion based on physical state of the drug and 
carrier matrix adopted from Kolter et al. (2012).  
 
Table 1.2: Types of Solid dispersion based on physical state of API and carrier matrix (Kolter et al., 2012) 
Types of solid dispersion Matrix API Phases 
I. Eutectics C C 2 
II. Amorphous precipitates in 
crystalline matrix 
C A 2 
III. Solid solution 
 Continuous vs discontinuous  
 Substitutional vs interstitial 
C M 1 or 2 
IV. Glass suspension A C 2 
V. Glass suspension A A 2 
VI. Glass solution A M 1 
C= crystalline, A= amorphous and M= molecularly dispersed 
 
For eutectic solid dispersion, two crystalline solids co-crystallized at their eutectics composition 
and temperature. Deviation from the eutectic composition will lead to crystallization of one of the 
two components before the other. In eutectics solid dispersion, dissolution rate enhancement is 
mainly attributed to the dispersion of drug as fine crystal which increases its surface area of 
dissolution process (Janssens and Van den Mooter, 2009). Amorphous precipitate is another 
possible physical state of a solid dispersion. However, there are limited reports regarding solid 
dispersion of this physical state. In solid solution, carrier matrix exist in crystalline state, whereas 
the drug is predominantly in molecularly dispersed state. Solid dispersion in this group could be 
further classified into continuous solid solution or discontinuous solid solution (Leuner and 
Dressman, 2000). In continuous SD, both the solute and the carrier are miscible in all proportions. 
Ideally, the bonding strength between the solute and carrier is greater than the bonding strength of 
individual molecule of each phase. In a discontinuous SD, distribution of the solute may be 
substitutional crystalline or interstitial crystalline as shown in Figure 1.4.  
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Figure 1.4: Substitutional crystalline or interstitial crystalline solid dispersion (Leuner and Dressman, 2000) 
 
Base on Table 1:2, type IV SD is categorised as crystalline glass suspension whereby the drug 
remains in its crystalline form but dispersed in the amorphous polymeric matrix. Whereas type V is 
amorphous glass suspension and type VI SD is referred as solid glassy solution. Figure 1.5 
illustrated the main three types of solid dispersion that cover types IV, V and VI. These three types 
of solid dispersion are the commonly obtained forms of solid dispersion.  
 
 
 
Based on Figure 1.5 crystalline and amorphous glass suspension are 2 phases solid dispersion. 
Between the glass suspensions, crystalline glass suspension is relatively more stable as the drugs 
exist in its stable crystalline forms. In this system, melting point of the drug shall be detected in 
analytical method such as differential scanning calorimetry (DSC) and X-ray powder diffraction 
(XRPD). On the other hand, amorphous domain in the amorphous glass suspension is only 
kinetically stabilized and tends to revert to its crystalline state overtime. Detection of the 
amorphous domain in this system is feasible by using DSC measurement which may reveal the Tg 
values of the drug. Among the three systems shown in Figure 1.5, molecular dispersed glass 
solution is the most desired form of SD as molecular dispersion of the drug in the carrier matrix is a 
one phase system which renders its good stability alongside with significant dissolution rate 
enhancement of the dispersed drug.  
 
 
 
 
 
Substiltutional crystalline 
solid solution 
 
 
 
 
 
Interstiltial crystalline 
solid solution 
Crystalline glass suspension Amorphous glass suspension 
Molecularly dispersed 
glass solution 
Drug 
molecule 
Carrier 
matrix 
Figure 1.5: Solid dispersion of amorphous polymeric carrier (Kolter et al., 2012) 
Introduction                                                                                                                          Chapter 1 
 
School of Pharmacy, University of East Anglia  12 
 
SDs offer promising effects in bioavailability enhancement of poorly soluble drugs as evidenced by 
several publications (Six et al., 2005, Zheng et al., 2007b). It is postulated that SD formulation 
increases the surface area available for dissolution process via particle size reduction, and improves 
wetting of compounds surfaces. In amorphous SDs, further advantages are assumed to be due to the 
removal of crystalline drug structure  (Chawla and Bansal, 2008). However, during the dissolution 
process of amorphous APIs, the API is often present in the supersaturation state in the medium. In 
such case, careful selection of carrier is essential whereby it should help to modulate the properties 
of the solvent (Craig, 2002) and to inhibit precipitation of the drug from the supersaturated 
solution. Moreover, it is postulated that if the drug does precipitate, it will precipitate into 
metastable polymorphs which have higher solubility properties than the original form (Vasconcelos 
et al., 2007). 
 
1.3.1. Preparation of solid dispersion 
SD can be prepared via several methods. These include melt quenching, milling or cryo-grinding, 
freeze drying, co-evaporation or co-precipitation and by the means of spray drying. The principle 
of each method will be introduced briefly in the subsequent sections. In particular, more detail will 
be given on the use of HME methods which is the main manufacturing method used in this study. 
 
1.3.1.1. Traditional melting methods 
Amongst the aforementioned methods, melting is one of the most conventional. This method 
involves the mixing of components at molten state and the cooling of  mixture into a solid form 
(Nagapudi and Jona, 2008).  The cooling of the melt could be performed through slow cooling at 
room temperature or fast / quench cooling by using ice or liquid nitrogen. The cooling rate is 
shown to be the crucial factor that determines the formation of thermodynamically unstable solid 
dispersion. This method is useful for the preparation of small quantity of sample. 
The melting method can only be applied to compounds which are thermally stable upon melting 
(Patterson et al., 2005, Forster et al., 2001a). For example, piroxicam starts to degrade upon 
melting, thus the use of melting methods might not be suitable for this compound (Forster et al., 
2001a). Besides, the time and temperature pause for complete melting determines the outcome of 
the generated amorphous system (Van den Brande et al., 2004, Wojnarowska et al., 2010). For 
example, Van den Brande et al. (2004)  reported a significant degradation of loviride processed at 
slow cooling (Van den Brande et al., 2004). However, a stable amorphous form of loviride could be 
obtained by using fast cooling of its melt. This is attributed to the long residence time of the 
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loviride molten at high temperature condition with their preparation at a slow cooling rate which 
promotes degradation of drug.   
To avoid potential degradation via the melting method, an alternative melting carrier method may 
be performed. This alternative method involves the use of carrier with low melting or glass 
transition temperature. The carries is first melted or softened. Then the API is mixed on top of the 
molten carrier. This alternative method entails high compatibility between the API and carrier or a 
high solid solubility of the API at a lower softening temperature of the carrier (Schachter et al., 
2004). 
 
1.3.1.2. Milling/cryogrinding 
The possibility of generating an amorphous pharmaceutical product through milling or 
cryogrinding has been reported (Balani et al., 2010, Descamps et al., 2007, Elamin et al., 1994, 
Nagapudi and Jona, 2008). Three mechanisms were proposed for the possible conversion of a 
crystalline material into its amorphous phase through milling or cryogrinding. Firstly is the local 
thermal melting and rapid quenching of the API during the milling process. Secondly, the 
amorphous form of the API is obtained from the intermediate state formed during polymorph 
conversion while milling. For instance, the milling of form IV fananserine could lead to its 
intermediate amorphous state which precedes the transformation of the metastable Form I 
polymorphs (Willart and Descamps, 2008). The third mechanism in amorphization of a crystalline 
API is the accumulation of defects or structural disordering of the API through milling (Descamps 
et al., 2007, Elamin et al., 1994). The huge accumulation defects in the crystal resulted in an 
increase in the Gibbs free enthalpy of the solid which will then be amorphized spontaneously at the 
milling temperature. This is reported in Elamin et al. (1994) whereby an increase of free energy of 
griseofulvin upon milling process was observed which lead to its reduction in molar heat of 
solution (Elamin et al., 1994).  
The amorphicity of a product prepared by milling is highly dependent on the milling temperature 
and its relation to the Tg and crystalline strength of the API. A few reports have shown that high 
proportion of amorphous content could be obtained in the condition where the milling temperature 
is below the Tg of the API.  When milling is performed at a temperature slightly below the Tg, the 
milling intensity was reported to be crucial in determining the nature of the transformation. For 
instance, milling the γ form of indomethacin at room temperature (which is approximately 20 oC, a 
temperature lower than the Tg of amorphous indomethacin) induces the production of amorphous 
at high milling intensity. However, polymorphic conversion occurs at a lower milling intensity 
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(Descamps et al., 2007). On the other hand, milling above Tg can cause crystal-crystal polymorphic 
transformation (Descamps et al., 2007). 
The milling method was shown to produce SDs with reduced physical stability as compared to the 
SD prepared from other methods such as spray drying and melt quenching methods (Graeser et al., 
2009a, Ke et al., 2012, Wojnarowska et al., 2010). According to Ke et al.,(2012) this is due to the 
heterogeneous relaxation of the milled sample at molecular level as indicated by its lower value of 
the relaxation distribution (β) in comparison to the same sample system prepared through spray 
drying and melt-quenching. This may be explained by the high proportion of nuclei available to 
undergo recrystallization as compared to the complete dissolution and melting of API in the other 
preparation methods such as solvent method or melting method.  
 
1.3.1.3. Solvent method : co-evaporation / co-precipitation 
The solvent method was described in 1965 by Tchibani and Nakumara who obtained a co-
precipitated solid dispersion by drying a mixture of lipophilic β-carotene in a water soluble PVP 
which were previously dissolved in a common solvent. Since then many workers have taken up this 
method for preparation of solid dispersion (Sekikawa et al., 1978, Wegiel et al., 2013, Biswal et al., 
2009, Mura et al., 2003).  
Principally, the solvent method requires a common solvent such as ethanol or chloroform to 
completely dissolve both the API and carrier.  The mixture is then allowed to mix at solution state. 
Subsequently the common solvent of the mixture is evaporating at reduced pressure and elevated 
temperature. During the evaporation of the solvent, the viscosity of the sample increases very 
rapidly leading to reduction in drug mobility. At the same time, concentration of the drug increases 
and reaches its solubility in the carrier; eventually, it exceeds this solubility which forms the 
precipitate. Thus, the formation and maintenance of an amorphous solid dispersion in co-
precipitation method is the result of crystallization inhibition attributed to drug-polymer interaction 
or the entrapment of the drug in the polymeric matrix during the evaporation process (Biswal et al., 
2009).  
The solvent method is useful to formulate a SD of thermolabile APIs which may not be prepared 
by the melting method due to the concern of degradation upon melting. However, the solvent 
method can cause environmental hazards due to the use of large amount of solvent use. Products 
obtained from this method have been shown to be less homogeneous as compared to the co-ground 
material of the same composition (Corti et al., 2008). 
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1.3.1.4. Spray drying 
Spray drying is another type of solvent method which is used for isolating dry compound from a 
solution or suspension. It is a well-established technology for the formation of solid particle 
whereby the yield of solid particle produced from this method is relatively high (Nagapudi and 
Jona, 2008, Thybo et al., 2008b).  
Similar to the first step of co-evaporation, spray drying manufacturing method of SD requires a 
common solvent to prepare a solution of API and carrier. Generally, aqueous solutions are used. 
However, organic volatiles are also frequently used as common solvent due to the wide range of 
their solubilisation capacity on most of the poor soluble drugs. Alternatively, solvent mixtures such 
as mixes of aqueous and organic solvent may be used. 
In the process of spray drying, the mixture of API and carrier in the common solvent is pumped by 
a peristaltic pump and sprayed via an orifice atomizer through an inlet whereby the temperature is 
pre-set for the drying process. Upon spraying, the mixture is atomized into the micrometer range 
and the droplets undergo solidification in milliseconds to form fine solid particles (Guns et al., 
2011). Guns et al. (2011) suggested that pre-treating the solution before spraying, such as 
preheating the mixture, could reduce the de-mixing tendency between API and carrier upon 
spraying.  
To achieve an effective drying process, an overall drying procedure is equipped in the spray drying 
machine apart from the inlet temperature drying. This drying process is mainly performed using 
nitrogen as a drying gas in a closed-cycle spray drying plant to dry off the residues of organic 
solvent, where the residues of solvent is condensed out of the exhaust gas and collected as waste. 
Close-cycle spray drying plant is used mainly for environmental reasons (Thybo et al., 2008a). This 
method will create a more homogeneous product when compared to the co-precipitated or co-
evaporated methods (Janssens et al., 2009). Similar to the co-precipitated or co-evaporated 
methods, major disadvantage of spray drying method is the concern on using non-environmental 
friendly solvent. Besides, the use of organic solvent in this case could limit the rise of inlet 
temperature in order to avoid explosion of organic vapour. 
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1.3.1.5. Freeze drying 
Freeze drying is also known as ‘lyophilisation’ which implies ‘to make solvent loving’ (Zhao, 
2010). It is a well-developed process that is frequently used for stabilization of labile substances or 
processing of pharmaceutical with biological origin such as protein, serum, vaccines, peptide drugs 
and liposomes (Tang and Pikal, 2004, Craig et al., 1999).  
The freeze drying process can be divided into three stages i.e. freezing stage, primary drying and 
secondary drying. In the freezing step, solvent, typically water, is separated from the solute to form 
ice. As the freezing step progresses, the concentration of the sample will increase. This 
concentrated sample is termed ‘freeze concentrate’ (Tang and Pikal, 2004). At the end of the 
freezing point, the ‘freeze concentrate’ would have around 20% of water content, or less than 1 % 
of water content from the initial solution. 
The next step is the primary drying process. This process involves the ice sublimation under 
vacuum with elevated shelf temperature in order to supply the heat required for ice sublimation. 
The sublimated ice is then condensed on a cooled plate / coils (< -50 
o
C) in the condenser (Craig et 
al., 1999, Tang and Pikal, 2004). This particular step is time consuming. Thus, the optimization of 
this step is crucial to make the method cost effective (Tang and Pikal, 2004).  
The final stage of freeze drying is the secondary drying phase. The main objective of this step is to 
remove any residual moisture content to an optimal level in order to maintain the stability of the 
product. The sample is further dried by absorbing the ‘unfrozen’ water from the ‘freeze 
concentrate’ via low pressure at elevated temperature. The secondary drying will occur 
spontaneously near the end of primary drying in the region of the sample where ice sublimation has 
completed (Craig et al., 1999). This secondary drying step takes relatively shorter time i.e. a few 
hours. Temperatures used at this stage are usually much higher (i.e. 25 - 60
o
C) than the temperature 
employed in primary step (Craig et al., 1999). Thus, the product temperature is increased in the 
secondary drying step (Tang and Pikal, 2004). 
The resultant solid form of a freeze dried sample is highly porous. This is considered as an 
advantage for rapid reconstitution / dissolution besides the formation of amorphous solid dispersion 
system (Craig et al., 1999). This method has been shown to be superior than co-evaporation method 
in dissolution performance and amorphization of meloxicam in the production of solid dispersion 
(El-Badry and Fathy, 2006). However, the powder obtained from this method may be presented 
with poor flowability which might potentially affect the downstream processes of tableting or 
capsule filling (Zhao, 2010).  
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1.4. Pharmaceutical hot melt extruded solid dispersions  
Besides the aforementioned preparation methods, recently HME has appeared as a robust method 
for SD preparation. This is the main method of SD preparation applied in this study; therefore, the 
basic principles of this instrument and its application in the pharmaceutical formulation field will 
be discussed.  
The first use of HME was reported in 1930’s for plastic manufacturing as well as in food industry. 
It was invented at the end of the eighteenth century by Joseph Brama for the production of lead 
pipe (McGinity et al., 2006). This technique was then extensively practiced in the plastics industry 
at mid of nineteenth century for preparation of polymeric insulation in wires (Crowley et al., 2007). 
More recently HME has found its place in the pharmaceutical field whereby many researchers have 
adopted this technique in producing SD system with promising formulations performances 
(Crowley et al., 2007, McGinity et al., 2006). 
The main process of this technology is to mix raw materials at the molecular level to produce an 
intimately mixed extrudate. The extrusion process involves different manufacturing steps, i.e. 
mixing, melting, homogenizing, and shaping. These processes are carried out in a single continuous 
step which could potentially give rise to overall cost sparing production (Breitenbach, 2002). This 
has attracted attention of applying HME manufacturing method in the pharmaceutical industry 
(Keleb et al., 2001).  
There are many potential formulations that could be produced by using HME manufacturing 
method. These include immediate release SD, targeted release dosage form (Andrews et al., 2008, 
Bruce et al., 2005, Mehuys et al., 2005a, Cassidy et al., 2011), multiple unit dosage forms 
(Brabander et al., 2004, Verhoeven et al., 2009a, Verhoeven et al., 2009b), floating dosage forms 
(Fukuda et al., 2006a, Nakamichi et al., 2001, Whitehead et al., 1998), implants (Cheng et al., 
2010, Ghalanbor et al., 2010, Rothen-Weinhold et al., 1999, Witt et al., 2000), transdermal and 
transmucosal delivery systems (Prodduturi et al., 2007, Repka et al., 1999, Repka and McGinity, 
2000, Repka et al., 2003, Trey et al., 2007), controlled release dosage form (Fukuda et al., 2006a, 
Fukuda et al., 2006b, De Brabander et al., 2003, Özgüney et al., 2009) as well as retarded release 
dosage form by the formation of nanocomposite (Campbell et al., 2010, Campbell et al., 2008, 
Campbell et al., 2009). In this study, immediate release SD dosage form is the main product of 
interest in formulation for its ability to overcome the problem of poorly soluble APIs, particularly 
BCS class II compounds.  
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1.4.1. Principles of HME 
From the regulatory standpoint, melt extrusion technology is a mature engineering technology. It 
allows the monitoring of various parameters (temperature, die pressure and torque which will be 
covered in Chapter 2.3) via typical readout information or load cell outputs. This contributes to 
comprehensive data documentation, good quality control and quality production (Breitenbatch and 
Mägerlein, 2007). Figure 1.6 depicts the HME processes range from feeding to extruding, which 
will be discussed in detail in next few sections. 
 
 
Figure 1.6: Schematic diagram of a hot melt extrusion system (Radl et al., 2010) 
 
As the name implies, HME process operates under elevated temperature (at least 30-60 
o
C above 
Tg of feedstock) in order to soften the processing compound (McGinity et al., 2006). Mixtures of 
materials, namely polymers as API carriers, the API itself and additives are passed through the 
feeding system and extruded in the extruder as shown in Figure 1.6. Processes within the closed 
barrel encompass solubilising of API in the polymeric matrix, intense mixing of additive and 
dispersion of materials within the molten. At the end of barrel, high pressure imparted within the 
metering zone will force the molten mass extrudes through an orifice to produce a product of high 
density and uniformity (Mollan, 2007, Andrews et al., 2008). Subsequently, molten material is 
transported to the downstream equipment for final dosage designation such as melt pelletization, 
milling, tableting and calendaring.  
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The extrusion process in the extruder could be divided into three typical zones, i.e. feeding zone, 
melting or compression zone, and metering zone. Each of the zones has different geometrical screw 
design that dictates the advance of the process (McGinity and Zhang, 2007).  
 
1.4.1.1. Feeding zone: feeding raw material 
The process of feeding is highly dependent on the flow properties of the feedstock. The angle 
between the wall of hopper and horizontal line must exceed angle of repose of the feedstock 
(McGinity et al., 2006, Crowley et al., 2007). This is to ascertain consistent feed rate and avoid 
throat bridging (feeding problem when feeding material are stuck at the throat of hopper) that 
potentially occurs in cohesive material or fine powder that might cause erratic flow in the hopper.  
In order to get easy flow and good conveying of feedstock,  a wide pitch and deep flight of the 
screw is designed in the feeding zone (Rina Chokshi, 2004 , Breitenbach, 2002). Figure 1.7 shows 
the definition of different parts of the screw extruder. 
 
 
Efficiency of pumping in this zone depends on friction coefficient between the feed material and 
barrel or screw which allows heat dissipation from the shearing process (McGinity et al., 2006). 
The feeding process generates high pressure for subsequent transportation of feedstock to the 
transition or compression zone by rotating screw. For bulk solid that is prone to bridging, a driven 
agitator could be used as a discharge aid in feeding the raw material into the extruder (Doetsch, 
2007). 
Figure 1.7: Diagram of a screw extruder (Crowley et al., 2007)  
Helix Angle 
Barrel 
Screw Barrel 
Diameter 
Deep flight 
Wide pitch 
Channel Depth 
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1.4.1.2. Transition Zone 
In the transition zone, the reduction of screw pitches and flight depth form progressively narrower 
spacing between turning and impart a high compression pressure to the material. The materials 
move along the circulation in helix path of the thread. Transverse flows, drag flow, pressure flow 
that were generated by the increase pressure following the shallower flight depth as well as leakage 
are the transporting mechanisms along the barrel (Breitenbach, 2002, McGinity et al., 2006, Rina 
Chokshi, 2004 , Crowley et al., 2007). In this zone, feedstock is compressed, melted, plasticized 
and mixed which will be further discussed in the subsequent sections. 
 
1.4.1.2.1. Melting / plasticization 
Melting and plasticization processes take place in the transition zone or also known as compression 
zone. The heating energy is obtained from the electrical heat band that was pre-set prior to the 
extrusion process as well as heat dissipated from the shearing effect between the screw and 
material while mixing in the barrel (Breitenbach, 2002, Rina Chokshi, 2004 , McGinity and Zhang, 
2007). With the heat energy, small molecule of the drug compound will be melted or diffused in 
the soften carrier system which causes further plasticization effect to the macromolecule polymer 
system.  
 
1.4.1.2.2. Mixing/ dispersion 
After feeding, the processing material is transported into the mixing or dispersion zone of the hot 
extruder. The purpose for mixing zone of HME is to produce a highly uniform extrudate. In this 
zone, the mixing can be further divided into dispersive and distributive mixing (Dreiblatt, 2007a). 
Dispersive mixing involves the sizing or breaking of the particulate into smaller size while 
distributive mixing involves the homogenization of particulate within carrier with no interruption 
on the particle size.  
The screw design in the mixing zone may influence quality of the end extrudate. Nakamichi et al. 
(2003) have successfully demonstrated the important role of kneading paddle (with the twist of 30
o
 
and 60
o
) in mixing nifedipine and an enteric polymer, hydroxyprophylmethylcellulose phthalate 
(HPMCP). In that study, the good uniformity of extrudate was attained from the extrusion with 
kneading paddle as compared to the extrusion without kneading paddle. This is due the intense 
mixing of the mixture by kneading paddles (Nakamichi et al., 2003). Similarly, Verhoeven et al. 
(2008) confirmed the need of kneading paddle for better extrudate quality (smooth extrudates) as 
compared to the extrusion of the same system without kneading paddles (Verhoeven et al., 2008).  
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1.4.1.3. Metering zone 
The primary function of metering zone is to ensure uniform thickness, consistent flow and steady 
delivery rate through the die (Breitenbach, 2002, McGinity et al., 2006, Crowley et al., 2007). The 
output rate of these molten material is dependent on the channel depth and length of meter zone 
(McGinity et al., 2006). Similar to transition zone, materials in this metering zone are conveyed via 
drag flow as well as pressure flow.  
 
1.4.1.4. Die pressurization 
The process after the metering zone involves pressurizing of the molten material through a die with 
desired shape (Liu et al., 2001). In some instance, extrudates emerge from the die and undergoes 
‘die swell’. This phenomena is particularly happen to polymer melt where it attempts to reform 
from its elastic energy stored within the extrudate while being shear in the die (C.Case, 2007, 
Schilling et al., 2008, Richardson, 1970). The unintended die swelling of extrudate can be avoided 
by controlling the drawing force, extrusion temperature and spinning velocity (van Laarhoven et 
al., 2004). Thus, die pressure should be monitored for desired output to match the geometry of the 
entangled die (Mollan, 2007).  
 
1.4.2. Materials used in HME solid dispersions  
1.4.2.1. Active pharmaceutical ingredient  
Intuitively, one may assume it is impossible to process thermally labile drug under HME 
(Hülsmann et al., 2000, Van den Brande et al., 2004). However, several reports have shown the 
successful production of pharmaceutical dosage form containing thermo labile API by means of 
HME. These include production of hydrocortisone films (Repka et al., 1999), delta-9-
tetrahydrocannabinol in polyethylene oxide matrices (Thumma et al., 2008b, Thumma et al., 
2008c), thermo labile p-amino salicylic acid with assistance of CO2
 
as a plasticizer (Verreck et al., 
2006a),  as well as protein implant, rh-interferon α-2a (IFN-α) (Schulze and Winter, 2009) and 
somastostatin vapreotide (Rothen-Weinhold et al., 1999). Schulze and Winter (2009) suggested that 
the solvent free HME is a good processing method for the formulation of proteins (Schulze and 
Winter, 2009) as biological activity of the proteins could be maintained even at elevated 
temperature in the dry powder state rather than in aqueous media.  
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Some APIs appear to plasticize its carrier, such as carvedilol (Lyons et al., 2008, Lyons et al., 
2007b), chlorpheniramine maleate (Wu and McGinity, 1999, Albers et al., 2009) and etc. These 
APIs are good candidates for HME production owing to their better HME processability without 
additional external plasticizer. More examples of APIs with plasticization behaviours will be 
provided in section 1.4.2.2.2 as ‘non-traditional’ plasticizer. 
Drug loading in the polymeric carrier may also affect the processability of HME. Schilling et al. 
(2008) confirmed that increase drug loading of diltiazem HCL necessitated higher processing 
temperature and therefore increased molten flow resistance in the barrel (Schilling et al., 2008). 
Another study by De brabander et al. (2003) showed that higher percentage of ibuprofen not only 
eased the HME process but also give rise to a good quality extrudate with an increase in drug 
release rate (De Brabander et al., 2003). Therefore, thorough understanding of the APIs is 
indispensable for the processing concern and formulation design of HME system. Table 1.3 
summarised the examined APIs from the literature. 
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Table 1.3: APIs used in HME production and characterization of HME process 
 API Comments references 
1.  17β-estradiol hemihydrate Solid dispersion of hormone was produced. The dissolution of drug was significantly 
enhanced. 
(Hülsmann et al., 2000) 
2.  5-amino salicylic acid 
(5ASA) 
It appeared to create microenvironmental pH that was able to modulate the final release 
profile. Enteric polymer was used to target the delivery to colon.  
 
(Andrews et al., 2008, Bruce et al., 2005)  
3.  Acetohydroxamic acid Floating dosage form was formed by addition of NaHCO3 as porous agent.  (Fukuda et al., 2006a) 
4.  Carbamazepine  Immediate release product was processed by HME and it showed an increase in dissolution 
compared to physical mixture as intimate mixing with hydrophilic polymer efficiently 
improved wetting.  
 
(Perissutti et al., 2002, Djuris et al., 2013b)  
5.  Carvedilol This drug was investigated in nanocomposite formulation, addition of PCL in the release 
pattern and impact to the process parameters. The most recent evaluation was done on the 
addition of CO2 in release profile as well as recrystallization. 
 
(Lyons et al., 2007b, Lyons et al., 2007a, Lyons 
et al., 2008) 
6.  Chlorpheniramine maleate Floating dosage form and retarded release tablet were successfully produced by HME process.  (Crowley and Zografi, 2002, Fukuda et al., 
2006a, Fukuda et al., 2006b, Repka et al., 1999)  
7.  Chloramphenicol  It was produced by two steps lipid plus PEG base extrusion. The final product revealed a good 
stability profile in 3 months accelerated studies.  
 
(Windbergs et al., 2010) 
8.  Clotrimazole Transdermal products were developed and exhibited excellent content of uniformity. However 
degraded products were detected in which necessitate future investigation. 
 
 (Repka et al., 2003) 
9.  Delta-9 
Tetrahydrocannabinol 
Prodrug 
Thermo labile properties justify the use of the component with assistance of excipients in Hot 
Melt extrusion process. It has been showed that its stability highly dependence on 
microenvironment pH of formulation.  
 
(Thumma et al., 2008a, Thumma et al., 2008b, 
Thumma et al., 2008c, Munjal et al., 2006) 
10.  Diltiazem HCl Diltiazem HCL could bind to Eudraggit RSPO that potentially reduces the free drug. Research 
confirmed it does not possess plasticizing effect. 
(Schilling et al., 2008)  
(continued) 
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11.  Dyphilline A derivative of theophyliine. Degradants of the product were detected thus it is at risk for long 
term stability. 
 
(Dong and Choi, 2008a) 
 
 
12.  Etonogestrel Controlled release co-axial fiber was prepared by single screw extruder.  (van Laarhoven et al., 2004) 
13.  Guaiazulene Sodium Water content is an essential key for its stabilization. (Nakamichi et al., 2003)  
14.  Guaifenesin  It possessed plasticizing effect toward Eudragit L100-55. Evaluation of crystal growth 
inhibitor and recrystallization by nucleating agent was carried out..  
(Bruce et al., 2007, Bruce et al., 2010, Crowley 
et al., 2007)  
15.  Hydralazine HME hydralazine capsule was constructed by extruded hollow pipe and inclusion of drug and 
additive as a core.  
 
(Mehuys et al., 2005a)  
16.  Hydrochlorothiazide Ampiphilic nature of lipid and water soluble polymer in the formulation enhanced wettability 
of drug and thus dissolution of the drug 
 
(Mehuys et al., 2004a) 
17.  Hydrocortison A thermal sensitive compound but able to process by HME due to the inclusion of plasticizer 
and versatility of HME process that enable the drug to process under short residence time 
frame (about 2 minutes) 
 
(DiNunzio et al., 2009, Repka et al., 1999)  
18.  Ibuprofen  Sustained release ibuprofen was fabricated via polymer blends. The drug showed plasticizing 
effect equivalent to conventional plasticizer DEP/DBS. 
(Brabander et al., 2002, Brabander et al., 2004, 
De Brabander et al., 2000, De Brabander et al., 
2003, Verhoeven et al., 2006, Wu and 
McGinity, 1999, Campbell et al., 2010)  
19.  Indomethacin  PVA is not a suitable HME candidate for indomethacin due to immiscibility of both. It 
possesses good thermal stability 
(Forster et al., 2001c, Zhu et al., 2006)  
20.  Insoluble microsomal 
triglyceride transfer protein 
inhibitor, R103757 
It is structurally similar to itraconzole and its HME extrudates (Drug to HPMC ratio, 25:75) 
possessed fastest in vitro release performance relative to the film coated bead and glass 
thermoplastic system. No changes detected in 3 months stability test indicated its good 
stability profile and protection of HPMC.  
 (Verreck et al., 2004) 
21.  Itraconazole Transdermal sustained release film intended for Onychomycosis and systemic micronized 
powder coupled with HME process were attempted. It’s supersaturated form was found to be 
stabilized in Methocel E50 (HPMC E50) after pH transition from acid to neutral. It was 
suggested that formulation of ITZ to be carried out in controlled release manner due to the fact 
(Miller et al., 2008b, Miller et al., 2008a, Miller 
et al., 2007, Shim et al., 2006, Six et al., 2003a, 
Six et al., 2005, Six et al., 2002, Six et al., 2003, 
Six et al., 2004, Trey et al., 2007)     (continued) 
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that rapid precipitation will take place if immediate release of drug occurred in upper GI 
condition which is acidic. 
 
(continued) 
22.  Lysozyme  Implant of this API was produced with biodegradable polymer, polylactide co-glycolide and 
low MW PEG as release modifying agent. 
 
(Ghalanbor et al., 2010) 
23.  Lacidipine Phase separation was observed by 2 Tg for the thermal analysis and it was further supported 
by solubility parameter. 
(Forster et al., 2001c)  
24.  Lopinavir/Ritonavir HME product of the combination revealed increase in bioavailability, less intra-patient 
variability and diminished food effect. 
(Klein et al., 2007) 
25.  Methylparaben A ‘non-traditional plasticizer’ (Wu and McGinity, 1999) 
26.  Metoprolol tartrate HME extruded mini-matrices with release modifying agents and its properties were 
characterized by groups of researcher.  
(Verhoeven et al., 2009a, Verhoeven et al., 
2008, Verhoeven et al., 2009b)  
27.  Nicardipine  Floating dosage form was developed by incorporating porous agent via HME (Nakamichi et al., 2001) 
28.  Nifedipine  Integration of kneading paddle in HME increases API dispersion. (Nakamichi et al., 2002) 
29.  Nimodipine  Both in vitro and in vivo studies were done with HME product to select the best carrier for 
bioavailability enhancing effect.  
(Zheng et al., 2007a, Zheng et al., 2007b) 
30.  Paracetamol  Tablet was prepared with layered silicate polymer to examine the influence in retard release 
and effect of recrystalline 
(Campbell et al., 2009, Qi et al., 2008b)  
31.  Phenylpropanolamine HCl A better particle size distribution was obtained via HME  (Liu et al., 2001) 
32.  Propanolol HCl Extensive first pass metabolism led to complicated analysis for evaluation of factors that may 
increase bioavailability of HME prepared products. 
(Mehuys et al., 2005b, Mehuys et al., 2004b, 
Mehuys et al., 2004a, Maniruzzaman et al., 
2013)  
33.  Theophylline Extensive studies were carried out in formulating mini matrices, sustained release 
formulation, incorporation of lipid matrix as well as co-extrudate. 
(Mehuys et al., 2004a, Özgüney et al., 2009, 
Quintavalle et al., 2008, Reitz and Kleinebudde, 
2007b, Wu and McGinity, 1999, Zhang and 
McGinity, 2000)  
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1.4.2.2. Carriers used in HME formulations 
Over the past decade, the application of various types of carriers system has been identified. Figure 
1.8 shows the different generations of SD based on their carrier systems that has been classified  by 
Vasconcelos et al. (2007). 
 
 
Figure 1.8: The evolvement of solid dispersion which gives rise to the different generations of the formulations 
(Vasconcelos et al., 2007) 
 
Amongst all carriers, polymeric systems are the most commonly investigated materials in the 
production of solid dispersion with the inclusion of surfactants, lipids and polymer blends 
described in some recent studies (Guns et al., 2011, Kalivoda et al., 2012a, Kalivoda et al., 2012b, 
Mehuys et al., 2004a, Djuris et al., 2013a, Herrmann, 2007, Özgüney et al., 2009, Reitz and 
Kleinebudde, 2007b, Six et al., 2004). Brief review on the use of these carriers system will be 
provided in the subsequent sections. 
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1.4.2.2.1. Polymers 
Polymeric carriers are usually used as the dispersing agent in HME solid dispersion systems to 
stabilize the amorphous API. During the HME process, polymers are subjected to high shear stress, 
chain scission, chemical de-polymerization as well as thermal degradation (McGinity et al., 2006). 
Thus, pharmaceutical grade polymer used in HME must be able to process under relatively low 
temperature. Enteric polymer, pH dependent polymers and hydrophilic polymers are the commonly 
used polymers in fabricating pharmaceutical dosage forms. Examples of these polymers include 
acrylic polymer (Eudragit S100, Eudragit L100-55, Eudragit L100, Eudragit RD 100), cellulose 
polymer (hydroxypropyl methylcellulose), phthalate polymer and polyvinylpyrrolidon (PVP K30, 
vinylpyrrolidone-vinylacetate copolymer, PVPVA 6:4).  
Among these polymers, hydrophilic polymers such as PVP/ PVPVA 6:4 are usually included in 
numerous HME compositions for immediate release solid dispersion. However, at high polymer 
concentration, PVP/ PVPVA 64 may result in extruder clogging due to their high glass transition 
temperature ( > 150
o
C) (Hülsmann et al., 2000). Other hydrophilic polymers, for example 
polyethylene oxide  (PEO) or polyethylene glycol (PEG), xanthan gum, plasdone S-630 and 
hydroxypropyl methylcellulose could also be added in a formulation to tailor the drug release and 
to yield desirable sustained release pattern (Verhoeven et al., 2009a, Verhoeven et al., 2008, 
Ghebremeskel et al., 2007).  
Some polymers exhibit a plasticizing effect toward other polymer in a polymers blend system. This 
is a benefit for HME process as the integrated polymer could aid the material transport in the hot 
barrel besides tailoring the drug release properties of the system (Repka and McGinity, 2000). For 
example, PEO 1K appeared to plasticize PEO 1M and enhanced stability of the HME processed 
polymer (Crowley et al., 2002b). A study performed by Lyons et al (2008) has indicated that the 
inclusion of poly ɛ-caprolactone in PEO polymer blend can function as a plasticizer in the blend by 
lowering melt viscosity, torque and head die pressure (Lyons et al., 2008).  
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1.4.2.2.2. Plasticizers used in HME systems  
The conventional role of plasticizer is to reduce brittleness, improve flowability, and impart 
flexibility, toughness and strength. More specifically, it is used to change certain physical and 
mechanical properties of a material. In the context of HME, plasticizers are applied to soften the 
polymer matrix where excessive temperature may be needed to process unplasticized based 
polymer that could lead to degradation or localized overheating of the polymer (McGinity and 
Zhang, 2007). By incorporating a plasticizer, the extrusion temperature and thermal degradation of 
the material may be reduced (Verhoeven et al., 2008, Ghebremeskel et al., 2007). Besides, 
plasticizer may exert a positive influence on content uniformity of the product by promoting good 
flowability and mixing of the blend materials (Thumma et al., 2008b). A study carried out by Bruce 
et al. (2005) has successfully improved the physical properties of Eudragit ®S 100 by 
incorporating of triethyl citrate as a liquid plasticizer (Bruce et al., 2005).  
The interest in investigating solid state plasticizers such as citric acid, PEG 8000 and 
methylparaben (MP) in HME system is increasing as these solid plasticizer are readily mixed in 
powder form prior to the extrusion at elevated temperature (Wu and McGinity, 2003). Upon 
extrusion, the solid state plasticizer is melted and solubilised in carrier in order to exert their 
plasticization effect (Andrews et al., 2008, Schilling et al., 2010). An example was given by Wu 
and McGinity, (2003) whom demonstrated that incorporation of methylparaben in the extrudates of 
Eudragit ® RS PO could reduce its Tg from 55 
o
C to 32 
o
C. The authors elucidated that the 
incorporation of methylparaben within the Eudragit ® RS PO polymer has weaken the cohesive 
interaction between its polymer chains and subsequently enhance its chain mobility (Wu and 
McGinity, 2003). Besides, citric acid was shown to alleviate the Tg of HME API-polymer system 
which indicates its plasticizing properties as a solid state plasticizer (Forster et al., 2001c, Bruce et 
al., 2005, Andrews et al., 2008).  
The combination of both triethyl citrate (liquid state plasticizer) and citric acid (solid state 
plasticizer) has resulted in the good flowability of a HME API-polymer system and render the used 
of low processing temperature in the HME manufacturing process (Bruce et al.,  2005). Similar 
attempt was carried out by Andrews et al. (2008) who incorporated the combination of both triethyl 
citrate (TEC) and citric acid in HME process of Eudragit. The authors elucidated that both TEC 
and acid citric have improved material flowability in the extruder, reduced Tg, and ultimately aided 
the extrusion process by lowering screw torque as well as die pressure. This is because TEC and 
citric acid are able to form hydrogen bonding with Eudragit by occupying ‘active site’ along the 
polymer and thus preventing inter-chain association (Andrews et al., 2008).  
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CO2 is proposed to be a temporary plasticizer in HME process (Verreck et al., 2005, Verreck et al., 
2006b). Verreck and co-workers examined the effect of CO2 in pharmaceutical polymer such as 
PVP-VA 64, Eudragit E100 or ethylcellulose. It has shown that CO2 reduced the processing 
temperature of HME, increased porosity and specific surface area of extrudate by forming a foam 
extrudate. The foam like structure of extrudates improved subsequent milling process and caused 
dissolution rate enhancement of the formulation (Verreck et al., 2005, Verreck et al., 2006b). 
However, CO2 was reported to exert a negative impact on physical stability of extrudate where it 
was shown to induce recrystallization owing to the increase in mobility and realignment of the 
polymer chains (Verreck et al., 2006b, Lyons et al., 2007a).  
Interestingly, some APIs could intrinsically be a plasticizer for polymer. An API has to be 
dissolved in the polymer system in order to contribute to the plasticizing effect (Verreck et al., 
2005). Ibuprofen was shown to possess plasticizer effect toward ethylcellulose and was known as a 
‘non- traditional plasticizer’ (Brabander et al., 2002). Its effect was investigated and compared with 
other traditional plasticizers such as diethyl phthalate and dibutylsebacate by by Brabander et al. 
(2002). It was elucidated that ibuprofen having equivalent plasticizer efficiency as the traditional 
plasticizer (diethyl phthalate and dibutylsebacate) toward ethylcellulose. The same effect was also 
reported in a study where API was found to plasticize Kollidon®SR (polyvinyl acetate: povidone 
8:2) (Özgüney et al., 2009). Table 1.4 outlines the different types of plasticizer used in HME 
pharmaceutical application. 
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Table 1.4: different types of plasticizer used in HME pharmaceutical application 
Types of plasticizer Polymers References 
Liquid state plasticizer  
Triethyl citrate TEC 
(Hydrophilic) 
Pre-plasticizing step with Eudragit S100 showed better results; Eudragit RD 100, 
Eudraagit L100-55, Eudragit RSPO, Kollidom SR (8:2), HPC:PEO (50:50, 
80:20),Hydroxypropylcellulose (HPC), ethylcellulose. Its plasticizing efficiency was 
twice as high compared to chlopheniramine maleate in Eudragit® RSPO.  
(Bruce et al., 2005, Andrews et al., 2008, Wu and McGinity, 
2003, Mehuys et al., 2005a, Özgüney et al., 2009, Zhu et al., 
2006, Repka and McGinity, 2000, Repka et al., 1999, Verhoeven 
et al., 2008, Zhu et al., 2002) 
Triacetin TA (Hydrophilic) Polyvinyl acetate phthalate, ethylcellulose (Mehuys et al., 2005a, Verhoeven et al., 2008) 
Dibutyl sebacate DBS 
(Lipophilic) 
Eudragit RSPO, ethylcellulose  
(Wu and McGinity, 2003, Mehuys et al., 2005b, Mehuys et al., 
2004b, Mehuys et al., 2004a, Verhoeven et al., 2008) 
Diethylpthalate DEP 
(Lipophilic) 
ethylcellulose (Verhoeven et al., 2008) 
Acetyl Tributyl 
Citrate(ATBC) 
HPC:PEO(50:50, 80:20),Hydroxypropylcellulose (HPC) (Repka and McGinity, 2000, Repka et al., 1999) 
Water content HPMCP (Nakamichi et al., 2002) 
Solid state plasticizer 
Traditional plasticizer   
Low MW PEO e.g., PEG 
400, PEG8000 
PEO1000000,HPC:PEO(50:50,80:20), 
Hydroxypropylcellulose (HPC) 
(Crowley et al., 2002b, Repka and McGinity, 2000, Repka et al., 
1999, Repka et al., 2003) 
Sorbitol PVP K30 (Lakshman et al., 2008) 
Citric acid/ Citric acid 
monohydrate (CA MH) 
Eudragit S10, Eudragit RSPO, Eudragit L100-55 (Bruce et al., 2005, Schilling et al., 2008, Andrews et al., 2008) 
  (continued) 
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Non-traditional plasticizer  (continued) 
Carvedilol PEO, PEO/PCL block copolymer (Lyons et al., 2008, Lyons et al., 2007b) 
Chlopheniramine maleate Eudragit RS PO, Eudragit E PO, Eudragit RS30 D (Fukuda et al., 2006a, Wu and McGinity, 1999, Zhu et al., 2002) 
 Vit E TPGS  HPC:PEO (50:50, 80:20) (Repka and McGinity, 2000) 
Guaifenesin Acryl-EZE/ Eudragit L100-55 , PEO (Bruce et al., 2007, Crowley et al., 2004a) 
Itraconazole Eudragit L100-55 (Miller et al., 2008a) 
Ibuprofen Kollidom SR (8:2), ethylcellulose, Eudragit RS30 D 
(Özgüney et al., 2009, Brabander et al., 2002, De Brabander et al., 
2003, Verhoeven et al., 2006, Wu and McGinity, 1999) 
Indomethacin Eudragit RLPO (Zhu et al., 2006) 
Ketoprofen  PEO (Crowley et al., 2004a) 
Lidocaine HCl Eugragit® E 100 (Aitken-Nichol et al., 1996) 
Methylparaben Eudragit RSPO, Eudragit RS30 D (Wu and McGinity, 2003, Wu and McGinity, 1999) 
Nimodipine  PVP/VA, Eudgragit ®PO (Zheng et al., 2007a, Zheng et al., 2007b) 
Paracetamol  Eudragit ®EPO (Qi et al., 2008b) 
Temporary plasticizer 
Carbon Dioxide (CO2) 
CO2 is termed as ‘temporary’ plasticizer due to its absence in the end product of the 
HME system. The effect of plasticizing appears to be best in ethylcellulose followed 
by PVP-VA 64 and lastly Eudragit E100.  
(Verreck et al., 2005, Verreck et al., 2006a, Verreck et al., 2006b) 
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1.4.2.2.3. Surfactant 
Surfactants such as Tween 80 and docusate sodium are regularly used in the pharmaceutical field 
as wetting agents and to increase solubilisation of the poorly soluble API. In the production of 
HME systems, the surfactant could also act as a plasticizer in the extrusion process (Ghebremeskel 
et al., 2007). Ghebremeskel et al. (2007) has demonstrated the reduction in Tg of the mixture of 
API and polymer after the addition of surfactant into the composition of extrudate. In that study, 
the authors suggested that the use of surfactant could aid the extrusion process through an increase 
in chain mobility of polymer carrier (Ghebremeskel et al., 2007).  More specifically, the extrusion 
torque of binary API-Plasdone was lowered from circa 55-65 Ncm to circa 28-30 Ncm with the 
addition of Tween 80 (Ghebremeskel et al., 2007). Table 1.5 displays the example of surfactants 
that have been applied in HME processes. 
 
Table 1.5: Example of surfactants used in HME process 
 Surfactant  Polymer system  References  
1.  Tween 80 As plasticizer to Plasdone S360, 
Hydroxypropyl methylcellulose (HPMC) E5, 
Polyvinylpyrrolidaone (PVP)  K30   
(Ghebremeskel et al., 
2006, Ghebremeskel et 
al., 2007) 
2.  Docuste Sodium As plasticizer to Plasdone S360, 
Hydroxypropyl methylcellulose (HPMC) E5, 
Polyvinylpyrrolidaone (PVP)  K30   
3.  Sodium Lauryl sulfate As plasticizer to Eugragit L100, 
Hydroxypropyl methylcellulose (HPMC) E5 
4.  Polyoxyethylene 40 
stearate (Myrj-52) 
No effect in lowering Tg 
5.  Poloxamer 188NF 
(Pluronic F68) 
No effect in lowering Tg, but showed to 
enhance drug release. 
(Ghebremeskel et al., 
2007, Zhu et al., 2006) 
 
1.4.2.2.4. Other additives used in HME processing 
Recent investigations of HME were carried out on incorporation of nanoclay within polymeric 
matrix to tailor the release of API (Campbell et al., 2008, Campbell et al., 2009, Lyons et al., 
2007b). Reduction of burst release was attained by addition of polymer layered silicate as carrier 
for SD of ibuprofen when compared to the same formulation without layered silicate (Campbell et 
al., 2010). Furthermore, the authors reported a reduction in tensile stress, elongation break and 
increment in modulus. Thence, mechanical properties of the extrudates by addition of nanoclay 
may be manipulated accordingly to ease subsequent downstream processes of the extrudates such 
as milling or compression of the extrudates systems into tablet (Campbell et al., 2010). 
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Studies have also been described whereby lipids are added to HME formulations to obtain the 
desired dissolution pattern (Reitz and Kleinebudde, 2007b, Reitz and Kleinebudde, 2007a, 
Windbergs et al., 2009a, Windbergs et al., 2009b, Schulze and Winter, 2009, Hülsmann et al., 
2000). It has been shown that that the use of lipid carrier in HME produced a sustained release 
product with good physical stability as the hydrophobic nature of lipid had reduced the water 
absorption during storage (Reitz and Kleinebudde, 2007b, Windbergs et al., 2009b). In 
formulations containing proteins and peptides, the inclusion of lipids in the HME process created a 
hydrophobic surrounding to the protein, therefore minimizing its denaturation tendency in aqueous 
conditions (Schulze and Winter, 2009). 
Addition of other components such as waxes (Liu et al., 2001, De Brabander et al., 2000), pH 
modifiers (Thumma et al., 2008c, Thumma et al., 2008b, Thumma et al., 2008a, Munjal et al., 
2006, Schilling et al., 2008, Bruce et al., 2005), antioxidants (Repka and McGinity, 2000, Crowley 
et al., 2002b, Thumma et al., 2008c), lubricants (Verreck et al., 2005, Verreck et al., 2006b) and 
controlled water content (Nakamichi et al., 2002, Nakamichi et al., 2003) are also possible in 
formulation of HME extrudates in order to obtain an optimum pharmaceutical dosage form.  
 
1.5. Stability issues 
A success pharmaceutical dosage form should exhibit good dissolution profiles, excellent 
pharmaceutical therapeutic outcome as well as good stability upon storage. Physical stability of 
SDs is the main concern and hurdle that has restricted commercialization of this type of product. 
This is due to the high tendency of physical transformation, i.e. recrystallization of the amorphous 
API into its crystalline counterpart. Besides recrystallization, phase separation has also been 
identified as physical instabilities in which the resulted formulation might display high variation on 
drug release and therapeutic result (Lakshman et al., 2008). Hence, in the context of the current 
study, physical stability of HME SD products will be discussed. 
Amongst modes of manufacturing, HME has ostentatiously yielded a relatively stable products as 
documented in numerous published papers (Dong et al., 2008b, Verreck et al., 2004, De Brabander 
et al., 2003, Fukuda et al., 2006a). In a 4 month accelerated stability study by Dong et al. (2008b), 
recrystallization was observed lower in HME extrudates as compared to co-precipitated samples. 
This is due to the lower surface area of the smooth HME extrudate that was available for water 
absorption as compared to the co-precipitated products (Dong et al., 2008b).  In another study, 
HME has shown to exhibit a better physical stability profile as compared to film coated beads 
(Verreck et al., 2004). A consistent drug release of HME product was maintained after 3 months of 
storage in ambient surrounding as compared to film coated beads, which showed a slight 
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deterioration in its API release. The stability of HME samples was also proven to be more superior 
than the direct compression production technique by probing recrystallization of the formulation 
due to the lower porosity and water sorption of HME moulded tablet compared to compressed 
tablets (Ndindayino et al., 2002b, Ndindayino et al., 2002a).    
 
1.5.1. Physical stability of HME solid dispersions  
Physical stability of extrudates can be categorized into in-process stability, post-extrusion stability 
and long term storage stability. In-process stability is mainly related to the processing parameters, 
types of fillers and additives. However, post-extrusion stability and storage stability are mainly 
influenced by water sorption and storage temperature in a define time frame. Figure 1.9 
summarises the factors involved in the stability of HME extrudates. 
 
 
 
 
Figure 1.9: Stability influences of HME extrudate 
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Based on Figure 1.9, the in process stability of extrudates is mainly dependent on the processing 
parameters and the extruded materials used for extrusion. A high processing temperature has been 
showed to be advantageous for the production of uniformity in drug content due to reduction of 
melt viscosity that ease mixing. However, it can cause cumulative heat exposure to the API which 
results in significant drug degradation. For instance, processing of Δ9-tetrahydrocannabinol- 
hemiglutarate at 90 
o
C for 7 minute exhibited excellent post processing content with < 5% 
degradation (Thumma et al., 2008b). However, the same processing parameters with a higher 
extrusion temperature of of 110 
o
C caused 5.4% degradation in that study. When the residence time 
was prolonged to 10 minutes and 15 minutes using 110 
o
C, 9.9% and 16.5% of drug degradation 
were detected, respectively (Thumma et al., 2008b). Thus the authors suggested that the thermal 
degradation of drug is dependent on cumulative heating, i.e. longer residence time in heating barrel 
has caused a higher percentage of degradation (Thumma et al., 2008b, Munjal et al., 2006). 
Therefore prudent options of processing temperature, additives, and residence time in barrel are 
essential for the best outcome.  
Extrusion temperature could also alter the polymorphism of lipid extrudates. This can be 
exemplified by the processing of tristearin which is appeared as β-form with its Tm at 65 
o
C. 
Tristearin is known to undergo melt crystallization to another polymorphs form (Windbergs et al., 
2009b). However, Windbergs et al. (2009b) has reported a polymorphism transformation of 
tristerin to an α-form endotherm when it was extruded at a temperature lower than its melting, i.e. 
55 
o
C. According to the authors, this is attributed to the temperature and friction of extrusion 
process that caused a certain degree of lipid melting specifically at the extruded point (Windbergs 
et al., 2009b).  
The effects of other processing parameters and formulation components in influencing the stability 
of extrudates are briefly explained in Table 1.6. 
 
Table 1.6: The effects of processing parameters and excipients the physical stability of extrudates 
Influence of processing parameters 
Factors Explanation References  
1. Processing 
temperature 
Higher processing temperature causes instability of component. 
E.g. ethylcellulose degrade at 190 
o
C but not at a lower 
temperature.  
(Crowley et al., 
2004b) 
2. Screw 
speed/ drive 
amperage 
 
Higher screw speed reduces residence time in barrel, but could 
cause melt fracture if too high.  
(DiNunzio et al., 
2009, Crowley et 
al., 2002b) 
 
 
(continued) 
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Influences of excipient/ formulation components                                                                        (continued) 
Factors Explanation References  
1. Drug load 
Homogeneously dispersed drug can prevent partial crystallization 
of carrier 
Percentage of drug load is important for the solubility in carrier 
system. Surplus of drug act as homogeneous nucleating agent 
that lead to recrystallization.  
(Six et al., 2002, 
Brabander et al., 
2002) 
2. polymer 
Polymeric interaction in hydrogen bonding give a better stability 
Hydrophobic nature of aPMMA lead to negligible water uptake 
hence could hamper the effect of water participation in 
formulation stability 
Sterical hindrance avoids crystal formation in extrudates 
Polymer layered silicate decreases crystallinity compare to pure 
polymer. It is ascribed to the reduction of chains mobility.  
(Forster et al., 
2001b, Six et al., 
2004, Yang et al., 
2010a, Bruce et al., 
2007, Miller et al., 
2007, Campbell et 
al., 2008, Campbell 
et al., 2009) 
3. plasticizer 
lowering torque, melt viscosity and reduce localized heating of 
API thus protect API from thermal degradation and increase 
stability 
Induce molecular mobility and rearrangement of polymer chains 
lead to higher crystallinity at post extrusion point. E.g. CO2 
(Lakshman et al., 
2008, Lyons et al., 
2007a, Munjal et 
al., 2006) 
4. Surfactant 
Serve as a barrier for particle re-aggregation and shield particle 
from ambient moisture e.g. poloxamer  
(Miller et al., 2007) 
5. lipid 
Lipophilic and hydrophobic nature of carrier impede water 
uptake and prevent water induce degradation and 
recrystallization. 
(Windbergs et al., 
2009b, Reitz and 
Kleinebudde, 
2007b) 
6. antioxidant 
It stabilizes formulation by reducing radical catalytic 
decomposition and chain scission.  
(Repka and 
McGinity, 2000, 
Crowley et al., 
2002b) 
7. Lubricant  
It could act as heterogeneous nucleant which promote nucleation 
at concentration lower than supersaturation of homogeneous 
nucleant. E.g. talc 
(Bruce et al., 2010) 
8. pH 
modulators 
Maintain optimum pH close to maximum stability. Mainly 
reduce chemical degradation  
(Thumma et al., 
2008c) 
9. Particle size 
distribution 
Wide range of size distribution give rise to phase separation or 
segregation and influence consistent flow rate which cause 
“surge” phenomena 
(Dreiblatt, 2007a, 
Luker, 2007) 
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1.5.1.1. Post-extrusion stability 
Post extrusion stability can be further divided into two categories. Firstly, short term stability which 
is usually correlated with the immediate solid state change upon extrusion and the impact of 
downstream processes. Secondly is the long term stability which is the main hurdle for product 
commercialization. 
 
1.5.1.1.1. Short term stability 
Mechanical stress such as milling can induce recrystallization of API after extrusion process. 
Recrystallization of itraconazole (ITZ) was found to be 25% and 14% in the milled and unmilled 
Eudragit  E100 extrudate, respectively at low loading of ITZ (Six et al., 2002). At high loadings of 
ITZ, the percentage of recrystallization increased dramatically in the milled extrudates as compared 
to the unmilled extrudates of Eudragit E100 which showed 60% and 20% of ITZ crystalline 
content, respectively (Six et al., 2002). This is due to the alteration in the kinetics of 
recrystallization of ITZ by the polymer molecules in the unmilled samples that hinder the 
conversion of the amorphous API to its more stable crystalline form. Similarly, milling of HME 
R103757 (water soluble microsomal triglyceride transfer protein inhibitor) – HPMC extrudates 
causes extensive recrystallization of the R103757 which was originally amorphous after extrusion 
(Verreck et al., 2004).  
Albers et al. (2009) demonstrated that external phase inclusion of polymer (40 mg HPMC) into the 
milled HME extrudate could delay recrystallization process of the system (Albers et al., 2009). 
Even though the downstream process of milling might affect the physical stability during the 
production of extrudate; there are other studies indicated that milling of HME extrudate has no 
effect on its physical stability (Albers et al., 2009, Forster et al., 2001b). 
 
1.5.1.1.2. Long term stability 
As discussed in Chapter 1.5.1, HME products has frequently presented its good physical stability 
due to the intense mixing, high compression and solubilisation of molten material in HME process 
(Young et al., 2005). In the subsequent sections, factors dictating the physical stability of HME 
extrudate will be further discussed. 
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Steric hindrance / polymer ratio 
Addition of polymer to the API has been shown to enhance physicochemical stability of an 
amorphous API by reducing the interaction among API molecules via steric hindrance and 
increasing the energy barrier for nucleation (Yang et al., 2010a, Six et al., 2004). Higher molecular 
weight (MW) of polymer has reported to exert bigger impact by hinder the rearrangement of drug 
molecule and thus reduce rate of crystallization (Prodduturi et al., 2005). Besides, the ratio of the 
polymer content is also playing a role in recrystallization inhibition. For instance, Yang et al. 
(2010a) reported the decrease in recrystallization rate of efavirenz when the ratio of polymer was 
increased. This is due to the greater number of efavirenz molecules that entrapped in a higher 
percentage of PVP polymer matrix (Yang et al., 2010a).  
In a study, hydrophilic polymers are used as crystallization inhibitor e.g. PVP K-25, Polycarbonil, 
PEG3350, Poloxamer 188 and Polyethylene oxide (Bruce et al., 2007). The use of these 
hydrophilic polymers in the composition of extrudate has shown to reduce the recrystallization rate 
of the API in comparison to the similar formulations without the inhibitors. This is because of the 
increase of API solubility in the matrix containing both polymer and hydrophilic carrier and which 
reduces the tendency of recrystallization (Bruce et al., 2007).  
 
Drug-polymer interaction 
Interaction between the polymer carrier and drug substance could also impart positive stability to 
an extrudate. A study conducted by Foster et al. (2001b) suggested the presence of hydrogen 
bonding between the API and polymer in the investigated extrudate. In that study, the authors 
proposed that the quantity of these hydrogen bonds is inversely correlated to the ability of water 
penetration upon storage. With a lower degree of hydrogen bonds between the API and polymer, 
the proton acceptor sites of the polymer will be exposed and enable its interaction with any 
absorbed water molecules (Forster et al., 2001b). This causes plasticization of polymer and 
subsequently promotes recrystallization of API. Hence, the choice of carrier can critically in 
determine the physical stability of a HME product.  
 
Water content of products 
Water content can profoundly affect the physical stability of a product (Forster et al., 2001b). It is 
particularly important for hygroscopic drugs. For instances, Foster et al. (2001) performed a 
physical stability tests on HME SD of indomethacin, lacidipine, nifedipine and tolbutamide. The 
study showed that nifedipine recrystallizes more than indomethacin attributed to the higher water 
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content of the former drug as compared to the latter (Forster et al., 2001b).  Besides, the high water 
uptake of Δ9 -tetrahydrocannabinol- hemiglutarate extrudate has caused a high percentage of drug 
degradation when the product is expose to humid condition (Thumma et al., 2008a). Similarly, high 
moisture content of HME ketoconazole films has resulted in high degradation of ketoconazole after 
6 months storage in humid condition despite the good stability of the product post extrusion 
(Mididoddi and Repka, 2007). 
Another study carried out by Six et al. (2003) has shown that the water content can cause phase 
separation and a significant change in Tg of a binary HME system of ITZ-HPMC. The authors 
suggested that the presence of water in the HME system could impart 2 major effects. Firstly, water 
acts as a plasticizer to the amorphous system. Secondly, water could interrupt the formation of 
hydrogen bonds between drug and polymer (Six et al., 2003a). 
The water content of a product is highly dependent on the storage humidity. Greater 
recrystallization of HME guaifenesin (GFN) in Eudragit® L10055 or Acryl-EZE® was seen in 
higher humidity storage condition (Bruce et al., 2010). In that study, the effect of RH cycling was 
also tested. The HME GFN guaifenesin Eudragit® L10055 were exposed to two different cycles. 
The first batch of the sample was stored firstly in a low RH condition (17%) for 6 days, then 
transferred to a high RH condition (78%) for 12 days and subsequently returned to the low RH 
condition. The second batch of sample was started with storing in high RH condition (78% ) for 6 
days followed by low RH condition in the intermediate stage and finally returned to the high RH 
storage condition. The results indicated that crystallization occurred rapidly when the samples was 
introduced to the high RH condition, and these crystals remain permanently in the samples to 
further induce the recrystallization process even though low RH storage conditions were used 
(Bruce et al., 2010).   
 
Addition of excipient 
Addition of excipient such as surfactant, disintegrant or lubricant has shown to benefit the 
dissolution performance of solid dispersion formulation (Ghebremeskel et al., 2006, Ghebremeskel 
et al., 2007). However, these excipients could potentially alter the physical stability of the drug 
product. A study reported that higher percentage of triacetin (TA) in polyvinyl acetate phthalate 
(PVAP) capsules has led to a higher moisture uptake of the product upon storage as compared to 
the similar product with a different carrier, hydroxylpropylmethylcellulose acetate succinate 
(HMPC AS) (Mehuys et al., 2005a). Changes of drug release were reported with PVAP capsules 
after one month storage at 25 
o
C / 75% RH and 25 
o
C / 60% RH, respectively.  
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In contrast, Ghebremeskel et al. (2006) demonstrated that the addition of surfactant did not change 
the performance of extrudate as indicated by the indiscernible change in drug release profile after 6 
month storage in accelerated humidity condition (Ghebremeskel et al., 2006). The authors 
suggested that recrystallization of the formulations were primarily determined by the polymer 
carrier rather than other additives, namely surfactant in this case. 
Chapter 1.4.2.2.4 describes the possibility of lipid addition to HME products. A more recent 
investigation has shown that addition of lipid could preserve the physical stability of the solid 
dispersion product (Unga et al., 2010). This research group demonstrated the influence of lipid in 
the process of folding and unfolding of polyethylene glycol (PEG 4000), where lipid has shown to 
form a continuous single phase system with PEG and affect the folding of PEG polymeric chain. In 
order to effectively retard the unfolding of PEG, Unga et al. (2010) suggested that the lipid 
molecule should be large, branched and possess a small portion of polar surface. Among the tested 
lipid systems, tristearin was identified to be the best lipid component in preventing the unfolding 
process of PEG (Unga et al., 2010). Therefore, a good physical stability of HME product could be 
obtained by incorporating lipid components.  
 
Storage Temperature 
Storage temperature is another important factor in determining physical stability of a SD system. A 
low storage temperature (T < Tg of the system) could lead to better stability of a SD product due to 
the reduce molecular mobility of the extrudates (Hancock and Zografi, 1997). On the other hand, 
storage of formulation at temperature higher than the Tg of product can lead to an increase in 
polymer ductility and transforms into its rubbery state which unfold the polymeric chain. 
Eventually, recrystallization occurred due to the rearrangement of drug molecules as a result of the 
increase in chain ductility of the polymer (Prodduturi et al., 2007).  
Besides, the storage temperature has also reported to affect the physical structure of polymeric 
chain. PEO was reported to be in a meta-stable folded state after treatment of thermal and high 
shear processing as indicated by the reduction of melting temperature (Tm) (Prodduturi et al., 2005, 
Prodduturi et al., 2007, Mididoddi and Repka, 2007). However, these meta-stable folded chains can 
unfold into its stable form at a particular storage temperature of the extrudates. Crowley et al. 
(2002) demonstrated that storage of PEO (a mixture of amorphous and crystalline polymer) at 
temperature lower than its Tm can cause degradation of the amorphous fraction of PEO, however, 
storage at higher temperature than Tm can cause oxidative degradation in both the amorphous and 
crystallites fractions of PEO (Crowley et al., 2002b).  
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1.6. Dissolution performance of solid dispersions 
The ability of SD in producing formulations with enhanced dissolution rate and bioavailability was 
widely reported (Fernandez et al., 1989, Tantishaiyakul et al., 1996, Craig, 2002). However, the 
number of marketed solid dispersion is disappointing despite of many papers published in this 
field. Besides the inherent physical instability of SD system, poor predictability on the dissolution 
behaviour of SD in has also been argued as one of the main reasons for the disappointing figures.  
Many reports were published on the dissolution enhancement of SD products, but the underlying 
mechanism of dissolution is still poorly understood. Nevertheless the potential factors to enhance 
dissolution have been suggested in these publications. These factors are summarised below: 
 
 The presence of amorphous phase 
During the dissolution process, less energy is required to break the structure of an amorphous API 
(high energy) as compared to the crystalline API (Corti et al., 2008, El-Badry and Fathy, 2006, 
Tantishaiyakul et al., 1996). El-Badry et al. (2006) has shown that similar crystallinity of PM and 
solvent-evaporated of 1:3 Meloxicam PVP K30 gave rise to an overlapped dissolution profile 
between the two. In the same study, a higher dissolution rate of co-evaporated 1:5 Meloxicam:PVP 
K30 was attributed to its crystallinity reduction as compared to the formulation of 1:3 
Meloxicam:PVP K30.  
 
 Carrier stabilization 
During the dissolution process, the sustainability of the supersaturation state of an API is highly 
dependent on the crystallization tendency of the amorphous drug molecules (Alonzo et al., 2010). 
Thus, the solubility advantages of amorphous API can only be achieved if the carrier possesses a 
capacity to stabilize the amorphous API against solution mediated recrystallization (Chawla and 
Bansal, 2008, El-Badry et al., 2009). This stabilization capacity is closely related to the solubilizing 
effect of the carrier to the API. For instance, greater solubilisation of indomethacin in PEG 4000 
than Gelucire 50/13 has led to better amorphization of indomethacin in the former carrier than the 
latter (El-Badry et al., 2009). Besides, intermolecular interactions between the carrier and API has 
also been reported to be important in imparting stabilization of the supersaturation state generated 
by the high degree of apparent solubility of the amorphous molecules (Miller et al., 2008a). 
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 Formation of complexes 
The dissolution enhancement of SD can be also ascribed to the formation of soluble complexes. 
These complexes could be formed via electrostatic forces, hydrogen bonding and hydrophobic 
interaction between drug and the carrier (Ilevbare et al., 2012a). The formation of soluble 
complexes is evidenced by the increase in apparent solubility constant of an API in its carrier 
solution (Verheyen et al., 2002, Biswal et al., 2009)  
 
 High surface area 
Solid dispersion is claimed to provide large surface area for dissolution process due to the 
dispersion of API at molecular level (Kapsi and Ayres, 2001, Dong et al., 2008b, Biswal et al., 
2009). This effect is found to be highly dependent on the fraction of the hydrophilic carrier (El-
Badry and Fathy, 2006). Nokhodchi et al. (2005) revealed that the fraction of molecularly dispersed 
API in tested lipid-solid compacts is directly proportional to the release rates of indomethacin at 10 
minutes point of dissolution experiments (Nokhodchi et al., 2005).  
 
 Hydrophilicity 
The use of hydrophilic carrier in SD has contributed to the dissolution rate enhancement. This is 
achieved through fast water penetration and the ability of the hydrophilic polymer in wettability 
enhancement or solubilisation of the API (Corrigan, 1985, Craig, 2002, Fernandez et al., 1989, 
Biswal et al., 2009, Chawla and Bansal, 2008).  
 
 Lowered Interfacial energy 
The interface between API and the dissolution medium has been shown to be an important factor in 
determining the dissolution performance of SD of a poorly soluble API (Swanepoel et al., 2000, El-
Badry and Fathy, 2006). A lower interfacial tension of SD/medium could give rise to a higher 
wetting effect to the hydrophobic API which can reduce the agglomeration event. In this context, 
the proportion of the carrier used is critical in lowering the interfacial tension between the poorly 
soluble API and dissolution medium.  
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Figure 1.10 presents a summary of the contributing factors in dissolution enhancement of poorly 
soluble API through the formation of SD.  
 
 
Figure 1.10: Summary of contributing factors in dissolution enhancement of poorly soluble API via the formation 
of an SD. 
 
1.6.1. Anomalous dissolution of solid dispersions 
API in an SD is generally exist in a high energy state, thus there is a risk of API recrystallization. It 
is difficult to predict the performance of SD in the in vivo hydrodynamic condition, as there is a 
high tendency of recrystallization of the API before drug absorption. A few publications have shed 
light on the anomalous drug release profiles and potential problems arise in the dissolution process 
of solid dispersion (van Drooge et al., 2004, Verheyen et al., 2002). In the subsequent sections, the 
current status of the dissolution performance of SD will be discussed with emphasis given on the 
different observations disclosed in the reported literature. 
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1.6.1.1. Crystallinity 
Crystallinity is often linked to the dissolution rate limiting step of BCS class II compounds. In 
general, a product with the lack of crystallinity dissolves faster than a product with fully crystalline 
structure (Ruan et al., 2005). Unexpectedly, few publications have shown the higher drug release 
rate (in weight) of the fully crystalline PM drug-polymer system than its corresponding amorphous 
SD system (Moneghini et al., 1998, Verheyen et al., 2002, van Drooge et al., 2004, Margarit et al., 
1994, Tajarobi et al., 2011a). For instance, dissolution of PM ketoprofen-PEG 6000 was faster than 
the dissolution rate of the corresponding co-evaporated SD system (Margarit et al., 1994). Another 
example was reported by Tajarobi et al. (2011) where co-evaporated solid dispersion of butyl 
paraben was revealed with a slower dissolution profile as compared to the corresponding 
crystalline PM despite the complete amorphization of drug compound in SD system (Tajarobi et 
al., 2011b). A similar observation was also noted for SD of co-evaporated of atenolol in PVP-CL 
and in PVPVA, whereby the corresponding PM formulations release faster than the amorphous SD 
products. In that study, the high viscosity effect exerted by the swellable carrier was claimed to be 
the main cause of the slow drug release of SD in that study (Moneghini et al., 1998). 
Results reported by Yan et al. (2012) revealed a slower API release of the partially amorphized 
spray dried valsartan-HPMC as compared to the fully crystalline powder of valsartan in alkaline 
medium (pH 6.8). However, a reverse dissolution performance were seen in acidic medium 
whereby the release of the spray dried valsartan-HPMC was faster than its PM system (Yan et al., 
2012).  This is mainly attributed to the ionization of valsartan at the low pH condition. Besides, 
William et al. (2005) has also concluded that there is no simple relationship between the 
crystallinity of ibuprofen with its dissolution rate. In that study, higher extent of ibuprofen was 
released in PM crystalline ibuprofen-PVP-CL as compared to the corresponding amorphous SD 
formulations (Williams et al., 2005).  
 
1.6.1.2. API / polymer loading 
Dissolution performance of a SD is also highly dependent on the proportion of API. There is a 
critical loading limit of API in a SD system that should not be exceeded in order to ensure good 
dissolution performance of the SD system when compared with its corresponding PM (Swanepoel 
et al., 2000, El-Badry and Fathy, 2006, Karavas et al., 2007). For instance, the loading limit for 
methylparaben and ketoprofen are 10-20% in PEG 6000 and 20% in PEG 6000, respectively 
(Margarit et al., 1994, Saers and Craig, 1992). Other examples of loading limits of API are 15% of 
PCM, 10% indomethacin, 5% phenacetin, and 2 % phenylbutazonein, (Fernandez et al., 1989, 
Verheyen et al., 2002). 
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In essence, a higher proportion of carrier in a SD system will lead to faster release of the API by 
increasing its solubilisation. However, Ruan et al. (2005) has demonstrated that the release of 
ampelopsin is not related to the proportion of PEG 6000 in the studied SD (Ruan et al., 2005). In 
another study, Tantishaiyakul et al. (1996) revealed that the highest dissolution rate was observed 
in the SD of 1:4 piroxicam-PVP when compared with SD of 1:1 and 1:6 piroxicam-PVP. The 
authors suggested that amorphicity of the sample is the main factor that contributed to this 
unpredicted dissolution profile as a complete amorphous product was obtained in SD 1:4 but not in 
SD of 1:1 or 1:6 piroxicam-PVP ratio (Tantishaiyakul et al., 1996).  
On the other hand, Doherty et al. (1987) has pointed out that high loading of carrier created the 
high viscosity layer at dissolving front of a system which could potentially retard the dissolution 
performance of SD, despite the increase wetting and solubilizing effect at high proportion of 
carrier. In that study, the highest dissolution rate of frusemide achieved an optimum loading of 
carrier at 60%, higher than this value, drug release of the carrier system reduced (Doherty and 
York, 1987). 
 
1.6.1.3. Molecular weight of carriers 
Molecular weight (MW) of the carrier in a SD system is another important factor that influences 
the dissolution performance of SD. Studies performed by Bettineti and Mura (1994) have shown 
that among a few tested carriers namely PVP K15, PVP K30 and PVP K90, PVP K15 (low MW 
carrier) is the best carrier to be used in the powdered naproxen-PVP SD, as far as the dissolution 
rate enhancement is concerned. However when the powder was compacted into disc, PVP K30 has 
turned out to be the best with the highest dissolution rate followed by PVP K 90, while PVP K15 
yielded the poorest dissolution rate among all. The authors suggested that this is attributed to the 
higher binding ability between the PVP K15 and naproxen while compaction process which lead to 
its slower dissolution rate (Bettinetti and Mura, 1994).  
A few studies have reported the negative impact of high MW polymer carrier on dissolution 
enhancement of SD (Mura et al., 2003, Kӧrner et al., 2005, Mokarram et al., 2010a). The use of 
high MW of chitosan as a carrier for naproxen SD resulted in slow release of the API, which was 
ascribed to the retardation of API diffusion through the high viscosity layer of high MW polymer 
(Mura et al., 2003). Likewise, Mokarram et al. (2010) demonstrated that the dissolution rate of 
indomethacin increases with a decrease in MW of PVP due to the ease of drug diffusion into the 
bulk medium through the non-viscous and short diffusion layer of the low MW carrier (Mokarram 
et al., 2010a). Similarly, Kӧrner et al. (2005) proposed that a low MW polymer release API at a 
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faster rate than a high MW polymer which is closely related to the intrinsic viscosity of the 
polymer carrier (Kӧrner et al., 2005).  
In contrast, a few other studies have found the reverse trend whereby the use of high MW carrier 
contributes positively to dissolution rate enhancement of SD. Chawla and Bansal (2008) suggested 
that higher Tg of hydrophilic carrier, with their high MW, is advantages in stabilizing amorphous 
API while dissolution (Chawla and Bansal, 2008). Similarly Kapsi and Ayres (2001) reported that 
dissolution of an investigated API improves considerably with the increase in MW of its PEG 
carrier. This is attributed to the higher proportion of oxyethylene molecule that lead to greater 
interspatial space for trapping of the drug molecule (Kapsi and Ayres, 2001). Likewise, results 
reported by De Brabander et al. (2003) revealed a faster release rate of API with the use of higher 
MW HPMC in its SD. The author explain the observation in terms of the presence of ethylcellulose 
that reduces chains entanglement of HPMC, which subsequently increase the accessibility of the 
product to the dissolution medium (De Brabander et al., 2003).   
Reviewing the available literature, there is no general trend to explain the effect of MW on 
dissolution performance of SD. On one hand, dissolution rate of a SD is directly proportionally to 
MW of the polymer carrier. On the other hand, dissolution rate of a SD is inversely proportionally 
to MW of the polymer carrier due to their high viscosity layer that inhibits drug diffusion during 
the dissolution process. As well as the aforementioned contradiction, some studies have shown the 
complex relationship between the MW and dissolution rate of a SD system. Verhoeven et al. 
(2009) cited that drug release from matrices is inversely correlated to the MW of carrier as 
confirmed by a slower drug release rate observed in the lower MW carrier system. However, when 
the concentration of PEO/PEG reached 20% or above, the drug release rate is directly correlated 
with the MW of PEO/PEG i.e. higher MWs of PEO/PEG caused an increase in gel strength which 
slows down the drug release (Verhoeven et al., 2009a). In addition, dissolution behaviour of co-
precipitated of probucol-PVP indicated that PVP K30 yielded a faster drug release than PVP K90 
and PVP K15 (Yagi et al., 1996). The results presented in the review above suggest an urgent need 
to clarify the effect of molecular weight of carrier in solid dispersion performance (Mokarram et 
al., 2010a). 
 
1.6.1.4. Structure of carriers 
The structure of the carrier is also found to exert an influence on the dissolution performance of 
SDs. According to Kapsi and Ayres (2001), API release of itraconazole-branched PEG is 2-fold 
higher than its identical composition but with linear structure PEG 20000. However, the reasons 
behind this phenomenon remain unknown (Kapsi and Ayres, 2001).  
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The hydrophilic nature of carrier has been suggested as an important factor to increase dissolution 
performance of SD of a poorly soluble API. However some researchers have suggested otherwise, 
whereby a poorer dissolution performance was observed in a relatively more hydrophilic carrier, 
i.e. PVP system as compared to the HPMC polymer (Alonzo et al., 2010, Callahan et al., 1982). 
According to study carried out by Alonzo et al. (2010), dissolution of amorphous felodipine at 37 
o
C has achieved higher supersaturation in the presence of pre-dissolved HPMC 606 and HPMCAS 
than in the presence of PVP K29-32 despite the same initial dissolution rate of both the systems as 
shown in Figure 1.11.  
 
 
Figure 1.11: The dissolution proﬁles of amorphous felodipine at 37°C in the presence of various polymers pre-
dissolved at 500 μg/mL concentration of; PVP (∆), HPMC (●) and HPMC-AS (■). Dissolution of crystalline 
felodipine at 37 °C is included as a reference (▲) (Figure reproduced from Alonzo et al., 2010). 
 
Furthermore, the achieved supersaturation state is less stable in PVP medium (less than 30 minutes) 
as compared to a stable concentration of felodipine in HPMC polymer solution for 5 hours. As a 
result, the less hydrophilic polymers (HPMC 606 and HPMCAS) with their slow dissolving rate 
has caused a higher degree of protection toward the amorphous molecule of API which 
consequently generates a better overall dissolution performance of the SD. In the same study, 
opposite effects of the tested polymers were seen on the release rate of indomethacin. In that case, 
the presence of PVP has caused a higher drug release rate and sustainability of supersaturation state 
of amorphous indomethacin as compared to HPMC 606 carrier (Alonzo et al., 2010). This implies 
the complexity of the dissolution process of amorphous pharmaceuticals.  
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Recently, Ilevbare et al. (2012) has suggested that there should be an optimal level on hydrophilic/ 
hydrophobic balance to be an effective crystal growth inhibitor (Ilevbare et al., 2012b). This could 
be achieved by the use of polymers blend carrier system. Miller and co-workers has shown that the 
use of polymer blend (HPMC and poloxamer) allows more loading of itraconazole for a faster 
release of drug from the SD system (Miller et al., 2007). Besides, addition of Carbopol
®
 974P to 
the itraconazole formulation was also attempted in the same group of researchers. The products 
obtained exhibited a greater therapeutic drug absorption and gastrointestinal stability in comparison 
to their previous investigated the SD system (HPMC and poloxamer) due to the better 
mucoadhesive properties of Carbopol
®
 974P (Miller et al., 2008b). 
 
1.6.1.5. Particle size influences 
In SD, there is no direct relationship between the particle size of the formulations and its 
dissolution performance as other factors such as agglomeration tendency and precipitation at high 
energy can occur during dissolution of the SD (Kapsi and Ayres, 2001). Conventionally, small 
particle size product will lead to greater dissolution performance of the product due to the high 
effective surface area of the product expose to the dissolution medium (Noyes and Whitney, 1897). 
Wu el al. (2009) showed that smaller particle size distribution of the piroxicam SD sample prepared 
via the co-precipitation method gave rise to a higher dissolution rate as compared to the similar 
sample prepared by spray drying method (Wu et al., 2009).  
In other studies, extensive agglomeration was reported upon dissolution of solid dispersion 
(Karavas et al., 2007, Stewart and Zhao, 2005). A decrease in the release rate of itraconazole was 
noted in the solid dispersion of small (< 240 μm) and big (381-1400μm) particle size fraction as 
compared to the intermediate size fraction (240-380 μm) which displayed the highest dissolution 
rate (Kapsi and Ayres, 2001). According to the authors, this observation is attributed to the higher 
tendency of recrystallization of smaller particles as compared with the larger fraction sized 
particles (Kestur et al., 2012). Therefore, the use of product with small particle size may be 
compromised by the extensive precipitation and higher recrystallization tendency of the product 
(Kapsi and Ayres, 2001, Kestur et al., 2012, Karavas et al., 2007). 
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1.6.1.6. Addition of surfactant 
Surfactant can be used to increase the dissolution rate of poorly soluble API (Sivert et al., 2009). It 
acts mainly by increasing the solubilisation of APIs and lowering the interfacial tension between 
solid particle of SD and dissolution medium which improves wettability of the extrudates (Zhu et 
al., 2006, Ghebremeskel et al., 2006). SD API/plasdone S630/surfactant undergoes complete drug 
release in 10 minutes. In comparison, the corresponding sample without surfactant undergoes 
complete drug release after 45 minutes. In parallel, complete dissolution time of  SD API/HPMC 
was shorten from 120 minutes to 10 minutes after the addition of surfactant into its composition 
(Ghebremeskel et al., 2006).  
It has been suggested that the concentration of surfactant should be kept lower than its critical 
micelle concentration (CMC) value when incorporating a surfactant into the composition of a SD 
system (de Waard et al., 2008). For example, a decrease in drug release rate of API/PVP 
K30/Docusate sodium was noted in the study of Ghebremeskel et al. (2007). According to the 
author, this is caused by the entrapment of API in the formed micelle as the amount of surfactant 
used had exceeded its CMC (Ghebremeskel et al., 2007). However, undesired dissolution profiles 
have also been reported in the SD products despite the used of surfactant below their CMC values 
(Dabbagh and Taghipour, 2007, Ilevbare et al., 2012a). For instance, addition of Tween 80 (a non-
ionic surfactant) (below its CMC) into the composition of SD ibuprofen-Eudragit RLPO has shown 
to reduce the dissolution rate of ibuprofen (Dabbagh and Taghipour, 2007) as compared to the SD 
formulation without surfactant. Thus, the role of surfactant in the formulation of SD remains 
ambiguous. 
 
1.6.1.7. Processing methods 
Different processing methods produce formulations with different dissolution performances. 
According to Dong et al. (2008) SD of co-precipitated (CP) API-HPMCAS revealed a faster 
dissolution rate than the HME on the same products due to higher specific surface area of the 
former system. However, intrinsic dissolution experiments have shown different results, whereby 
the HME system exhibited faster dissolution rate than the CP system due to the higher extent of 
drug-polymer interaction in CP product compares to the HME product (Dong et al., 2008b).  
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In contrast, some studies have shown the inferior dissolution performance of HME SD system. 
HME ibuprofen-PVP-CL was released slower than the same composition prepared by SD 
(Williams et al., 2005).  The authors cited that this is due to the extensive drug-polymer interaction 
as a result of solvent was used in the preparation of SD. Likewise, a study carried out by Patterson 
et al. (2008) revealed that the drug release rate of spray dried dipyridamole-PVPVA 3:7 is higher 
than the drug release rate of the corresponding system prepared by HME (Patterson et al., 2008). 
Besides, Mura et al. (2003) reported that SD naproxen prepared via co-grinding method had higher 
dissolution rate than the same samples produced via co-evaporated and kneading processes (Mura 
et al., 2003).  
 
1.6.1.8. Extreme storage conditions 
In contrast to usual expectations, insignificant changes of the dissolution profiles of SD after 
extreme storage condition such as 75% RH or high storage temperature (40 
o
C and 60 
o
C) have 
been reported (Bruce et al., 2007, Jijun et al., 2010, Gupta et al., 2002, Ghebremeskel et al., 2006). 
Bruce et al. (2007) reported similar dissolution profiles between the fresh SD and aged SD. 
According to the authors, this is mainly due to the limited growth of crystal on the surface of the 
aged tablet, as a result, the total amount of amorphous state inside the matrix remains high in 
proportion to the content of growth crystal (Bruce et al., 2007).  
Unexpectedly, the release rate of diazepam from SD PEG-diazepam after humidity storage (75% 
RH) was found to be higher than the corresponding sample desiccated at 0% RH (Jørgensen and 
Torstenson, 2008). Likewise, Gupta et al. (2002) suggested that the increase of drug-polymer 
interaction after storage is the main factor leading to the increased dissolution rate of naproxen 
after storage (Gupta et al., 2002). Jijun et al. (2010) has demonstrated that short period of high 
storage temperature or also known as “post heating” gave rise to low solution mediated 
recrystallization tendency and therefore it sustains the supersaturation state during dissolution 
(Jijun et al., 2010). However, the detail of the mechanism of the advantage from this “post heating” 
effect is still poorly understood. The inconsistent literature reports infer a need to further 
investigate the role of crystalline material in the dissolution performance of SDs. 
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1.7. Objective of this study 
As stated in Chapter 1.6, hydrophilic carrier has been frequently used in SD of immediate release 
formulations.  In this case, PVP has shown to be a great carrier in dissolution enhancement of solid 
dispersion (Biswal et al., 2009, Garekani et al., 2003, Tantishaiyakul et al., 1999). Nevertheless, 
there are limited reports available for the use of PVP in HME procedure (Lakshman et al., 2008, 
Forster et al., 2001c, Miller et al., 2008a, Miller et al., 2007, Bruce et al., 2007, Andrews et al., 
2010, Thybo et al., 2007, Ghebremeskel et al., 2006, Ghebremeskel et al., 2007) due to the 
potential of its degradation in the thermal processing (Bühler, 2005, Chokshi et al., 2005).  
However, PVP has the ability to greatly depress the melting point of API which might enable its 
usages at lower processing temperature of HME (Marsac et al., 2006, Paudel and Van den Mooter, 
2011). Besides, PVP has also been reported with good physical stabilizing effect on SD (Khougaz 
and Clas, 2000) although its stability enhancing ability could be negated by its hygroscopic nature. 
This could be resolved using the solvent/aqueous free of HME processing method. Thereby, PVP 
was investigated as the main carrier in this study. The properties and reviews of PVP polymers will 
be covered in Chapter 2.2.2 under the section of material. 
Previous sections have highlighted the possible factors that may influence the quality of amorphous 
pharmaceuticals, physical stabilization and dissolution performance (Chapter 1.6.1) of a SD based 
upon the available literatures. However, by unveiling those factors superficially without having 
thorough understanding of their impact in the SD performance does not solve the real problem. 
Therefore, considering the three broad aspects of SD development, i.e. manufacturing, stability 
issue, and formulations performance, specific objectives of this study are presented as below: 
1) To understand and explore the possible means in the use of PVP homopolymers and its 
copolymer derivative in HME application with regards to API-polymer miscibility and 
processing ability for the production of amorphous SD.  
2) To understand the stabilization factors of a PVPs-based HME SD product and to determine the 
critical storage condition that allows a longer shelf life of PVP based HME SD. 
 
3) To understand the governing factors in the dissolution performance of PVP-based physical 
mixture and PVP-based HME amorphous SD across different poor soluble APIs. 
 
4) To examine the influence of different APIs, loadings of carrier, MW of carriers and the 
addition of excipients in modulating the release profile of HME PVP-based SD formulation.  
 
5) To further understand the mechanism of release of a HME PVP-based SD for a poor soluble 
API. 
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Figure 1.12 outlines the research that will be covered in the latter part of this thesis. 
 
 
Figure 1.12: Flow chart of the development of HME PVP-based system 
 
As displayed in Figure 1.12, the feasibility of using PVP for HME processing was assessed by 
characterising the extrudates incorporating both interacting and non-interacting API models. It was 
found that APIs which do not interact with PVP polymer could not result in fully amorphous 
dispersions when it was extruded at temperatures lower than Tm of the API (Figure 1.12 (a)). 
Hence, physical stability studies of the fully amorphous systems with an interactive API 
(paracetamol) were exclusively carried out (see Figure 1.12 (b)). Then, HME interacting API-
PVPVA 6:4 products were subsequently produced and investigated for their dissolution 
performance in order to identify the possible issues that may occur during the dissolution process 
(Figure 1.12 (c)). The issues identified were further explored by studying the dissolution 
performance of HME API prepared using different PVPs carriers in various compositions (Figure 
1.12 (d)). By exploring the factors influencing these issues, a dissolution mechanism of HME PVP-
based solid dispersion is proposed at the end of this thesis. Experimental details of the investigated 
areas as shown in Figure 1.12 will be provided in the subsequent chapters. 
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Chapter 2. Material and Methods 
2.1. Introduction 
The advent of the hot melt extrusion (HME) process in the pharmaceutical field has led to its 
potential usage in the formulation of solid dispersions (SDs) (Shah et al., 2012). Based on the 
knowledge gaps that have been introduced in previous Chapter, fundamental study of the 
processing and overall performance of the HME formulations is needed. To fill these gaps, a range 
of active pharmaceutical ingredients (API) and carriers were used in develop an immediate release 
HME PVP-based formulation. In addition, a laboratory scale of HME equipment was used for the 
manufacturing of these SDs.  
In order to produce a successful HME SD system, it is very important to understand the 
characteristics and performances of the prepared HME-based systems. Several techniques were 
used to characterize the thermal and physicochemical properties of the raw materials and the 
prepared formulations. These techniques include Differential Scanning Calorimetry in standard or 
modulated mode (DSC or MTDSC), thermogravimetric analysis (TGA), hot stage microscopy 
(HSM), Fourier Transform Infrared-Attenuated Total Reflectance (ATR-FTIR), X-ray powder 
diffraction (XRPD) and laser diffraction (LD) particle size analysis. Other techniques such as 
scanning electron microscopy (SEM), atomic force microscopy (AFM) and contact angle 
measurements were also used to study surface morphology and surface properties of the prepared 
formulations.  
In this chapter, the general physicochemical characteristics and clinical usages of the applied APIs 
(Chapter 2.2) will be summarised. In addition, processing parameters of HME (Chapter 2.3) and 
the operational principles of the aforementioned characterization techniques will be introduced 
(Chapter 2.4 and 2.5). 
 
2.2. Materials 
2.2.1. Model drugs 
6 model APIs were employed in this study. Paracetamol (PCM) and caffeine (CAF) were selected 
to represent interacting and non-interacting APIs, respectively, based on the availability of 
hydrogen bond interaction with respect to PVP. The other APIs were naproxen (NAP), ketoprofen 
(KTP), indomethacin (INDO) and olanzapine (OZP); these are BCS class II compounds whereby 
their clinical therapeutic effect is limited by the dissolution process (please refer to Chapter 1.1 for 
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details of BCS classification). These APIs were selected based on their poorly water soluble nature 
in order to access their dissolution enhancement after formulating into the HME SD system. The 
clinical usages and physicochemical properties of each API model of will be introduced in the 
following sections. 
 
2.2.1.1. Paracetamol 
PCM is an antipyretic compound that is clinically used as an analgesic. Physically, PCM is 
reported to exist in 3 polymorphic crystalline forms and an amorphous form. The reported 
crystalline forms include the stable monoclinic crystal (or also known as form I PCM) and its 
metastable orthorhombic form (or also known as form II PCM) and an as yet poorly defined crystal 
Form III (Di Martino et al., 1997). Amorphous PCM is found to possess a low glass transition 
temperature at circa 25 
o
C which suggests a high tendency for recrystallization under room 
conditions (Qi et al., 2008a). This has made it as an excellent model of API for studying the 
stabilization capacity of different polymers carrier in the SD of amorphous PCM. Figure 2.1 and 
Table 2.1 present the chemical structure and other physicochemical properties of PCM, 
respectively. 
 
Figure 2.1: Chemical structure PCM 
 
Table 2.1: Physicochemical properties PCM 
PCM Properties References 
IUPAC chemical name N-(4-hydroxyphenyl) ethanmide (de Villiers et al., 1998) 
Formula C8H9NO2  
Molecular weight 151.16  g / mol (Baird et al., 2010) 
pKa 9.7  (Lemieux et al., 2010) 
Melting points Form I 169-172 
o
C  Monoclinic (Di Martino et al., 1997, 
Di Martino et al., 1996) Form II 158 
o
C Orthorhombic 
Form III 123 
o
C Undefined crystal shape 
Glass transition 
temperature 
≈ 25 oC (Qi et al., 2008a, Baird et 
al., 2010) 
Density 1.38 g / cm
3
 (Baird et al., 2010) 
Solubility Sparingly soluble in water (14 mg / ml) 
Freely soluble in alcohol 
(British Pharmacopoeia 
Commission, 2012) 
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2.2.1.2. Caffeine 
CAF is a purine derivative that usually prescribed as a central nervous system stimulant. It is a 
white crystalline powder with water sparingly soluble properties (British Pharmacopoeia 
Commission, 2012). Two polymorph forms of CAF were reported where the Form II is a stable 
form at room temperature while From I is a metastable form (Lehto and Laine, 1998). However, 
the metastable Form I was reported to be able to maintain its stability at room temperature for up to 
up to a month (Lehto and Laine, 1998, Epple et al., 1995). To date, no glassy state of caffeine has 
been reported although pseudo-glassy state of caffeine was reported by Descamps et.al. (2005). 
Figure 2.2 and Table 2.2 show the chemical structure and physicochemical properties of CAF, 
respectively. 
 
Figure 2.2: Chemical structure CAF 
 
Table 2.2: Physicochemical properties CAF 
CAF Properties References 
IUPAC chemical 
name 
1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione (Pinto and Diogo, 2006) 
Formula C8H9NO2 (Derollez et al., 2005) 
Molecular weight 194.19 g / mol (Baird et al., 2010) 
pKa 10.4 (Kang et al., 2011) 
Melting points 234-239 
o
C  (Kishi and Matsuoka, 
2010) 
Pseudo-glass 
transition 
temperature 
≈-13oC (Descamps et al., 2005a) 
Density 1.35 g/cm
3
 (Baird et al., 2010) 
Solubility Sparingly soluble in water (16.7 g/L at 25
o
C) 
Slightly soluble in ethanol (96 %) 
(British Pharmacopoeia 
Commission, 2012) 
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2.2.1.3. Naproxen 
NAP is a potent non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic 
properties. It is clinically used for the treatments of pain, fever, muscle stiffness and inflammation.   
NAP is categorized as BCS class II substance, a poorly soluble compound (Kindermann et al., 
2011). This has granted its usages as a model API for designing immediate release formulation 
(Bettinetti and Mura, 1994, Mura et al., 2002, Türk and Bolten, 2010, Zahedi and Lee, 2007).  
There is no polymorphism reported for crystalline NAP. In the glassy state, NAP has a low Tg 
which implies instability of its amorphous form. Thus, NAP is also a suitable API model for the 
study of its physical stabilization in a SD system (Paudel and Van den Mooter, 2011, Malaj et al., 
2010). The chemical structure and physicochemical properties of NAP are presented in Figure 2.3 
and Table 2.3 respectively. 
 
Figure 2.3: Chemical structure NAP 
 
 
Table 2.3: Physicochemical properties NAP 
NAP Properties References 
IUPAC chemical name  S-2-(6 methoxy-2-napthyl) propionic acid (Mura et al., 1995) 
Formula C14H14O3  
Molecular weight 230.26  g / mol (Malaj et al., 2010) 
pKa 4.5 (Corti et al., 2008) 
Melting point 155 – 156 
o
C (Mura et al., 2003) 
Glass transition 
temperature 
-6 to -3 
o
C (Gashi et al., 2009, 
Malaj et al., 2010) 
Density 1.268 g / cm
3
 (Malaj et al., 2010) 
Solubility Practically insoluble in water  
(≈ 0.027 mg / ml at 25 oC);  
sparingly soluble in alcohol 
(Mura et al., 1995) 
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2.2.1.4. Ketoprofen 
KTP is a NSAID which possesses both analgesic and antipyretic effects. Clinical applications of 
KTP include the treatments of arthritis related inflammatory pain, severe pain, musculoskeletal 
pain and stiffness. Similar to other NSAIDS, the main side effect of KTP is GI irritation. Various 
attempts were made aiming to reduce the side effect of KTP by formulating into topical 
formulations such as medicated patches, sustained release dosage forms and solid dispersion 
formulations (Kulkarni et al., 2010, Jachowicz et al., 2000, Patil et al., 2010, Yang et al., 2008).   
KTP is classified as BCS class II compound with no previous report of polymorphic forms. It 
possess a low Tg value at  circa -5 to -6 
o
C (Malaj et al., 2010). Figure 2.4 and Table 2.4 display 
both the chemical structure and physicochemical properties of KTP, respectively. 
 
 
Figure 2.4: Chemical structure KTP 
 
  
Table 2.4: Physicochemical properties KTP 
KTP Properties References 
IUPAC chemical name  (RS)2-(3-benzoylphenyl)-propionic acid  
Formula C16H14O3 (Malaj et al., 2010) 
Molecular weight 254.28 g / mol (Baird et al., 2010) 
pKa 4.6 (Sheng et al., 2006) 
Melting point 94.6-94.9 
o
C (Baird et al., 2010) 
Glass transition temperature -5.61 
o
C (Malaj et al., 2010) 
Density 1.28 g / cm
3
 (Baird et al., 2010) 
Solubility Practically insoluble in water 
Poorly soluble in pH 1.2 at 37 
o
C (0.17 
mg/ml); sparingly soluble in alcohol 
(Margarit et al., 
1994) 
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2.2.1.5. Indomethacin 
INDO is also a NSAID. It is clinically used to reduce pain as well as to relieve symptoms of 
muscular stiffness, fever and swelling by inhibiting the production of prostaglandins. INDO is 
categorized as BCS class II compound (low solubility and high permeability) in which its 
dissolution process in gastrointestinal tract is the rate limiting process in exerting its therapeutic 
effect (Nokhodchi et al., 2005). Hence, many studies have been carried out to enhance solubility 
and dissolution rate of INDO (Nokhodchi et al., 2005, Sivert et al., 2009, Yadav and Yadav, 2009). 
Crystalline INDO has been reported to exist in three polymorphic forms, α, γ, δ forms. The γ form 
is the most stable form in dry state followed by α and δ (Wu and Yu, 2006). In the γ polymorph, 
INDO exists as a dimmer where two molecules of INDO are associated with a hydrogen bond 
(Taylor and Zografi, 1997). Whereas, amorphous INDO was reported to have a Tg value at circa of 
43 
o
C (Sivert et al., 2009). Its properties as an amorphous pharmaceutical have also been widely 
studied (Greco and Bogner, 2010, Hilton and Summers, 1986, Liu et al., 2009, Taylor and Zografi, 
1997). The chemical structure and physicochemical properties of INDO are presented Figure 2.5 
and Table 2.5, respectively. 
 
Figure 2.5: Chemical structure of INDO 
 
Table 2.5: Physicochemical properties INDO 
INDO Properties References 
IUPAC chemical name  2-(1-[4-chlorophenyl carbonyl]-5-
methyl-1H-indo-3-ly) acetic acid 
(Mokarram et al., 2010a) 
Formula C19H16ClNO4  
Molecular weight 357.79 g / mol (Baird et al., 2010) 
pKa 4.5 (Mokarram et al., 2010a) 
Melting point 155 
oC (α form) 
161 
oC (γ form) 
90 
oC (δ form) 
(Baird et al., 2010, Crowley 
and Zografi, 2002) 
Glass transition temperature ≈ 43.1 
o
C (Sivert et al., 2009) 
Density 1.41  g / cm
3
 (Baird et al., 2010) 
Solubility Practically insoluble in water (< 1 
μg/ml); sparingly soluble in alcohol 
(Nokhodchi et al., 2005) 
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2.2.1.6. Olanzapine 
Olanzapine (OZP) is an atypical antipsychotic agent which is clinically applied for schizophrenia 
and bipolar mania (Odaci et al., 2009). It is categorized as BCS class II compound due to the low 
water solubility of this API. Thus, many attempts have been made to generate formulations with 
enhanced dissolution and bioavailability properties of the drug (Freitas et al., 2012, 
Krishnamoorthy et al., 2012, Krishnamoorthy et al., 2011).  
Physically, OZP is reported to exist in 60 distinct solid forms which include 56 non-solvated 
polymorphs and an amorphous phase (Bhardwaj et al., 2013). Its amorphous form is found to have 
a Tg higher than the room temperature, i.e. circa 68 
o
C. This implies that amorphous OZP could be 
stored at room temperature (25 
o
C) as the kinetics of converting to its crystalline counterpart would 
be slow and OZP amorphous phase would be stable during its storage at room temperature. Figure 
2.6 and Table 2.6 display the chemical structure and physicochemical properties of OZP, 
respectively. 
 
Figure 2.6: Chemical structure of OZP 
 
  
Table 2.6: Physicochemical properties of OZP 
OZP Properties References 
IUPAC chemical name  2-methyl-4-(4-methyl-1-piperazinyl)-
10H-thienol[2,3-b][1.5]benzodiazepine 
(Krishnamoorthy et al., 
2012) 
Formula C17H20O4S  
Molecular weight 312.43 g / mol  
pKa (s) 4.69 and 7.37 (Freitas et al., 2012) 
Melting point Form II = 194.47 
o
C (Freitas et al., 2012, 
Krishnamoorthy et al., 2012) 
Glass transition temperature 68 
o
C  
Density 1.32  g / cm
3
  
Solubility Practically insoluble in water 
(≈5μg/ml); sparingly soluble in alcohol 
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2.2.2. Carriers 
Polyvinylpyrrolidone (PVP) is a widely investigated hydrophilic carrier for the development of SD 
formulation of poorly soluble APIs (Leuner and Dressman, 2000). It is a highly hygroscopicity 
polymer (Callahan et al., 1982), for which the use of aqueous components in the processing of PVP 
based solid dispersion might be not desirable. This is because the residue of moisture could 
possibly promote the initiation of a re-crystallization process which causes physical instability of 
the solid dispersion product (Khougaz and Clas, 2000). Hence, an aqueous or solvent free 
processing method such as HME process (Khougaz and Clas, 2000) will be favourable for the 
production of a physically stable PVP-based SD. 
 As discussed in Chapter 1.5, many studies have highlighted the ability of HME to produce highly 
stable product. Therefore there is a good potential in coupling the hygroscopic PVP polymers and 
HME for the production of a physically stable end product.  
In this study, PVP polymer and its derivative co-polymer were chosen as the main carriers in the 
HME processes. The main properties of PVP polymers (including both homopolymer and co-
polymer) and its current status in the production of amorphous SD system will be introduced in the 
next few paragraphs.  
 
2.2.2.1. Homopolymer PVP 
PVP, also known as Povidone, is a class of water soluble polymers (Kibbe, 2002) which has been 
classified into a group of extremely hygroscopic substances by Callahan et al. (1982). Its 
hygroscopic nature is attributed to the electronegative groups of the carbonyl in the pyrrolidone 
structure that are able to from hydrogen bond with water. Besides, PVP is frequently incorporated 
as a hydrophilic carrier in SD formulation due to its ability to increase wetting of poorly soluble 
API and may eventually increases the bioavailability of the API (Tantishaiyakul et al., 1999, 
Khougaz and Clas, 2000, Leuner and Dressman, 2000). Figure 2.7 displays the repeating unit of the 
PVP homopolymer. 
 
Figure 2.7: Chemical structure of soluble polyvinylpyrrolidone (Kibbe, 2002) 
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There are different grades of PVP homopolymers which are grouped according to their viscosity in 
1% w/v of PVPs solution by K values via Fikentscher’s equation (Kibbe, 2002). A higher K value 
is related to a higher viscosity of the PVP solution. Table 2.7 and Table 2.8 outline the different 
grades of PVP available commercially and the relationships between their K values and molecular 
weight of PVP, respectively.  
 
Table 2.7: Grades of PVP available on the market (Kibbe 2002) 
Povidone grades Trade names Manufacturer 
Povidone K12 * Kollidon ® 12 PF,  Plasdone ® K-12 BASF, ISP 
Povidone K17 * Kollidon ® 17 PF, Plasdone ® C-15 BASF, ISP 
Povidone K25 Kollidon ® 25, Plasdone ® K-25 BASF, ISP 
Povidone K30 Kollidon ® 30, Plasdone ® K-29-32 BASF, ISP 
Povidone K90 Kollidon ® 90F, Plasdone ® K-90 
Plasdone ® K-90 D**, Plasdone ® K-90 M** 
BASF, ISP 
 ISP 
*endotoxin or pyrogen free grades; **D=densified, M=milled 
Kollidone ® is a registered trademark of BASF AG, Ludwigshafen, Germany 
Plasdone ® is a registered trademark of ISP Investments Inc., Wilmington, Delaware, USA 
 
Table 2.8: Average molecular weight (Mv) of various grades of PVP polymer which are calculated from the K-
value,  i.e. viscosity of 1 % polymer solution (Kibbe 2002) 
Povidone grades Mv calculated from the nominal K-
value 
Mv calculated from the K-value 
range given in Ph.Eur. 
Povidone K 12 3900 2600-5500 
Povidone K 17 9300 7100-11000 
Povidone K 25 25700 19300-31100 
Povidone K 30 42500 31700-51400 
Povidone K 90 1100000 790000-1350000 
 
PVP has been reported to have good stabilizing effects on amorphous pharmaceutical API. It acts 
by inhibiting and retarding the recrystallization process of API via formation of polymer network 
around the crystal surface or between the drug molecules (Tantishaiyakul et al., 1999) which limits 
the molecular mobility of the API (Khougaz and Clas, 2000, Sekikawa et al., 1978).  
API-PVP interaction such as hydrogen bond and dipole interactions between API and PVP polymer 
is reported to be another possible stabilizing effect of PVP (Tantishaiyakul et al., 1996). In this 
context, the proportion of PVP is reported to be important for the optimum hydrogen bond 
interaction between the API and PVP as orientation of the proton donor and acceptor would assist 
in the hydrogen bond interaction of API-PVP (Tantishaiyakul et al., 1996, Khougaz and Clas, 
2000). 
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Crystallization inhibition could also be linked to the anti-plasticizing effect of PVP and amorphous 
API. The incorporation of PVP may increase the overall Tg of the SD system by creating a 
thermodynamically barrier to retard the recrystallization process or alter the favourable pathway of 
recrystallization of the API (Hancock and Zografi, 1997), thus reducing the overall recrystallization 
tendency of API. 
To summarise, stabilizing effects of PVP in a SD formulation include:  
 Physical hindrance of the polymer chains folded around the API molecule which 
reduces molecular mobility of API 
 The formation of hydrogen bond interaction between the proton donors of API and the 
proton acceptors of PVP (N and carbonyl site) which reduce both the nucleation rate 
and crystal growth 
 Increase glass transition temperature, Tg and crystallization temperature (Tc
obs
) of final 
blend for better storage ability. 
 
Choice of PVP homo-polymer for HME  
In the context of HME, different grades of PVP might lead to a different result in processibility, 
dissolution, API-drug interactions and recrystallization of drug.   
In this study, high grades of PVP polymer, e.g. PVP K90, were not employed due to the potential 
problems in its processing. PVP K90 possess a high Tg values (174 
o
C) close to its degradation 
temperature (180 
o
C), which make it not suitable to be processed in HME process. Besides, PVP K-
90 solution was reported to be highly sticky (Tantishaiyakul et al., 1999). This stickiness effect 
might be worsening under the hot and solvent free process of HME method.  
Furthermore, the commercial product of high MW of PVP such as PVP K90 are commercially 
prepared via roller dried manners which resulted in non-spherical particles (Kibbe, 2002). This 
leads to the high fraction of the non-spherical particle in high MW of PVP which might affect the 
flowability of its powder form during the feeding step of HME processes (Kibbe, 2002). In order to 
get a good flowability through the HME hopper, material with spherical particles is preferred, i.e. 
PVP K30 and its lower MW polymer which are commercially prepared via spray drying method 
that give rise to spherical hollow structure (Schilling et al., 2008, S.Craig Dyar, 2007, Luker, 
2007).  
In terms of physical stabilization, a study carried out by Khougaz and Clas (2000) reported that 
PVP K90 was not superior to PVP K30 in inhibiting the recrystallization of API (Khougaz and 
Clas, 2000). According to that study, the stabilization ability of PVP polymer against 
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recrystallization of API was found to be in the order of, PVP K90 ≈ PVP K30 > PVP K17 > 
PVPVA > PVP K12 (Khougaz and Clas, 2000). Therefore, in this study, the investigated 
homopolymers were PVP K30, PVP K17 and PVP K12 with the exclusion of PVP K90 based on 
its limited advantage in a SD system and potential problematic usage in HME process.  
 
2.2.2.2. Co-polymer PVPVA 6:4 
PVPVA 6:4 is a derivative of PVP which is fabricated via free radical polymerization with 6 parts 
of N-pyrrolidone and 4 parts of the lipophilic vinyl-acetate in 2-propanol. Figure 2.8 demonstrates 
the chemical structure of the repeating unit of PVPVA (Bühler, 2005).  
 
Figure 2.8: Chemical structure of the repeating unit of PVPVA (Bühler, 2005) 
 
As with the PVP homopolymer, PVPVA 6:4 is mainly used as a binder for the production of 
granules and tablets as well as film forming agent for coating tablets (Kolter et al., 2010). It was 
produced to address the drawbacks encountered by the homopolymer PVP, namely that the 
homopolymer may be too viscous and hygroscopic for many applications. The 40% replacement of 
the lipophilic vinyl-acetate functional group makes this co-polymer to be relatively less 
hygroscopic and less viscous which has resolved some processing and handling problems of the 
homopolymer system. 
A few researchers have compared the advantages of this newly derived co-polymer (PVPVA 6:4) 
with the homo-polymers, where PVPVA 6:4 appeared to be not always advantages in the physical 
stabilization and dissolution enhancement of the SD as compared to the use of homopolymer 
carrier in a similar system (Matsumoto and Zografi, 1999, Kanaujia et al., 2010, Ghebremeskel et 
al., 2006, Ghebremeskel et al., 2007).  
Matsumoto and Zografi (1999) have found that PVPVA 6:4 did not offer additional advantages in 
physical stabilization of INDO in its SD system at 30 
o
C, 0% RH (Matsumoto and Zografi, 1999). 
Furthermore, in vitro dissolution studies carried out by Kanaujia et al. (2010) revealed that PVP 17 
is more efficient than PVPVA 6:4 in inhibiting particle growth upon dissolution (Kanaujia et al., 
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2010). Conversely, the use of PVPVA 6:4 carrier in a HME API -surfactant SD was found to have 
a faster dissolution profile than the corresponding formulation using the homo-polymer as its 
carrier, i.e. PVP K 30 (Ghebremeskel et al., 2007). The authors relate the results to the processing 
condition whereby higher Tg of the homo polymer, PVP K30, requires a much higher extrusion 
temperature which could potentially resulted in degradation of the added surfactant (Ghebremeskel 
et al., 2007). As a result, the superiority of the co-polymer PVPVA 6:4 as a HME SD carrier as 
compared to the homo polymer PVP remains uncertain. This uncertainty will be further studied by 
incorporating PVPVA 6:4 as one of the investigated carrier system in this study. Table 2.9 lists the 
main properties of PVPVA 6:4 used in this study. 
 
Table 2.9: Physicochemical properties polyvinylpyrrolidone vinyl acetate (PVPVA 6:4) 
Polyvinylpyrrolidone vinyl acetate Properties References 
Appearance White to creamy free flowing powder (Ashland, 2012) 
Molecular weight ≈ 47000 g / mol (Ashland, 2012) 
K value 26-29 (1% in water) (Bühler, 2005) 
Glass transition temperature 109 
o
C (Ashland, 2012) 
Bulk density 0.3 g / cm
3
 (Ashland, 2012) 
Solubility  Soluble up to 50% in water, ethanol, 
isopropanol, methanol up to n-butanol. 
Soluble up to 10% in methylene chloride, 
glycerol and propylene glycol 
 Less soluble in ether, cyclic, aliphatic and 
alicyclic hydrocarbons 
(Bühler, 2005) 
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2.2.3. Raw Material Sourcing  
Table 2.10 lists the APIs, polymer carriers and other materials used in this study and the sources of 
each product. 
Table 2.10:  Sources of materials employed in this study 
Categories  Substances Sources 
Model drug 
PCM Rhodia Organique, BN: 0312536 
CAF Acros Organics (New Jersey, USA)  
NAP AFINE Chemical LTD, BN: 106032456 
KTP AFINE Chemical LTD, BN: 1102017 
INDO Signa Aldrich, BN: 115k0689, Italy 
OZP BN: 20080901, China 
Carrier 
PVP K29-32  ISP (Switzerland) A.G., Lot: 05000243915 
PVP K17 ISP (Switzerland) A.G., Lot: 05000250512 
PVP K12 ISP Technologies, Inc Lot: 05000242592 
PVP S-630 (PVPVA 6:4) ISP Technologies, Inc Lot: 05000241890 
Tween 80 Sigma Aldrich, USA 
DSC calibrants 
n-Octedacane Fluka, Sigma Aldrich, USA 
Tin 
Aldrich Chemical Company, Inc, Lot: HZ02912HZ, 
USA 
Sapphire disc TA Instrument 
DSC & TGA 
calibrants 
Indium 
Aldrich Chemical Company, Inc, BN:05112MU, 
USA 
DVS calibrant Sodium Bromide Sigma Aldrich, Lot: SZBB1170V, Germany 
Salts used for 
stability test 
Sodium Chloride Fischer Scientific, UK 
Magnesium nitrate 
hyxahydrate 
Fluka, Lot: 1377926, Germany 
Calcium chloride 
BDH Laboratory supplies, Lot: A265200 124, 
England 
Potassium Acetate  Alfar Aesar, Lot: 10152143, UK 
Phosphorus pentoxide Alfar Aesar, Lot: 10160482, Great Britain 
Dissolution test 
Hydrochloride Acid Sigma Aldrich, Lot: SZBB2230V, Germany 
Sodium dihydrogen 
orthophosphate 
monohydrate 
Fischer Scientific, BN: 0936146, UK 
Sodium phosphate 
monobasic monohydrate 
Sigma Aldrich, Lot: BCBC2211, Japan 
Micro-filter cellulose 
membrane, 0.45 μm 
Sartorius Stedim biotech GmbH, Germany 
Micro-filter polyvinylidene 
fluoride (PVDF) membrane, 
0.45 μm 
MILIPORE, Lot: RISA50559K, Ireland 
 
Distilled water  
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2.2.4. Summary of the properties of raw materials 
Table 2.11 displays melting and glass transition temperatures of model APIs and glass transition 
temperatures of the amorphous PVP polymers. 
 
Table 2.11: Melting and glass transition temperatures of model APIs and carriers employed in this study 
Components Tg (
o
C) Tm (
o
C) References 
Paracetamol ≈25 Form I = 169-172  (Qi et al., 2008a, Baird et al., 2010, Di Martino et 
al., 1997, Di Martino et al., 1996) 
Caffeine ≈-13 234-239 (Kishi and Matsuoka, 2010, Descamps et al., 
2005a) 
Ketoprofen -5.61 94.6-94.9 (Malaj et al., 2010, Baird et al., 2010) 
Naproxen -6 to -3  155 – 156 (Gashi et al., 2009, Malaj et al., 2010, Mura et al., 
2003) 
Indomethacin ≈ 43.1   γ form = 161 
o
C 
 
(Baird et al., 2010, Crowley and Zografi, 2002, 
Sivert et al., 2009) 
Olanzapine 68 
o
C 194.47 (Freitas et al., 2012, Krishnamoorthy et al., 2012) 
PVP K12  120  (ISP Pharmaceuticals, 2007) 
PVP K17  126  
PVP K29-32 164  
PVPVA 6:4  109  
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2.3. Preparation of solid dispersion : Hot Melt extrusion 
Hot melt extrusion is the main manufacturing method of the SD systems used in this study, where 
the HAAKE Minilab intermeshing twin screw extruder was used to prepare all the PVP based-SD 
systems. Figure 2.9 presents the extruder used in this study, i.e. HAAKE MiniLab II Micro 
Compounder. 
 
 
Figure 2.9: Hot Melt Extruder of Thermo Scientific HAAKE MiniLab II Micro Compounder 
 
The basic principle and the processing zones of this manufacturing method have been described in 
Chapter 1.4.1. In this section, attention will be paid to the processing parameters of the HME 
methodology. There are several parameters that need to be considered in order to obtain an 
acceptable SD extrudate. These include extrusion temperature, torque, screw speed and residence 
time, which will be further discussed in each of the sub-section below. 
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2.3.1. Extrusion temperature  
The extruder is preheated prior to extrusion process (McGinity et al., 2006). The extrusion 
temperature should be monitored before each extrusion process in order to ensure the consistent 
batch to batch production of SD (Stuart J.Kapp, 2007).  
The processing temperature can influence the physical and mechanical properties of the obtained 
extrudates. Crowley et al. (2004 b) suggested that higher processing temperature promotes the 
formation of guaifenesin-ethyl cellulose SD with less porous matrix which leads to the slower 
release of guaifenesin. In other studies, attempts were made to demonstrate the influence of 
temperature control on HME extrudability. The relationship was given by the Equation (2.1),  
 
      
  
                                                                                    
 
where η is viscosity, K’ is a constant, Ea is the activation energy of melt flow, R is universal gas 
constant and T is temperature (DiNunzio et al., 2009). Based in Equation (2.1), viscosity of the 
softened polymer is dependent on the employed temperature. As the extrusion temperature 
increases, the viscosity of the molten material will decrease which results in better flowability of 
the molten material (Schilling et al., 2008).  
The commonly employed extrusion temperatures are recently reviewed and categorized into two 
regimes (Shah et al., 2012). Firstly is miscibility regime where T process > Tm of the API. In the 
miscibility regime, miscibility of the API and polymer is an important factor in dictating the 
production and stabilization of amorphous solid dispersion. Secondly is solubilisation regime 
where the T process < Tm. In this regime, the production of amorphous solid dispersion is mainly 
depending on the solubilisation of the API into the melted carrier at a certain extrusion temperature 
(Shah et al., 2012). This regime could be understood by using the well-known Noyes Whitney 
equation (2.2) (Noyes and Whitney, 1897, Liu et al., 2010). 
 
  
  
   
 
 
                                                                        
 
where M is the mass, t is the time, A is the total surface area of the drug exposed to the dissolutiom 
medium, D is the diffusion coefficient (m
2
/s), h is thickness of the diffusion layer and Cs and Cb is 
the solubility and concentration of the solute, respectively, in the bulk solution which is the soften 
molten polymer in the hot melt extrusion process. Each of the parameters in Equation (2.2) could 
be manipulated in order to achieve a better solubilisation of the API in its carrier during extrusion 
process. Longer residence time of the molten mixture could lead to a better solubilisation of the 
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API into its carrier during the extrusion process. The increase of API solubility in this regime could 
also be achieved by increase the diffusivity of the API while extrusion. For instance, additions of 
plasticizers or shear force by incorporating of kneading paddle will lead to reduction of molten 
viscosity; thereby enhance the diffusivity and dissolution of the API into its carriers. 
 
2.3.2. Screw Speed 
Control of screw speed can impact on the material viscosity by mechanical shearing and affect the 
degree of mixing of components in the HME barrel (Stuart J.Kapp, 2007, Lyons et al., 2008). 
Besides, the screw speed adjustment can also have an impact on stability of the polymer. A study 
by Crowley et al. (2002) indicated that higher screw speed during HME processing may decrease 
polymer degradation by lowering its residence time in the hot barrel. On the other hand, a high 
screw speed of HME processing may cause mechanical degradation of polymer such as melt 
fracture (Crowley et al., 2002b).  
Other researchers have also reported that good control of screw speed could increase material 
transit and reduce the residence time of material in HME barrel which bring a benefit for thermo 
sensitive components (DiNunzio et al., 2009). In that study, process modulation such as increasing 
the extrusion temperature and screw speed was carried out to access its impact on the residence 
time of the molten extrusion. To do that, a tracer dye was added to the formulation to allow visual 
determination of material transit. Figure 2.10 illustrates the relationship of screw speed, extrusion 
temperature and residence time of the molten extrusion of hydrocortison in Kinetisol
® 
studied by 
DiNunzio et al. (2009).  
 
Figure 2.10: The changes of molten residence time as a result from process modulations during HME of binary 
hydrocortisone and Kinetisol®, i.e. screw speed and extrusion temperature (adopted from reference DiNunzio et 
al. 2009) 
Material and Methods                                                                                                        Chapter 2 
 
School of Pharmacy, University of East Anglia   70 
 
According to Figure 2.10, increases in temperature and screw speed will cause reductions of 
residence time. At lower screw speeds, a more pronounced effect of temperature on screw speed 
was observed due to the higher viscosity of the material. However at a higher screw speeds, the 
residence time of the molten system was less affected due to the low material viscosity (DiNunzio 
et al., 2009). Thus, DiNunzio et al. (2009) suggested that the residence time of a molten material in 
a HME barrel could be determined by manipulating the screw speed and extrusion temperature. 
 
2.3.3. Torque 
Motor load also known as torque is generally described as a measure of resistance registered by 
materials to a processing system. These resistances include the viscosity, elasticity, shear 
sensitivity or temperature sensitivity as indicated by the response of a material to its thermal profile 
during processing (Martin, 2007). 
In the case of HME, torque is a measure of resistance exerted by melt viscosity in the barrel which 
represents the rate of movement of polymer chains relative to each other, i.e. chain flexibility (Wu 
and McGinity, 2003). It could also be used as an indicator for batch differentiation or influence of 
additive such as plasticizer and lubricant on drug-polymer blend (Verreck et al., 2005, Verreck et 
al., 2006b). An unsteady torque may indicate inconsistent feeding or arching at the feed throat or 
inadequate speed control (Stuart J.Kapp, 2007). Therefore monitoring the torque is critical for 
identifying processability as well as quality control of the system during processing. The 
relationship between torque and other processing conditions such as extrusion temperature and 
screw speed was also studied by DiNunzio et al. (2009). Figure 2.11 shows the changes of torque 
as a result from process modulations (screw speed and extrusion temperature) during HME of 
binary hydrocortisone and Kinetisol
®
.  
 
Figure 2.11: The changes of torque as a result from process modulations during HME of binary hydrocortisone 
and Kinetisol ®, i.e. screw speed and extrusion temperature (adopted from reference DiNunzio, et al. 2009) 
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According to Figure 2.11, as the temperature increases, material flow was improved due to a 
reduced viscosity of the melt. However, increases in screw speed result in the increase of torque 
values.  Since the value of torque is proportional to viscosity, the increment of this parameter can 
be correlated with the non-Newtonian behaviour of the molten material (DiNunzio et al., 2009). 
Thus, the flow characteristic of the material within the extruder is a function of extrusion 
temperature and rotational speed. 
For the ease of processing, the torque value should not be too high. Thus, in the design of hot melt 
extrusion equipment, a monitoring device is set up with an alarm or interlock to create alarming 
alert and automatic shutdown of extruder when the maximum torque is achieved (Verreck et al., 
2006b, Dreiblatt, 2007a, Schilling et al., 2010). 
 
Parameter used in this study 
In this study, the extrusion temperatures used were adjusted based on the Tm and Tg of the APIs 
and polymers. Due to the concern of PVP degradation, the overall extrusion temperature of not 
more than 180 
o
C was used. The screw speed of 100 rpm was kept constant for all the prepared 
formulations.  
During the extrusion process, torque was recorded as a dependent variable of the resistance of flow 
and viscosity of the molten material. The obtained extrudates were transported out from the die 
through a conveyer belt (as shown in Figure 2.12), cooled in ambient condition and then collected 
into sample tubes.  
 
Figure 2.12: Conveyer belt used to collect the extruded material from the HME die 
Conveyer belt 
Motor to control 
speed of the belt 
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The HAAKE Minilab twin screw extruder enables the circulation of molten materials in the hot 
barrel before extrusion of the molten mass on activation of the extrusion valve. Therefore, the 
residence time of the molten mass could be controlled. Table 2.12 lists the parameters used for the 
production of HME systems.  
Table 2.12: Parameter used in the production of HME systems 
Formulations (HME % w/w API-
carrier) 
Tm (
o
C) Tg (
o
C) 
Extrusion 
temperatur
e (
o
C) 
Screw 
speed 
(rpm) 
Residenc
e time 
(minutes) 
HME 20-70% PCM PVP K29-32 169-172 164 120 100 5 
HME 20-50% PCM PVPVA 6:4 169-172 109 120 100 5 
HME 10-20% CAF PVP K29-32 234-239 164 155 100 5 
HME 10-20% CAF PVPVA 6:4 234-239 109 180 100 5 
HME 30-50% PCM PVP K12 169-172 120 160 100 5 
HME 30-50% PCM PVP K17 169-172 126 160 100 5 
HME 30-50% PCM PVP K29-32 169-172 164 160 100 5 
HME 30-50% PCM-PVP PVPVA 6:4 169-172 109 160 100 5 
HME 30% KTP PVPVA 6:4 94.6-94.9 109 120 100 10 
HME 30% INDO PVPVA 6:4 161 109 160 100 10 
HME 30% OZP PVPVA 6:4 194.47 109 180 100 10 
HME 10-40% NAP PVPVA 6:4 155 – 156 109 150 100 10 
HME 30% NAP PVPVA 6:4+ 2% 
Tween 80 
155 – 156 109 150 100 10 
HME 30% NAP PVPVA 6:4 + 10% 
Tween 80 
155 – 156 109 150 100 10 
HME 30% NAP PVP K12 155 – 156 120 150 100 10 
HME 30% NAP PVP K17 155 – 156 126 150 100 10 
HME 30% NAP PVP K29-32 155 – 156 164 150 100 10 
* Tm values of model drug were summarised from literature. Please refer to the references of model drug in section 2.2.1 
(Table 2.1-2.6). Values of Tg were obtained from the suppliers (ISP Pharmaceuticals, 2007). 
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2.4. Characterization techniques 
2.4.1. Differential scanning calorimetry  
Differential scanning calorimetry (DSC) is a technique used for measuring the energy needed in 
establishing a zero temperature different between the sample and its reference material. It has been 
used widely in analysing thermal properties of pharmaceutical materials. Both qualitative and 
quantitative information could be extracted such as physical and chemical changes of the tested 
components which involving endothermic, exothermic processes and heat capacity changes of the 
components upon temperature change (Craig and Reading, 2007).  
There are two type of DSC instruments i.e. power compensation DSC and heat flux DSC. In power 
compensation DSC, the temperature of the sample and reference are made identical by adjusting 
the power input to two separate furnaces. The change of the power input is a measure of changes in 
heat capacity or enthalpy of the sample in relative to the reference. On the other hand, heat flux 
DSC uses only one furnace. In the furnace, sample and the reference are placed on separate 
crucibles linked by a low resistance heat flow path. The temperature between the sample and the 
reference are made identical by supplying heat flux (Bhadeshia, 2002). By using the heat flux DSC, 
any thermal event of the sample that causes the use of heat or release of heat will be recorded as a 
function of heat flux supply in maintaining an identical temperature between the sample and 
reference. The differential heat flux for this processes are monitored by a thermocouples and 
recorded as a function of enthalpy and heat capacity changes.  
In a conventional DSC, the temperature of the furnace is raised and lowered in a linear fashion. 
However, there will be difficulties in data interpretation when multiple thermal events of a multi-
components system occur at a same temperature in the scanning by using the linear temperature 
programmer of DSC. To solve the complex interpretation, modulated DSC (MTDSC) was 
introduced which will be further introduced in the next paragraphs.  
In MTDSC, a sinusoidal modulation of temperature program is overlaid on a linear temperature 
ramp (Gill et al., 1993). With the modulation, the heating rate is no longer constant but varies in a 
periodic fashion (modulated) of its minimum and maximum values. However, the average heating 
rate (which is also termed as underlying rate) is the same as conventional DSC. The underlying 
heating rate, period and amplitude of the superimposed temperature wave determine the range of 
modulation. The heat flow effect of these parameters is represented by Equation (2.3) (Gill et al., 
1993): 
  
  
  
  
  
[          ]                                                               
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where dQ/dt = heat flow out of the sample, dT/dt = heating rate, Cp = heat capacity of sample, t = 
time, T= temperature, f’ (t,T) = thermodynamic heat flow component and f(t,T) = kinetically-
limited heat flow. From the equation, heat flow components of MTDSC are divided into two. The 
first term of the right hand side is the function of heat capacity and rate of temperature change 
which is also known as reversing signal. The heating rate dependent thermal event will be revealed 
in this part of the signal such as glass transition event. The second term is a function of absolute 
temperature and time. For absolute temperature dependent transition, once initiated cannot be 
reversed by cyclic modulation of temperature change and is also known as non-reversing signal. 
These transitions include enthalpic relaxation, crystallization, evaporation, decomposition and cure 
(Gill et al., 1993). 
In the current study, the thermal properties of the raw materials and formulations were mainly 
studied by using modulated DSC (Q2000, TA Instrument, Newcastle USA. Samples were weighed 
accurately (1 to 3 mg) into pinhole aluminium pans (Perkin Elmer) to allow the removal of 
excessive moisture in the sample in order to minimize influence of water content on the sample’s 
properties. Temperature and cell constant calibration of DSC were performed using indium, n-
octedacane and tin. Heat capacity in modulated mode was calibrated with an aluminium oxide 
sapphire disc provided by TA instruments. The heating rate was 2 
o
C per minute, 60 sec for the 
modulation period and ± 0.318 
o
C for the amplitude or otherwise specified. Tg of the samples were 
determined from half height of the glass transition event (please refer to Figure 1.2 for half-height 
of Tg) using the TA propriety software, i.e. Universal Analysis. High-speed standard mode DSC 
(Q2000, TA Instrument, Newcastle USA) was also used; the details of this method will be covered 
in Chapter 4. 
 
2.4.2. Thermogravimetric Analysis  
Thermogravimetric analysis (TGA) measures the changes of sample weight caused by the chemical 
or physical processes as a function of temperature or isothermally as a function of time (Craig and 
Reading, 2007). In the pharmaceutical field, it is often used to detect dehydration, water content 
and chemical decomposition of solid drugs and pharmaceutical excipients. In the current study, 
TGA were mainly used for the detection of thermal decomposition temperature as well as water 
content of raw material and solid dispersion samples.  
All TGA experiments were carried out using TGA Q5000 (TA Instruments, Newcastle, USA) to 
detect the mass changes due to either water loss or decomposition of samples. To effectively 
identify moisture content, samples were heated from room temperature up to 100 
o
C at heating rate 
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of 10 
o
C per minute and held isothermally for at least 15 minutes before continuing the heating 
ramp up to 300 
o
C. 
 
2.4.3. Attenuated total reflectance-Fourier transfer Infrared 
Infrared (IR) spectroscopy is a reliable and well-recognized technique for characterizing and 
analysing a wide range of solids, liquids and gases. When a sample is exposed to an infrared beam, 
the electric field of the radiation will interact with the electric field generated by the varying dipole 
of molecules in the sample. These vibrations of molecules (symmetric and a symmetric stretching, 
bending, rocking, twisting and wagging mode) interact with an electromagnetic wave that matches 
their frequency of oscillation. Consequently, different functional groups of a molecule absorb the 
different characteristic frequencies of IR radiation (Sherman Hsu C.P., 1997). The IR radiation, 
after passing through the sample, is detected and transformed by the spectrometer into a spectrum 
which reflects the molecular structure. IR information is generally presented in transmittance or 
absorbance intensities at y-axis versus wave number as the x-axis.  
Due to the complication of sample preparation (especially solid sample) in the conventional IR 
instrument, an attenuated total reflectance (ATR) accessory was utilized. The ATR operates by 
measuring the changes in a totally internally reflected the IR radiation when the beam is exposed to 
the sample. The reflectance radiation protrudes only few microns (effective path length) beyond the 
surface of the crystal (approximately 6 μm) (Larrabee and Choi, 1993). Thus, it is important to 
have a good contact between the sample and the surface of ATR crystal. This method has reported 
to be useful due to its non-invasive sample preparation, the small amount of sample required,  fast 
sample preparation and measurement as well as possibility of interfacing with other instruments 
(Oberg and Fink, 1998, Vrettos and Meuse, 2009).  
In this study, attenuated total reflectance-Fourier transfer infrared (ATR-FTIR) was mainly 
employed to analyse the difference in the peak positions of certain chemical functional groups 
between the raw API, PM sample, the freshly prepared HME samples and aged HME samples. 
Infrared spectra of these samples were recorded in the wavenumber range of 4000 to 500 cm
-1
 
using IFS-60/S Fourier transform infrared (Bruker Optics, Conventry, UK) with an ATR accessory 
fitted to a heating system (SPECAC, Orpington, UK). Samples were scanned with a total of 64 
scans at resolution 2 cm
-1
. Spectra were analysed using OPUS software (version 6.0, Bruker Optics, 
Conventry, UK). 
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2.4.4. Hot stage microscopy 
Hot stage microscopy (HSM) is an optical microscopic method fitted with hot stage accessory. It is 
often used as a complementary tool to provide corroborating data on melting points, 
recrystallization, volatilizations, solid-solid transformation, decomposition and etc (Craig and 
Reading, 2007). During the thermal events, the sample is observed as a function of temperature and 
time and the appearance recorded by a high resolution color video camera via collection of 
successive frames. 
In this study, polarized light was used to discriminate the crystalline material via birefringence 
from the amorphous counterpart which does not reveal birefringence. HSM were performed with 
heating rate of 10 
o
C per minutes from room temperature up to the thermal event of interest or 
otherwise specified. The investigated material was placed in the hot stage accessory and placed on 
the microscope stage. Without the hot stage accessory, it could also be used as an optical 
microscope, in which only the photography or video microscopy was utilized for the collection of 
videos or images. 
 
2.4.5.  X-ray Powder Diffraction 
X-ray is a short wavelength of electromagnetic radiation. It is mainly used for determining the 
atomic or molecular structure of a crystalline material and quantification of amorphous content in 
partially crystalline mixture (Du et al., 2011).  
A solid matter can be described as crystalline when the molecules are arranged in regular manner 
by repetition in three dimensions. When an X-ray is exposed to an atom, electron surrounded the 
atom will be oscillated in the same frequency as the incoming beam. For a crystalline matter, due to 
regular pattern of the atoms, there will be constructive interference specific to the way of atom 
arrangement within the crystalline structure. The well-defined X-ray beam will leave the sample at 
various directions and intensities over a range of incident angle brought about by the periodic 
arrangement of the atoms / planes. The positions of the diffracted peaks are expressed as Bragg’s 
angle, θ and interplanar spacing dhkl between the diffraction planes. These parameters could be 
defined by Bragg’s law according to Equation (2.4), 
                                                                                     
where λ is the wavelength of the diffracted X-ray, d is the interplanar spacing of the diffracting 
planes and θ is the incidence angle of the X-ray beam (Bandyopadhyay et al., 2005). Conversely, 
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the atoms of amorphous are randomly distributed or disorder. There is no constructive interference 
and no resultant energy leaving the sample. Hence, no diffracted peaks would be expected.  
There are two types of X-ray instruments, one being single crystal diffractometer and the other is 
powder diffractometer. Single crystal diffractometer is usually used to elucidate the molecular 
structure of a compound; whereas the powder application (XRPD) is used for “finger print 
identification” of a solid matter. Since there is no long range three-dimensional molecular order 
associated with amorphous system, X-ray Powder diffraction was applied in this study to 
distinguish crystalline solid from amorphous solid (Scintag Inc, 1999). 
X-ray Powder Diffraction analysis of raw materials, PMs and ground HME extrudates were 
performed with a XRPD, Thermo ARL Xtra model (Switzerland) equipped with a copper X-ray 
Tube (1.540562 Å). Samples were pressed into a sample holder to generate a flat and smooth plane 
surface. The samples were then exposed to an X-ray beam with voltage of 45 kV and a current 40 
mA. All XRPD experiments were performed at step scan of 0.01
o
 and 1 second for every step. The 
scanning range is based on the characteristics peaks of the APIs employed in different studies 
which will be further detailed in each chapter. 
 
2.4.6.  Scanning electron microscopy  
Scanning electron microscopy (SEM) is a microscopic technique utilizing electron beam in 
collecting the micrograph. The electron beam was generated via heating a ‘hairpin’ tungsten 
filament until the electrons are emitted in the electronic optic column. Then the electrons are 
accelerated at 5-20 kilo voltage at typical working distance of 10 mm. At the same time, the 
electrons was also demagnetized and focused into a finely focus beam which bombards the sample. 
While the traverses of the primary electrons beam, secondary electron emitted from the sample 
surfaces is collected by the electronic console and then figured into the SEM image of the samples  
(Welton, 1984). 
 
The SEM instrument employed in this study was JSM 5900LV Field Emission Scanning Electron 
Microscope (Jeol Ltd, Japan) fitted with a Tungsten filament. It was used to investigate surface 
morphology of the freshly prepared sample, aged sample and the changes of sample appearance 
after dissolution processes.  The fresh of aged extruded were cut into 3 - 4 mm. The cut sample was 
then attached to a SEM specimen stub (carbon). This step was carried out carefully with disposable 
gloves and tweezers in order not to introduce artefacts by scrapping the surfaces to be examined. 
Other samples such as raw API powder and PM of API-polymer were attached directly to the 
specimen stubs by double-sided tap. All the samples were coated with gold (thickness of 15nm) by 
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a Polaran SC7640 sputter gold coater (Quorum Technologies, city, country) prior imaging. After 
coating, the samples specimens were imaged in the highly vacuumed sample chamber equipped 
with electron optic column and electronics console. 
 
2.4.7. Laser diffraction for particle size analysis 
Laser diffraction is a widely used technique in measuring particle size of different physical forms 
of material such as powder, suspension and emulsion. It is a fast and precise technique for the 
measurement of a wide range of particle size.  
When a sample passes through a broadened beam of laser light, particles scatter the light at an 
angle onto a Fourier lens. The diffracted laser light data of the analysed particles is a representation 
of particle size distribution. In this case, the intensity of the scattered light is inversely proportional 
to the particle size, i.e. large particles scatter the incident light at smaller angles with higher 
intensities while small particles scatter the incident light at wider angles with lower intensities. 
Figure 2.13 reveals the example of scattering off a spherical particle. 
 
 
Figure 2.13: example of scattering off a spherical particle (HORIBA Scientific, 2013) 
 
Laser diffraction measurement provides only particle size in an equivalent to volume diameter 
which assumes all particles to be spherical. Thus, this measurement did not reveal the particle 
shape of the scanned sample (Tinke et al., 2005). Moreover, this technique is generally used to 
detect particle larger than 1 μm due to the maximum angular intensity pattern of about 45 degrees 
(Tinke et al., 2008).  
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In this project, laser diffraction is used to monitor the particle size changes of the dissolving solid 
powder during dissolution. The collected sample solutions from dissolution bath was transferred 
into the quartz cuvette and measured by using Sympatec HELOS/BF (HI146, TYPE: cuv-50 mL / 
US, Germany) particle size analyser. Each sample was scanned 3 times using a lens of size 
detection range of 0.25 / 0.45 to 87.5 μm. 
 
2.4.8. Contact angle measurement 
Contact angle of a substance is a critical property for the evaluation of adhesion and wettability of 
the substance. In principle, the higher the contact angle, the lower the adhesion and wetting 
properties of the solid surface. The theoretical description of the contact angle stems from the 
relative balance between three different components of interfacial energies, i.e. γlv, γsl and γsv as 
shown in Figure 2.14 (Tavana and Neumann, 2007).  
 
Figure 2.14: Schematic of a sessile drop, contact angle (θ), and the three components of interfacial tensions, i.e.  
γlv: liquid-vapor, γsv: solid-vapor and γsl: solid-liquid. 
 
γsv is the solid–vapor interfacial energy, γsl is the solid–liquid interfacial energy, and γlv is the 
liquid–vapor interfacial energy (γlv is also known as the surface tension). The contact angle, θ is 
described by the three interfacial components through Young's Equation (2.5) (Young, 1804). 
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Several methods have been introduced to assess the contact angle of a powder system such as 
Washburn's method and Wilhelmey plate technique. In Washburn's method, the measurement of 
the powder wetting is not straight forward as it could be potentially influence by the powder 
density, size and porosity of the powder bed (Dahlberg et al., 2008). The Wilhelmey plate 
technique is operated by gluing the powder onto the Wilhelmey plate and measuring the contact 
angle. However, in that method, the sample preparation can pose a major variable and the effect of 
the glue is not clear (Buckton et al., 1991, Dahlberg et al., 2008).  
Hence, in this study, an indirect contact angle measurements in studying the wetting properties of 
the PM and HME systems were assessed macroscopically via drop shape analysis performed on a 
flat surface compressed from the powder materials (Swanepoel et al., 2000, Dahlberg et al., 2008). 
This method has been reported to be the most widely used method in assessing wetting properties 
of powder solid (Buckton et al., 1991). Besides, it was also descried to be suitable for a reasonable 
wetting assessment of powdered system (Chibowski and Perea-Carpio, 2002, Chokshi et al., 2007, 
Dahlberg, 2010, Dahlberg et al., 2008)  
In this study, the drop of medium (liquid phase) was saturated with the corresponding API with 
respect to the analysed surface of solid phase so that the liquid phase could not further disolve the 
API on the surface of the solid phase. This is performed to avoid any possible alteration of the 
wettability study due the API dissolution into the liquid phase of the drop.  
Surface tension of the liquid phase was determined via pendent drop measurement. Both the 
contact angles and surface tension measurements were determined with Theta Optical Tensiometer 
(zoom lens 0.7 magnifications) (Biolin Scientific, Finland). A liquid dispenser holder with manual 
control was used to create a drop. Then, OneAttension software was used to analyse the surface 
tension Young-Laplace surface properties mode. The changes of the surface tension were recorded 
up to 120 seconds at 1 frame per second.  
In the contact angles measurement, a drop of the liquid phase which was pre-saturated with 
corresponding APIs was deposited on the flat surface of the compressed tablet Changes of the 
contact angles at the first 120 seconds were recorded as a video at 6 frames per second for first 10 
seconds and 1 frame per second subsequently. All measurements were performed at 25 ± 0.1 
o
C 
and 45% RH. All measurements were performed at 25 ± 0.1 
o
C and 45% RH. 
The result of contact angle between a solid and liquid substances can be translated into surface free 
energy (SFE) information of the solid liquid interfaces by performing mathematical calculation 
such as using Young’s equation (Żenkiewicz, 2007). SFE of a pharmaceutical API may be altered 
when an excipient is absorbed onto its surface. In this study, interfacial energies between the SD 
and dissolution medium were determined by using Fowkes method due to its convenient when 
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applied to polymeric system (Żenkiewicz, 2007). According to Fowkes, SFE of a solid or liquid is 
a sum of the free energy of the independent components within the solid or liquid associated with 
their specific interactions i.e. dispersion component and remaining non-dispersive component. At 
the interface between the two substances, Fowkes assumed that only the dispersive interaction 
appears. Thus, the assumption of applying this method is that this method is based on the 
independence and additivity of the dispersion and polar interactions, respectively (Żenkiewicz, 
2007). Details calculation of interfacial energies using the Fowkes method was conducted in 
Chapter 6.2.6, Equation (6.1) to (6.4). 
 
2.4.9. Atomic Force Microscopy  
Atomic Force Microscopy (AFM) is a near-field technique which was used to analyse surface of 
solid or liquid up to atomic scale. The concept behind this technique is the generation of images of 
surfaces by measuring the physical interaction between a sharp tip / probe and the surface of a 
sample. The origin of the physical interactions of the tip / probe to the examined surface could be 
ionic repulsion, Van der Wall forces, capillary, electrostatic or magnetic force, as well as elastics / 
plastic deformation. These interactions is monitored by the tip / probe attached to a soft cantilever 
which acts as a spring, and measuring the bending (or deflection) of the cantilever of the tip / 
probe. AFM could be operated in various mode bases on the requirement of the experiment. These 
comprise contact mode and non-contact mode, i.e. tapping mode. 
In this study, AFM was used to study the surface roughness of compacted tablets whereby the 
tablets were prepared using an IR press at 5 tons for 1 minute. The investigation of these surfaces 
was to ensure the comparable surfaces between the prepared tablets which will be utilized for 
contact angle measurement. AFM images were recorded by using a Veeco Caliber scanning probe 
microscope head (Veeco, CA) in contact mode. The scan areas for all the AFM images were 50 μm 
x 50 μm with a resolution of 512 pixels and scan rate of 0.5 Hz.  
 
2.5. Dissolution studies  
Dissolution studies are important for formulation development processes. Although there are 
limitations associated with in vitro dissolution process, when a dissolution test was performed 
correctly, it can provide valuable information and in vivo correlation regarding the bio-performance 
of a dosage form (Swanepoel et al., 2000). Moreover, it can also be used as a quality control tool in 
monitoring batch - to - batch consistency and manufacturing deviations (Azarmi et al., 2007). 
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2.5.1. The theory of dissolution 
Dissolution of a solid matter is a process when the solid enter into a medium and dissolve into the 
medium. The dissolution of this solid matter is according to the relative affinity between the 
affinity of ‘solid molecule - solid molecule’ in the solid substance and the affinity of ‘solid 
molecule - solvent molecules’ in which, the high affinity between the solid molecule and solvent 
molecules of a dissolution experiment will promote the dissolution process (Aulton, 2007).  
From a broad view, two steps are involved in dissolution of a solid surface. Firstly, drug molecules 
detach from the solid surface. Secondly, the detached molecule will diffuse through a diffusion 
layer adjacent to the solid surface into the bulk of the dissolution medium (Sugano et al., 2007). In 
most cases, step 1 is much faster and step 2 is the dissolution rate limiting step. The rate of drug 
diffusion can be described by Fick’s first law which stated that the rate of change in the 
concentration of a dissolved material with time is directly proportional to the concentration 
between the two sides of diffusion layers as shown in Equation (2.6), 
 
  
  
                                                                                   
 
where C is the concentration of the solute in solution at any time point of t, k is the rate constant 
and ΔC is the difference between the concentration of the solution at the solid surface (C) and the 
bulk of solution (Cb). When the dissolution process of the solute at surface of the dissolving front 
approaches equilibrium, the solution in contact with the solid will be saturated and achieving a 
concentration where C=Cs (solubility of the solute). At this time, the concentration in the bulk, Cb 
will be the determining factor for the movement of solute. If Cb << Cs, dissolution will continue to 
occur while molecules move from the solid surface to the bulk.  
 
Dissolution mechanism of solid dispersion 
Many have shown the dissolution enhancement of poorly soluble drug by the production of SD 
system. However, as mentioned in Chapter 1.6.1, a few studies have the reported unpredictable 
dissolution performance of the obtained SDs in water soluble polymer. This might be due to the 
poor understanding of the mechanism underlying the dissolution process of the API in a SD 
system. Craig (2002) has reviewed and suggested possible mechanism for dissolution process from 
solid dispersion in water soluble polymers. Figure 2.15 illustrates the suggested dissolution 
mechanism of SD in water soluble polymer by Craig (2002). The proposed mechanism is largely 
determined by the solubility of the solid in the carrier system. 
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Figure 2.15: : Possible mechanism as proposed by Craig 2002 (a) Carrier-controlled dissolution, whereby the drug 
dissolves into the concentrated carrier layer prior to release and (b) drug-controlled dissolution whereby the drug 
is released effectively intact into the dissolution medium. Large spheres represent un-dissolved drug particles, 
small spheres partially dissolved drug particles, and shaded regions correspond to hydrated material (Figure 
adopted from Craig 2002). 
 
Pathway (a) involves significant dissolution of the solute in the polymer-rich layer upon wetting of 
the polymer carrier system. Thus, there is insufficient time for the particles to be released intact 
into the medium. Consequently, diffusion of the solute is highly dependent to the release of the 
polymer into the bulk of the medium. Dissolution mechanism of this system is  therefore termed as 
‘carrier controlled’ release (Craig, 2002). On the other hand, in pathway (b), there is limited 
dissolution effect of the drug in the diffusion layer of the carrier. Consequently the drug will be 
released in the medium as solid particle which was termed as ‘drug controlled’ mechanism. With 
that, properties of the drug (such as size, physical form and etc) will be significant in final 
dissolution performance of the SD formulations. However, in the latter pathway, dissolution 
improvement could still be realized due to the improved wetting, de-aggregation and reduction of 
drug particle size that gives rise to higher effective surface area for the dissolution process. 
 
2.5.2. Factors Affecting the Dissolution Rate 
The factors affecting the in vitro dissolution rate of a formulation are indicated in the Noyes-
Whitney Equation (2.2). These factors include surface area of un-dissolved solid, solid solubility of 
the sample in the dissolution medium (Cs), concentration of solute in the bulk solution at time t 
(Cb), thickness of the diffusion layer (h) and diffusion coefficient of the solute in the dissolution 
medium (D). 
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2.5.2.1. Surface area of un-dissolved solid 
According to Equation 2.2, dissolution rate of a solid is directly proportional to the surface area of 
the solid. Particle size reduction to about 3 – 5 μm is suggested as a useful strategy in enhancing 
the dissolution rate of poorly soluble drug with a conventional example of griseofulvin (Hӧrter and 
Dressman, 2001).  
Solid dispersion is claimed to provide large surface area for dissolution process due to the 
dispersion of drug at molecular level (Kapsi and Ayres, 2001, Dong et al., 2008b, Biswal et al., 
2009). However, the available surface area will be reduced when agglomeration of the solid 
dispersion powder occurs which will affect the formulations performance significantly. Thus, the 
available surface area for dissolution process is highly influenced by dispersibility of the powdered 
solid in the dissolution medium.  
 
2.5.2.2. Solubility of solid in the dissolution medium (Cs) 
Solubility of an API is depending on the presence of excipients or additive that can induce complex 
formation or solubilisation as well as ionization of the API. Other factors such as temperature, the 
nature of dissolution medium and the solid form in terms of whether it is amorphous or crystalline 
are also important in affecting the dissolution rate of a system by the solubility effect. 
 
2.5.2.3. Concentration of solute in the bulk solution at time t (Cb) 
Assuming that other factors of dissolution are fixed, the concentration of solute in the bulk solution 
is highly affected by the volume of the dissolution medium. When the medium is small, Cb will be 
building up to an extent where Cb is approaching Cs, hence no dissolution occurred (Cs=Cb). For an 
effective dissolution study, Cb is usually negligible with respect to Cs by using large volume of 
dissolution medium which is termed as sink condition. According to USP (US pharmacopeia), sink 
condition is when the volume of medium used is 3 times more that the volume of medium used to 
achieved saturation of the solute. 
 
2.5.2.4. Thickness of diffusion layer (h) 
Thickness of diffusion layer will determine the rate of movement of the solute molecule across the 
carrier into the bulk medium. This parameter can be affected by agitation of the medium which is 
mainly determined by the speed of stirring rate, size and position of the stirrer and viscosity of 
medium used during in vitro dissolution process. 
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2.5.2.5. Diffusion coefficient of solute in the dissolution medium (D) 
According to Stoke equation, the diffusion coefficient (D) of a solute is depending on the variables 
presented in Equation (2.7),  
  
  
    
                                                                              
 
where k is the Boltzmann constant, T is temperature, η is the viscosity of the dissolution medium 
and r is the radius of the diffusing molecules. As diffusion rate of an API increase in the carrier, the 
dissolution rate of the API in the system will be also increased. However, in a SD system, this 
effect might be irrelevant when the solute is highly soluble in its polymer carrier.  
According to Equation (2.7), when a solute is significantly dissolved in its polymer carrier, its 
diffusion in the polymer is too slow as the r is small at a molecular level, thus the overall release 
would be irrelevant to the diffusion rate of the API in the carrier system but highly dependent on 
the release rate of the polymer carrier which is shown as a carrier controlled system as mentioned 
in the dissolution mechanism proposed by Craig (2002) in Figure 2.15. 
 
2.5.3. Preparation of Dissolution Media 
In this study, dissolution medium of 0.1M HCl were prepared by transferring 900 ml of 37% w/w 
HCl into 10 Litre of container prefilled with 5 L of distilled water. A further amount of distilled 
water was added up to 10 Litre and the mixture were stirred to achieve homogenous solution. The 
final pH was checked using a calibrated pH meter, pH was adjusted when necessary. 
 
2.5.4. Dissolution method 
Dissolution experiments were carried out using BP Apparatus II (D8000, Copley Scienfitic Ltd., 
Nottingham, UK) paddle method. Each vessel was filled with 900 ml dissolution medium. The 
temperature was set at 37 ± 0.5 
o
C at 50 rotations per minute. At predetermined time interval, 10 ml 
sample was withdrawn from each vessel using a 10 ml syringe.  The samples were filtered through 
a 0.45 μm membrane filter. The collected solution samples were measured at the wavelength of 
maximum absorbance (λmax) of each API. All dissolution experiments were carried out in triplicate. 
The obtained results were presented in percentage of cumulative API release versus time profiles. 
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2.5.5. Ultraviolet-Visible Spectrophotometer (UV-VIS) 
Molecules can absorb energy in the form of ultraviolet or visible light to excite the electron within 
to higher molecular orbital. This enables the measurement of an analyte of interest by using 
UV/VIS. Ultraviolet absorbance of a substance could be described by Beer-Lambert law, Equation 
(2.8),  
                                                                                            
whereby A is the light absorbance of molecules at a concentration, c, l is the path length of UV and 
ε is the molar absorptivity which is also known as the extinction coefficient. To simplify, a path 
length of 1 cm is usually used to calculate the absorbance and molar absorptivity. The Beer-
Lambert law applies when absorbance of sample increases linearly with the concentration of the 
analyte.  
To quantify the API content in a medium sample, a Perkin-Elmer Lambda XLS spectrophotometer 
(USA) was used. Each sample was scanned at the wavelength of maximum absorbance, λmax 
specified for each API which was identified to be devoid of any interference from the added 
excipients. 
Calibration curves were constructed by using Beer Lambert plots for each drug in the 
corresponding medium or buffer. API was weighed accurately in a weighing boat then transferred 
into a dry volumetric flask. Then the solution was made up to the desired volume with known 
concentration of API. The API was dissolved by stirring for at least 48 hours. Once the API 
solution (stock solution) had been prepared, 1, 2, 3, 4, 5 ml aliquot of the stock solution were 
transferred into separate 10 ml volumetric flasks for dilution. A further amount of medium was 
added to each volumetric flask to obtain a series of 10 ml solutions. The series of solutions were 
analyzed with a Perkin-Elmer Lambda XLS UV/VIS spectrophotometer (USA). The average 
absorbance readings were plotted against the respective API concentrations to get a calibration line. 
Each point in the calibration line was an average value of three measurements.  
Figure 2.16 to 2.19 display the calibration curve of the all poorly soluble APIs (NAP, KTP, INDO 
and OZP) in their respective dissolution media.  
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Figure 2.16: Calibration curve of NAP in 0.1M HCl pH 1.2 at 272 nm 
 
 
Figure 2.17: Calibration curve of KTP in 0.1M HCl pH 1.2 at 259 nm 
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Figure 2.18: Calibration curve of INDO in distilled water at 265 nm 
 
 
Figure 2.19: Calibration curve of OZP in distilled water at 254 nm 
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Chapter 3. Theoretical miscibility estimation and basic 
characterization of hot melt extruded solid dispersions 
3.1. Introduction 
Hot melt extrusion (HME) has attracted considerable attention in the preparation of solid dispersion 
(SD) formulations due to its cost sparing and readily scalable production as described in Chapter 
1.4 (Hancock et al., 2002). In order to successfully extrude an HME polymer-based amorphous SD, 
the extrusion temperature is often set at 10 to 20 
o
C higher than the Tg (glass transition 
temperature) or Tm (melting temperature) of the polymer to ensure good flowability of the mixture 
during the extrusion process (Chokshi et al., 2005). However, based on the proposal of employing a 
high Tg polymer for the physical stabilisation of amorphous solid dispersion (Zhao, 2010, Sathigari 
et al., 2012, Shah et al., 2012, Hancock and Zografi, 1997), Tg of many pharmaceutical polymers 
are too high for the extrusion process. Indeed, the use of high processing temperatures is usually 
not favourable due to the heat induced degradation of many polymeric and drug systems; hence, a 
more moderate working temperature is required. Nevertheless, simply abandoning potentially 
useful polymers such as polyvinylpyrrolidone (PVP) without adequate understanding of the 
processing options and material characteristics could lead to the inefficient use of resources due to 
premature rejection of polymer candidates. 
PVPs are hydrophilic polymers and are the main carriers (i.e. PVP K29-32 and PVP vinyl acetate 
6:4) for this study. The advantages of these polymers in solid dispersions have been widely 
published as described in Chapter 2. However, the use of PVP is lacking in the field of HME SD 
due to threat of degradation in the hot processing. Therefore, the purpose of this chapter is to 
investigate the possibility of using PVP polymer in the context of HME. In light of this, the high Tg 
of PVP polymers may be softened at suitably low temperatures when mixed with a miscible active 
pharmaceutical ingredient (API), as the low molecular volume of the API compound can plasticize 
the polymeric matrix (Forster et al., 2001c). This plasticizing effect often confers versatility in 
terms of widening the extrusion temperature window of HME production.  
In the extrusion of HME PVP-based SD,  structurally interacting API, i.e. paracetamol and limited-
interacting API with PVP, i.e. caffeine (Sekikawa et al., 1978) were employed . Besides, 
miscibility behaviour of these model APIs and the PVP polymers were determined by measuring 
the interaction parameters obtained via the Hansen solubility parameter and melting point 
depression approaches (Marsac et al., 2009). In particular, the intention is to explore whether the 
production of fully amorphous HME PVP-based SD may be predicted using these theoretical 
approaches.  
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3.2. Materials and methods 
 
In this study ‘PVP polymers’ or ‘PVP carriers’ represents both the homopolymer PVP and its 
derivative copolymer PVPVA 6:4 or otherwise specified.  
 
3.2.1. Preparation of physical mixtures 
Physical mixture (PM) of APIs (i.e., Paracetamol (PCM) and caffeine (CAF)) and PVP carriers 
were weighed according to the desired drug-polymer ratio and the mixtures were gently mixed in a 
mortar and pestle for approximately 2 minutes. 
 
3.2.2. Estimation of drug-polymer miscibility 
Prior to the preparation of solid dispersions, the miscibility of the drug-polymer systems was 
investigated. The Flory-Huggins theory has been used for calculating free energy mixing and 
estimating miscibility of drug-polymer components. Although limitations of this approach have 
been described (Zhao et al., 2011, Marsac et al., 2006, Tian et al., 2012), this method is still useful 
as a starting point for the understanding of drug-polymer thermodynamics.  
In considering the mixing of a large molecular weight polymer and a low molecular weight API, 
the Flory Huggins theory defines a hypothetical “lattice” in space. It assumes that the probability of 
the solvent (in this case the API) making contact with the segment of polymer (in this case 
monomer) is equal to the volume fraction of the polymer segments, i.e. its monomer (Gong et al., 
1989). Following the Flory-Huggins theory of polymer solution, with the description of interaction 
parameter, χ to account for the enthalpy of mixing, the equation for free energy mixing of an API-
polymer system, ΔGm is given by Equation (3.1) 
 
   
  
                                                                           
 
where        is number of mole of the drug,           is number of moles  of polymer,       is 
volume fraction of the drug,           is the volume fraction of the polymer,              is the 
interaction parameter between the drug and polymer, R is gas constant, and T is absolute 
temperature. By the knowledge of the interaction parameter, χ, one can estimate the mixing 
behaviour of an API to polymer system using the Flory-Huggins theory via estimation of the free 
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energy of mixing which in turn indicates the driving energetics of the process.  However the 
approach requires the interaction parameter χ to be known.  
Earlier reports indicated that the solubility parameter and melting point depression approaches 
maybe used to estimate the interaction parameter of a blend and hence, possibly, the degree of 
miscibility and solid solubility (Marsac et al., 2009, Marsac et al., 2006, Zhao et al., 2011, Tian et 
al., 2012). Both of these approaches were tested in the current study in relation to the 
characteristics of both the raw materials and the prepared products. 
 
3.2.2.1. Solubility parameter approach 
The solubility parameter approach is a widely used method in estimating the miscibility and 
compatibility of a mixture system. The origin concept of this approach is described by Hildebrand 
(1961) who stated that solubility of a given solute in a solvent is determined by the cohesive energy 
density, i.e. cohesive energy per unit volume of the substance (Van Krevelen and Te Nijenhuis, 
2009). This concept is developed to specify a parameter (the solubility parameter) that is defined to 
be the square root of the cohesive density energy. According to Van Krevelen and Te Nijenhuis 
(2009) the solubility of a given solute is largely determined by the chemical structure. As a general 
rule, similar chemical structure between the solute and solvent favours solubility, i.e. solubility is 
favoured when structures of solute and solvent possess similar solubility parameters (Van Krevelen 
and Te Nijenhuis, 2009). 
In a low molecular weight liquid, the cohesive energy is closely related to the molar heat of 
evaporation ΔHvap, as presented in Equation (3.2) 
 
                                                                                 
 
where      is cohesive energy, p is pressure,    is volume changes, R is universal gas constant 
and T is temperature. Since it is not possible to obtain the vaporization energy of a polymer 
directly, an indirect method was developed to estimate the solubility parameter of polymer system 
i.e. via group contribution methods.  
In the literature, two chemical group contribution methods are reported for the indirect prediction 
of solubility parameter of the API and polymer system, i.e. the Hoftyzer/ Van Krevalen method and 
the Hoy method (Van Krevelen and Te Nijenhuis, 2009). Based on these methods, the cohesive 
energy of a molecule is dependent on different forces in the chemical structure of the molecule 
which include dispersive force (Fdi) , hydrogen bond force (Ehi), as well as polar force (Fpi). The 
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values of these forces are given as a reference table in Van Krevelen and Te Nijenhuis (2009).  
With the known of these forces, the solubility parameter of a molecule can be estimated.  
 
3.2.2.2. Melting point depression approach 
Apart from the solubility parameter approach, the melting point depression approach is another 
method that can be used to estimate the miscibility in a mixture of different components. The 
miscibility of the components is presented by the negative value of a defined parameter, namely 
interaction parameter, as a function of melting point depression phenomenon.  
Additionally, this approach is also introduced for the prediction of solid solubility of a drug in a 
polymer system which is strongly attributed to the drug-polymer interaction. When a drug interacts 
with a polymer system, the chemical potential of the mixture will reduced and thus the melting 
point of the drug would be reduced (Tian et al., 2012). Consequently, by accessing the degree of 
melting point depression as a function of polymer composition, the energy density of the 
interaction between the two systems could be anticipated (Marsac et al., 2009, Zhao et al., 2011). 
This density of interaction is frequently represented by the interaction parameter, χ12, where 
subscription 1 denotes the first component and subscription 2 denotes the second component. 
To predict the interaction parameter by using the melting point depression method, PM API-
carriers were prepared in drug rich proportions (from 70 - 90% w/w drug loading) and scanned by 
modulated DSC with ± 0.212 
o
C every 40 s at 2 
o
C per minute to 200 
o
C using pin hole pan. 
MTDSC was used to separate the Tg or relaxation endotherm of the polymer particularly, PVP K 
29-32 from the melting endotherm of PCM. This is to avoid misinterpretation of the Tg related 
endotherm (particularly PVP K29-32) as a depressed melting point of PCM. 
 
3.2.3. Preparation of hot melt extruded solid dispersions  
HME sample of PCM PVP K29-32 ranging from 20%-70% of PCM loading was prepared. While 
20%-50% of PCM loading were prepare in HME PCM PVPVA 6:4. For both HME system of CAF 
PVP K29-32 and CAF PVPVA 6:4, only 10% and 20% loading of CAF systems were prepared. 
The discrepancy of the API loading is dependent on the experimental observation whereby the 
loading limit of preparation was extruded up to a point where the appearance of the extrudate was 
opaque. Please refer to Table 2.12 for the processing parameters used in the production of HME 
systems. 
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3.2.4. Hot stage microscopy  
The melting or Tg temperature of pure PCM, CAF, PVP polymers and fusion temperatures of the 
PM of drug and polymer were observed by hot stage microscopy (HSM). Samples were heated 
from room temperature up to 200 
o
C at a heating ramp of 10 
o
C per minute. Events that occurred in 
the samples while heating were recorded using a JVC colour video camera with studio capture 
software. 
 
3.2.5. Thermogravimetric analysis 
Thermogravimetric analysis (TGA) was used to measure the water content and detect the 
decomposition temperature of the raw materials and the prepared HME PVP-based formulations. 
Raw powders or intact extrudates (3-4 mm) were heated from room temperature and isothermed at 
100 
o
C for 15 minutes before further heating to 350 
o
C at a heating rate of 10 
o
C per minute. 
Weight loss after 15 minutes of isotherm at 100 
o
C was taken as water content of the samples. 
Dramatic weight loss at higher temperatures was regarded as being indicative of the decomposition 
temperature.  
 
3.2.6. Modulated temperature differential scanning calorimetry  
All samples, including the drugs, polymers, physical mixtures and HME PVP-based extrudates 
were analysed using a DSC with modulated mode (MTDSC). Pin-hole lids were used to allow 
removal of water, particularly given the hygroscopic nature of the PVP polymers (Callahan et al., 
1982). Samples were heated from 0 
o
C in modulated mode (± 0.212 
o
C every 40 s) at 2 
o
C per 
minute to 200 
o
C. All experiments were run in triplicate.  
 
3.2.7. Attenuated total reflectance -Fourier transform infrared spectroscopy  
Attenuated total reflectance -Fourier transform infrared spectroscopy (ATR-FTIR) measurements 
were carried on freshly ground extrudates. The spectra were recorded over a wavenumber range of 
500 cm
-1
 to 4000 cm
-1
 with a resolution of 2 cm
-1
 and 64 scans. To detect changes as a function of 
heating, the ATR crystal was heated to the desired temperature (ranging from room temperature to 
200 
o
C) before scanning. Extrudates were scanned in powder form by gently grinding in a mortar 
and pestle.  
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3.2.8. Powder X-ray diffraction 
Powder X-ray diffraction (XRPD) experiments were performed on freshly prepared HME PVP-
based extrudates. The extrudates were crushed into powder form and compacted into the sample 
holder of the XRPD. Measurements were performed from 10
o
 to 30
o
 (2θ) coupled with scanning 
speed of 0.01
o 
/ step and 1 second for every scan step to cover the characteristic peaks of the 
crystalline PCM and CAF.  
To detect crystallinity of the HME PVP based extrudates using XRPD method, a calibration curve 
was constructed based on the relationship between the area under the characteristic peaks and the 
crystallinity of PM was performed. This method of quantifying PCM using XRPD was reported 
before by de Villiers et al., 1998 (de Villiers et al., 1998). PMs of 10% to 80% w/w were prepared 
by simple mixing in a mortar and pestle. The PMs were then compacted into the X-ray sample 
holder and scanned from 10
o
 to 30
o
 (2θ) to cover the characteristic peaks of the crystalline PCM 
and CAF. Calibration curves were constructed according to the intensity of the two sharp peaks at 
23.4 and 24.5
o
 2θ Bragg diffraction peaks versus the known crystal content.  
 
3.2.9. Scanning electron microscopy 
The surface morphology of the fresh extrudates was investigated using scanning electron 
microscopy (SEM). The extrudates were cut through by cross section using a microtome. Both the 
cut extrudates and whole spaghetti–like extrudates were placed on a sample stub and sputtered with 
a thin layer of gold prior to imaging.   
 
3.3. Results  
3.3.1. Estimation of drug-polymer miscibility 
3.3.1.1. Solubility parameter approach 
In this study, the solubility parameters of the drug and polymer were both estimated. Theoretical 
background of this approach has been described in section 3.2.2.1. Table 3.1 and Equation 3.3 
provide the example of solubility parameter calculation of PCM. Table 3.1 lists the values of the 
chemical group forces of PCM based on the cohesive energy values given in Van Krevelen and Te 
Nijenhuis (2009). By knowing the forces of each chemical group, the summation of all the forces 
was carried out in each column of Table 3.1.  
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Table 3.1: Solubility parameter calculations for PCM using the Hoftyzer and Van Krevelen methods. Column 1 
represents the chemical group contribution of PCM. Columns 2 to 4 represent the respective forces attributed by 
each of the chemical group. The last column represents the molar volume of the contributed groups (Van 
Krevelen and Te Nijenhuis, 2009). 
Structural Group Fdi (MJ/m
3
)
1/2
 mol-
1
 Fpi
2
 (MJ/m
3
)
  
mol-
2
 Ehi J/mol V cm
3
/ mol 
1-CH3 420 0 0 33.5 
1-OH 210 250000 20000 10 
1-CO- 290 592900 2000 10.8 
1-NH- 160 44100 3100 4.5 
1 Ring 1430 12100 0 71.4 
Σ 2510 899100 25100 117.2 
 
 
Then, the solubility parameter was calculated from Equation (3.3).  
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where V is the molar volume Fdi is dispersive force, Fpi is polar force and Ehi is hydrogen bond. By 
using Equation (3.3), the solubility parameter of PCM could be obtained by combination of the 
square root of the cohesive energy density of the different contributions forces. The solubility 
parameter of PCM molecule was calculated to be 27.17. 
On the other hand, Hoy has incorporated the molar attraction constant in the calculation of 
solubility parameter (Van Krevelen and Te Nijenhuis, 2009). For comparison, Table 3.2 presents 
the example of solubility parameter estimation of PCM via the Hoy method. In a similar manner to 
the Hoftyzer/ Van Krevalen method, the Hoy method entails the calculation of density of the 
cohesive energy which involves the molar attraction function (Ft), its polar component (Fp), molar 
volume (V) of the solvent molecule or structural unit of the polymer and the Lydersen correction 
for non-ideality (ΔTi). These values could be obtained from a reference table published in Van 
Krevelen and Te Nijenhuis (2009). Table 3.2 lists the values the involved forces obtained from Van 
Krevelen and Te Nijenhuis (2009). Values of each column in Table 3.2 was summed up and used 
for further calculation of the solubility parameters by using Equation (3.4) or (3.5).  
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Table 3.2: Solubility parameter calculations for PCM using the Hoy methods. Column 1 represents the chemical 
group contribution of PCM. Columns 2 and 3 represent the molar attraction function and polar component, 
respectively attributed by each of the chemical group. Column 4 represents the molar volume of the contributed 
groups and the last column is the Lydersen correction for non-ideally of each chemical group (Van Krevelen and 
Te Nijenhuis, 2009). 
Structural Group Ft (MJ/m
3
)
1/2
 mol-
1
 V cm
3
/ mol ΔTi 
1-CH3 303.5 21.55 0.023 
4- CH aromatic 964 53.68 0.044 
2 -C aromatic 402 14.84 0.22 
1-CONH 1131 28.3 0.054 
1-OH-(phenol) 350 12.45 0.031 
1Aromatic 
substitution-para 
83 0 0 
Σ 3233.5 130.82 0.174 
 
 
 
 
 
 
 
 
 
   
    
 
                                                                         
   
        
 
                                                                         
From Equation 3.4,    is the solubility parameter, Ft is molar attraction function, Fp is polar 
component and the B is a base value which has been proved to be essential to be incorporated 
(Traube 1895). B is equal to 277 for low molecular weight liquids. For calculations for the 
amorphous polymer Equation (3.5) should be used where ‘n’ is an auxiliary number which could be 
obtained by Equation (3.6) with the knowledge of the value of Lydersen correction for non-ideality, 
  
   
, which is obtained by summation of value of ΔTi as shown in Table 3.2. 
        
                                                                           
The average magnitudes of solubility parameters obtained from the Hoftzyer/Van Krevelen method 
and Hoy method has been previously suggested to be the best prediction due to the good agreement 
between the theoretical calculation and experimental data obtained from heat of vaporization of 
low molecular weight molecules (Van Krevelen and Te Nijenhuis, 2009). Therefore, in this study, 
solubility parameters of the materials were the average values obtained from both Hoftzyer/Van 
Krevelen (Table 3.1 and Equation (3.3)) and Hoy (Table 3.2 and Equation (3.4) or (3.5)) methods 
Table 3.3 displays the calculated solubility parameter for each method and their average and the 
difference between the solubility parameters of drug and polymer carriers.  
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Table 3.3: Solubility parameters of APIs and PVP polymers 
Compound Solubility parameter, δ Δδ (δd - δp) 
 
Hoftyzer/ Van 
Krevelen (MPa)
1/2
 
Hoy (MPa)
1/2
 Average PVP K2932 PVPVA 6:4 
Paracetamol 27.17 26.83 27.00 3.68 4.17 
Caffeine 35.19 27.48 31.34 8.16 9.01 
PVP K29-32 26.29 20.05 23.17   
PVPVA 6:4 24.38 20.54 22.32   
 
 
The difference of the solubility parameters between the drug and polymer is an indication for drug-
polymer miscibility. When the difference is more than 10 MPa
1/2
, there is potential for 
immiscibility between the mixture components. Conversely, when the difference is less than 7 
MPa
1/2
, the mixture is expected to a show good miscibility (Forster et al., 2001c).  
The last two columns of Table 3.3 (highlighted in grey) represent the differences of solubility 
parameters between the drug and polymer carriers. Binary systems of PCM-PVP K29-32 and 
PCM-PVPVA 6:4 were expected to show good miscibility as indicated by the low differences 
between the PCM and its carrier systems (PVP K29-32 and PVPVA; < 7 MPa
1/2
 ). On the other 
hand, difference of the solubility parameters between the drug and polymer in binary systems of 
CAF-PVP K29-32 and CAF-PVPVA 6:4 are Δδ > 8 MPa
1/2
 suggesting limited miscibility of the 
drug and carriers. These results further discussed based on the nature of the prepared extrudate 
formulations in the subsequent sections. 
 
3.3.1.2. Melting point depression approach 
Drug-polymer miscibility was also estimated using melting point depression approach as described 
in section 3.2.2.2. Figure 3.1 shows an example of MTDSC thermograms of the depressed melting 
point of PCM in the PM of binary PCM-PVP K29-32 ranging from 70% to 95% of drug loading.  
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Figure 3.1: DSC thermograms of PM of PCM-PVP K29-32 (from 70% w/w to 90% w/w drug loading) measured 
at 2 oC/min. Onset melting point of the DSC thermograms was taken as the melting temperature of the systems. 
 
Apparent melting point depression was detected for PCM in the presence of PVP K29-32 in which 
the onset of Tm of PCM was recorded as 150 
o
C at 70% w/w PCM loading.  
 
Figure 3.2 compares the changes in melting temperatures of PCM and CAF in the presence of PVP 
K29-32. In presence of PVP K29-32 systems, PCM displays a higher melting point depression than 
CAF as indicated by the steeper slope of the curves of PM PCM-PVP K29-32 in Figure 3.2. 
Besides, the onset melting point of PCM and CAF also decreased with the higher proportion of 
polymer. 
 
Figure 3.2: Change in onset of Tm of PM PCM and CAF in PVP K29-32 as a function of percentage API loading 
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As mentioned in the beginning of this section (Chapter 3.2.2.2), melting point depression of the 
drug system is attributed to the change in overall chemical potential of the mixture as a result of 
interaction between the drug and the polymer (Zhao et al., 2011, Tian et al., 2012). These 
interactions include Van der Waal interaction, hydrogen bond interaction, charge transfer 
complexation as well as ionic interaction. 
Structurally, hydrogen bond formation was anticipated between PCM and PVP K29-32 due to the 
presence of proton donor in PCM and proton acceptor in pyrrolidone of PVP K29-32. However, 
this is not anticipated in the binary CAF and PVP K29-32 because of the lack of proton donor in 
the chemical structure of the CAF molecule. Therefore, the difference in ability of hydrogen bond 
formation in PCM-PVP K29-32 system and CAF-PVP K29-32 may explain the different degree of 
depressed melting point of PCM and CAF in the presence of PVP K29-32. In the context of HME, 
the depressed melting temperature of the melted API will promote flowability of the mixture in the 
HME barrel as the solid of the drug melts into its liquid state. This might allow the good mixing 
process between the drug and polymer.  
 
Interaction parameters 
To predict the drug-polymer interaction parameter by using the melting point depression approach, 
the data of the depressed melting point detected from MTDSC scan was used in Equation (3.7) 
(Paudel and Mooter, 2012, Marsac et al., 2006, Zhao et al., 2011). 
 
(
 
     
 
 
      
)   
  
     
[        (  
 
 
)                    
 ]            (3.7) 
where TMpure is the melting temperature of the pure API, TMmix is the depressed melting temperature 
of the mixture, R is universal gas constant, ΔHfus is heat of fusion of the pure API, m is the volume 
ratio of polymer to its volume lattice (which is taken as the volume of drug),      is interaction 
parameter,       and          is the volume fraction of the drug and polymer respectively which 
were obtained from Equation (3.8).  
 
       
     
              
                                                                  
 
where V is volume of the component which is denoted by its subscription. Volume of a component 
is calculated from the value of weight divided by value of density, i.e. V= m/ρ. 
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By rearranging Equation (3.7) into Equation (3.9), the interaction parameter,     between the drug-
polymer could be obtained by plotting the function of depressed melting temperature (left side of 
Equation (3.9)) of PCM against the volume fraction of the polymer (right side of Equation 3.9), i.e.  
 
[      
    (      
  )  
     
  
]  [  (
 
 
)          ]  [       ]              
                 
 
Figure 3.3 displays the example plots of the function of depressed melting temperature against 
volume fraction of PVPs polymer with good correlations. The slopes of the lines in Figure 3.3 were 
taken as interaction parameter,    . 
 
 
Figure 3.3: Plot used to determine the interaction parameter of PCM-PVP K29-32 and CAF-PVP K 29-32 
 
According to the relationship between the free energy mixing and interaction parameter as 
presented in Equation (3.1), a favourable mixing can be realized only if the drug-polymer 
interaction parameter is negative. Besides, the smaller the magnitude of interaction parameter 
would give rise to a more negative free energy mixing, ΔGm which indicating a bigger change in 
chemical potential between the mix and unmixed state. Thus a more negative interaction parameter 
indicates a higher potential of drug-polymer interaction. 
Table 3.4 summarise the interaction parameters of the investigated API-polymer systems. From 
Table 3.4, interaction parameters for both PCM and CAF with both PVP K29-32 and PVPVA 6:4 
system are negative.  
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Table 3.4: Flory-Huggins interaction parameters based on melting point depression 
Formulation Interaction parameters, χ12 Correlation, R
2
 
PM PCM / PVP K29-32 -1.652 0.9765 
PM PCM / PVPVA 6:4 -0.7752 0.8974 
PM CAF / PVP K29-32 -0.9467 0.8852 
PM CAF / PVPVA 6:4 -0.4992 0.7908 
 
Interaction parameters of PCM – PVP carriers are slightly more negative than CAF – PVPs. This 
suggests better interactions between PCM and both PVPs carriers (PVP K29-32 and PVPVA 6:4) 
as compared to the interaction between CAF and PVPs carriers (PVP K29-32 and PVPVA 6:4). 
Furthermore, the interaction parameter of PCM-PVP K29-32 is more negative than PCM-PVPVA 
6:4 at a temperature close to the melting of the APIs which implies a better interaction between 
PCM and PVP K29-32 than between PCM and PVPVA 6:4. 
To extend the discussion, the free energy of mixing (   ) of the systems were also calculated 
based on the interaction parameters from Table 3.4 by using Equation (3.1) in section 3.2.2.. Figure 
3.4 displays the obtained Gibbs free energy values plotted against the volume fraction of PVP 
carriers. 
 
 
Figure 3.4: The changes in free energy of mixing as a function of volume fraction of polymer as predicted using 
interaction parameter of Flory-Huggins lattice theory 
 
-0.06
-0.05
-0.04
-0.03
-0.02
-0.01
0
0 0.2 0.4 0.6 0.8 1 1.2
Δ
G
m
ix
/R
T
 
weight fraction of PVPs, φ PVPs   
ΔG/RT PCM-PVPK2932 ΔG/RT PCM-PVPVA 6:4 
ΔG/RT CAF-PVP K2932 ΔG/RT  CAF-PVP VA 6:4 
Preparation and characterization of HME PVP-based solid dispersions                          Chapter 3 
 
School of Pharmacy, University of East Anglia   102 
 
The Gibbs free energies for the PCM-PVPs (PVP K29-32 and PVPVA 6:4) were negative which 
indicated miscibility of the PCM and PVP-carriers. This is in good agreement to the conclusion 
drawn from the close values of solubility parameters (Table 3.3).  
However, the Gibbs free energy curves of CAF and PVPs carriers (PVP K29-32 and PVPVA 6:4) 
were also found to be negative which suggested some extent of miscibility between the CAF and 
PVP carriers. This is in agreement with the prediction from solubility parameters whereby the high 
difference (> 8 MPa
1/2
) between solubility parameters of the CAF and PVPs infers potential 
immiscibility (Chapter 3.3.1.1, Table 3.3).  
According to Gibb free energy curves in Figure 3.4, the minimum negative value of the concave of 
PCM-PVPVA 6:4 system lies at a higher value of polymer fraction (i.e. at 0.7 mole fraction of 
PVPVA 6:4) as compared to PCM-PVP K29-32 which has a minimum at 0.6 mole fraction of PVP 
K29-32. This indicates that a higher PVPVA 6:4 fraction is needed to achieve a maximum 
miscibility between PVPVA 6:4 and PCM in comparison to the homopolymer PVP K29-32. A 
similar trend was also noted in the binary system of CAF and PVPs carriers. These predictions will 
be correlated to the nature of the prepared SD extrudates in a later section (Chapter 3.3.3.4). 
Based on the miscibility prediction using both the Hansen solubility approach and melting point 
depression approach, the structurally interacting API, i.e PCM was shown to be highly miscible 
with PVP K29-32 and PVPVA 6:4. On the other hand, the limited-interacting API, i.e. CAF was 
revealed with limited miscibility with PVP K 29-32 and PVPVA 6:4. 
 
Solid solubility prediction 
With the knowledge of interaction parameter, solid solubility of the product could be determined. 
Here, the interaction parameters that were predicted from melting point depression approach were 
used for the calculation of solid solubility by using Equation (3.10). 
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where γdrug is activity coefficient and x drug is the mole fraction.       is heat of fusion for API, 
Cp is the change of heat capacity, Tm is the melting point of API, R is universal gas constant and T 
is the temperature where is the solid solubility was predicted. In the context of HME (i.e. in this 
study), the expected ‘extrusion temperatures of preparing the formulations’ was used as the values 
of T in predicting the solid solubility. According to the Flory-Huggins lattice theory, the activity 
coefficient of a drug substance can be obtained from Equation (3.11) (Marsac et al., 2009). 
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where m is the ratio of the volume of the polymer to that of the lattice site which is defined as 
volume of the drug (Marsac et al., 2009). Other terms in Equation 3.11 have been previously 
defined. It is clear from Equation (3.11) that the activity coefficient of the drug is highly dependent 
to the interaction parameter and the discrepancy in molecular size between the drug and polymer. If 
there is only minimal difference in molecular size between the drug and monomers of polymer, 
ideal mixing entropy can be assumed. By assuming ideal mixing, the first two terms on right hand 
side are equal to zero. Thus the solid solubility in mole fraction of the drugs in PVPs polymer can 
be calculated by substituting value of activity coefficient from Equation (3.11) into (3.10). The 
predicted solid solubility values,       in molar ratio could be obtained. These calculated molar 
ratios      were converted into its weight ratios (%w/w) as listed in Table 3.5. 
 
Table 3.5: Theoretical solid solubility of APIs in PVP carriers at their corresponding extrusion temperatures 
predicted by using melting point depression approach 
Solid Solubility of APIs in polymer (% w/w) 
PCM-PVP K29-32 PCM-PVPVA 6:4 CAF- PVP K29-32 CAF-PVPVA 6:4 
32 - 55 27- 40 23- 31 31- 42 
* Solid solubility prediction via the melting depression approach involves the estimation from drug rich proportions of 
the drug and polymer systems i.e. 75% to 95% of API. A different concentration of drug will result in a different 
predicted value of the solid solubility (based on Equation 3.11), thus, a range of apparent solid solubility results will be if 
a different range of mixtures system is used.  
 
From Table 3.5, the solid solubility of PCM is relatively higher in PVP K29-32 than in PVPVA 
6:4. On the other hand, solid solubility of CAF is higher in PVPVA 6:4 than in PVP K 29-32. This 
might be due to the different magnitude of T used in the calculation as a higher T value was used in 
the solid solubility calculation of CAF-PVPVA 6:4 system. This is because of the higher expected 
processing temperature that will be used in producing CAF-PVPVA 6:4 extrudates system (please 
refer to Table 2.12 for processing temperature).  
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3.3.2. Preparation of HME PVP-based SDs  
3.3.2.1. HME parameter investigation: Extrusion temperature  
Before the extrusion of an HME formulation, it is important to understand the thermal properties of 
the raw materials in order to avoid the inappropriate use of processing parameters (such as high 
extrusion temperature and long residence time of extrusion).  To do this, TGA was used to measure 
the degradation temperature and water content (%) of the raw materials. On the other hand, DSC 
was used to measure the Tm or Tg of the drug and polymer, respectively. Table 3.6 lists the thermal 
properties of the raw materials from both DSC and TGA analysis.  
Table 3.6:  Thermal properties of raw materials from DSC and TGA analysis 
Compounds 
Melting (Tm)/ Tg 
temperature (
o
C) 
Degradation  
temperature (
o
C) 
Water content (%) 
PCM Tm=169-172 199.1 ± 9.1 0.12 ± 0.14 
CAF Tm=231-234 172.4 ± 6.7 0.15 ± 0.06 
PVP K29-32 Tg=164 177.6 ± 1.7 5.53 ± 0.94 
PVPVA 6:4 Tg=106 282.1 ± 2.3 3.97 ± 0.91 
 
It is interesting to note that an apparent weight loss was seen for raw CAF powder well below the 
reported melting temperature (Table 3.6). This is ascribed to the sublimation of CAF molecule at a 
temperature around ≈ 175 oC (Moura Ramos et al., 2006).  
The water contents for both the crystalline PCM and CAF are almost negligible. In contrast, the 
water content of homopolymer was noted to be relatively high as compared to PVPVA 6:4. This is 
due to the hygroscopic nature of the PVP (Callahan et al., 1982). The relationship between the 
water content of the raw material and the extrudates will be further commented on in a later section 
(Chapter 3.3.3.1). 
To determine an appropriate extrusion temperature, HSM was used to identify the fusion 
temperature of the drug and polymer. The purpose of identifying the fusion temperature, a 
temperature which leads to the liquid state formation of the mixture, is to anticipate an appropriate 
extrusion temperature that will ease the flowability of the mixture in the HME barrel while 
processing. It should be emphasized that the fusion temperature here refers to a temperature that 
causes the transformation of the solid state of the mixture to a liquid or fluidized state. Thus, it may 
not necessary be equivalent to the Tm or Tg of the drug and polymer, respectively. Figure 3.5 (I) to 
(IV) show images of the 50% API-polymer physical mixture which were captured during heating.  
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Figure 3.5: HSM screens of PM of 50% API-polymers. I) Fusion of PCM- PVP K29-32 at T ≈ 140 oC, II) Fusion of 
PCM- PVPVA 6:4 at T ≈ 130 oC, III) Fusion of CAF- PVP K29-32 at T ≈ 180 oC, and IV) Fusion of CAF- PVPVA 
6:4 at T ≈ 175 oC. Figures on the left which is denoted as (a) are  screens captured before the apparent fusion was 
noted and figures on the right which is denoted as (b) are screens captured when the fusion event was clearly seen. 
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The fusion temperature between the PCM and PVP K29-32 (Figure 3.5 I (a) and (b)) occurs at a 
temperature well below (i.e. circa 140 
o
C) the Tm and Tg of the PCM and PVP K29-32, 
respectively. The depressed temperature is in good agreement to the melting point depression data 
obtained previously in the DSC scan (Figure 3.2). It may therefore be expected that the extrusion of 
PCM in PVP K29-32 could be performed at lower temperatures than their individual thermal 
properties would indicate. 
On the other hand, the fusion temperature between the PCM and PVPVA 6:4 occurred at 
temperature around 130 
o
C in the presence of PVPVA 6:4 (Figure 3.5 II (a) and (b)). This is due to 
the low Tg of PVPVA 6:4 leading to its softening below the melting of PCM and, subsequently, the 
dissolution of PCM into the softened PVPVA 6:4. Thus, it was also expected that this mixture 
could also be extruded at temperatures lower than the melting point of PCM. 
HSM screens of the PM CAF-PVP carriers also show lower fusion temperatures i.e. ≈ 180 oC and ≈ 
175 
o
C for PM CAF PVP K29-32 and PM CAF PVPVA 6:4, respectively. Both temperatures were 
below the Tm of the drug (Figure 3.5 (III) and (IV)). However, due to the low degradation 
temperature of PVP K29-32 (i.e. 180 
o
C from TGA data) it was thus expected that extrusion of the 
CAF PVP K29-32 needed to be performed at a lower temperature than 180 
o
C, whereas mixture of 
CAF PVPVA 6:4 could be extruded at 180 
o
C as the polymer degradation temperature is > 200 
o
C. 
 
The extrusion of PCM PVPs and CAF PVPs 
Previous studies have indicated that the extrusion processes may be performed at temperatures 
below the melting point of PCM due to the melting point depression of the PCM in the presence of 
PVP polymers. Thus, HME PCM-PVPs extrudates was prepared using an extrusion temperature of 
120 
o
C. Clear extrudates were obtained up to 40% and 50% of PCM PVPVA 6:4 and PCM PVP 
K29-32 system, respectively. On the other hand, only 10% and 20% caffeine loading produced 
clear extrudates for PVPVA 6:4 and PVP K29-32, respectively. However, it should be emphasized 
that the extrusion of 10% HME PVP based extrudates was difficult as a low yield and high value of 
processing torque was noted. This is ascribed to the insufficient plasticization of the small fraction 
of API to the high fraction of PVP polymers which causes high viscosity of the resultant molten 
system.  
Figure 3.6 illustrates the example of HME 20 to 70% PCM and PVP K29-32 extrudates that had 
been prepared at 120 
o
C. It was suspected that the extrudates with an opaque appearance provided 
evidence of incomplete drug solubilisation, while the transparent extrudates showed complete 
solubilisation of the drug. However, further investigation was needed to confirm the amorphicity of 
the clear extrudates.  
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Figure 3.6: Appearance of extrudates of HME 20 - 70% PCM-PVP K29-32 prepared at 120 oC  
 
3.3.2.2. HME parameter investigation: Torque  
During the processing of the HME products, the viscosity of the molten material in the HME barrel 
was recorded as torque. This is a processing dependent variable, the value of which is a result of 
the parameters used in the processing such as temperature, residence time and screw speed. In this 
section, the effect of torque change during the extrusion process was studied. The effect of API 
loading, API types (interacting versus non-interacting) and polymer types (homopolymer and co-
polymer) on the torque are discussed. 
 
The influence of API loading on torque 
Figure 3.7 plots the changes of torque value while preparing the HME PCM PVPs as a function of 
PCM loading after 5 minutes of molten circulation. 
 
Figure 3.7: Torque value recorded during the processing of HME 20-70% w/w at 120 oC after approximately 5 
minutes of molten circulation 
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As the API loading increased, the observed torque values were reduced. This is due to the 
plasticization of the polymer by the API in which the extent of plasticization increases with API 
loading. At 60% w/w of PCM, there was no further reduction in torque of the process which 
matches the appearance of the opaque extrudates as shown in Figure 3.6. Thus it is suggested that 
at the processing temperature of 120 
o
C, the viscosity of the molten system was at a minimum at a 
loading of PCM lower than 60%, i.e. 50%, which imply a maximum plasticizing effect of PCM on 
the PVP carriers. In other words, the higher drug loading led to increased plasticization of the 
system and hence a lower torque value. At the same loading system (50% PCM), the yields and 
output rates of the extrudates were also recorded to be the highest due to the good flowability of the 
molten mixture at a maximum plasticizing level. 
It is worth mentioning that, during the extrusion process, the torque values were noted to increase 
gradually with time. This increment is particularly obvious for low drug loading systems. The 
mechanism of this change will be further discussed in the next sections.  
 
The influence of the interacting and non-interacting API on torque 
As mentioned previously, the torque values were noted to increase over the time of the processing, 
particularly at low drug loading. To effectively compare the influence of API types on the torque 
profile of HME PVP-based SD, both CAF and PCM were extruded with PVP K29-32 at a same 
processing temperature 160 
o
C. Figure 3.8 compares the torque profiles of PCM-PVP K29-32 and 
CAF PVP K29-32 across 5 minutes processing time.  
 
Figure 3.8: The comparison of torque profiles of a) HME 20% PCM-PVP K29-32 and b) HME 20% CAF-PVP 
K29-32. The peak at beginning of the profiles indicated the manual pressure applied to the raw material upon 
loading. The profile of torque was thus considered after this peak. 
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The peak noted at the beginning of the torque profile was attributed to the pressure applied while 
manual feeding of the mixture. It indicates the last sampling point of the mixture into the barrel. 
Thus, the torque profile of the molten mixture starts after the torque surge of the last sampling 
point. According to Figure 3.8, the torque value of HME 20% PCM in PVP K29-32 was higher 
(120 Ncm) than HME 20% CAF PVP K29-32 system (60 Ncm) after 5 minutes of extrusion, at the 
same extrusion temperature. 
It is worth reminding that, extrusion process of PCM and PVP was performed at a temperature 
lower than Tg of the PVP, i.e. Tprocess < Tg. This extrusion process is feasible due to the 
plasticization effect of the tested drugs to PVP. However, this plasticization effect could be 
opposed by the drug-polymer interaction (Immergut and Mark, 1965). According to Figure 3.8, the 
torque profile of HME PCM -PVP K29-32 system increased gradually over time which suggests an 
increase in viscosity of the molten over time (Alsarra et al., 2011). This is an indication of opposing 
plasticization effect as a result of hydrogen bond interaction between the PCM with PVP during 
circulation of the molten in the barrel. Such behaviour was reported earlier for PVP hydrogels with 
PEG and thermal processing of Zein or Kafirin protein (Di Maio et al., 2010, Alsarra et al., 2011). 
In Alsarra et al. (2011), the increase in viscosity of the mixture at a constant shear was reported to 
be a result of inter-particulate interaction build-up in the mixture during shearing  (Alsarra et al., 
2011). 
Unlike the torque profile of HME 20% PCM in PVP K29-32, the torque values of HME 20% CAF-
PVP K29-32 remain almost constant for 5 minutes during the molten circulation period.  This is 
due to the small molecular size of CAF in comparison to PVP which causes plasticization of PVP 
polymer chain. The constant torque profile was expected as the non-interacting CAF with respect 
to PVP polymer will not lead to the phenomena of opposing plasticization which was seen with 
PCM. Hence, it is suspected that hydrogen bond interaction between the API and PVPs could affect 
the flow properties of the mixture. The difference in flow properties of a molten mixture during 
production may cause a different mixing efficiency between the drug and polymer which could 
eventually alter the overall performance of solid dispersion. 
 
The comparison of torque profile between PVP K29-32 and PVPVA carrier HME PCM system  
The influence of different types of PVPs on the torque profile was also investigated. Figure 3.9 
displays the torque profiles for HME 40% PCM system using both the PVP K29-32 and PVPVA 
6:4 carrier system.  
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Figure 3.9: Torque of the HME twin-screw during hot melt extrusion at 120 oC as a function of processing time, a) 
HME 40% PCM PVP K29-32, b) HME 40% PCM PVPVA 6:4. The peak at beginning of the profiles indicated the 
manual pressure applied to the raw material upon loading. The profile of torque was considered after this peak. 
 
As presented in Figure 3.9, HME PCM PVP K29-32 revealed an apparent increase in torque values 
across time which indicating the occurrence of opposing plasticization phenomena at the extrusion 
temperature, i.e. 120 
o
C lower than its Tg. Whereas, HME APIs in PVPVA 6:4 systems revealed 
relatively smaller torque values with minimal torque profile increment at HME 40% PCM-PVPVA 
6:4 at the extrusion temperature of 120 
o
C. The different torque profiles seen for both the PVPs 
carrier system might be related to the Tg of the carrier in relation to the extrusion temperature, i.e. 
120 
o
C. A more apparent opposing plasticization phenomenon would be seen in the processing of 
PVP K29-32 whereby, Tprocess is less than Tg. In comparison, the effect of opposing plasticization 
was not seen in PVPVA 6:4 system as the Tprocess is higher than its Tg.   
To summarise, the torque value of a HME process is a dependent variable. It reflects the viscosity 
changes of the melt within the barrel (Chokshi et al., 2005). In this study, the decrease in torque 
value with higher PCM loading supports the suggestion of a plasticization effect exerted by PCM. 
An increase in torque values over the processing time was only noted in the interactive API (PCM) 
but not observed in the not-interactive API (CAF). On comparing PVP K29-32 and PVPVA 6:4, 
HME PVPVA 6:4 molten system was showed to have lower torque values with lower increase of 
torque values over the processing time. Following these observations, it should be kept in mind that 
the extent and direction of change in torque for different formulations may vary and hence may 
exert a variable effect on the final performance of the HME PVP-based SD. 
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3.3.3. Characterization of HME solid dispersions 
After exploring the processing parameters in the preparation of HME PVP-based SD, the 
characterization of the extrudates was performed. In order to allow comparison between the 
interactive API, PCM to the non-interactive API, CAF, the extrusion temperatures used were each 
approximately 50 
o
C below the corresponding melting point of each API unless the degradation of 
the polymer necessitated use of a lower temperature. On that basis, mixtures of PCM-PVP K29-32 
and PCM-PVPVA 6:4 were extruded at 120 
o
C. On the other hand, CAF-PVPVA 6:4 was prepared 
at 180 
o
C; however, extrudates of CAF-PVP K29-32 was prepared at temperature 155 
o
C due to 
possible degradation of PVP K29-32 at 180 
o
C.  
 
3.3.3.1. Water content of physical mixtures and hot melt extrudates 
Sorbed water could compromise the stabilizing effect of PVPs by plasticising the polymer, 
resulting in an increase in molecular mobility of the system (Tamaki et al., 2004). Hence, water 
content determination of the PVP based extrudates is a crucial step for better understanding of the 
effect of the HME process on stability of HME PVP-based SD (Callahan et al., 1982). To do this, 
water content of the prepared extrudates were investigated using TGA. Figure 3.10 shows an 
example of water content determination of HME 40% PCM-PVP K29-32 system by performing 
isothermal analysis on the samples at 100 
o
C for 30 minutes. This was conducted to erase the 
possible masking of water-related weight changes upon approaching the decomposition 
temperature (Peniche et al., 1993). 
 
 
Figure 3.10: Water content determination of HME 40% PCM-PVP K29-32 system by performing isothermal 
analysis on the samples at 100 oC for 30 minutes. The marked value (1.232%) is the water content of this SD  
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All the freshly prepared HME PVP-based SDs were found to have lower water content as 
compared to their corresponding PM. Table 3.7 displays the values of water content for all the 
prepared extrudates. 
Table 3.7: Water content (% w/w) of freshly prepared extrudates as a function of composition 
Drug loading 
% w/w 
Water content (%w/w) 
HME PCM- PVP 
K29-32 
HME PCM-
PVPVA 6:4 
HME CAF-PVP 
K29-32 
HME CAF-PVPVA 
6:4 
10 - - 2.59 ± 0.52 2.25 ± 0.38 
20 1.73 ± 0.26 2.16 ± 0.39 2.44 ± 0.08 2.07 ± 0.38 
30 1.45 ± 0.14 1.56 ± 0.13 - - 
40 1.27 ± 0.17 1.57 ± 0.16 - - 
50 1.24 ± 0.11 1.24 ± 0.15 -  
60 1.20 ± 0.26 - - - 
70 1.45 ± 0.18 - - - 
 
The low moisture content of HME PVP-based SD was ascribed to the water evaporation of the 
mixture while hot melt processing condition. Interestingly, the HME CAF formulations possessed 
slightly higher moisture content despite the used of higher extrusion temperatures in preparing this 
formulations (please refer Table 2.12 for processing conditions).  
 
3.3.3.2. MTDSC of HME PVP-based SD 
3.3.3.2.1. MTDSC of HME PCM in PVP K29-32 and PVPVA 6:4 
The thermal behaviours of the HME PVP-based SD were studied using MTDSC. Figures 3.11 and 
3.12 display the thermograms of the HME PCM in PVP K29-32 and PVPVA 6:4 systems, 
respectively. From Figure 3.11 and Figure 3.12, it can be seen that a single Tg was obtained for the 
tested HME PVP-based extrudates; this allowed elucidation of the miscibility of PCM in both the 
PVP K29-32 and PVPVA 6:4 carrier systems. More specifically, the Tg(s) of the extrudates were 
numerically in between the Tg(s) of the API and carriers. These values indicated a strong 
plasticizing effect of PCM within PVP K29-32 and PVPVA 6:4. The Tg values reduced 
consistently with increased PCM loading, as is consistent with the plasticizing behaviour of PCM 
to its PVPs carrier.   
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Figure 3.11: MTDSC thermograms of HME 20% - 70% PCM-PVP K29-32 using aluminum pin-hole pans 
From Figure 3.11, no melting endotherm was noted in the thermograms (first heating cycle) of 
formulations ranging from 20% to 50% w/w PCM loading, suggesting the production of a wholly 
amorphous dispersion. However, melting peaks were noticeable for 60% and 70% w/w PCM 
loaded systems which indicated the existence of crystalline traces within these formulations. 
Dividing the melting enthalpy of the extrudates by the melting enthalpy of the pure crystalline 
PCM, there were approximately 14.43% and 29.17% crystalline drug detected in HME 60% PCM-
PVP K29-32 and HME 70% PCM-PVP K29-32 respectively. 
 
Figure 3.12: MTDSC thermograms of HME 20% - 70% w/w PCM-PVP VA 6:4 
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According to Figure 3.12, MTDSC thermograms of PVPVA 6:4 carrier systems show an apparent 
endotherm melting peak in the sample of HME 50% PCM-PVPVA 6:4. This implies the inability 
of the excess PCM to be dissolved in carrier matrix at the operating temperature. According to the 
melting endotherm, the amount of crystalline materials detected in the sample of HME 50% PCM 
PVPVA 6:4 was 8.91% of PCM, calculated from the ratio of the sample heat of fusion to that of the 
pure crystalline PCM.  
 
Comparison between the theoretical Tg and experimental Tg 
The nature of drug-polymer mixing can be studied by comparing the measured Tg(s) of the 
extrudates to the theoretical Tg(s) as estimated from the Gordon-Taylor (G-T) equation (Gordon 
and Taylor, 1952). Strongly interacting components tend to give a mixture with Tg value higher 
than that would be expected theoretically. Assuming ideal mixing, Tg values of a mixture could be 
estimated  based on volume additivity theory  as described in Equation (3.10) (Gordon and Taylor, 
1952).   
   
            
      
                                                                  
 
where    and    are the weight fractions of drug and polymer, and     and     are glass 
transition temperatures of drug and polymer, respectively. Based on the thermodynamically 
consideration, Couchman and Karasz has derived an equation similar to G-T Equation (3.10) but 
the K-value was obtained by Equation (3.11) (Couchman and Karasz, 1978),  
 
  
    
    
                                                                              
 
where     is the change in heat capacity between the liquid-like and glassy state. Many have 
found that this equation is useful for prediction of Tg of a mixture (Shamblin et al., 1998, Hancock 
and Zografi, 1994). Thus in this study, Tg of the mixture were estimated from Equation (3.10) with 
K-value obtained from Equation (3.11). 
It is noted from the previous TGA that there were appreciable water content detected from the 
HME PVP-based extrudates (circa 1.2 - 2%). Thus the resultant HME extrudates is effectively a 
ternary system of the mixture of API-carrier-water. To predict the theoretical Tg for the ternary 
systems (PCM-polymer-water), Equation (3.12) and (3.13) was used (Truong et al., 2002). 
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where the             are the weights of PCM, polymer, and water respectively, the  
                 are the glass transition temperatures of API, polymer, and water respectively, 
and the                    are the changes in heat capacity of of API, polymer, and water 
respectively, between the liquid-like and glassy sate of the components. The constant value of K12 
and K13 can be estimated by Equation (3.13).  
 
    
    
    
                          
    
    
                                             
 
Along with the calculation, the numbers used for the calculation of theoretical Tg values were 
presented in Table 3.8.  
Table 3.8: Values used to calculate the theoretical Tg of the mixture of Ternary PCM-Polymer-Water system 
Component Tg (K) Heat Capacity (J/g.
 
K) Reference 
PCM 298.29 ± 0.0954 0.713 ± 0.022 - 
PVP K29-32 437.33 ± 0.249 0.291 ± 0.012 - 
PVPVA 6:4 375.5 ± 0.821 0.293 ± 0.036 - 
Water 136 ± 1 0.089 ± 0.005 (Hallbrucker et al., 1989) 
 
Figure 3.13 demonstrated the theoretical and experimental Tg values for the binary and ternary 
systems of PCM PVPs (for both PVP K29-32 and PVPVA 6:4) and PCM-PVP-water, respectively. 
 
Figure 3.13: Comparison of experimental Tg(s) to calculated Tg(s) based on Gordon Taylor equation a) HME 
PCM PVP K29-32, b) HME PCM PVPVA 6:4: binary PCM-PVPs polymer theoretical value based (∆), ternary 
PCM-PVPs polymer-water theoretical value (+) and experimental glass transition values (◊) 
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It is known that the existence of drug-polymer interactions may cause the observation of 
experimental Tg values higher than the theoretical ones. However, in this study, a reverse trend was 
seen, whereby the Tg (s) of the products were unexpectedly lower than the values predicted via G-
T equation (Figure 3.13). Van de Mooter et al. (2001) suggested that the incorporation of water 
content in GT-prediction could accurately estimate the Tg of the mixtures which contain moisture 
traces (Van den Mooter et al., 2001). After the consideration of moisture content in calculations of 
the theoretical Tg in the ternary system as shown by the + in Figure 3.13, the predicted Tg values 
remain higher than the experimental Tg (s) of the HME PVP-based SD extrudates.  
The large negative deviations of the experimental Tg (s) of HME PVP-based SD from the predicted 
Tg (s) suggests non-ideal mixing between the two components. Similar findings have also been 
encountered in previous publications where negative deviation of the detected Tg(s) were noted 
(Shakhtshneider et al., 2007a, Shakhtshneider et al., 2007b, Di Martino et al., 2004, Hancock and 
Zografi, 1997, Malaj et al., 2010, Gashi et al., 2009). The authors explained this effect in terms of 
the small molar volume of drug molecules that led to their diffusion inside the polymer which 
causes a higher free volume of the system than the theoretically anticipated state. Furthermore, 
according to Nair et al. (2001) the negative deviation from the theoretical predicted values could 
also be accounted for the lower intermolecular strength of the blend as compared to the 
intermolecular strength of the single components, i.e. adhesive energy is lower than cohesive 
energy of the system (Nair et al., 2001).  
With the presence of the proton acceptor in PVP structure and the proton donor in PCM molecule, 
hydrogen bond between these two compounds is reported before (Sekikawa et al., 1978, Garekani 
et al., 2003). On one hand, PVP is a hygroscopic homopolymer which interacts preferentially with 
water through its carbonyl group and did not interact among the main chain (Gangopadhyay, 2008, 
Callahan et al., 1982). Therefore the cohesive interaction of PVP alone is expected to be low. On 
the other hand, when the crystalline PCM is turn into amorphous form, it loses its intermolecular 
hydrogen bond which also infers its low cohesive energy. Thus, in this study, the lower 
intermolecular strength of the blend as compared to the intermolecular strength of the single 
components could not be the main reason for the observed negative deviation. Further 
investigations were performed to understand the unexpected Tg values deviation.  
Conventionally, Tg is easily lowered by the presence of small molecules such as water. Here, the 
effect of water molecules was further explored to test if water causes the large negative deviation of 
Tg(s) as seen in Figure 3.13. To do this, Tg(s) of the ground extrudates (prepared by gently milling 
in a mortar and pestle) and intact extrudates were compared by scanning both samples in pinhole 
pan using MTDSC.  Figure 3.14 shows the MTDSC thermograms of HME 20% PCM PVP K29-32 
for both the ground and intact extrudates with total heat flow and reversing heat flow signals.  
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It is obvious from Figure 3.14 that the MTDSC thermogram of the ground extrudates indicates an 
obvious endotherm in the region of 60-80 
o
C which is ascribed to the efficient moisture removal 
upon heating the sample in pin-hole pan. On the other hand, MTDSC thermograms of the intact 
extrudates show no apparent endotherm signal in the same region of 60-80 
o
C which implies 
inefficient water loss from the intact extrudates.  
 
 
Figure 3.14: MTDSC thermograms of HME 20% PCM PVP K29-32 a) intact extrudates of  circa 4 mm, b) ground 
extrudates from the same sample by using aluminium pin-hole pan 
 
Furthermore, the Tg value in the ground extrudates is higher than the same sample of intact 
extrudate, despite the possibility of absorbing moisture during the grinding process. This is due to 
the more efficient removal of moisture from the ground extrudate than the intact one. Accessing Tg 
values of the ground extrudates, the newly detected Tg values coincide well with the predicted 
values from the G-T equation of binary system. Following this observation, it is suggested that 
there were excess moisture trapped in the matrix of extrudates which increased molecular mobility 
of the solid dispersion systems while DSC experiments. This results in the large negative deviation 
of the experimental Tg from the theoretical one as seen in Figure 3.13.  
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3.3.3.2.2. MTDSC of HME CAF PVP K29-32 and PVPVA 6:4  
After analysing the DSC data of HME PCM system, this section will outline the DSC 
characteristics of the non-interactive API, CAF, in HME PVP systems. CAF is an easily 
crystallisable drug (Sekikawa et al., 1978). There is no reported Tg for CAF but there have been 
some reports of an anomalous event at -13 
o
C to -10 
o
C which might be associated with its Tg 
(Descamps et al., 2005b, Moura Ramos et al., 2006). In this study, recrystallization of molten CAF 
was immediate upon quench cooling in the DSC (data not shown) and all attempts to produce the 
glassy CAF by preventing its recrystallization were unsucessful, as shown by the absence of Tg in 
the DSC thermogram. This is mainly due to the intensive molecular motion of CAF molecules 
which favors its free energy loss and recrystallization process (Descamps et al., 2005b). On this 
basis, G-T calculations were not performed due to the perceived unreliability and experimentally 
undetectable of the glass transition temperature value for the CAF alone.  
 
HME CAF-PVP K29-32 
Figure 3.15 shows the MTDSC thermograms of HME 10% CAF-PVP K29-32 extruded at 155 
o
C.  
 
 
Figure  3.15: MTDSC thermograms of HME 10% CAF-PVP K29-32 by using pin-holed pan 
According to Figure 3.15, HME 10% CAF-PVP K29-32 exhibited partially glassy behaviour as 
indicated by a single Tg detected at 95.6 ± 4.1 
o
C and  a small melting peak at circa 207 
o
C.  
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Figure 3.16 shows the MTDSC thermograms of HME 20% CAF-PVP K29-32 extruded at 155 
o
C. 
Similar observation was seen in HME 20% CAF-PVP K29-32 extrudate as it shows a single Tg at 
75.4 ± 3.9 
o
C, and a melting endotherm at 212 
o
C in its DSC thermogram. However, an anomalous 
peak at around 115 
o
C was also noted in the total heat flow and non-reversing heat flow of Figure 
3.16. The cause of the anomalous exothermic peak at 115 
o
C was unknown. It is suspected that the 
anomalous peak may be related the recrystallization of the amorphous CAF which will be further 
confirmed by HSM investigation in the later part of this section.  
 
 
Figure 3.16: MTDSC thermogram of HME 20% CAF - PVP K29-32 by using pin-holed pan 
 
The detected melting endotherm in both HME 10% and 20% CAF-PVP K29-32 formulations 
suggested the existence of surplus crystalline material within the extrudates.   
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HME CAF-PVPVA 
Figure 3.17 displays the MTDSC thermogram for HME 10% CAF – PVPVA 6:4. According to 
Figure 3.17, the thermogram showed a Tg at around 60.9 ± 1.0 
o
C and an anomalous exotherrmic 
transition temperature at about 115 
o
C similar to that detected in HME 20% CAF-PVP K29-32 in 
Figure 3.16. No melting endotherm was noted from the profile which suggested the absence of 
crystalline material in the sample or dissolution of the crystalline material into the polymer carrier 
upon heating. 
 
 
Figure 3.17: MTDSC thermogram of HME 10% w/w CAF in PVPVA 6:4 by using pin-holed pan 
 
The MTDSC thermograms of the 10% CAF in PVPVA 6:4 (Figure 3.17) is complex, with 
transitions seen at circa 50 
o
C, 115 
o
C and 140 
o
C.  Given the non-linear nature of the baseline, 
interpretation becomes even more challenging as the exothermic, endothermic and reversing or 
non-reversing nature of the transitions becomes unclear. Nevertheless, it is possible to gain insights 
into these events via a combination of supportive HSM experiments and consideration of previous 
work on CAF polymorphs performed by Descamps et al. (2005). Figure 3.18 displays the captured 
screens of HME 10% CAF-PVPVA 6:4 upon heating from room temperature up to 250 
o
C by using 
HSM. 
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Figure 3.18: HSM investigation of HME 10% CAF-PVPVA 6:4 at a heating rate of 10 oC per minute. The marked 
temperatures at left bottom corner of each screen indicates the temperature of sample  
 
HSM screens in Figure 3.18 (c) show the appearance of crystalline material at circa 112 
o
C, which 
was in coherent to the anomalous exothermic peaks observed in both HME 20% CAF-PVP K29-32 
(Figure 3.16) and HME 10% CAF-PVPVA 6:4 (Figure 3.17). Thus it is suggested that the 
anomalous exothermic peaks observed in these thermograms were related to the recrystallization of 
some of the amorphous CAF from the dispersion.  
Besides, these observed crystals were disappearing at circa 140 
o
C (in Figure 3.18 (e)) which is 
well below the melting point of the drug but coincident with the transition between Form II and 
Form I caffeine. Descamps et al. (2005) have suggested that the transformation between Form II 
and Form I on heating is accompanied by a significant change in dielectric mobility, in turn 
reflecting a sizeable increase in molecular mobility as the drug goes through this enantiotropic 
transition on heating. The disappearance of the crystals may well be associated with this increased 
mobility leading to a greater tendency to dissolve in the PVPVA 6:4 on formation of the more 
mobile Form I at circa 140 
o
C.          
 
 
 
c) 112
o
C b) 100
o
C a) 37
o
C 
e) 149
o
C f) 160
o
C d) 132
o
C 
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Figure 3.19 shows the MTDSC thermogram of HME 20% CAF-PVPVA 6:4. From the Figure, a 
Tg was noted at 48.0 
o
C which indicated certain extent of amorphicity of the HME 20% CAF-
PVPVA 6:4 extrudate.  
 
 
Figure 3.19: MTDSC thermogram of HME 20% CAF PVPVA 6:4 by using pin-holed pan 
 
Unlike the HME sample with 10% loading of CAF, the recrystallization phenomenon was clearly 
shown in MTDSC curve of HME 20% CAF-PVPVA 6:4. The obvious recrystallization occurred at 
78.8 
o
C which revealed at a slightly lower temperature than the recrystallization temperature in 
HME 10% CAF-PVPVA 6:4. This is due to the lower proportion of polymer in retarding the 
recrystallization event in the HME 20% CAF-PVPVA 6:4 system. Finally, an apparent melting 
endotherm of CAF was seen at temperature 208 
o
C which was suggested the partially crystalline 
nature of this system (HME 20% CAF-PVPVA 6:4). An end point endotherm of 155 
o
C was 
observed which might be ascribed to the prolonged process of polymorphic transformation of Form 
II to Form I CAF in the presence of PVPVA 6:4 started from 140 
o
C which was anticipated by the 
HSM data in Figure 3.18 (Moura Ramos et al., 2006, Pinto and Diogo, 2006).  
In summary, therefore, it is suggested that the system in PVPVA 6:4 is initially amorphous and 
undergoes a glass transition at circa 50 
o
C; on further heating the Form II crystallizes out at around 
72 
o
C (for HME 20% CAF-PVPVA 6:4) or 115 
o
C (for HME 20% CAF-PVP K29-32 and HME 10 
CAF-PVPVA 6:4) and converts to Form I at circa 140 to 150 
o
C which subsequently melts at circa 
200 
o
C.  This is in contrast to dispersions in PVP K29-32, (Figure 3.15 and 3.16) whereby the 
system appears to be largely but not entirely amorphous, with a Tg coincident with the water loss 
peak, and a small melting peak detected at the melting point of Form I.  
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3.3.3.3. ATR-FTIR studies of HME preparation  
It is worth emphasizing at this point that PCM was chosen as an interactive API due to the 
availability of proton donor in its chemical structure. Whereas, CAF is chosen as a non-interactive 
API as there is no proton donor available in its chemical structure for the interaction with proton 
acceptor of PVP monomer. This could be further confirmed from ATR-FTIR study of the prepared 
samples. 
 
3.3.3.3.1. ATR-FTIR studies of HME PCM - PVP K29-32 
Figure 3.20 shows the ATR-FTIR spectra of pure PCM, PVP, PM and HME of 20-70% PCM PVP 
K29-32.  
 
Figure 3.20: ATR-FTIR spectra of PM and HME PCM-PVP K29-32 a) Form I PCM, b) raw PVP K29-32, c) PM 
50% PCM and PVP K29-32, d) HME 20% PCM-PVP K29-32, e) HME 30% PCM-PVP K29-32, f) HME 40% 
PCM-PVP K29-32, g) HME 50% PCM-PVP K29-32, h) HME 60% PCM-PVP K 29-32, i) HME 70% PCM-PVP 
K29-32 
 
Carbonyl (C=O) group of PVP monomer reveals stretching at 1652 cm
-1
. After the HME 
processing of PVP K29-32 with PCM, this band was slightly shifted to the lower frequency i.e. 
1647 cm
-1
. This indicated a certain extent of interaction that occurred at the carbonyl group of PVP 
monomer. 
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The ATR-FTIR spectrum of crystalline PCM indicates a characteristic band at 3324 cm
-1
 which is 
attributed to the NH stretching of PCM. This band was broadened in HME product which 
suggested the weakening or disappearing of the original –NH stretching vibration.  Furthermore, 
the –OH stretching band of crystalline PCM at region 3100 cm -1 was also broadened in the HME 
PCM PVP K29-32 products as compared to its pure crystalline ATR-FTIR spectrum which shows a 
moderate stretching band. Both changes of the characteristic peaks in the regions of 3100 cm
-1
 and 
3324 cm
-1
 indicated different vibration mode of -NH and –OH in the HME PVP-based SD. This 
might be due to the breaking of intermolecular hydrogen bonds of the crystalline PCM that 
dissolves into the polymer carrier while HME processing.  
At the fingerprint region of circa 900-700 cm
-1
, triplet peaks were seen for pure PCM and PM 50% 
PCM-PVP K29-32. However, in HME products, only a doublet was seen. According to Qi et al. 
(2008), the triplet peaks in this region was attributed to the crystalline material of PCM, whereas a 
doublet peaks infer amorphousness of the PCM. Therefore, based on the ATR FTIR spectra in 
Figure 3.20, HME 10% to 50% PCM PVP K29-32 extrudates were amorphous in nature as shown 
by the double band in print region of 900-700 cm
-1
. At higher PCM loading of HME PVP-based 
(60% and 70%) SD, the ATR-FTIR spectra show the reappearance of the diagnostic peaks of 
crystalline PCM (3100, 3324 and 807 cm
-1
) which implies the minor crystal trace in these samples. 
This result is in agreement to the MTDSC thermograms as presented in Figure 3.11.  
Combining the observations of down-shifted carbonyl stretching band in PVP monomer and the 
broadening in –NH/-OH stretching band of PCM molecules, it was thus suggested that hydrogen 
bond interactions were formed between the C=O group of PVP monomer and NH or OH groups of 
PCM (Nair et al., 2001, Wang et al., 2002). Attributions of each band from the spectra of HME 
products are further detailed in Table 3.9.  
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Table 3.9: Infrared bands of hot melt extrudate of PCM PVP in comparison to the corresponding PM 
Wavenumber 
(cm
-1
) 
Attribution in pure 
PCM (Wang et al., 2002) 
Changes observed in HME extrudates 
3324 NH stretching vibration Broadening of the band indicated stretching of -NH via 
intermolecular hydrogen bond within the crystal 
disappears, i.e. irregularity induced by incorporation of 
PVP or dissolved PCM molecules. 
3126 H-OH/OH stretching 
vibration plus 
combination band 
The glassy state of HME products causes slight shift in this 
band to higher wave-number which representing the 
solidified state of solid solution  
3174 H-OH/OH This band is till observed due to intra and intermolecular 
hydrogen bond with polymer molecules 
1650 C=O stretching vibration The glassy state of HME products causes slight shift in this 
band to lower frequency representing the hydrogen bond 
interaction 
1560 NH in plane bending It reduced intensity, shifted to lower frequency due to 
intermolecular hydrogen breaking in PCM crystal thus 
indicated amorphous formation  
1609, 1504, 
1433 
Aromatic mode  1512-shift to higher wavenumber due to solid solution form  
1374 CH bend Higher peak relatively to aromatic mode 
1328 OH bending vibration Shifted to lower wavenumber indicated stronger hydrogen 
bond interaction 
1226-1259 C-O/C-N stretching 
vibration 
broaden and higher frequency due to dispersive within 
polymer and amorphous have weaker bonds than crystal  
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3.3.3.3.2. ATR-FTIR studies of HME PCM in PVPVA 6:4 
Figure 3.21 shows the ATR-FTIR spectra of pure PCM, PVPVA 6:4 and HME PCM-PVPVA 6:4 
systems. According to Figure 3.21 (b), ATR-FTIR spectra of PVPVA 6:4 indicates two peaks at 
C=O stretching region, i.e. 1734 cm
-1
 and 1667 cm
-1
 which correspond to the C=O stretching of 
vinyl acetate and pyrrolidone, respectively. 
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Figure 3.21: ATR-FTIR spectra of PCM, PVPVA 6:4 and HME PCM-PVPVA 6:4 systems 
 
Interestingly, it is found that the C=O stretching (1734 cm
-1
) of the VA moiety in both PM and 
HME preparations of binary PCM-PVPVA 6:4 did not shift in comparison to the spectra of 
PVPVA 6:4 alone. This is in contrast to the C=O stretching of pyrrolidone where down-shifting of 
its peak position (from 1667 cm
-1
 to 1656 cm
-1
) was noted in HME PCM-PVPVA 6:4 in 
comparison to the PM and raw PVPVA 6:4. Therefore it was believed that the main interactions 
between PCM and PVPVA 6:4 occurs preferentially at the C=O group of the pyrrole group rather 
than the C=O in vinyl-acetate group. On that basis, the intensity of PCM-polymer interaction was 
higher in PVP K29-32 carrier system than in HME PVPVA 6:4 system.  
 
3.3.3.3.3. ATR-FTIR studies of HME CAF-PVP K29-32 and PVPVA 6:4 
Figure 3.22 compares the ATR-FTIR spectra of CAF, PVP K29-32 and HME CAF in PVP K29-
32. ATR-FTIR spectra of HME 10-20% CAF in PVP K29-32 did not show any significant peak 
position shift in the carbonyl stretching region of the PVP as compared to its corresponding PM 
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(Figure 3.22). This was attributed to the absence of physical interactions between the CAF and 
PVP (PVP K29-32 and PVPVA 6:4) molecules.  
 
Figure 3.22: FTIR spectra for a) CAF, b) PVP K29-32, c) PM 10% CAF-PVP K 29-32, d) HME 10% CAF-PVP 
K29-32, e) HME 20% CAF-PVP K29-32 
 
Figure 3.23 shows the ATR-FTIR spectra of CAF, PVPVA 6:4 and HME CAF-PVPVA 6:4. 
Similarly, no significant peak shift is noted in the PM and HME of CAF-PVPVA 6:4 which 
reconfirms the lack of drug-polymer interaction in these systems.  
 
Figure 3.23: ATR-FTIR spectra for a) CAF, b) PVP VA 6:4, c) PM 10% CAF-PVPVA 6:4, d) HME 10% CAF-
PVPVA 6:4 e) HME 20% CAF-PVPVA 6:4 
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3.3.3.4. X-ray Powder Diffraction of HME solid dispersions 
The ability of PVP polymers to maintain molecules in a non-crystalline form has been studied by 
several groups (Tamaki et al., 2004, Nair et al., 2001, Thybo et al., 2008b, de Villiers et al., 1998). 
In this context, X-ray Powder Diffraction (XRPD) measurement was frequently performed to 
confirm the presence or absence of crystallinity in the SD formulation. Thus, to reconfirm the 
nature of the prepared HME PVP-based extrudates, their XRPD behaviour was measured. The 
percentage of crystalline material within the extrudates was calculated based on a calibration curve 
that could be found in Appendix I (Figure (i)).  
 
3.3.3.4.1. XRPD of HME PCM in PVP K 29-32 
Figure 3.24 shows the XRPD diffractograms of HME PCM PVP K29-32 systems. The 
diffractograms showed halo patterns up to 50% drug loadings. At higher PCM loading i.e. 60%-
70%, clear diffraction peaks were noted as anticipated from the opaque appearance of the extrudate 
at these loadings.  
10 12 14 16 18 20 22 24 26 28 30
a) 20%
g)PM20%
e)60%
f)70%
b)30%
2θ degree
c)40%
d)50%
PCMPVPK29/32
h)Pure PCM
 
Figure 3.24: X-ray Diffraction patterns of PCM and PVP K29-32, a) HME 20% PCM, b) HME 30% PCM , c) 
HME 40% PCM, d) HME 50% PCM, e) HME 60% PCM, f) HME 70% PCM, g) PM 20% PCM  and h) Pure 
PCM 
 
The diffracted peaks in the X-ray diffractograms of HME 60% and 70% PCM PVP K29-32 (Figure 
3.24) corresponded to the initially used polymorphs form, i.e. Form I crystals (Al-Zoubi et al., 
2002). The detection of  crystalline material for HME 60% PCM-PVP K29-32 and above was due 
to the use of a relatively low extrusion temperature, i.e. 120 
o
C, which rendered only a certain solid 
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solubility limit at about 50% of drug loading in PVP K29-32. However, the reduction of crystal 
content were still seen in extrudates of 60% and 70% drug loading compared to the PM. The 
percentage of crystalline PCM is compared to the calculated crystallinity from previous section on 
MTDSC (Figure 3.11). Table 3.10 summarise the percentage of crystalline PCM detected by using 
both XRPD and MTDSC methods. It was noted that the calculated percentages of crystalline PCM 
were in good agreement to that prediction from MTDSC data. 
 
Table 3.10: Percentage crystalline PCM in HME PCM- PVP K29-32 
Samples XRPD Crystallinity (%) MTDSC Crystallinity (%) 
HME 60% PCM-PVP K29-32 13.72 14.43 
HME 70% PCM-PVP K29-32 29.25 29.17 
 
 
3.3.3.4.2. XRPD of HME PCM in PVPVA 6:4 
 
Figure 3.25 shows the XRPD data of HME PCM in PVPVA 6:4 systems. Unlike PVP K29-32 
carriers system of PCM, HME 50% w/w PCM-PVPVA 6:4 gave rise to X-ray diffraction peaks. 
This in turn implies that the solubility limit of PCM in PVPVA 6:4 is lower than that in PVP K29-
32. Table 3.11 outlines the percentage of crystalline material in HME 50% PCM in PVPVA 6:4. 
10 12 14 16 18 20 22 24 26 28 30
PCM PVPVA
a)20%
c)40%
b)30%
d)50%
e)PM20%
 
Figure 3.25: X-ray diffraction patterns of PCM with PVPVA 6:4, a) HME 20% PCM, b) HME 30% PCM , c) 
HME 40% PCM, d) HME 50% PCM, e) PM of 20 % PCM-PVPVA 6:4 
 
Table 3.11: Percentage of crystal based on Bragg reflection peak from XRPD 
Samples XRPD Crystallinity (%) MTDSC Crystallinity (%) 
HME 50% PCM-PVPVA 6:4 10.52 8.91 
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The excess crystalline material seen in HME 60% PCM PVP K29-32 and HME 50% PCM in 
PVPVA 6:4 led to the conclusion that the solid solubility of PCM in the presence of PVP K29-32 
and PVPVA 6:4 at 120 
o
C were circa 50% and 40% of drug loading, respectively. Interestingly, 
this observation corresponded to the theoretical estimation in Chapter 3.3.1.2, Table.3.5. 
 
3.3.3.4.3. XRPD of HME CAF in PVP K29-32 and PVPVA 6:4 
X-ray Powder diffraction was also used to analyse extrudates of HME CAF in PVP systems. Since 
the diffracted peaks in the X-ray diffractograms of HME PVP-based CAF systems indicated a 
different polymorphic form of CAF which was different from the PM of raw CAF, percentage of 
CAF crystallinity in the HME extrudates was not performed. Thus the discussion below describes 
only the XRPD characteristic of the HME CAF-PVP based samples without quantification of the 
crystalline CAF. 
 
HME CAF-PVP K29-32 
Figure 3.26 displays the XRPD spectra of CAF, PM and HME of CAF PVP K29-32 systems. A 
halo pattern was only detected in HME 10% CAF-PVP K29-32. 
 
Figure 3.26: X-ray diffraction patterns of CAF and PVP K29-32, a) HME 10% CAF, b) HME 20% CAF, c) PM of 
10% CAF d) commercial CAF as received 
 
In XRPD diffractograms of HME 20% CAF-PVP K29-32, a single characteristic peak at 2θ = 
26.86
o
 was noted which is attributed to Form I CAF (Figure 3.26 (b)). The detection of Form I in 
the hot processed HME PVP-based extrudates was not unexpected as Form I CAF was reported to 
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be stable at high temperatures (Descamps et al., 2005b, Moura Ramos et al., 2006, Kishi and 
Matsuoka, 2010). Besides, X-ray diffractogram of HME 20% CAF PVP K29-32 shows a reduction 
in degree of crystallinity of CAF as compared to its PM. Therefore, it is suggested that CAF 
dissolves into PVP K29-32 to a minor extent upon heat processing. 
Recalling the DSC thermogram of HME 20% CAF PVP K29-32, an anomalous peak and a melting 
peak were noted at 115 
o
C and 212 
o
C, respectively. The melting peak corresponds to the detection 
of crystalline trace which is in accordance to the diffracted peak seen in the XRPD diffractogram 
(Figure 3.26). 
 
HME CAF-PVPVA 6:4  
Figure 3.27 presents XRPD diffractograms of HME CAF-PVPVA 6:4 systems. From Figure 3.27, 
HME CAF-PVPVA 6:4 reveals a halo pattern for HME 10-20% CAF-PVPVA 6:4 systems. This 
result did not agree with the data obtained from MTDSC and HSM (refer to Chapter 3.3.3.2.2, 
Figure 3.17 to 3.18) which indicated the presence of crystalline material in both 10% and 20% of 
HME CAF PVPVA 6:4 system. This might be due to the limited sensitivity of XRPD in detecting 
low percentage of crystalline material (Saleki-Gerhardt et al., 1994).   
 
Figure 3.27: X-ray diffraction patterns of CAF and PVPVA 6:4, a) CAF, b) PM of 10% c) HME  30%, d) HME 
20%, e) HME 10% 
 
Unlike HME CAF-PVP K29-32, a higher amorphous content was noted in HME CAF 20% 
PVPVA 6:4 as shown by its halo patterns in XRPD diffractograms. This might be ascribed to the 
higher extrusion temperature employed in HME PVPVA 6:4 system (i.e. 180 
o
C) as compared to 
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PVP K29-32 (i.e. 155 
o
C). Similar to the HME 20% CAF-PVP K29-32, XRPD diffractograms of 
HME 30% CAF-PVPVA 6:4 system indicated single peaks at 2θ = 26.86o which was attributed to 
the Form I CAF (Lehto and Laine, 1998). This is due to the transformation of CAF Form II (raw) 
to Form I while hot processing at 180 
o
C. Therefore, at 30% CAF loading of HME CAF-PVPVA 
6:4, system, there was certain amount of un-dissolved crystalline CAF in the formulations.  
 
3.3.3.5. Scanning Electron Microscopy 
3.3.3.5.1. SEM of HME PCM in PVPK29-32 and PVPVA 6:4 
SEM was used to image the surface and cross sectional morphology of extrudates. Figure 3.28 
shows the SEM micrographs of PM 40% PCM-PVP K29-32, the surface of the freshly prepared 
HME 40% PCM-PVP K29-32 extrudates and the corresponding cross section and also the surface 
of HME 60% PCM-PVP K29-32. 
 
Figure 3.28: SEM image of a)PM of PCM-PVP K29-32, b) fresh extrudate of HME 40% PCM-PVP K29-32 
surface, c) fresh extrudate of HME 40% PCM-PVPVA 6:4, d) Cross section of extrudates of HME 60% PCM-
PVP K29-32 
 
SEM image of PM PCM and PVP K29-32 (Figure 3.28 (a)) reveals needle-shape crystals of PCM 
embedded on the raw spherical PVP K29-32 particles which were prepared commercially via spray 
a) 
d) c) 
b) 
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drying. As displayed in Figure 3.28 (b), extrudates of PVP K29-32 with drug loading of 40% 
indicated shark skinning features on its surface. This was due to the high friction and low 
flowability of the molten material during the extrusion process at temperature lower than Tg of the 
polymer. However, for HME 40% PCM-PVPVA 6:4 system, smooth surfaces were noted (Figure 
3.28 (c)). At high loading of PCM, i.e. HME 60% PCM-PVP K29-32 systems, small crystals were 
embedded at both the surface and cross section of the HME 60% PCM-PVP K29-32 extrudate 
(Figure 3.28 (d)). This is in good agreement to the proposed solubility threshold of PCM in PVP 
K29-32 prepared at 120 
o
C whereby 55% of PCM is the solubility limit of PCM in PVP K29-32 
(please refer to Table 3.5 for solubility threshold). To summarise, all the observed features of 
extrudate in SEM were in agreement with the concluded amorphicity / crystallinity of HME PCM-
PVP K29-32 and HME PCM-PVPVA 6:4 systems deduced from XRPD data in Chapters 3.3.3.4.1 
and 3.3.3.4.2.  
 
3.3.3.5.2. SEM of HME CAF in PVP K29-32 and PVPVA 6:4 
Figure 3.29 displays the SEM micrographs of raw CAF (Form II), Form I CAF and HME PVP-
based dispersions of CAF.  
 
Figure 3.29: a) raw CAF (Form II), b) heated CAF (Form I was prepared by heating the From II in a covered 
petri-dish condition. The sublimated product were Form I as confirmed by XRPD), c) HME 10% CAF-PVPVA 
6:4 and d) c) HME 10% CAF-PVP K29-32 
(a) (b) 
(d) (c) 
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As expected from the lower miscibility of CAF with both the PVP carrier systems (predicted from 
solubility parameter and Gibb free energy of mixing), Figure 3.29 (c) and (d) reveal tiny crystal 
traces of needle-shape in both HME 10% CAF in PVP K29-32 and HME 10% CAF in PVPVA 6:4 
which corresponds to the Form I CAF as shown in Figure 3.29 (b). This might be attributed to the 
recrystallization upon extrusion or incomplete solubilising of these materials during the HME 
manufacturing process. These observations agree with the results from the DSC thermograms but 
the contradict XRPD data which did not indicate the presence of crystalline material. This might 
due to different sensitivity of the analysis methods in which XRPD was reported to have the 
detection limit down to only 10% of crystalline material in a mixture (Saleki-Gerhardt et al., 1994). 
To summarise this section, SEM images showed the partially crystalline nature in all the HME 
CAF PVP-based systems. Hence, SEM images of all the HME PVP-based systems have supported 
the results of extrudate characterization studies described in the previous sections.  
 
3.4. Discussion 
3.4.1. Theoretical estimation of miscibility 
It is reported that when difference in solubility parameters of drug-polymers is < 7.0 MPa
1/2
, 
significant miscibility between the two components is expected (Forster et al., 2001c, 
Maniruzzaman et al., 2013). In this study, good miscibility was predicted in the binary system of 
the interacting API, i.e. PCM and PVPs polymers as shown by the small difference in their 
solubility parameters. In contrast, solubility parameters of the non-interacting API, i.e. CAF with 
PVPs polymers show differences of > 8 MPa
1/2
 which imply limited miscibility. As a result it is 
expected that the CAF and PVP carriers may not easily form fully amorphous solid dispersions in 
the HME processing. Similarly, interaction parameter prediction from melting point depression 
studies also implied the trend described above. Larger negative values, indicating high miscibility, 
of the interaction parameter were obtained for PVP K29-32 and PVPVA 6:4 with PCM (the 
structurally interacting API) as compared to CAF (the structurally non-interacting API). This result 
is in agreement to a recently published paper whereby the authors reported the importance of drug-
polymer interaction in promoting miscibility of the components (Maniruzzaman et al., 2013). 
On comparing the homopolymer (PVP K29-32) and co-polymer (PVPVA 6:4), more negative 
values of interaction parameter were seen in the former with both the APIs. This is because of the 
higher interactive units available in PVP K29-32 for drug-polymer interaction than the co-polymer, 
PVPVA 6:4. This difference might potentially affect the ability to produce fully amorphous solid 
dispersions as well as influencing the stability of the systems. Production of amorphous solid 
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dispersions will be detailed out at later section and the influence of carrier system on the stability 
issues of the prepared extrudates will be presented as separate chapter (Chapter 4). 
 
3.4.2. Production of amorphous solid dispersion 
The non-interacting CAF which was shown to have limited miscibility was not successfully 
extruded as a fully amorphous solid dispersion. On the other hand, the interacting PCM, which was 
predicted to have good miscibility with PVP was shown to be extruded as fully amorphous solid 
dispersion up to 40% and 50% of PCM loading in PVPVA 6:4 and PVP K29-32, respectively. This 
result is in agreement to some recently published reports whereby the use of Hansen solubility 
parameter has been shown to be useful in predicting miscibility of API and polymer for the 
production of solid dispersion (Djuris et al., 2013b, Forster et al., 2001c, Maniruzzaman et al., 
2013, Sarode et al., 2013). The drug polymer miscibility is attributed by  balancing the  energy of 
mixing  released from the  intermolecular interaction between the API and polymer with the energy 
release from the intramolecular interaction in the components (Maniruzzaman et al., 2013). As a 
result, an interacting API is preferred in the production of fully amorphous solid dispersion at 
temperature lower than its melting temperature. In this context, the prediction of miscibility could 
be estimated from the Hansen solubility parameter as well as melting point depression approach. 
In addition, the limits of PCM loading in PVPs polymer (up to 40% and 50% of PCM loading in 
PVPVA 6:4 and PVP K29-32) were found to have good correlation to the solid solubility 
calculated using Equation (3.10) and (3.11) as tabulated in Table 3.5. It is worth mentioning that 
the T envisaged in this calculation was the extrusion temperature employed during the extrusion 
process (i.e. Tprocess < Tm). Thus, the calculated solid solubility in this case may only represent the 
loading of drug that could be incorporated in the formulation in order to achieve a fully amorphous 
solid dispersion at Tprocess < Tm. On the other hand, solid solubility prediction of CAF in PVPs by 
using the melting point depression approach did not agree to the results obtained experimentally in 
that some miscibility was predicted but at concentrations of 10% w/w and above, crystalline 
material was detected in both polymer systems. This was probably due to the sublimation 
characteristics of CAF molecules near to its melting temperature (as shown in TGA result, Table 
3.7), hence, complicating the use of the melting point depression approach for this material.   
On comparing the homopolymer (PVP K29-32) and co-polymer (PVPVA 6:4) as a carrier in SD 
system, the former was found to have higher accommodation of PCM (higher PCM loading) in 
producing fully amorphous dispersions. This is attributed to the higher extent of hydrogen bond 
interaction between PCM and carrier in HME PCM PVP K29-32 system than in HME PCM 
PVPVA 6:4 system which was confirmed by their ATR-FTIR spectra. According to the infrared 
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spectra, hydrogen bond interaction between PCM and carrier occurred preferentially at the C=O 
group of PVP monomer (for both PVP K29-32 and PVPVA 6:4) compared to the C=O of the vinyl 
acetate. These results are comparable to a previous work on colyophilized indomethacin with PVP 
and PVPVA 6:4 (Shamblin et al., 1998) where the drug polymer interaction occurs preferentially in 
the C=O group in the pyrrole ring as compared to the C=O found in vinyl acetate.  
The preferential  hydrogen bond interaction on C=O of pyrrolidone group compared to the C=O of 
the vinyl-acetate group is reported to be due to the stronger basic nature and the higher partial 
atomic charges on the oxygen functional group of the C=O in pyrrolidne which acts as a stronger 
proton acceptor as compared to the C=O of vinyl acetate (Trasi and Taylor, 2012, Shamblin et al., 
1998, Matsumoto and Zografi, 1999). Thus the C=O of vinyl-acetate in PVPVA 6:4 system was 
found to not play a significant role in the drug-polymer interaction which may be associated with 
the lower solubilizing effect of this polymer on the crystalline drug during the  hot melt extrusion 
process. 
 
3.4.3. Extrudate properties 
Water contents of the HME extrudates were consistently lower than their corresponding PMs. This 
was due to the nature of the process whereby heating of the mixture allowed the removal of 
moisture. Even so, HME is a closed barrel process whereby less than 100% of the moisture could 
be released during the feeding process and upon extrusion, thus a certain amount of moisture could 
be trapped within the extrudate. This is clearly evidenced by the grinding experiment in Figure 3.14 
that led to the observation of reduced glass transition temperature from the theoretical prediction 
via Gordon-Taylor (G-T) equation (Figure 3.13). Similar observations were noted by Patterson et al 
(2008) in comparison between the Tg of SD obtained from melt extrusion and spray drying 
processes. In that study, the melt extrusion product possessed lower Tg values than the spray dried 
equivalents, despite the use of higher processing temperatures in HME process (Patterson et al., 
2008).   
 
3.5. Conclusion 
The agreement between the experimental data and miscibility behaviour predicted from a 
theoretical group contribution approach was found to be very good. Since the reference table of the 
chemical group contributions forces is widely available and it provides a good estimation in most 
cases, it is suggested that this approach could be suitable for predicting the suitability of a material 
to be processed by HME. The Flory Huggins interaction parameter predicted from melting point 
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depression approach was also in agreement to the data obtained from experimental studies. This 
implying that both theoretical predictions of miscibility (Hansen solubility parameters and melting 
point depression) may be used to anticipate the successful formulation of a molecularly dispersed 
hot melt extruded system.  
Similarly, the solid solubility prediction for HME PCM PVPs system shows good agreement to the 
limit of PCM loading in producing a fully amorphous solid dispersion obtained from 
characterization of the extrudates experimentally. This suggested the good predictability of the 
melting depression method in estimating the loading limit of API in the production of fully 
amorphous HME PVP-based SD at Tprocess < Tm. This is provided there is not complication in data 
interpretation of the depressed melting point of API in the DSC thermogram. 
In the context of processing, small molecular size of API was found to plasticize the big molecular 
size of PVP polymer which leads to its flowability at temperature lower than its Tg which resolve 
the worries of PVP degradation at temperature higher than its Tg. In this respect, the interacting 
API could further aid the production into fully amorphous solid dispersion due to the melting point 
depression of API in the presence of PVP polymer alongside with its good miscibility with the PVP 
polymer.  However, one should bear in mind on the processing condition of interacting PCM with 
PVP whereby an increase in viscosity of the molten system were noted with the Tprocess < Tg of 
polymer. The rigidity build-up of the molten during the extrusion process might limit subsequent 
diffusivity of the API within the polymer system. At a macroscopic level, this parameter was 
seemed to be irrelevant in the properties of freshly prepared extrudates. However, the effect of this 
parameter in other performances of solid dispersion such as physical stability shall not be 
overlooked. This will be further correlated to the physical stability of the extrudates in next chapter 
(Chapter 4). 
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Chapter 4. An investigation into the recrystallization of 
paracetamol in HME PCM PVP-based solid dispersions 
 
4.1. Introduction 
HME is a well-known process for the production of amorphous SDs with relatively good physical 
stability profiles as reviewed in Chapter 2.2.2.1, (Dong et al., 2008b, Verreck et al., 2004, De 
Brabander et al., 2003, Fukuda et al., 2006a). In this process, the use of PVP, despite its good 
physical stabilization capacity (Balani et al., 2010, Berggren and Alderborn, 2004, Yoshioka et al., 
1995), is discouraged due to the possible degradation of PVP at high temperature (Chokshi et al., 
2005). Previous chapter (Chapter 3) has suggesting the feasibility of employing PVP polymers in 
HME processes based on the phenomenon of melting point (Tm) depression of API in the presence 
of polymer, thereby providing a means by which the issue of PVP degradation may be overcome. 
As there are only limited studies of PVP in the context of HME processes, understanding of the 
physical instability of the PVP-based HME formulations is somewhat lacking. Thus in this chapter, 
the physical stability of the HME PVP-based SD was investigated by studying its recrystallization 
behaviour.  
The previous chapter (Chapter 3) has shown the different molten flowability of API in the 
homopolymer of PVP K29-32 and copolymer PVPVA 6:4 during the extrusion process. This 
difference might affect the characteristics of the system at a molecular level, potentially causing the 
physical stability variation of the HME product. Therefore, a physical stability study of the HME 
PVP-based product was carried out with a focus on the possible effect of molten flowability of the 
samples during the HME process. In this case, in addition to both PVP K29-32 and PVPVA 6:4, 
polymers with lower molecular weights (i.e. PVP K17 and PVP K12), which represents low molten 
flowability SD systems during processing, were investigated in this study.  
In this chapter, the physical stability of the HME PVP-based SD was reflected by recrystallization 
profile of the PCM in the PVP matrix of HME product. To access the crystallinity of PCM, a 
method for quantifying the crystalline content of paracetamol (PCM) was developed by using 
Attenuated Total Reflectance - Fourier Transform Infrared (ATR-FTIR). This was achieved by 
investigating the relationship between a characteristic crystalline peak in the ATR-FTIR spectrum 
of the PCM and its thermal behaviour using Differential Scanning Calorimetry (DSC), which forms 
the first part of the chapter. Then, the developed ATR-FTIR method was used at the later sections 
of this chapter to probe the crystallinity the aged HME PCM PVPs-based samples under heat and 
humidity conditions which will be presented.  
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4.2. Material and methods 
4.2.1. Establishment of quantification methods for crystalline PCM 
4.2.1.1. Preparation of amorphous and Form II of PCM 
Form I polymorph of PCM was used as received. Form II PCM was prepared by slow cooling of 
the melted PCM (Qi et al., 2008a). To do this, the raw PCM was melted on a hot plate at 180
 o
C for 
1 minute, and then the molten PCM was slow-cooled on the same hot plate in power off conditions 
(switched off). The prepared forms of PCM were re-confirmed by using XRPD with detailed 
scanning parameters being presented in section 4.2.2.1. On the other hand, amorphous PCM was 
prepared by freshly quench-cooling (QC) PCM. This was carried out by heating the raw PCM 
above the melting temperature, i.e. at 180 
o
C for 1 minute by using a hot plate (noting that TGA 
had previously indicated that this would not result in degradation), and then quench cooling the 
melted sample in liquid nitrogen for 10 seconds. However, it is worth emphasizing that, QC PCM 
will lose its fully amorphous nature when it is left under room conditions for more than 1 minute. 
This is ascribed to the low Tg of the amorphous PCM i.e., circa 23 
o
C that prone to undergo 
recrystallization at room temperature (Qi et al., 2008a, Di Martino et al., 1997, Di Martino et al., 
1996, Di Martino et al., 2000).  
 
4.2.1.2. The detection of crystalline PCM by using ATR-FTIR and high speed DSC 
Detection of crystalline PCM using ATR-FTIR 
The prepared forms of PCM (Chapter 4.2.1.1) were distinguished by using ATR-FTIR. According 
to the literature, ATR-FITR spectra could be used to distinguish the different forms of crystalline 
PCM. In particular, it is suggested that band of 807 cm
-1
 in the spectra of PCM can be used as 
specific identification for Form I PCM as this band is absent in Form II PCM (Ivanova, 2005, Al-
Zoubi et al., 2002, Qi et al., 2008b). In order to observe the recrystallization behaviour of QC PCM 
as reflected by the growth of 807 cm
-1
 over time, multiple infrared measurements of the QC PCM 
were performed at the rate of 1 measurement per minute over 2 hours. In each measurement, the 
infrared spectra were collected between 500 - 4000cm
-1
 with a resolution of 2 cm
-1
 and 32 scans.  
 
Quantification of crystalline PCM using DSC 
DSC was used to determine the percentage of crystalline material in the QC PCM over time. The 
freshly prepared QC PCM was immediately analysed using conventional DSC run at high speeds 
heating, i.e. from -50 to 300 
o
C at a calibrated rate of 100 
o
C per minute. This speed was chosen so 
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as to minimise polymorphic conversion during the run itself. In this measurement, pinhole 
aluminium pan was used based on preliminary work, which indicated the recrystallization of the 
QC PCM into only Form I of PCM. Then, the recrystallization of the QC PCM was tracked as a 
function of time by DSC measurement. Crystalline content of the recrystallized QC PCM obtained 
from DSC data was correlated to the profile of relative peaks intensity (band 807 cm
-1
 to 797 cm
-1
) 
changes obtained from ATR-FTIR method. Details of the correlation will be presented in section 
4.3.1.  
 
4.2.2. Preparation of amorphous HME solid dispersions 
In the preparation of HME PVP-based SD, four different types of carrier were employed. These 
include three different molecular weights of homopolymers, i.e. PVP K12, PVP K17, PVP K29-32 
and a co-polymer, PVPVA 6:4. HME 30-50% (w/w) PCM loading in PVP carriers were prepared. 
Please refer to Table 2.12 for the processing parameters used in the manufacturing of HME 30-50% 
PCM-PVP K29-32, 30-50% PCM-PVP K17, 30-50% PCM-PVP K29-32, 30-50% PCM-PVPVA 
6:4 systems.  
 
4.2.2.1. Basic characterisation of HME solid dispersions 
The amorphicity of the SD extrudates (HME 30-50% PCM in PVP(s) and PVPVA 6:4) was 
confirmed by using complementary results obtained from ATR-FTIR and XRPD. The scanning 
parameters as presented in Chapter 3, section 3.2.6 and 3.2.7 were used for ATR-FTIR and XRPD, 
respectively. 
 
4.2.2.2. Fragility calculation of the HME solid dispersions 
DSC was used to measure the Tg of the prepared extrudates. In order to calculate the fragility index 
of the HME sample, which was correlated to their physical stability, DSC measurements of the 
freshly prepared extrudates were performed in standard mode at different heating rates (5, 10, 20, 
50 
o
C per minute). The changes of Tg obtained at different heating rates were used to estimate the 
fragility index of the extrudates.  
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4.2.3. Recrystallization studies of HME PCM-polymers system 
 
The influence of storage humidity 
In recrystallization studies, the SD extrudates were cut into pieces of extrudates circa 3-4 mm long 
prior to storage. The influence of the degree of relative humidity on recrystallization behaviour of 
HME 40% PCM-PVPVA 6:4 system were studied by desiccating the cut extrudates in different 
humidity conditions ranging from 0% RH (phosphorus pentoxide), 22% RH (potassium acetate), 
33% RH (magnesium chloride), 53% RH (magnesium nitrate) to high humidities of 75% RH 
(sodium chloride) at the room temperature. The humidity condition of the desiccator was confirmed 
by using a hygrometer before the storage of extrudates.  
 
The influence of different PVPs carriers and PCM loading 
Subsequently, an accelerated storage condition, i.e. 75% RH was used to study other factors in 
affecting recrystallization behaviour of the HME PCM-PVP based system. These factors include 
the effect of different carriers system and the effect of drug loadings.  
In studying the effect of different carriers (three homopolymers of different molecular weights, i.e. 
PVP K12, PVP K17, PVP K29-32 and a co-polymer), HME 40% PCM different carriers systems 
were aged in the 75% RH for up to 3 months. On the other hand, the effect of drug loading was 
studied by storing the HME 30% PCM-carriers system and HME 50% PCM-carriers system at the 
accelerated humidity condition, i.e. 75% RH at 25 
o
C. Their recrystallization patterns were 
compared to the recrystallization pattern of formulations with 40% PCM loading under the same 
storage condition.  
  
The influence of storage temperature 
The effect of temperature on recrystallization behaviour of the HME 40% PCM-carrier was also 
studied by storing the extrudates under 0% RH / 40 
o
C oven. The annealed extrudates were sampled 
at predetermined time points and tested by using DSC, ATR-FTIR, and SEM for the detection of 
crystalline material.  
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4.2.3.1. DSC studies 
For the recrystallization study, the aged SD of HME 30-50% PCM-carriers were analysed using a 
DSC with modulated mode (MTDSC). Pin-hole lids were used to allow removal of water, 
particularly given the hygroscopic nature of the PVP polymers (Callahan et al., 1982). Samples 
were heated at 2 
o
C per minute from -20 
o
C with modulation of ± 0.212 
o
C every 40s to 200 
o
C. All 
experiments were run in triplicate. 
 
4.2.3.2. TGA studies 
Thermogravimetric analysis was performed to quantify the water content of the aged HME 30-50% 
PCM-carriers after humidity storage. The same parameters as stated in Chapter 3, section 3.2.5 
were used.  
 
4.2.3.3. ATR-FTIR 
ATR-FTIR measurement of the aged HME 30-50% PCM-PVPs were performed daily for the first 
14 days of sample storage in humidity conditions using the same parameter. After that, the ATR-
FTIR measurements of the aged extrudates were performed monthly up to 3 months. The same 
scanning parameters as stated in section 4.2.1.2 were used. 
 
4.2.3.4. XRPD 
XRPD experiments were also performed on the aged HME 30-50% PCM-carriers. Upon XRPD 
measurement, the aged extrudate was ground gently in a mortar and pestle before compaction into 
the sample holder of XRPD machine. Measurements were performed using the same parameters as 
described in Chapter 3, section 3.2.8.  
 
4.2.3.5. SEM 
Surface morphology of the aged extrudate was investigated using Scanning Electron Microscopy 
(SEM). Please refer to Chapter 3, section 3.2.9 for experimental details.  
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4.3. Results 
4.3.1. Development of ATR-FTIR method as a quantification method for crystalline PCM 
In order to study the recrystallization behaviours of the HME PVP-based SD, a quantification 
method of the recrystallized API was developed. DSC is an excellent technique in recrystallization 
study of a pure API. However, this technique might post a problem in recrystallization study of a 
drug-polymer blend system due to the possible drug dissolution into the polymer during heating 
scan of DSC that might lead to complex data interpretation. Hence, the quantification of the 
recrystallized material in the aged HME systems was assessed by using ATR-FTIR. Nevertheless, 
DSC was employed in the later sections to study the Tg (s) of the aged samples in order to detect 
possible phase separation after storage. 
Prior to the recrystallization study, a quantification method of PCM by using ATR-FTIR is 
developed based on the recrystallization kinetic of PCM in its pure amorphous state. This will be 
further detailed in the subsequent sections.  
 
4.3.1.1. Identification of different polymorphs of PCM in ATR-FTIR 
Prior to the quantification of crystalline PCM, different forms of PCM were distinguished by using 
the ATR-FTIR. Figure 4.1 displays the ATR-FTIR spectra of amorphous, Form I and Form II of 
PCM that were produced as outlined in section 4.2.1.1. 
According to Figure 4.1, Form I PCM was characterized by a unique absorption band at 807 cm
-1
 
which is attributed to the out of plane bending mode of methyl group in PCM molecule (Al-Zoubi 
et al., 2002, Ivanova, 2005). This band (807 cm
-1
) is absent in both the Form II and amorphous 
PCM. Thus it is suggested that this peak (807 cm
-1
) could be useful for the identification of Form I 
PCM.   
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Figure 4.1: ATR-FTIR spectra of different solid-state forms of PCM. (a) Form I was scanned as received (raw), 
(b) Form II was prepared by slow cooling as described in the method section, (c) ATR-FTIR spectra of amorphous 
PCM which was obtained by immediately scanning after the quenched-cooling of the molten PCM. 
 
On the other hand, Form II PCM reveals a different ATR-FTIR spectrum from the amorphous form 
and Form I PCM. According to Figure 4.1, Form II gave rise to double bands in the region of 1665 
cm
-1
 and 1608 cm
-1 
which was shown as single broad band in the spectra of amorphous and Form I 
PCM. Furthermore, ATR-FTIR spectrum of Form II could also be distinguished from the 
amorphous PCM by the peak at 3324 cm
-1
 which is absent in spectrum of amorphous PCM. This 
peak (3324 cm
-1
) is responsible for the NH stretching of the intermolecular H-bond within the 
crystal (Wang et al., 2002), which is not present in the non-crystalline structure of amorphous PCM 
(Al-Zoubi et al., 2002, Ivanova, 2005). 
 
4.3.1.2. Tracking of the relative intensity of 807 cm-1 in QC PCM by using ATR-FTIR 
From the identification of different forms of PCM in ATR-FTIR, it was noted that 807 cm
-1
 could 
be used to exclusively represent Form I PCM. By detecting the intensity of this peak in the ATR-
FTIR spectra, the amount of Form I PCM presence in a sample could be estimated. With that, the 
freshly prepared QC PCM was scanned by ATR-FTIR as a function of time. Figure 4.2 shows the 
multiple ATR-FTIR spectra of the freshly prepared QC PCM over 2 hours.  
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Figure 4.2: Multiple ATR-FTIR spectra of quench-cooled PCM that were taken every 2 minutes. Growing of the 
diagnostic 807 cm-1 band was started from the grey line (lowest absorbance), in which its IR absorbance was found 
to increase with time. 
 
Immediate scanning of the QC PCM revealed no characteristic band of 807 cm
-1
, (as indicated by 
the arrow corresponding to ‘fully amorphous’ material), which indicated the amorphous nature of 
the PCM immediately after the QC process. However, this band started to appear in the second 
spectrum, which was scanned after 1 minute of the quench-cooling procedure. In addition, the band 
of 807cm
-1
 was found to increase with time, which indicating the progress of recrystallization into 
Form I PCM. The relative intensity of this band was expressed as a ratio to a band with constant 
intensity, i.e. 797 cm
-1 
as shown in Equation (4.1). 
 
                    
                     
                     
                                                 
 
According to Equation (4.1), the percentage of crystallinity could be estimated if the relationship of 
the relative intensity and its real crystalline content is known. This was performed by correlating 
the relative intensity in Equation (4.1) to the percentage of crystallinity calculated from the high 
speed DSC which will be presented in the subsequent sections. 
 
 
 
  
     
780    
Wavenumber (cm-
1
) 
0.00 
 
 
 
 
 
 
 
A
b
so
rb
a
n
ce
 U
n
it
s 
 
  
 
Fully amorphous 
Growing of the  
diagnostic band of  
crystalline counterpart 
Reference 
 band 
Recrystallization of HME PCM PVP-based solid dispersions                                           Chapter 4 
 
School of Pharmacy, University of East Anglia   146 
 
4.3.1.3. Quantification of the recrystallized PCM using DSC 
DSC was used to determine the amount of crystal PCM in the QC PCM. This estimation was based 
on the melting endotherm of PCM by scanning the QC PCM. DSC measurements of the QC PCM 
were performed at the corresponding time points of ATR-FTIR spectra of the QC PCM that were 
presented in Figure 4.2. Figure 4.3 displays DSC profiles of the QC PCM at 3 different time points. 
.  
Figure 4.3: Examples of DSC profile of QC PCM run at 100 oC / minute with pin-holed pans at the specified time 
points 
 
According to Figure 4.3, recrystallization peak of the QC PCM was seen at an onset temperature of 
circa 73 
o
C. Subsequently, a melting of the crystalline material in the sample was measured at an 
onset temperature of around 169 
o
C which agrees well with the onset melting temperature of Form 
I PCM in the literature (Qi et al., 2008a, Di Martino et al., 1997, Di Martino et al., 1996, Di 
Martino et al., 2000). Based on the DSC thermogram of QC PCM in Figure 4.3, crystal content of 
the scanned samples could be approximated by comparinng the recrystallization enthalpy and 
melting enthalpy of the QC sample to the melting enthalpy of the pure crystalline material as 
shown in Equation 4.2 (Mooter et al., 2001). 
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However, as the two thermal events (recrystallization and melting) take place at different 
temperatures, correction on the values of temperature dependence enthalpies is thus necesssary. 
The mean of achieving this was reported before (Grisedale et al., 2011, Lefort et al., 2004). In this 
correction, it does not assume complete recrystallization on heating. Therefore the correction was 
done by defining the ratio, α, which is the fraction of amorphous material that may not have 
recrystallized on heating. The α ratio could be obtained from Equation (4.3)  
    
        
   
      
                                                                              
where          is the melting enthalpy of the partially amorphous material and    
       is the 
melting enthalpy of the fully crystalline material. Then the initial amorphous content,   could be 
estimated by Equation (4.4) taking into consideration the corrected melting enthalpy which 
theoretically occurrs at the recrystallization temperature. 
  
        
   
      
   
 
     
                                                                     
According to Equation (4.4),          is the experimental enthalpy of recrystallization occurring at 
recrystallized temperature and    
       is the corrected melting enthalpy which theoretically takes 
place at the temperature of recrystallization. This corrected enthalpy could be estimated by using 
Equation (4.5), 
   
         
                                                                        
where Tc and Tm are recrystallization and melting temperatures, respectively.     is the difference 
in heat capacity of the liquid and solid phase which is assumed to be a constant (Grisedale et al., 
2011, Lefort et al., 2004). Thus, by knowing the initial amorphous content, one could also easily 
calculated the initial crystalline content of the sample by the subtraction the obtained amorphous 
content (obtained using Equation (4.4)) from unity. Crystallinity of the QC PCM at the 
corresponding time points of ATR-FTIR spectra in Figure 4.2 was calculated by using correction 
presented in Equation (4.3) to (4.5). 
 
Correlation between ATR-FTIR and DSC data 
Figure 4.4 (a) and (b) exhibits the relative intensity changes of 807 cm
-1
/ 797 cm
-1
 detected from 
ATR-FTIR of QC PCM, and the percentage of crystalline PCM detected from DSC, respectively. 
The growth of crystallinity as estimated by DSC methods indicated exponential growth which is in 
Recrystallization of HME PCM PVP-based solid dispersions                                           Chapter 4 
 
School of Pharmacy, University of East Anglia   148 
 
coherent to the exponential growth of the characteristic peak, 807cm
-1
 (Figure 4.4 (b)) as 
demonstrated by the multiple ATR-FTIR spectra of QC PCM in Figure 4.2. 
 
Figure 4.4: a) Exponential recrystallization profile of PCM as a function of time predicted by DSC b) Exponential 
profile of relative peak intensity 807 cm-1 / 797 cm-1 as a function of time predicted by ATR-FTIR. 
 
As both the ATR-FITR data and DSC data display an exponential growth as shown in Figure 4.4, 
simple regression of these data sets was performed. Figure 4.5 showed the simple regression of the 
data sets from ATR-FTIR and DSC at their corresponding time points.  
 
 
Figure 4.5: Correlation curves between the relative peak intensity of 807 cm-1 / 797cm-1 as obtained of ATR-FTIR 
spectra of QC PCM and the crystal percentage of QC PCM as approximated from DSC thermograms. 
 
The value of R
2
= 0.9937 in Figure 4.5 indicates good correlation between the percentage of crystal 
calculated from DSC and the relative intensity obtained from ATR-FTIR. Based on this 
relationship, crystal content of PCM in a sample could be described by using Equation 4.6, 
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Equation 4.6 enables the determination of the content of Form I PCM from an ATR-FTIR spectrum 
of a sample with a known relative intensity of 807cm
-1
 to 797cm
-1
. The applicability of this 
quantification method in the crystallinity detection of HME partially crystalline SD was also 
verified by using XRPD and DSC heat capacity / melting endotherm methods which was presented 
as a separated work in Appendix (II). In the subsequent sections, the develop quantification method 
of crystalline PCM will be employed crystallinity detection of the PCM in HME PVP-based SD. 
 
4.3.2. Fully amorphous HME solid dispersions 
Before the detailed recrystallization studies of HME PCM-PVPs extrudates, physical state of the 
freshly prepared extrudates was examined. All the freshly prepared hot melt extruded PCM-PVPs 
products, with a drug loading ranging from 30 to 50% w/w, revealed amorphous characteristics as 
confirmed via the halo pattern seen for XRPD spectra (data not shown). This is further supported 
by the absence of the characteristic peak of crystalline PCM, i.e. 807 cm
-1
 and 3324 cm
-1
 in the 
ATR-FTIR spectra of the freshly prepared HME systems.  
Prior to recrystallization study, the commonly used stability predictive parameters such as glass 
transition temperature and fragility index, m were determined. In this context, Tg of the HME 30 to 
50% w/w PCM-PVPs system were analysed by using DSC measurement. 
The concept of fragility was previously discussed in Chapter 1.2.1.2. This parameter is an indicator 
of the molecular transport via thermally activated hopping barriers (Ojovan and Lee, 2005). A 
fragile glass will undergo rapid thermal excitation with high configurationally change of the 
molecule in order to approach its structural equilibrium which promotes recrystallization process 
(Ojovan and Lee, 2005). On the other hand, molecular mobility of a relatively strong glass is less 
influenced by a temperature variation. Hence, this system is less susceptible to solid state changes 
which resulting in a better physical stability profile. In relation to physical stability, this parameter 
was used to predict physical stability of a system by estimating its susceptibility to solid state 
change upon annealing process.  
To estimate fragility of the HME PCM-PVPs system, samples were scanned in DSC at different 
heating and cooling rates. Then, natural logarithm heating rate was plotted against the Tg values 
with the corresponding measurements. Figure 4.6 shows an example of natural logarithm of the 
heating rate versus the inverse of the glass transition temperatures of HME 40% PCM-PVPVA 6:4 
at the corresponding scanning rate.  
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Figure 4.6: An example of heating rate dependence of the glass transition temperature of extrudates (HME 40% 
PCM-PVPVA 6:4). Error bars indicate the standard deviation, n = 3 
 
Activation energy, Ea was calculated from the slope of Figure 4.6 (which represents -Ea/R) using 
Equation (1.4). The value of Ea was then used in the calculation of fragility using Equation (1.3) as 
presented in Chapter 1.2.1.2. Table 4.1 displays the glass transition temperature of the sample at 
heating rate of 2 
o
C / minute, activation energy obtained (calculated from Equation (1.4)), fragility 
index of the HME PCM-PVPs systems (calculated from Equation (1.3)), and R
2 
which indicated 
the correlation between the scanning rate and changes of 1000/ Tg as presented in Figure 4.6. 
 
Table 4.1: Glass transition temperature/ activation energy/ fragility for different HME PCM-PVP systems 
Drug loading 
(%w/w) 
Glass transition 
temperature, Tg (
o
C) 
Activation Energy, 
Ea (kJ / mol) 
Fragility, m R
2
 
PVP K29-32     
30 84.97 ± 2.74 205.62 30.77 0.8688 
40 68.40 ± 2.10 193.06 29.54 0.8729 
50 51.34 ± 0.07 172.90 28.29 0.8490 
PVPVA 6:4     
30 61.34 ± 0.13 167.97 26.81 0.9825 
40 52.20 ± 0.20 183.45 30.55 0.9810 
50 44.10 ± 0.23 180.16 30.49 0.983 
PVP K12     
30 58.68 ± 0.20 210.80 32.31 0.9238 
40 54.66 ± 1.67 235.50 37.95 0.971 
50 48.32 ± 0.34 193.70 32.08 0.9332 
PVP K17     
30 54.40 ± 0.61 208.53 32.08 0.9298 
40 48.78 ± 0.42 181.20 29.92 0.9397 
50 42.54 ± 0.12 173.98 29.30 0.9811 
y = -22.065x + 71.826 
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As shown in Table 4.1, fragility indexes of the HME PCM-PVPs systems that being less than 40, 
i.e. m < 40 (Table 4.1) were categorized as strong glasses. These values are considerably lower than 
the at corresponding fragility of the pure amorphous PCM, i.e. 86.7 (Yu, 2001, Qi et al., 2008a), 
which was categorised as a fragile glass ( m > 75) (Yu, 2001, Qi et al., 2008a). This indicates the 
less susceptibility of the solid state changes of the prepared HME systems upon annealing. 
Table 4.2 summarise the trend of stabilization based on the magnitude of fragility (where a product 
with a higher m value was deemed to have lower stability and vice versa) and Tg estimation. 
 
Table 4.2: The predicted trend of product stability based in fragility and Tg prediction 
HME PCM 
carriers (drug 
loading, % w/w) 
Trend of stabilization (most stable  from the left to less stable on the right) 
Based on Fragility Based on Tg 
30% 
PVPVA > PVP K29-32 > PVP K17 > 
PVP K12 
PVP K29-32 > PVPVA > PVP K12 > 
PVP K17 
40% 
PVP K29-32 > PVP K17 > PVPVA > 
PVP K12 
PVP K29-32 > PVP K12 > PVPVA > 
PVP K17 
50% 
PVP K29-32 > PVP K17 > PVPVA > 
PVP K12 
PVP K29-32 > PVP K12 > PVPVA > 
PVP K17 
 
Tg is generally thought to be a ‘thermodynamic necessity’ to prevent ‘entropy crisis’ of an 
amorphous material toward recrystallization (Hancock et al., 1995). Researchers suggest that the 
storage conditions of an amorphous material should be 50 
o
C below the Tg in order to prevent 
devitrification of the amorphous material (Hancock et al., 1995). Therefore, the highest Tg of HME 
PCM-PVP K29-32 is expected to be the most stable followed by HME PCM-PVP K12 or HME 
PCM-PVPVA 6:4 and finally HME PCM PVP K17.  
Unlike the Tg values of the products, there is not a general trend of stabilization prediction among 
the different drug loading systems based on fragility prediction as the predicted fragility index were 
all very similar (Table 4.1). However, among the carriers examined, PVP K12 carrier systems 
consistently revealed the highest fragility value in all the different drug loading systems and hence 
this polymer may be predicted to produce the most unstable HME systems (Table 4.2). The rank 
order of physical stability of HME PCM-different PVPs based on the Tg and predicted fragility 
index will be correlated to the stability profile of the products under recrystallization studies in the 
next section. 
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4.3.3. Recrystallization profile of aged HME PCM-PVPs on storage at elevated humidities 
Recrystallization of HME PCM PVP-based systems in humidity induced conditions was 
investigated in two aspects. In the first instance, the influence of different humidity storage 
conditions on recrystallization behaviour of HME 40% PCM-PVPVA 6:4 system was investigated. 
This is carried out by storing the HME 40% PCM-PVPVA 6:4 systems in different relative 
humidity conditions, i.e. 22% RH, 33% RH, 53% RH and 75% RH, at room temperature. 
Subsequently, the effects of PCM loading, i.e. 30 - 50% w/w on the recrystallization behaviours of 
the aged HME different carriers systems (PVP K12, PVP K17, PVP K29-32 and PVPVA 6:4) were 
also studied exclusively at 75% RH.  
The recrystallization studies of PCM under various humidity conditions were investigated up to 3 
months. Different analytical methods were used to study the solid state changes. ATR-FTIR was 
used to probe the incremental change in crystalline content over time. As stated in section 4.2.3.3, 
samples were scanned daily for the first 14 days, then weekly up to one month, and subsequently 
monthly up to 3 months. DSC was used to detect the Tg changes of the samples after 3 months 
humidity storage. SEM was utilized for surface morphology inspection which was particularly 
useful for early stage of stability study as the content of crystalline material remained below the 
detection limit for other analytical methods. Thus SEM micrographs of early stability study (few 
hours, 1 week or 1 month) are preferentially presented. 
 
4.3.3.1. Recrystallization of HME 40% PCM PVPVA 6:4  at different humidity conditions 
Moisture-induced immiscibility upon storage has been widely reported for PVP-based SD due to its 
hygroscopic nature (Rumondor et al., 2009). Thus, it is important to study the influence of moisture 
content on the miscibility of the HME PVP-based SD upon storage. Figure 4.7 depicts the 
representative DSC thermograms of HME 40% PCM-PVPVA 6:4 system after 3 months storage at 
various humidities (22% RH – 75% RH).  
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Figure 4.7: DSC curves for HME 40% PCM-PVPVA 6:4 system after 3 months storage under different humidity 
conditions a) 0% RH, b) 22% RH, c) 33% RH, d) 53% RH and e) 75% RH 
 
Freshly prepared sample indicated a single Tg at 52.80 
o
C. After 3 months storage in the dry 
condition, i.e. 0% RH, two Tg (s) were detected which is an indication of classical phase 
separation. This phenomenon was also seen in all of the aged samples under higher humidity 
conditions. 
First Tg in the thermograms of the aged HME 40% PCM-PVPVA 6:4 system reveals a consistent 
reduction with the increase in storage humidity (Figure 4.7). This might be ascribed to the 
plasticization of the absorbed moisture content in the sample which was more considerable in the 
higher relative humidity conditions. This is further indicated by the noticeable water loss 
endotherm in the total heat flow signal at 60 to 100 
o
C, and this endotherm increased with higher 
humidity storage conditions. The absorbed water molecules have resulted in an increase in the free 
volume of the system which subsequently increases the molecular mobility of the system. With the 
increase free volume of the system, the small molecule of drug will diffuse within the polymeric 
network and separate from the polymer into an amorphous API rich phase which gave rise to the 
first separated Tg as observed from the DSC profile (Vasanthavada et al., 2004). Figure 4.8 
presents the overall picture of the Tg values and water content of the aged HME 40% PCM-
PVPVA 6:4 after 1 month storage.   
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Figure 4.8: Moisture contents ang Tg values of aged HME 40% PCM PVPVA 6:4 after 1 month storage in 
different humidity conditions. Bar chart in red indicated the early water content of the aged HME 40% PCM 
PVPVA 6:4 after 9 days and 3 days storage in 53% and 75% RH, respectively 
 
The second Tg detection in the DSC thermograms of the aged HME PCM-PVPVA 6:4 sample 
might be attributed to two possibilities. Firstly, it may be indicating moisture induced separation of 
PVPVA 6:4 polymer in the aged HME 40% PCM-PVPVA 6:4 (Figure 4.7). Based on Figure 4.8, 
the second Tg values of the aged HME PCM-PVPVA 6:4 in different humidity conditions were 
almost constant and closed to the Tg value of pure PVPVA 6:4, despite its extensive plasticization 
that expected from the presence high water content (blue bar chart). This might be ascribed to the 
moisture evaporation through the pinhole cover as could be evidenced noticeable endotherm in the 
DSC thermogram during the DSC scan (Figure 4.7), which leads to the detection of the Tg value 
close to its original Tg instead of the plasticized one. Secondly, the detected second Tg may be an 
indication of polymorphic transformation of the possibly recrystallized Form III PCM which was 
reported to reveal a transition temperature at circa 120 
o
C into Form II PCM (Di Martino et al., 
1997).  
As the detected second Tg (s) in these highly plasticized samples were circa 110 
o
C which were 
slightly higher than the pure Tg of PVPVA 6:4, i.e. 106 
o
C, the second possibility is more likely. 
However, further study is required to confirm the presence of form III PCM in the aged HME 
PCM-PVPs system which will be included as future work. 
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Recrystallization of the aged HME 40% PCM-PVPVA 6:4 system was further studied by using 
ATR-FTIR. The fast analysis of this method enables the tracking of the crystallinity on a daily 
basis with minimal sample preparation procedure. No characteristic peak of 807 cm
-1
 was detected 
in the ATR-FTIR spectra of HME 40% PCM-PVPVA 6:4 stored in 22% RH. However, in 53% RH 
and 33% RH, this peak was seen after 14 days and 1 month storage, respectively. In 75% RH 
conditions, this characteristic peak was seen 48 hours after storage which indicated the highest 
recrystallization rate of HME 40% PCM-PVPVA 6:4 in high humidity condition. The presence of 
peak at 807 cm
-1
 in ATR-FTIR spectra of aged HME systems suggested the presence of Form I 
crystal in the aged HME 40% PCM PVPs-based system. Instead of doublet peaks, a single peak 
was shown in the region of 1608 cm
-1
 and 1655 cm
-1
 which indicated the absence of Form II 
crystals as previously discussed in section 4.3.1.1 and Figure 4.1. The recrystallized polymorph 
was further confirmed by scanning the aged sample in XRPD (data not shown). 
Crystallinity of the aged sample was approximated from the quantification method that was 
developed in the earlier section (section 4.3.1) to obtain a recrystallization profile of the aged 
samples. Figure 4.9 shows the recrystallization profiles of the HME 40% PCM-PVPVA 6:4 system 
at different humidity conditions.  
 
 
Figure 4.9: Recrystallization profiles of HME 40% PCM-PVPVA 6:4 under different humidities condition at room 
temperature detected by scanning the aged samples overtime using the developed ATR-FTIR quantification 
method. Dotted lines shown in the Figure is just a guide in following the data points 
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The results show a trend of faster recrystallization at higher humidity conditions. Calling back to 
the early water content detected in the aged HME 40% PCM-PVPVA 6:4 system in Figure 4.8, a 
lower water content of the aged sample stored in 22% RH has led to the undetectable of crystalline 
material in this system which infers its limited recrystallization in this storage condition. However, 
in 33% RH, the aged sample showed a higher water content i.e., circa 3.20 ± 1.05% with a small 
percentage of crystalline materials detected after 1 month storage at this condition. Furthermore, 
aged samples stored in 53% RH reveal an absence of detectable crystal until day 9 whereas an 
exponential growth of crystal was measured and its water content was found to be circa 3.58 ± 
1.06% (Figure 4.8). As anticipated, crystalline materials were detected in the aged sample with a 
water content of 6.08 ± 0.63% after 3 days storage in 75% RH. Therefore, the amount of water 
content required for the initiation of recrystallization event is predicted to be between 3.5 - 6%. 
The result of ATR-FTIR is in contrast to DSC thermograms whereby no melting endotherm was 
detected (Figure 4.7). This suggested the potential dissolution of the existing crystalline material 
upon the DSC heating scan which was further confirmed by scanning the aged sample using 
variation temperature of ATR-FTIR (Appendix III). Besides, the principle in detecting the 
crystalline materials of both the analytical instrument should be taken into consideration. Firstly, 
DSC is a techniques that scanning the whole of the extrudate which including the bulk and the 
surface. On the other hand, ATR-FTIR is a surface detection techniques, where its measurement is 
limited to only approximately 6 μm beyond the surface of the ATR accessory (Larrabee and Choi, 
1993). Thus, the recrystallization profile obtained by using the ATR-FTIR techniques might only 
be used to represent the percentage of crystal that was detected near the surface of the extrudates. 
This will be further confirmed in a later section in HME 50% PCM-PVPs-based system.  
 
4.3.3.2. Recrystallization of HME 40% PCM with different PVPs carriers  
After the recrystallization study of HME 40% PCM-PVPVA 6:4 system in different humidity 
storage conditions, the effect of different carriers on recrystallization behaviour of the HME 
products was also studied. In this case, recrystallizations of the samples were studied only in 75% 
RH. Figure 4.10 and Figure 4.11 display the DSC thermograms of freshly prepared HME 40% 
PCM- carriers and aged HME 40% PCM- carriers, respectively after 3 months storage in 75% RH. 
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Figure 4.10: DSC thermograms of the freshly prepared HME 40% PCM -carriers, (a) PVP K12, (b) PVP K17, (c) 
PVP K29-32 and (d) PVPVA 6:4 
 
As demonstrated in Figure 4.10, the HME 40% PCM-PVPs systems revealed a single Tg expect 
HME 40% PCM-PVP K12 whereby two apparent Tg(s) were seen. There is a minor endotherm in 
the same thermogram at a temperature slightly lower than the normal melting temperature of PCM. 
This could be possibly ascribed to the depressed melting point of the PCM in the presence of PVP 
K12. 
 
Figure 4.11: DSC curve for HME 40% PCM-carriers at 75%RH after 3 months storage 
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In the DSC thermograms of aged samples as shown in Figure 4.11, two Tg (s) were noted for all 
the different carriers based system of 40% HME which indicated a phase separation after humidity 
storage.  The two separated Tg (s) coincided to the Tg of amorphous PCM, i.e. 25 
o
C and Tg of the 
pure polymer phase with the exception for PVP K29-32 system. In PVP K29-32 carrier system, the 
second Tg remained much lower than the Tg of the pure polymer phase. This indicated that a 
fraction of drug molecules remains miscible with PVP K29-32 (Vasanthavada et al., 2004). As 
described previously (section 4.3.3.1), the detection of the high value of second Tg might be related 
to the water evaporation during DSC heating scan as a result of the used of pin-holed pans or the 
possibility of the presence of Form III PCM in the aged samples.  
From Figure 4.11, minor endotherm was seen in HME 40% PCM-PVP K12 at circa 121
o
C which 
was accompanied by an obvious transition in the reversing heat flow signal. Similar minor 
endotherm was also seen in both HME 40% PCM-PVP K17 and PVPVA 6:4 system, where both 
show the endotherm at an onset of 129 
o
C and 110 
o
C respectively. To summarise, phase separation 
were seen in all the HME 40% PCM-PVP systems.   
Recrystallization profiles of the HME 40% PCM in different carriers were produced by using the 
quantification method that has been developed in the section 4.3.1. Figure 4.12 displays the 
recrystallization of 40% HME of PCM in different carrier systems at 75% RH over 120 days based 
on ATR-FTIR data using Equation (4.1). 
 
Figure 4.12: Recrystallization of 40% loading of PCM in different carriers at 75% RH calculated based on 
characteristic peak of 807 cm-1 /797 cm-1 in ATR-FTIR spectra of the aged sample using Equation 4.6. Dotted lines 
shown in the Figure is just a guide in following the data points 
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As could be seen in Figure 4.12, HME 40% PCM-PVPVA 6:4 system appeared to show the earliest 
crystal detection (highest early recrystallization rate) using the ATR-FTIR method. This is 
followed by HME 40% PCM-PVP K29-32 where the crystalline content was detected in ATR-
FTIR after 5 days of storage in 75% RH. However, the percentage of crystals in HME PCM-PVP 
K29-32 system was higher than HME PCM-PVPVA system after one week of storage in 75% RH, 
as shown by overshooting of the crystal growth profile of HME 40% PCM-PVP K29-32 over HME 
40% PCM-PVPVA 6:4  (Figure 4.12). Under the same storage conditions, the crystal content in 
HME 40% PCM-PVP K17 and PVP K12 was detected only after 12 days and 21 days, 
respectively. Lag phases were seen in the profiles of these samples (HME 40% PCM in PVP K17 
and PVP K12) which might be attributed to the nucleation phase of the aged extrudates. The lower 
crystal content detected in the low MW carrier of HME PCM PVPs system was unexpected. This is 
because a low MW carrier should impose a lower physical hindrance toward the recrystallization 
process of the drug molecule as compared to the high MW carrier system which might possibly 
lead to its higher recrystallization rate (Prodduturi et al., 2005). This unexpected result will be 
further communicated in a latter section (section 4.4.4) in relation to the processing conditions of 
HME. 
 
In order to confirm the recrystallization trend obtained from the Figure 4.12, surface morphologies 
of the aged HME SD extrudates were also investigated under SEM. Figure 4.13 shows the SEM 
micrographs of HME 40% PCM PVPs after 1 month storage in 75% RH (next page).  
It was found that the aged HME 40% PCM-PVP K12 and 17 did not show any apparent drug 
crystalline structure on their surfaces (Figure 4.13 (a) i and (b) i). However their magnification 
images reveal some interesting features (Figure 4.13 (a) ii and (b) ii).  In addition, HME 40% 
PCM-PVP K29-32 demonstrated tiny pores visible on its surface after humidity storage. 
Magnification of this image reveals some particles on its surface. Unlike the other HME PVP 
carrier systems, surface of the aged HME 40% PCM-PVPVA 6:4 (Figure 4.13 (d) i) was rough. 
The magnification of this image in Figure 4.13 (d) ii indicated small indentations on its surface. 
Overall, the observed features on the surface of the extrudate were not conclusively to be regarded 
as distinctive crystalline structure. However, the trend of the significance of this surface features 
was coincided to the trend of early recrystallization rate of the aged HME 40% PCM-PVPs system 
as deduced from Figure 4.12. 
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Figure 4.13: Surface morphology of HME 40% PCM-PVPs after 1 month storage in 75% RH a) PVP K12, b) PVP 
K17, c) PVP K29-32 and d) PVPVA 6:4. Right (ii) images are the corresponding magnification of the left (i) 
images. 
(a) i 
(b) i 
(c) i 
(d) i 
(a) ii 
(b) ii 
(c) ii 
(d) ii 
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To summarise, recrystallization rate and extent of HME 40% PCM-PVP systems were highly 
dependent on the storage humidity. In particular, the recrystallization process was faster under the 
higher humidity storage conditions. Apart from that, in 75% RH storage condition, PVPVA 6:4 
carrier displayed the earliest onset crystallisation followed by PVP K29-32, PVP K17 and PVP 
K12. This recrystallization trend based on the carrier system is not in agreement to the trend 
predicted by the values of fragility index and Tg as tabulated in Table 4.1. Therefore, more studies 
were carried out afterwards to further investigate this as will be discussed in the following sections. 
 
4.3.3.3. Effect of PCM loading on the recrystallization behaviour of HME different PVPs 
carrier system 
The previous section has shown the disadvantageous physical stability of HME sample utilizing 
PVPVA 6:4 as the carrier system. This was unexpected as PVPVA 6:4 was less hygroscopic as 
compared to the homopolymer carriers. In order to further understand this unexpected result, the 
effects of drug loading on the relative recrystallization behaviours of different carriers of interest 
were investigated. This was performed by studying the recrystallization profiles of both the high 
loading of PCM, i.e. 50% and the low loading of PCM i.e., 30% in the HME different carriers 
system. In the subsequent sections, recrystallization profiles of both the aged systems of HME 50% 
PCM-PVPs and HME 30% PCM-PVPs will be presented and complemented by the results deduced 
from SEM micrographs. 
 
4.3.3.3.1. Recrystallization profile of aged HME 50% PCM-carriers at 75% RH 
The crystal growth profile of HME 50% PCM-PVP-based SD after 75% RH storage was probed by 
using ATR-FTIR scanning. The diagnostic band at 807 cm
-1
 was detected in the spectra of HME 
50% PCM-PVPs system after 12 hours of storage at 75% RH which indicated the presence of 
crystalline content. The relative intensity of this band was used to calculate the percentage of 
crystallinity using Equation (4.6). Figure 4.14 presents the crystallization profile of the HME 50% 
PCM PVPs-based SD up to 3 months using the ATR-FTIR method. 
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Figure 4.14: Recrystallization of HME 50% PCM in different polymer systems at 75% RH measured by using 
ATR-FTIR. Dotted lines shown in the Figure is just a guide in following the data points 
 
According to the Figure 4.14, a single maximum profile (as indicated by the arrow in Figure 4.14) 
was observed for the recrystallization of HME 50% PCM-PVP K29-32 and PVPVA 6:4 systems 
after the exposure to 75% RH. A surge of crystal growth in the early stage of storage in 75% RH 
was noted in the recrystallization profile of the aged samples (HME 50% PVP K29-32 and 
PVPVA) detected by using ATR-FTIR. Eventually, the crystallinity of aged samples (HME 50% 
PVPVA 6:4 and PVP K29-32) achieved a constant value up to 3 months storage (Figure 4.14). 
However, this behaviour was not observed in the aged 50% PCM extrudate of PVP K12 and PVP 
K17 carriers.  
The single maximum recrystallization profile of HME 50% PCM in PVP K29-32 and PVPVA 6:4 
may have occurred due to two possibilities. Firstly, this might be ascribed to the nature of the 
crystal PCM, which is a water soluble drug. During the sample storage, there is a continuation of 
water absorption of the extrudates due to the hygroscopic nature of PVP, which initiated the 
recrystallization of the crystal on the surface of the extrudates. However, when the water content 
reached a certain value above the rubbery state of the sample, chain re-orientation of the polymer 
occurs. This may cause the dissolution of the recrystallized PCM (generated from an early 
recrystallization process) into the co-solvent of PVP and the absorbed water which gave rise to a 
reduction in crystal content after certain period of humidity storage (Figure 4.14).  
Secondly, it might be caused by the better drug-polymer interaction following high humidity 
storage that eventually dissolves the present crystal. Recent study has indicated that the pyrrolidone 
subgroup of PVP possesses different conformations in the dry and humidified state as indicated by 
the molecular docking and intermolecular energies studies (Malaj et al., 2010). In that study, 
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crystallinity of the poorly soluble drugs was observed to reduce with time at high humidity storage. 
The authors presented that pyrrolidone subgroups are folded along the main chain in the dry PVP, 
whereas the pyrrolidone subgroups appears to be perpendicular to the main chain in a hydrated 
PVP, thus leading to the higher accessibility for interaction. Therefore, it is suggested that the 
combination of both of the ‘water soluble nature of PCM’ and ‘higher drug-polymer interaction’ 
following humidity storage have contributed to the single maximum profile of recrystallization 
observed in Figure 4.14. Further study is required to understand the effect of high humidity storage 
on crystal re-dissolution phenomena which is beyond the scope of this study. 
 
In addition, it is unexpected that the samples with high MW carrier recrystallized (HME 50% 
PCM-PVP K29-32) faster than the same composition of sample extruded with a low MW (HME 
50% PCM in PVP K12 and PVP K17). This might be ascribed to the different tendencies of 
recrystallization process between the surface and bulk of the extrudates in different MW PVP 
systems, as ATR-FTIR is a surface technique that scanned up to approximately 6 μm beyond the 
surface of the ATR accessory (Larrabee and Choi, 1993). This phenomena will be further presented 
in the next section by comparing the crystallinity of PCM on the surface and ground extrudates. 
 
Crystallinity comparison between surface and whole extrudates by using ATR-FTIR 
It is expected that the ground extrudate would give rise to a value of total crystallinity of the sample 
as the grinding process has mixed the crystals on the surface and the bulk to produce a 
homogeneous powdered system. The crystallinity of the ground extrudates were probed by using 
ATR-FTIR and compared to the crystallinity of the system measured on the surface of the 
extrudates. Figure 4.15 indicates the percentage of crystallinity obtained from both ground and 
surface of the extrudates (next page).  
As demonstrated in Figure 4.15, the overall crystal content of the extrudates (spectra obtained from 
ground extrudates) and the crystal contents on its surface (spectra obtain from intact extrudate) 
were different. Crystal content on the surfaces of the higher MW HME carrier systems, i.e. PVP 
K29-32 and PVPVA 6:4, was higher than that of their ground form (ground extrudates). However, 
crystal content on the surface of the extrudates with low MW carrier system, i.e. PVP K12 and PVP 
K17 were slightly higher than the crystal content in their ground state. Overall, crystal contents of 
all the ground extrudates of homopolymer carriers are comparable. However, PVPVA 6:4 shows a 
consistently highest crystalline content in both the surface and the bulk extrudates. This coincides 
to the relative instability of HME system with PVPVA 6:4 as a carrier as deduced from the 
previous section in recrystallization of HME 40% PCM-PVPVA 6:4. 
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Figure 4.15: The comparison of crystallinity on surface and bulk extrudates after 4 days in 75 % RH measured by 
using ATR-FTIR 
 
The reason behind the different recrystallization of the surface and the bulk extrudates of the high 
MW carrier HME system may be related to the high MW carrier matrix that exerts a restraining 
pressure in preventing the internal crystal growth (Bruce et al., 2007). Besides, it could also be 
explained by the different relaxation processes occurring on the surface and bulk of a solid 
dispersion system as suggested by Ke et al., 2012 who differentiated the surface and bulk 
relaxation of the SD system with inverse gas chromatography (ICG) and DSC methods (Ke et al., 
2012). However, the discrepancies of difference in crystalline content between the surface and bulk 
of the four different PVPs carrier system were unexpected. This is because all the aged HME 50% 
PCM-PVPs systems show similar values for the first Tg and the second Tg which implies that 
phase separation have occurred in all the aged systems. The phase separation indicated the presence 
of partially rubbery state and partially glassy state in the aged samples at the temperature of room 
condition, i.e. 25 
o
C. However, the relative portion of the rubbery and glassy state of the different 
carrier of aged HME system may be responsible for the discrepancies of differences in crystalline 
content seen between surface and bulk of the extrudates which will be served as a ramification for 
future study. 
 
The surface of the aged HME 50% PCM-PVPs systems after exposed to the 75% RH was also 
investigated by SEM. The investigation was performed at 2 time points (after 4 hours and 1 week 
of storage) in order to understand the different recrystallization rates at early and later stages of 
humidity exposure. Figure 4.16 displays the SEM images of the aged samples after 4 hours in 75% 
RH. 
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Figure 4.16: Surface images after 4 hours in 75% RH HME 50% PCM-PVPs a) PVP K12, b) PVP K17, c) PVP 
K29-32, and d) PVPVA 6:4 
 
After 4 hours storage of RH HME 50% PCM-PVPs in 75% RH (Figure 4.16), small angular 
structures were seen on the surfaces of the PCM PVP K12 system (Figure 4.16 (a)). Obvious 
indentation were noted on the surface of HME 50% PCM-PVP K17 system as seen in Figure 4.16 
(b). Similarly to HME PVP K29-32 carrier system, tiny pores were seen. However, no obvious 
crystal shapes were noted in all the homo-polymer carrier system (PVP K12, PVP K17 and PVP 
K29-32). Based on the SEM micrographs (Figure 4.16), PVPVA 6:4 carrier system exhibited the 
highest surface changes intensity, (Figure 4.16 (d)) which might indicate the beginning of 
recrystallization process in this samples. 
Figure 4.17 shows the surface of the extrudates after 1 week storage under 75% RH. After 1 week 
storage in 75% RH, SEM micrographs of HME 50% PCM-PVPs revealed regular repeating unit on 
surface of PVP K12 carrier system (Figure 4.17 (a)). Surface of the aged HME 50% PCM-PVP 
K17 shows some indentations and elongated shaped features. On the other hand, an obvious 
crystalline structure was seen in HME 50% PCM high MW carrier Figure 4.17 (c). Also, well-
ordered block-like structures (circa 5μm) were noted on the surface of the HME 50% PCM-
PVPVA 6:4 carrier Figure 4.17 (d). This result is in agreement to the recrystallization trend of the 
different HME carriers system obtained by using ATR-FTIR method where the rank order of 
recrystallization is PVPVA 6:4 > PVP K29-32 > PVP K17 > PVP K12.  
(a) (b) 
(d) (c) 
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Figure 4.17: SEM images of HME of 50% PCM PVPs (a) PVP K12, (b) PVP K17, (c) PVP K29-32 and (d) PVPVA 
6:4 after 1 week in 75% RH 
 
To summarise the stability study of HME 50% PCM-PVPs carriers, HME PVPVA 6:4 carrier 
system showed the poorest stabilising effect on recrystallization of PCM. In addition, the 
recrystallization of PCM was preferentially occurred on the surface of the extrudate when a high 
MW carrier was used. Overall, PVPVA 6:4 carrier remains inferior in physical stabilization of 
PCM where the stability trend of HME 50% PCM-PVP is in the order of PVP K29-32 ≥ PVP K17 
≥ PVP K12 > PVPVA 6:4 
 
4.3.3.3.2. HME 30% PCM-carriers on storage at 75% RH 
With the recrystallization trend of HME PCM in different PVPs system at high PCM loading, the 
recrystallization trend of the HME PCM in different PVPs at low PCM loading system were 
investigated. This is to provide a further insight into the recrystallization behaviour of the drug in 
the different carriers of HME system. Figure 4.18 indicated the recrystallization profiles of the aged 
formulations of HME 30% indifferent PVPs systems. Recrystallization of the HME 30% PCM-
PVPs were observed only after 10 days storage in 75% RH as measured by using ATR-FTIR 
method.  
(a) (b) 
(d) (c) 
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Figure 4.18: Recrystallization profile of HME 30% PCM PVPs system at 75%RH over 120 days produced by 
using the data from ATR-FTIR  
 
Unlike the recrystallization trend seen in higher drug loading system, HME 30% PCM-PVPVA 6:4 
system showed a similar crystalline content to the HME 30% PCM-low MW carrier systems i.e. 
PVP K12 and PVP K17 as shown in Figure 4.18. This implies similar stability among HME 30% 
PVPVA 6:4, PVP K12 and PVP K17 systems under 75% RH. The aged extrudates of HME 30% 
PCM-PVP K29-32 exhibited the highest crystallinity on its surface as indicated by the 
characteristic peak of 807 cm
-1
 in its ATR FTIR spectrum. However, it is noteworthy from Figure 
4.18 that the percentages of crystallinity detected for the HME 30%-different PVPs were all below 
1% w/w. 
To confirm the recrystallization trend of the different PVP polymers in the HME PCM systems, 
surface morphologies of the aged HME 30% PCM different PVPs system were investigated. Figure 
4.19 show the SEM images of the HME 30% PCM different PVPs carrier after two weeks storage 
in 75% RH. According to the SEM images, surfaces of the HME 30% PCM with homo-polymers 
revealed tiny repetitive features especially in PVP K17 carrier system. This feature was not noted 
in HME 30% PCM-PVPVA 6:4 after storage (Figure 4.19 (d)). However, the topography of the 
HME 30% PCM-PVPVA 6:4 surface was distorted and rough which was suspected to be attributed 
to the ingress of moisture under humidity storage. Hence, the aged HME 30% PCM-PVPVA 6:4 
was suggested to have a similar recrystallization behaviour in comparison to the homopolymer 
carrier system. This trend of recrystallization base on the carrier types is not in coherent to the trend 
shown in the previous studies of HME 40% and 50% PCM-PVPs system. 
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Figure 4.19: SEM images of HME of 30% PCM different PVPs carriers (a) PVP K12, (b) PVP K17, (c) PVP K29-
32 and (d) PVPVA 6:4 after 2 weeks in 75% RH 
 
To summarise the recrystallization study of 30 to 50% PCM-PVP carriers under 75% RH storage 
condition, a bar chart in Figure 4.20 is presented. It is based on the recrystallization rate of each 
formulation at early recrystallization process (first 5 days).  
 
 
Figure 4.20: The summary of recrystallization rate of HME 30 to 50% PCM-carriers system. The rate of the 
recrystallization was obtained from the slope of initial (first 5 days) crystallization profile of each formulations 
detected from ATR-FTIR method 
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According to Figure 4.20, PVPVA 6:4 carrier was found to be inferior in stabilising HME PCM-
PVPs system under high humidity conditions (75% RH) particularly in extrudates with 40% and 
50% of PCM loading. However, at low loading of PCM, the trend of stabilising the PCM was not 
following the same trend as that observed in higher PCM loading. In the low PCM loading system 
(30% drug loading), PVPVA 6:4 carrier showed a lower surface recrystallization rate than PVP 
K29-32 system and revealed almost similar degree of recrystallization to the low MW PVP carrier 
system (PVP K12 and PVP K17). The reason behind these observations will be discussed in 
Chapter 4.4.3. 
 
4.3.4. Influence of storage temperature on the stability of HME PVP-based SD 
Temperature is another important factor for the determination of stability of a thermodynamically 
unstable solid dispersion. Thus, it is essential to understand the influences of temperature on the 
recrystallization behaviour HME PVP-based system. In this case only HME 40% PCM different 
PVPs were investigated. Samples were stored at room temperature and at 40 
o
C / 0% RH for the 3 
months temperature storage study.  
 
4.3.4.1. Annealed sample of HME 40% PCM with different polymers 
The annealed HME 40% PCM PVPs system did not indicate the appearance of 807 cm
-1
 in the 
ATR-FTIR spectra which indicated the absence of Form I PCM (data not shown). This is further 
supported by the halo pattern of their XRPD diffractograms after 3 months storage in 0% RH, 40 
o
C (data not shown). Tg changes of the system were analysed by DSC measurement. Figure 4.21 
shows the representative DSC thermograms of the aged sample HME 40% PCM-PVP carriers after 
3 months storage in 40
o
C / 0%RH.  
 
Figure 4.21: DSC thermograms of HME 40% PCM PVPs after 3 months storage at 0RH 40oC 
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As expected, no apparent melting endotherm of API was detected in the DSC thermograms of the 
annealed HME 40% PCM-PVPs samples. However, Tg of the annealed samples were clearly 
increased as compared to the freshly prepared samples (refer to Figure 4.10 for DSC thermograms 
of fresh samples) due to the evaporation of moisture under the dry (0% RH) and warmer 
conditions. Based on Figure 4.21, relaxation event were also noted superimposed upon the glass 
transition of the tested HME 40% PCM-carriers samples. The magnitude of this endotherm is then 
an indication of the non-equilibrium fraction of the samples which dictate the thermodynamically 
driving force for recrystallization process (Figure 4.21).  
As crystalline material could not be detected using the previously presented technique, SEM was 
used in this case to study crystallinity on the surface of the annealed extrudates qualitatively. Figure 
4.22 presents the SEM images of the annealed HME 40% PCM-PVPs at 40 
o
C. Some minor 
features were seen on the surface of extrudates. These were more profoundly observed on surface 
of HME 40% PCM-PVPVA 6:4 system (Figure 4.22 (d)) where the observed feature was crystal-
like as compared to other carriers. Thus, it is suggested that, HME 40% PCM-PVPs system is 
relatively stable in temperature-induced condition, i.e. 40 
o
C in this study rather than in humidity 
induced conditions.  
 
 
Figure 4.22: SEM images of HME of 40% PCM in polymer for different carriers (a) PVP K12, (b) PVP K17, (c) 
PVP K29-32 and (d) PVPVA 6:4 after 3months in 40oC 
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4.4. Discussion 
4.4.1. Establishment of quantification methods for crystalline PCM 
One of the key aspects of this chapter was the development of reliable quantification methods to 
detect crystalline materials.  In this respect, the diagnostic band of 807cm
-1
 detected in ATR-FTIR 
was calibrated using crystallinity changes of QC PCM calculated from DSC scan. In this 
development, data obtained from DSC was served as a calibrant whereby it could convincingly and 
accurately measure a single compound such as QC PCM samples.  
Complications arise if DSC was used for the detection of minute crystal in a mixture of different 
components (Biswal et al., 2009). This is because drug might potentially dissolve into the mixed 
polymer upon heating especially the scanning with a low heating rate (Craig and Reading, 2007, 
Yang et al., 2010b). Moreover, huge moisture sorption of the aged HME PVP-based systems would 
further complicate the data analysis of DSC thermograms. The endothermic water loss signal may 
mask some of the thermal events such as recrystallization or glass transition which will be recorded 
in the same temperature region of water loss. Even though the masking effect of water could be 
effectively separated in modulated mode of DSC (heating or cooling rate of < 2
o
C), however the 
use of the low heating rate would promote the drug dissolving problem. Therefore, in this study, 
DSC was not employed as a method for crystallinity detection in the blend system of HME PCM-
PVPs but instead it was used to detect the Tg changes of the aged sample after storage. 
 
4.4.2. The influence of humidity on HME PCM in PVP-based polymers 
During the humidity storage HME system absorbs a considerable amount of water due to the  
hygroscopic nature of its PVP carriers (Callahan et al., 1982). This lead to the observation of phase 
separation of the aged system following humidity storage system as inferred from the 2 detected Tg 
(s) shown in Figure 4.7 (Vasanthavada et al., 2004, Vasanthavada et al., 2005, Rumondor et al., 
2009). Water is well-known plasticizer due to its low molecular size that increases the free volume 
of the system and alters the chain conformation of the macromolecule polymer (Airaksinen et al., 
2005, Szakonyi and Zelkó, 2012). This phenomenon is particularly augmented by the hydrogen 
bond interaction between the polymer-water, as the water molecule could replace the bonded polar 
group of the polymer (i.e pyrrolidone group in PVP polymer of this study) and weaken the 
attracting forces between the polymeric chains, consequently increase the free volume of the whole 
polymeric system (Szakonyi and Zelkó, 2012).  
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This increment in free volume of an amorphous system leads to the greater molecular mobility of 
the API molecule embedded in the polymer. This molecular mobility of the API can be further 
promoted by the replacement of water molecules on the polar group of PVP which was previously 
bonded with API. Thus, with the higher molecular mobility of API, recrystallization of API could 
easily ripen (Heljo et al., 2012). This is clearly shown in the recrystallization rate and extent of the 
aged HME 40% PCM-PVPVA 6:4 that were found to be directly correlated to the absorbed 
moisture after humidity storage. Therefore, recrystallization of the HME 40% PCM-PVPVA 6:4 
system was found to be highly humidity dependent.  
Based on the crystallization profile in Figure 4.9, a lag time occurred before crystallization. This 
lag time was longer in lower humidity storage conditions. According to the ATR-FTIR results of 
the HME 40% PCM-PVPs system, samples stored in 22% RH did not reveal apparent diagnostic 
band of 807 cm
-1
 which implied the absence of crystalline material on the surface of these samples. 
Nevertheless, these samples underwent moisture absorption (moisture content of fresh samples < 
2%) with water content of circa 2.57 ± 1.04 % (refer to Figure 4.8). At 33% RH storage condition, 
the aged HME 40% PCM-PVPVA 6:4 system absorbed circa 3.20 ± 1.05% of water content after 1 
month storage. This amount of water coincides to the onset of crystalline material detection by 
using ATR-FTIR. This could be further confirmed by the early water content of the aged samples 
stored in 53% RH. In 53% RH, the crystalline PCM was detected after 9 days of storage whereby 
its water content was in coherent to the amount of water detected for the initiation of 
recrystallization, i.e. 3.58 ± 1.06%. Thus, it is not unexpected to note the immediate 
recrystallization of the aged HME 40% PCM-PVPVA 6:4 in 75% RH as the sample absorbed a 
considerable amount of water in a short period of storage time, i.e. 6.08 ± 0.63% just after 3 days of 
storage in 75% RH. Thus, it is suggested that there is a minimum amount of moisture that dictates 
the minimum mobility of drug molecules in ripening the event of recrystallization. On the basis of 
the moisture content detected from TGA and the trend of immediate recrystallization profiles 
(recrystallization profiles in Figure 4.9), the minimum moisture level for the initiation of 
recrystallization of aged HME 40% PCM-PVPVA 6:4 is estimated to be between 3.5 to 6%. 
 
4.4.3. Hydrogen bonding between drug and polymer: a key for physical stability? 
Base on the recrystallization studies of HME PCM-in different PVPs carrier, PVPVA 6:4, a 
relatively hydrophobic polymer with its lowest moisture absorption following humidity storage, 
revealed consistently the highest recrystallization tendency in HME 40% and 50% PCM PVPs 
systems. As the recrystallization tendency was correlated to the ability of the water molecule in 
replacing the API on the polar group of the pyrrolidone monomer, it is hypothesized that hydrogen 
bonds interaction between the drug-polymer might critically determine the recrystallization 
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behaviour of HME PCM PVP-based system. This effect was previously identified to be important 
in stabilization of solid dispersions (Matsumoto and Zografi, 1999, Trasi and Taylor, 2012). In 
further understand this, the relationship between the hydrogen bond tendencies to the 
recrystallization process was considered.  
PCM molecules possess two proton donors whereas PVP monomer possesses one proton acceptor 
in the carbonyl group of pyrrolidone. The quantities of carbonyl groups from each monomer were 
correlated in molar ratio of possibility of hydrogen bond formation resulting in 1:2, PCM: PVP 
monomer ratio. Since the possibility of hydrogen bonds formation is in 1:2 PCM : PVP monomer 
ratio, thus any value of the ratio that is above 1:2 (i.e. > 0.5) is deemed to have the PCM 
oversaturated in view of drug-polymer hydrogen bond interaction. Table 4.3 presents the ratio of 
PCM: polymer based on hydrogen bond capacity of the proton acceptor of pyrrolidone or vinyl-
acetate. The highlighted rows in Table 4.3 indicate the limit of PCM loading where the molar ratios 
of the PCM : PVP monomer are just below 0.5. 
 
Table 4.3: Ratio of PCM to polymer in different composition (hydrogen bonding limit of PCM-PVP polymers are 
highlighted in pink) 
Drug loading (% 
w/w) 
Ratio of PCM: monomer of Polymers 
PVP 
Homo-polymers 
PVPVA 6:4 
Pyrrolidine 
PVPVA 6:4 
pyrrolidine + acetate 
20 0.19 0.28 0.17 
30 0.33 0.47 0.28 
40 0.49 0.73 0.44 
50 0.76 1.10 0.66 
60 1.13 1.65 0.99 
 
According to Table 4.3, the drug-homopolymer (PVP) hydrogen bonding interaction limit is lies in 
composition of 40% w/w PCM loading (Table 4.3, column 2). Base on this, HME of 50% PCM-
PVPs is existed in the oversaturated (in term of hydrogen bond interaction) state which coincides to 
its immediate recrystallization upon humidity storage as the non-bonded amorphous PCM is readily 
to recrystallize (recrystallized within 12 hours of 75% RH storage). On the other hand, a lag time 
was observed for formulations with 40% drug composition possibly due to its optimum drug-
polymer hydrogen bond interaction. 
From the relative recrystallization behaviours of different PVP carrier, HME 40% PCM PVPVA 
6:4 system revealed an immediate recrystallization profile despite its optimum hydrogen bond 
interaction between the PCM and PVPVA 6:4 as anticipated from involving both the carbonyl 
groups from pyrrolidone and vinyl acetate. However, according to the ATR-FTIR spectra of HME 
PCM–PVPVA 6:4 copolymer system (Chapter 3), red-downshift was only seen in carbonyl 
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stretching region of pyrrolidone but not in the carbonyl region of vinyl acetate. Thus, it is suggested 
that hydrogen bonding of the PCM and PVPVA 6:4 is preferential formed through the pyrrolidone 
rather than vinyl acetate groups. This might be due to the reported lower partial atomic charges on 
the oxygen functional group of the vinyl acetate (i.e. poorer proton acceptor) as compared to 
pyrrolidne  (Trasi and Taylor, 2012). Therefore, the intensity of hydrogen bond interaction between 
PCM-PVPVA 6:4 is relatively lower as compared to the PCM-PVP homopolymer. This leads to a 
higher proportion of free amorphous PCM molecule in PVPVA 6:4 carrier system which in turn 
promotes its higher recrystallizations tendency as compared to the HME PCM homopolymer, PVP 
system. 
The important of drug-polymer interaction in recrystallization behaviour of PCM was further 
confirmed by studying HME 30% PCM- carriers systems. At the end of 3 months stability studies, 
all the different HME 30% polymer systems (PVP K29-32, PVP K17, PVP K12 and PVPVA 6:4) 
displayed <1% crystal content with a similar lag time (i.e. 10 days) and recrystallization profile. 
Based on Table 4.3, composition of 30% PCM-PVPs systems would theoretically have all the PCM 
drug molecules hydrogen bonded to the polymer carrier, thereby, no drug molecules existed in 
surplus for the driving of crystallization. 
The comparison of recrystallization behaviours in HME PCM-PVPs of different carriers and PCM 
composition systems suggested that hydrogen bond interaction between the drug and polymeric is a 
decisive factor in the recrystallization process of the HME PVP-based SD upon humidity storage. 
 
4.4.4. The effect of molecular weight of PVP on physical stability of HME formulations 
Among the homopolymer carrier systems, HME PCM-PVP K29-32 consistently revealed a highest 
crystalline content on its surface after humidity storage. This is unexpected as the high MW PVP 
K29-32 might exert a higher physical hindrance for the recrystallization of PCM as compared to 
the carrier with low MW. Besides, PVP homopolymers in their same composition of PCM-polymer 
shall possess the same number of available interaction unit (carbonyl group from pyrrolidone) with 
the PCM which give rise to their similar recrystallization behaviour, however, it is not as such. The 
result in Figure 4.18 demonstrated that PCM dispersion in PVP K29-32 was relatively unstable as 
compared to the PCM dispersion in low MW systems, i.e. PVP K12 and PVP K17 which show 
similar recrystallization profiles of the both. 
Generally, it is reported that the extrusion temperature should be 10-20 
o
C higher than the polymer 
in order to achieve good flowability in the hot melt barrel during preparation (Chokshi et al., 2005). 
However, this principle was not employed in this study due to the potential degradation of PVP 
polymer at high temperature. In this study, solubilisation regime of processing temperature was 
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employed whereby Tprocess (at 160 
o
C) is lower than < Tm and Tg of PCM and PVP K29-32, 
respectively (please refer to Chapter 2.3.1 for the review of the processing temperature regimes 
summarised in literature). Based on this regime, viscosity of the molten dictate diffusivity of the 
API and hence the extent of API solubilisation. High torque values (i.e. 20-30 Ncm for PVP K29-
32 carrier and  0 - 2 Ncm for PVP K12 and K17 carrier) in the extruder barrel, indicated high 
viscosity of the extruded material in the barrel, which could led to suboptimal drug polymer 
interaction and limited solubilisation of the PCM in PVP K29-32 (Lakshman et al., 2008). Thus, it 
is proposed that the suboptimal drug polymer interaction and limited solubilisation of the PCM in 
PVP K29-32 during the HME process has led to the higher recrystallization of HME PCM PVP 
K29-32 system tendency as compared to low MW carriers, i.e. PVP K12 and PVP K17.  
However, the effect chain conformation change of polymer following high humidity storage that 
lead to a better accessibility of the carbonyl group of the pyrrolidone for drug-polymer interaction 
should not be overlooked, as it might be a possible reason of the undetectable crystalline material 
in the low MW HME PCM PVPs system. This phenomenon might be closely related to the solid 
state conversion, i.e. from glassy state to the rubbery state. Thus, the relationship on the relative 
portion of the glassy and rubbery state of the aged HME PCM-PVP system in recrystallization 
behaviour of the system shall serve as a study for the future work.  
 
4.4.5. The influence of temperature on physical stability of HME PCM-PVPs 
Amorphous solid dispersion may undergo mixing and de-mixing under the influence of 
temperature. In this study, endothermic relaxations accompanied by the glass transition temperature 
were seen (Figure 4.21) in DSC thermograms of HME PCM-PVPs sample after 3 months storage at 
40 
o
C / 0% RH .  
Preparation of HME products involves the extrusion of sample from a high temperature (i.e 160 
o
C 
in this study) to room temperature which led to the production of a supercooled liquid after 
extrusion. Therefore, the HME samples possess an excess amount of configurationally enthalpy 
through frozen-in of the degree of orientation freedom from the molten state (Suga, 2000). Hence, 
the relaxation endotherm shown in DSC thermogram implies a change of the annealed samples 
from a non-equilibrated state to an equilibrated state upon heating up to above the glass transition 
temperature.  
Despite the detection of samples relaxation, there was no significant recrystallization observed over 
the timescale of experiment using the analytical approaches of DSC, ATR-FTIR and XRPD except 
SEM, where crystalline materials were noted on the surface of the annealed HME 40% PCM-PVPs 
system. Besides, surface of annealed HME 40% PCM-PVPVA 6:4 system consistently shows a 
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higher amount of crystalline materials as compared to the other carrier of HME PCM-PVPs system 
(SEM images in Figure 4.22). This trend is in agreement to the stability profiles of the HME 
different carriers system whereby the stabilizing effect of PVPVA 6:4  was inferior as compared to 
the hompolymer PVP at HME 40 % PCM-PVPs system. 
Based on the trend of fragility index in Table 4.1, HME PVPVA 6:4 carrier system shows a lower 
value than the HME PVP K12 system in which the former system was theoretically predicted to be 
relatively more stable than the PVP K12 system. However, this is not as such as the annealed HME 
PVPVA 6:4 carrier system shows highest crystalline proportion on its surface as compared to the 
PVP K12 system. This indicated that the annealed HME 40% PCM-PVPVA 6:4 had undergone the 
highest recrystallization rate as compared to the other system annealed in the same condition, 0% 
RH and 40 
o
C. Therefore, it is suggested that there is poor correlation between the fragility index of 
a material and physical stabilization of the product which is in agreement to some recently 
published literature (Graeser et al., 2009, Kawakami et al., 2012, Graeser et al., 2009a, Ke et al., 
2012).  
 
4.5. Conclusion 
A quantification method of Form I PCM was developed using ATR-FTIR measurement. This 
method was found to suitable in detecting low crystalline content of the sample. Besides, it should 
be reminded that ATR-FTIR is a surface technique whereby the only approximately 6 μm of the 
surface contacted to the ATR accessory was detected. Nonetheless, it is a valuable technique which 
has been found to be particularly useful to complement the result of DSC that may be affected by 
the kinetic dissolution of the crystal during DSC heating scan.  
Recrystallization tendency of HME PVP based products was found to be highly humidity 
dependent as higher recrystallization rate was detected in storage condition of higher humidity. 
Preceding the dramatic crystallization growth in recrystallization profiles of the aged HME PCM 
PVPs system, a lag phase of the profiles was noted. This lag phase was found to be highly 
correlated to its water content which might be responsible for the nucleation phase of the aged 
HME PVP-based sample. Besides, recrystallization profiles of HME PVP-based systems indicated 
that the early crystallization process was predominantly controlled by hydrogen bond interaction 
between drug and polymer systems at an early stage of the humidity storage.  
Furthermore, drug-polymer composition of a HME PVP-based SD is preferably accord to the 
optimum or under-saturated of hydrogen bond interaction between drug-polymer in order to reduce 
the driving force of recrystallization. This could be clearly seen in the immediate recrystallization 
of the hydrogen bond supersaturated state in the high drug loading of HME PCM-PVP (i.e. 50% 
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PCM for homopolymer carrier and > 40% PCM for PVPVA 6:4 carrier systems). On the other 
hand, the under-saturated (hydrogen bond between drug and polymer) of HME 30% PCM-PVPs 
systems show no immediate recrystallization (recrystallized only after 10 days) of PCM occurred 
even in the high humidity condition (75% RH). Above all, it should be re-emphasized that, the 
degree of drug-polymer hydrogen bond interaction of HME product stems from the HME 
preparation process, where a lower viscosity (low torque value) and optimum flowability of the 
molten mixture is preferred in order to obtain an optimum hydrogen interaction between the drug 
and polymer.  
Apart from that, this chapter has shown that HME PVP based products exhibited a better physical 
stability in ‘temperature induced’ condition as compared to the ‘humidity induced’ condition. 
Moreover, the trend of Tg and fragility index did not correlate well to the recrystallization rate of 
the aged HEM PCM-PVPs carrier system. Therefore, the factor of Tg and fragility index was 
concluded to have minimal roles in the physical stabilization of HEM PCM-PVPs carrier system.
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Chapter 5. An investigation into factors governing the drug release 
mechanism of PVP-based hot melt extrusion 
formulations Part I: Dissolution performances of HME of 
poorly soluble drugs with PVPVA 6:4 
 
5.1. Introduction 
Solid dispersions (SD) are often associated with the dissolution and bioavailability enhancement of 
poorly soluble drugs (Chawla and Bansal, 2008, Craig, 2002, Hülsmann et al., 2000, Kalivoda et 
al., 2012b). This is mainly attributed by several factors that have been discussed in Chapter 1.6 
which include, the conversion of crystalline into amorphous dispersion in SD, carrier solubilisation 
effect, hydrophilicity and wettability enhancement by the carrier, formation of complexes and high 
surface area of the dissolving API in the SD system due to their molecularly dispersed nature 
(Kapsi and Ayres, 2001, Dong et al., 2008b, Biswal et al., 2009).  
Many studies reported the significant increases in dissolution rate of poorly soluble compounds 
when they are formulated into a SD (Corrigan, 1985, Craig, 2002, Fernandez et al., 1989, Biswal et 
al., 2009, Chawla and Bansal, 2008). However, a number of papers have revealed undesired 
dissolution behaviour of SD whereby a slower release of drug was noted when the drug was 
processed into a SD as compared to their corresponding physical mixture (PM) (Verheyen et al., 
2002, Tajarobi et al., 2011a, Moneghini et al., 1998, van Drooge et al., 2004, Saers and Craig, 
1992). Further details of this contradiction were reviewed in Chapter 1.6 and 1.6.1. Based on this 
literature, there are no general principles regarding the benefit of production of SD that can be 
guaranteed to the user, hence there remains uncertainty regarding the relationship between structure 
of API-polymer and dissolution performance for these systems.  
Therefore, a detailed understanding on the dissolution mechanism of the SD system is required to 
guide the formulation scientist in developing a successful SD system. In this chapter, the aspect of 
formulation performances of HME PVP-based SD was focused on. Here, dissolution performances 
of SD of four different poorly soluble active pharmaceutical ingredients (APIs) were investigated. 
PVPVA 6:4, a hydrophilic polymer, was employed as a carrier with a view to enhance the 
dissolution performance of the poorly soluble APIs. Possible factors in affecting the desired 
dissolution performance that arise from the use of different APIs in the prepared HME PVP-based 
SD system were investigated.  
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5.2. Material and methods 
The APIs employed in this study include ketoprofen (KTP), naproxen (NAP), indomethacin 
(INDO) and olanzapine (OZP). Chemical structures and physicochemical properties of these four 
APIs and PVPVA 6:4 could be found in Chapter 2.21. To compare the effect of the four different 
APIs in dissolution performance of HME PVP-based SD, the carrier of the systems was made 
constant, i.e. PVPVA 6:4.  
 
5.2.1. Estimation of the amorphous solubility advantage 
The dissolution advantage of an immediate release SD system is often linked to its amorphous 
nature due to the lack of strong bond in the structure of API in this state. In amorphous state, the 
API exists in its readily dissolvable state which is deemed to be an advantage of its form. This 
amorphous advantage could be reflected by the free energy difference between the amorphous and 
its crystalline form (Hancock and Parks, 2000) as described by Hoffman Equation (5.1) (Hoffman, 
1958), 
 
   
        
  
                                                                           
where     is the enthalpy of melting which could be obtained from DSC experiment,    is the 
melting temperature of the crystalline form, and    is       (Alonzo et al., 2010, Hancock and 
Parks, 2000). Besides, the free energy differences is also a function of solubility advantage offered 
from the amorphous form (Alonzo et al., 2010). This ratio of solubility advantages could be 
approximated from Equation (5.2),  
 
       
        
  
  
                                                                            
 
where                  represent the ratio of the solubility of amorphous API to the solubility of 
its crystalline counterpart,    is the different of free energy between the amorphous and crystalline 
forms, R is universal gas constants and T is the respective solubility temperature at Kelvin (Alonzo 
et al., 2010). 
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5.2.2. Solubility testing 
Solubility tests of the pure APIs were performed in their corresponding discriminatory media as 
outlined in Table 5.1. Apparent solubility of the APIs in the presence of low (0.0001% w/v), 
intermediate (1% w/v) and high concentration (10% w/v) of PVPVA 6:4 in the corresponding 
discriminatory medium were also performed. 
 
Table 5.1: Medium and UV wavelength used for the solubility measurement of pure API and PM API-PVPVA 
Drugs / carrier Medium UV wavelength (λmax) 
Ketoprofen 0.1M HCl 259 nm 
Naproxen 0.1M HCl 272 nm 
Indomethacin Distilled water 265 nm 
Olanzapine Distilled water 254 nm 
PVPVA 6:4 0.1M HCl/ distilled water No absorbance after 240nm 
 
In general, the solubility of APIs were carried out by dissolving excess powder of APIs in 200 ml 
of the medium (with or without the presence of PVPVA 6:4) to form a mixture which were stirred 
for at least 48 hours at 37 
o
C. Then, these mixtures were filtered using a 0.45 μm polyvinylidene 
fluoride (PDVF) filtration unit and examined spectrophotometrically at the corresponding UV 
wavelength, λmax of the APIs (Table 5.1).  
 
5.2.3. Preparation of PM 
PMs were prepared by mixing the API and PVPVA 6:4 using a ball milling equipment without the 
insertion of ball. Both the powders of APIs and PVPVA 6:4 were sieved into a control particle size 
range of 63 - 106 μm. Then, 30% (w/w) of API loading and 70% (w/w) of PVPVA 6:4 were 
weighed accordingly and transferred into the ball-milling chamber without the insertion of ball. 
Subsequently, the milling chamber was fixed to the milling equipment and oscillated horizontally 
at 30 Hz for 10 minutes. The used of this technique allows the preparation of a homogenous and 
reproducible PMs between the API and PVPVA 6:4 that has been verified from preliminary data. 
 
5.2.4. Hot melt extruded products 
HME of the binary APIs-PVPVA 6:4 were prepared using a hot melt extruder. Details of the 
extruder used in this study could be found in Chapter 2.3. Please refer to Table 2.12 for the 
processing parameters used in the manufacturing of HME 30% KTP PVPVA 6:4, HME 30% NAP 
PVPVA 6:4, HME 30% INDO PVPVA 6:4 and HME 30% OZP PVPVA 6:4systems.  
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5.2.5. Characterization of the amorphous solid dispersions 
5.2.5.1. Differential scanning calorimetry 
API and the freshly prepared HME API-PVPVA 6:4 systems were scanned in DSC by using 
modulated mode at ± 0.318 
o
C every 60 seconds, 2 
o
C / min. In these measurements, pierced 
aluminium pans were used in order to allow the removal of moisture during the heating processes.  
 
5.2.5.2. Attenuated total reflectance-fourier transform infrared  
The same parameters of ATR-FTIR as described in Chapter 3, section 3.2.7 were used to scan the 
prepared HME APIs-PVPVA 6:4 systems. 
 
5.2.5.3. X-ray diffraction 
X-ray powder diffraction (XRPD) experiments were performed on the freshly prepared HME API-
PVPVA SDs. These extrudates were gently crushed into powder form (in a mortar and pestle) and 
compacted into the sample holder of the XRPD prior scanning. Measurements were performed 
from 3
o
 to 40
o
 (2θ) coupled with scanning speed of 0.01o / step and 1 second for every scan step to 
cover the characteristic peaks of each APIs.   
 
5.2.6. Dissolution studies of PM and HME of APIs – PVPVA 6:4 
Dissolution studies of the HME APIs-PVPVA 6:4 formulations were performed in the 
corresponding discriminatory dissolution media as outlined in Table 5.1. Dissolution experiments 
were carried out using the USP paddle method at 37 
o
C, 50 rpm. At pre-determined time intervals, 
10 ml of solution was withdrawn and filtered with a 0.45 μm PVDF membrane syringe filter. The 
filtrate was then analyzed spectrometrically to evaluate the concentration of API in the medium. 
For comparison, dissolution behaviors of the API and PM systems were also studied. All the 
dissolution studies were performed under sink condition with the exception of the pure INDO due 
to its extremely poorly solubility properties in the dissolution medium.  
To compare the dissolution performances between the PM and HME systems, similarity factor (f2) 
was used. This is a model independent approach that measures the similarity in percentage between 
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the 2 profiles of dissolution (FDA, 1997). Similarity factor (f2) is a logarithmic reciprocal square 
root transformation of the square error, which could be expressed by Equation (5.3).   
 
         {[  (
 
 
)  ∑        
 
 
   
]
    
    }                                    
 
where n is the number of time points, Rt is the percentage of drug release of a reference batch at the 
time t and Tt is the percentage of drug release of the comparison batch at time t. When f2 is greater 
than 50 (i.e. 50-100), this indicates the sameness or equivalence of the both compared profiles. 
Conversely, when f2 is less than 50 then it is taken as which both the profiles are different. 
Generally, it is used for comparison of a product before and after minor changes in a formulation 
for industrial approval. In this study, dissolution profiles were compared up to a point after 80% 
drug release of the formulation. Similarity factor was utilised as a tool to provide a gross idea on 
the rank order of the dissolution performance differences of different API systems between the 
prepared amorphous SD and their PM systems. 
 
5.2.6.1. Light microscopy observation  
The change in particle appearance of the HME SD system upon contact with the dissolution 
medium was observed using a light microscope. The freshly ground HME API-PVPVA 6:4 
particles were loaded on a slide under the microscope with a pre-focused position of the lens. Then, 
2 drops of selected dissolution mediums were dropped on the particles and immediately covered 
with a cover slide. The appearances of the particles shown under the microscope were captured up 
to 60 minutes.   
 
5.2.6.2. Particle size analysis 
Particles size changes of the HME SD system during the dissolution experiment were measured 
using a particle size analyser. This experiment is aimed to detect the possible agglomeration of the 
dissolving particles while dissolution process. To do this, 20 ml of dissolution medium was 
collected from the dissolution bath after 2, 15, 30 minutes of dissolution experiment and 
immediately (within 1 minute) analysed by using particle sizer.  
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5.2.6.3. Scanning electron microscope 
Surface morphologies of the particles collected from the dissolution vessel during the dissolution 
experiment were investigated using scanning electron microscopy (SEM). These collected particles 
were placed on a sample stub and dried for not more than 1 hour at room temperature before 
sputtered with a thin layer of gold prior to SEM imaging.   
 
5.2.6.4. Contact angle measurement 
As mentioned in Chapter 2.4.8, an indirect contact angle measurements were used in studying the 
wetting properties of the PM and HME systems. Contact angle measurements between the surface 
of compacted tablets (which includes tablets of raw API, PM API-polymer and ground HME API-
polymer) and their corresponding dissolution media were performed with surface drop shape 
analysis. This method has been reported for reasonable wetting assessment of powdered system 
(Swanepoel et al., 2000, Dahlberg et al., 2008, Buckton et al., 1991). 
 
Powder compaction parameters 
PMs with a controlled particle size (63-106 μm) were produced using the same method outlined in 
Chapter 5.2.3. On the other hand, HME API-PVPVA SDs, which were prepared in Chapter 5.2.4, 
were gently milled in a mortar and pestle and then sieved into the 63-106 μm particle size range. 
300 mg of the powdered samples (both PM or HME) were weighed and compressed into tablet by 
using an GRASEBY SPECAC hydraulic press. The powders were pressed with a pressure of 5 tons 
for 60 seconds. The resultant flat surface was examined for their surface roughness using atomic 
force microscopy (AFM). ‘z’ variations of the piezoelectric scanner of AFM were used to provide 
the surface roughness information which could be found in Appendix IV. 
 
Surface tension and contact angles analysis 
The equipment used for the surface tension and contact angle measurement has been described in 
Chapter 2.4.8. To determine surface tension of the dissolution media and 1% w/v PVPVA 6:4 
solutions, pendent drop measurements were performed. A liquid dispenser holder with manual 
control was used to create a drop. Then, OneAttension software was used to analyze the surface 
tension by Young-Laplace surface properties mode. The changes of the surface tension were 
recorded up to 120 seconds at 1 frame per second. 
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In the contact angles measurement, a drop of the liquid phase which was pre-saturated with 
corresponding APIs was deposited on the flat surface of the compressed tablet by using a dispenser 
holder (pure APIs, PMs of APIs and PVPVA and HME APIs-PVPVA). The changes of the contact 
angles at the first 120 seconds were recorded as a video at 6 frames per second for first 10 seconds 
and 1 frame per second subsequently. All measurements were performed at 25 ± 0.1 
o
C and 45% 
RH. Table 5.2 summarises the combination of solid phases to their corresponding liquid phase in 
the contact angle experiments.  
 
Table 5.2: Experiments of contact angles between the solid phase and the liquid phase 
Surfaces (tablets) Medium 
 Distilled water 
(DW) 
1% w/v PVPVA 
in DW 
0.1M HCL 1% w/v PVPVA 
in 0.1M HCl 
PVPVA 6:4 √  √  
NAP √  √ √ 
KTP √  √ √ 
INDO √ √   
OZP √ √   
PM 30% NAP PVPVA 6:4 √  √  
PM 30% KTP PVPVA 6:4 √  √  
PM 30% INDO PVPVA 6:4 √    
PM 30% OZP PVPVA 6:4 √    
HME 30% NAP PVPVA 6:4 √  √  
HME 30% KTP PVPVA 6:4 √  √  
HME 30% INDO PVPVA 6:4 √    
HME 30% OZP PVPVA 6:4 √    
 
These combinations are based on the types of media used in the solubility and dissolution test of 
the API and its HME PVPVA formulations. Besides, 1% of PVPVA used in the respective medium 
was to understand the influence of high polymer concentration in the wettability of the hydrophobic 
API, as a dissolving system was reported to have a high polymer concentration at its dissolving 
front (Tajarobi et al., 2011b, Baumgartner et al., 2005, Siepmann and Peppas, 2001). 
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5.3. Results  
5.3.1. Estimation of amorphous solubility advantages ratio of APIs  
The advantages of an amorphous pharmaceutical have been discussed in Chapter 1.2. These 
amorphous avantages are mainly ascribed to the difference in free energy of the amorphous form 
and its crystalline counterpart (Hancock and Parks, 2000). Thus, in this study, the free energy 
different between the amorphous and crystalline form of the studied APIs were calculated 
according to the Hoffman Equation (5.1) based on the DSC data of the pure APIs. Athe same time, 
the ‘solubility ratio’ between the amorphous form to the crystalline form could be also estimated 
according to Equation (5.2). Table 5.3 displays the melting temperatures and enthalpies of the 
different APIs, free energy difference between the amorphous form and crystalline form of 
different APIs, experimental solubility of the APIs and calculated solubility ratio of crystalline 
drugs to their corresponding amorphous forms using Equation (5.2).  
 
Table 5.3: Experimental solubility of APIs, free energy difference between the crystalline APIs and their 
amorphous form, solubility ratio and theoretical amorphous of amorphous form to their crystalline counterpart in 
the selected media 
Drug-
PVPVA 
Melting 
Temperature 
(K) 
Melting 
enthalpy 
ΔH 
(KJ/mole) 
Free energy 
difference, 
ΔG, 
(KJ/mole) 
Experimental 
Solubility 
(mg/ml) 
Solubility 
ratio 
Theoretical 
amorphous 
solubility 
(mg/ml) 
Medium 
KTP 366.76 29.37 3.83 0.170 4.24 0.7531 
0.1M 
HCl 
NAP 428.53 30.94 6.18 0.032 11.01 0.3522 
0.1M 
HCl 
INDO 434.15 37.56 7.66 0.0094 19.53 0.1941 
Distilled 
water 
OZP 467.62 38.42 8.58 0.069 27.88 1.9237 
Distilled 
water 
 
Based on Table 5.3, OZP was shown to have highest free energy difference between its amorphous 
and crystalline state (column 4). This is followed by INDO > NAP and > KTP. This trend is in 
parallel to the predicted solubility ratio (amorphous API to crystalline API) of the APIs as shown in 
column 6 of Table 5.3.   
According to the well-known Noyes-Whitney Equation (2.2), dissolution rate of a substance can be 
correlated to the concentrations difference between the solid surface (Cs) and the bulk of solution 
(Cb) in which the solution at the dissolving front would be equivalent to the solubility of the API 
upon achieving a constant release rate at the dissolving front (Aulton, 2007). Thus, the higher 
solubility advantage of an amorphous API could drive its dissolution process assuming other 
parameters in the Equation (2.2) are constant. Consequently, the release enhancement of 
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amorphous OZP as compared to its crystalline form would expected to be highest followed by 
INDO > NAP > KTP. 
 
5.3.2. Equilibrium phase solubility studies of APIs in the presence of PVPVA 6:4 
A few papers have suggested the solubilising effects of hydrophilic polymer in contributing to the 
dissolution enhancement of poorly soluble API (Nokhodchi et al., 2005, Sjokvist et al., 1992, 
Craig, 2002). This may be attributed to the enhanced solubility of API in the polymer rich diffusion 
layer which could subsequently drive the dissolution of the poorly soluble API (Doherty and York, 
1987). According to Craig (2002), the carrier controlled release mechanism of a SD system is 
mainly attributed to the high solubility of the API into the hydrophilic polymer carrier which may 
allow the dissolution of the API to occur before the reaching of dissolution front to the API 
particles. On the other hand, when the solubility of API in its hydrophilic polymer carrier is low, 
the particle may be released intact into the bulk of the medium. Therefore, in order to understand 
the effect of solubilising capacity of the PVPVA 6:4 in its influence on dissolution process of the 
HME SDs, the solubility of the APIs in the PVPVA 6:4 solutions were studied.  
Besides, API solubility is reported to increase disproportionally in higher polymer concentration 
solutions (Craig 2002). Thus, the significance of the PVPVA 6:4 concentration in the solubilisation 
of APIs was also examined by performing the apparent solubilities studies of the tested APIs in 
three different concentrations of PVPVA 6:4 solutions in distilled water, i.e. high concentration 
(10% w/v), intermediate concentration (1% w/v) and low concentration (0.0001% w/v) of PVPVA 
6:4. Figure 5.1 displays the multiple of solubility enhancement of the APIs at the tested 
concentrations of PVPVA 6:4 solutions using solubility of API in the media without PVPVA 6:4 as 
a reference.  
 
Figure  5.1: Apparent solubility of APIs in the presence of PVPVA 6:4 after 48 hours at 37 oC 
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According to Figure 5.1, OZP was showed to have the highest apparent solubility enhancement for 
all the tested concentrations of PVPVA 6:4. However, there is no apparent difference in the 
apparent solubility enhancement of the acidic APIs (KTP, NAP and INDO) at low PVPVA 6:4 
concentration (0.0001% w/v). In contrast, noticeable differences in solubilities enhancements of the 
acidic APIs were seen at the high concentration of PVPVA 6:4 (10% w/v PVPVA 6:4), in which 
the solubility enhancement was in a trend of NAP > INDO > KTP. This implies the importance of 
high concentration of PVPVA 6:4 in any possible solubilizing effects of these APIs.  
 
5.3.3. Basic characterization of HME products: XRPD and DSC 
Before investigating the dissolution performances of HME API-PVPVA 6:4 extrudates, basic 
characterisation of the extrudates was performed. Figure 5.2 displays the XRPD curves of the 
freshly prepared HME API-PVPVA 6:4.  
 
 
Figure 5.2: XRPD profiles of HME 30% APIs-PVPVA 6:4 
 
All the extrudates were predominantly amorphous in nature as indicated by the halo pattern of X-
ray diffractograms in Figure 5.2. This result can be further complemented by MTDSC scanning of 
the prepared HME API-PVPVA 6:4 systems. Figure 5.3 shows MTDSC thermograms of the 
freshly prepared HME 30% APIs-PVPVA 6:4 systems  
0 10 20 30 40 50
In
te
n
si
ty
  
Degree (2θ) 
HME NAP PVPVA6:4 
HME INDO PVPVA 6:4 
HME OZP PVPVA 6:4 
HME KTP PVPVA 6:4 
Dissolution performances of HME APIs PVPVA-based solid dispersions                         Chapter 5 
 
School of Pharmacy, University of East Anglia   188 
 
 
Figure 5.3: MTDSC thermograms of HME 30% APIs-PVPVA 6:4. Blue lines present the reversing heat flow 
signal, whereas the green lines present the total heat flow of the corresponding samples 
 
According to the thermograms in Figure 5.3, a single Tg was observed in the reversing signal (blue 
lines) of the freshly prepared HME SD, which is a classical indication for homogeneity of the SD 
system. The detected Tg of the HME system as shown in Figure 5.3 were all lower than the Tg of 
the PVPVA alone (data not shown) due to the plasticization effect of the APIs. Besides, there were 
no apparent melting endothermic peaks detected in the total heat flow signal (green lines) of each 
of the HME systems, which supports the conclusion obtained from XRPD data as the HME 
systems were amorphous in nature.  
 
5.3.4. Interaction between APIs and PVPVA 6:4 
Drug polymer interaction has been reported to be important in the dissolution performance of SD 
due to the formation of soluble complexes and reduction of agglomeration of the hydrophobic 
particles (Karavas et al., 2006, Ilevbare et al., 2012a). Therefore, in this study, interaction between 
the APIs-PVPVA 6:4 was also investigated to check its effect on dissolution rates enhancement of 
HME SD system.  
ATR-FTIR spectra of PMs API and PVPVA 6:4 revealed a summation of the individual ATR-
FTIR spectra of the respective components with no apparent wavenumber shift of the peak (data 
not shown). This suggests only a limited interaction between API and PVPVA 6:4 in their PM 
systems.  
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On the other hand, ATR-FTIR spectra of the investigated HME systems shows significant peak 
shift in as compared to the ATR-FTIR spectra of the pure API and PVPVA 6:4. Figure 5.4 shows 
the theoretical PVPVA 6:4 spectra from the all the HME APIs-PVPVA 6:4 system which were 
obtained via subtraction of the HME APIs-PVPVA 6:4 systems by their corresponding API spectra, 
i.e. HME API- PVPVA 6:4  spectra-API spectra.  
 
Figure 5.4: Theoretical FTIR-ATR sepctra of PVPVA 6:4 from different HME-drugs-PVPVA 6:4 systems 
 
According to Figure 5.4, dried PVPVA 6:4 possesses an amide carbonyl stretching from its 
pyrrolidone group at 1672 cm
-1
. This peak was shifted down in the theoretical spectra of PVPVA 
6:4 obtained from the HME systems (Figure 5.4) which indicating the existence of interactions on 
the C=O group of the pyrrolidone in PVPVA 6:4. Besides, new peaks were observed in the 
theoretical PVPVA 6:4 spectra obtained from all the tested HME systems. The appearance of these 
new peaks are possibly due to the new stretching mode of the C=O following the hydrogen 
interaction of API with the PVPVA 6:4 (Paudel and Van den Mooter, 2011). This interaction 
between the APIs and PVPVA 6:4 was also confirmed by the observation of downshifting in the 
wavenumber of OH / NH stretching of the APIs (data not shown). 
The extent of C=O downshifting reflects the trend of hydrogen interaction between the APIs and 
polymer as weakening of the vibration energy of carbonyl stretching causes the down-(red) shift to 
lower wavenumber (Van Eerdenbrugh and Taylor, 2012, Marsac et al., 2009). From Figure 5.5, the 
highest extent of down-(red) shift of the C=O peak is seen in OZP followed by > NAP > INDO > 
KTP. This trend was observed to be following the similar trend of enhanced solubility of APIs in 
the PVPVA 6:4 solution (Chapter 5.3.2, Figure 5.1).  
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5.3.5. Comparison of dissolution profiles of PM and HME products 
After the basic characterisation of the prepared HME APIs-PVPVA 6:4 system, their dissolution 
performances were investigated. To assess the advantages in dissolution performance of SD 
system, dissolution performances of their corresponding pure APIs and PMs were also performed. 
Figure 5.5 displays the dissolution profiles of the four different APIs in their pure powder form, 
PMs and HME APIs-PVPVA systems.  
  
Figure 5.5: Dissolution profiles of pure API (orange dotted line), HME 30% API-PVPVA (in red) and their 
corresponding PM (blue dotted line) in their respective dissolution media: a) KTP, b) NAP, c) INDO and d) OZP. 
The similarity factors, f2 indicated the comparison of dissolution profile between PM and HME formulations. 
 
According to Figure 5.5, dissolution rates of the APIs were noted increased in the PM of the acidic 
drugs (KTP, NAP and INDO) but not in the PM OZP PVPVA 6:4 system. This might be ascribed 
to the wetting effect of the PVPVA 6:4 which will be further investigated in a later section 
(Chapter 5.3.6.1).  
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Comparison between the HME and PM 
Based on Figure 5.5, it is interesting to note that the dissolution rate of HME amorphous API-
PVPVA 6:4 systems (red lines) did not consistently show a higher release rate than their 
corresponding PM crystalline API-PVPVA 6:4 systems (blue-lines). These could be quantitatively 
analysed by using magnitude of similarity factor f2 that has been described in Chapter 5.2.6 which 
indicates similar dissolution profiles between the comparing systems when its value of f2 is more 
than 50 and a difference profile when f2 is less than 50.   
Among the tested APIs, the lowest similarity factor f2 between the HME and PM was noted in OZP 
system which indicating its highest dissolution performance difference between its HME and PM 
systems (Figure 5.5 (d)). It was then followed by HME 30% INDO-PVPVA 6:4 which also shows 
a difference in the dissolution performance between the HME and its PM systems (Figure 5.5 (c)), 
but the difference was slightly lower as compared to OZP system. In NAP system (Figure 5.5 (b)), 
there was almost no difference in the dissolution profiles between its HME and PM as indicated by 
the similarity factor f2 > 50. Whereas for KTP system (Figure 5.5 (a)), although f2 is less than 50 
which indicates a difference between PM and HME KTP PVPVA 6:4.  However, this difference is 
based on the higher dissolution rate of PM KTP PVPVA 6:4 than its HME systems which is in 
oppose to the differences seen in OZP and INDO system whereby their HME systems release faster 
than PM system. These observation give rise to a rank order of the increased release rate of API in 
HME in comparison to their PM, i.e. OZP > INDO > NAP > KTP which was found to be following 
the exact trend seen in solubility advantages ratio of APIs calculated from the difference in free 
energy of the amorphous form and crystalline form of the APIs (Table 5.3).  
Table 5.4 display the summary of dissolution rate comparison among the APIs, PMs and HME 
systems for the tested APIs in this study. 
Table 5.4: Summary of the dissolution performances among pure APIs, PMs and HME PVPVA systems  
HME Dissolution rate  PM Dissolution rate  API 
KTP-PVPVA 6:4 < KTP-PVPVA 6:4 > KTP 
NAP-PVPVA 6:4 = / < NAP-PVPVA 6:4 > NAP 
INDO-PVPVA 6:4 > INDO-PVPVA 6:4 > INDO 
OZP-PVPVA 6:4 > OZP-PVPVA 6:4 = OZP 
 
Following the summary in Table 5.4, two main phenomena were observed in the dissolution 
experiments. On one hand, API release rate was significantly improved by physical addition of 
PVPVA 6:4 as shown in the dissolution performances of the PM API-PVPVA 6:4 system with the 
exception for OZP system. On the other hand, HME APIs-PVPVA 6:4 formulations show only 
limited dissolution rate enhancement in comparison to their corresponding PM system with the 
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exception of OZP system. These inconsistent observations of SD leave the formulation scientist in 
an uncertain position as one may argue that some of the PM systems seem to sufficiently enhance 
the API release rate without necessitating the generation of an SD at all. This entails more 
fundamental investigation into the factors affecting the dissolution behaviours of the PM and HME 
systems.  
 
5.3.6. Investigation of factor governing dissolution performance of HME API-PVPVA 6:4 
system  
Following the inconsistent dissolution profiles of the PM and HME systems, possible factors that 
could influence the dissolution performance of HME 30% APIs-PVPVA 6:4 systems were 
investigated. These factors include wetting properties, agglomeration tendency and recrystallization 
behaviour of the HME API-PVPVA 6:4 systems during their dissolution processes.  
 
5.3.6.1. Wetting properties of the solid system  
Wetting effects of a hydrophilic polymer are generally deemed to be relevant to the dissolution 
process of an immediate release SD formulation due to the associated increase in effective surface 
area for well wetted systems (Chokshi et al., 2007, Dahlberg et al., 2008). Dahlberg et al. (2010) 
have demonstrated that the combination of API and hydrophilic polymer into a SD system may 
affect the wetting of the surface system in an unexpected and nontrivial manner. This situation 
could be further complicated by the manufacturing method of the formulation system which may 
cause a change of the functional group of the system that are present on the surface of the system 
(Dahlberg et al., 2008). Thus, it is essential to understand the change in wetting properties of both 
PM and HME of binary API-PVPVA 6:4 in comparison to their API which will be presented in the 
next sections.  
Firstly, contact angle studies of APIs/ medium, APIs/ PVPVA solution and their PMs/medium 
were investigated to understand the wetting effect of PVPVA 6:4 in these systems which are being 
presented in section 5.3.6.1.1. The relative wettability between the PM and HME systems were 
subsequently compared in section 5.3.6.1.2. It is worth mentioning that the liquid phase of the 
contact angle measurement was based on the medium used in dissolution experiments (please refer 
to Table 5.1 for the medium type). The use of these dissolution media as a liquid phase in the 
contact angle measurements was to undertaken in order to understand the wettability effect of these 
systems, with a view to explaining the unpredictable dissolution performance as seen in the 
dissolution experiments in section 5.3.5. 
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Contact angle profile of pure APIs-dissolution medium 
Figure 5.6 shows the contact angle of the compacted crystalline APIs in response to the 
corresponding saturated medium.  
 
Figure 5.6:  Contact angles between the pure APIs and their dissolution media.  0.1 M HCl was used as the liquid 
phase in contact angle measurement of KTP and NAP, whereas distilled water was used as a liquid phase in the 
measurement for the surfaces of INDO and OZP.  
 
From Figure 5.6, KTP, NAP and INDO were showed to possess superimposable contact angle 
profiles which were higher than the contact angle profile of OZP. This implies that wettability of 
crystalline OZP is relatively better than the other tested APIs. 
 
5.3.6.1.1. Wetting properties of PM APIs-PVPVA 6:4 in comparison to their APIs 
Dissolution enhancement of poorly soluble API in PM is always associated to the increased in 
wetting of the API with the presence of the hydrophilic polymer. Thus, to understand the change in 
wetting properties of the system in the presence of the hydrophilic polymer, the contact angles of 
the PM systems were performed.  
 
Before detailing the contact angle data, it should be pointed out that the use of compacted surface 
in determining the wetting of the system via contact angle might not be directly related to the exact 
wettability of the powder form during their dissolution experiments. However, the relative values 
of the contact angles among the different tested systems could still be useful for the approximation 
of relative wettability of the different APIs in their PM systems. Figure 5.7 displays the contact 
angle profiles of the PM systems in contact to their corresponding dissolution mediums.  
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Figure 5.7: Contact angles of the compacts PMAPIs-PVPVA 6:4 to its corresponding dissolution medium. 0.1 M 
HCl was used as the liquid phase in contact angle measurement of KTP and NAP, whereas distilled water was 
used as a liquid phase in the measurement for the surfaces of INDO and OZP 
 
Unlike the contact angle profile of pure API, contact angles profile of the PM shows time 
dependent receding angle in the first 10 seconds which suggests some changes in the interface of 
the measurement (Figure 5.7). As a high proportion of PVPVA 6:4 was covering the surface at this 
composition (70%) it is plausible that the time dependent receding contact angle profiles is a 
reflection of change in configuration of the surface polymer upon contact with the liquid phase. 
This change can take place through short-range motion such as diffusion of the hydrophilic 
moieties of the polymer into the liquid phase, swelling and reorientation of polymer chain that 
might potentially reduce the surface tension and reorganisation of the liquid molecules at the solid-
liquid interface (Lam et al., 2002, Tavana and Neumann, 2007). All the PM systems revealed 
almost similar contact angle profiles except PM of KTP-PVPVA 6:4 which reveal a higher contact 
angle.  
By comparing the contact angle profile of the PM API PVPVA (Figure 5.7) and its pure API alone 
(Figure 5.6), the reduction of contact angle could be assessed. It is a reflection of increased 
wettability of the PM system as compared to its pure APIs. The contact angle reductions of all PM 
systems were circa 30
o
 in comparison to their corresponding APIs except PM KTP PVPVA 6:4 
system which show a reduction of circa 22
o
. These similar reductions in contact angle of PM 
systems did not show any trend in affecting their degree of dissolution rate enhancement. Hence, it 
could be suggested that the increased wettability of the PM system at the pre-dissolved state of 
PVPVA 6:4 is not a major factor in determining the extent of dissolution enhancement of PM in 
comparison to their pure APIs. 
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Dissolution rate enhancement of PM was also reported to occur via wetting the hydrophobic drug 
particles by the surrounded polymer layer which provides a lower energy pathway for its 
dissolution (Yadav and Yadav, 2009). In this case, it is hypothesized that the carrier shall be in its 
dissolved state to exert the wetting effect. To test this, wetting effect of PVPVA 6:4 in its post-
dissolved state were carried out by measuring the contact angle of API with the 1% PVPVA 6:4 
solutions as liquid phase. The obtained data (data not shown) were compared to the contact angles 
profiles of APIs/media without PVPVA 6:4 (Figure 5.6). This was done by subtracting the contact 
angle profiles of ‘API /1% w/v PVPVA 6:4 medium’ from the contact angle profiles of ‘API/ 
medium without PVPVA 6:4’. Figure 5.8 displays the results of the subtracted contact angles 
profiles for all the 4 tested APIs.  
 
Figure 5.8: The differences of contact angles profiles between ‘APIs-dissolution medium’ and ‘APIs -1% w/v 
PVPVA in dissolution medium’  
 
It is noted from Figure 5.8 that the extent of the contact angle differences between API/1%PVPVA 
in media and API/media exhibit a rank order of wettability enhancement, i.e. KTP > NAP > INDO 
> OZP which is similar to the rank order in the extent of dissolution rate enhancement of PM API-
PVPVA 6:4 as compared to their APIs alone (Figure 5.5). Therefore it is suggested that the 
increase wettability of API at post-dissolved state of the PVPVA 6:4 might be the decisive role in 
determining the extent of dissolution rate enhancement of the APIs in their PM systems.  
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5.3.6.1.2. Wetting properties of the HME and PM system  
After acknowledging the importance of wetting properties in the dissolution of the PM system, the 
relative wettability between the PM and HME system was also investigated. With the same 
compositional surface of HME and PM system, the contact angle profiles of both these systems are 
deemed to be comparable. Figure 5.9 displays the comparison of contact angles between the HME 
and PM systems. 
 
 
 
Figure 5.9: Comparison of contact angle profiles between PM and HME API-PVPVA 6:4 solid dispersions using 
corresponding dissolution medium a) KTP, b) NAP, c) INDO, and d) OZP  
 
According to Figure 5.9, it is interestingly to note that HME systems displayed higher contact angle 
values as compared to their corresponding PM except HME OZP-PVPVA 6:4 system (Figure 5.9 
(d)). This implies the poorer wettability of the HME API PVPVA 6:4 systems as compared to their 
PM system except HME OZP-PVPVA 6:4 system which suggests a negative influence on 
wettability of the binary API-PVPVA 6:4 system after the production into HME API-PVPVA 6:4 
systems. Similar observations were noted before in literatures whereby the PVP-based SD 
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possessed a higher contact angle than its corresponding PVP-based PM (Chokshi et al., 2007, 
Dahlberg, 2010, Dahlberg et al., 2008). Among these systems, the highest negative impact was 
seen in HME INDO PVPVA/media as compared to its PM. However, in OZP system, it could be 
deduced that the wettability between the PM and HME systems was similar as indicated by their 
superimposable contact angle profiles in Figure 5.9 (d).  
The reduced of wettability of the HME system may be related to two possibilities. Firstly, it might 
be ascribed to the dissolution of the hydrophobic API into the polymeric system to form a one 
phase HME system while hot melt extrusion process. This may reduce the overall hydrophilicity of 
the PVP carrier. Secondly, the reduced wettability of HME system might also be associated with 
the orientation of its hydrophilic polymer chain as compared to the PM system. In PM, the 
hydrophilic PVPVA 6:4 polymer could orientate freely and swell upon contact with the medium. 
This may cause a reduction in surface tension of the liquid phase which spread well on the solid 
surface (Lam et al., 2002). However, this is limited for the HME system, as the coordination of the 
hydrophilic polymer was restricted as a result of API-polymer interaction as evidenced in Figure 
5.4. This result is in agreement with Dahlberg et al. (2010) who have demonstrated that the high 
possible hydrogen bonding site of hesperetin with the PVP carrier in SD has caused a higher 
contact angle of the SD system as compared to its PM system.  
 
To summarise, wettability of the system was evaluated by using contact angle measurements. 
Based on the results, the wetting of API was greatly enhanced with the presence of PVPVA 6:4 in a 
post-dissolved state in a rank order similar to the dissolution rate enhancement of the PM system 
(Figure 5.5). This indicated the significance of post-dissolved PVPVA 6:4 in dissolution rate 
enhancement of the PM system. Besides, the results also show lower wettability of HME system as 
compared to their corresponding PM systems. This might cause a change in the agglomeration 
tendency of the HME system as a result of surface hydrophobicity which could potentially alter the 
desired dissolution rate enhancement of SD system. This effect will be further investigated in the 
next section. 
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5.3.6.2. Agglomeration of the dissolving solid 
During the dissolution experiments of the HME API- PVPVA 6:4 systems, opaque-white particles 
were visibly formed and floated within the dissolution media. Figure 5.10 illustrates the example of 
opaque particles observed during the dissolution experiment of HME 30% NAP-PVPVA 6:4.  
 
 
Figure 5.10: Observation during dissolution process of HME 30% NAP-PVPVA 6:4 
 
According to the well-known Whitney Noyes Equation (2.2), the surface area of the dissolving 
particles could potentially affect the dissolution rate of a dissolving system (Noyes and Whitney, 
1897). Therefore, the precipitated particles observed in this study (Figure 5.10) may cause a 
reduction in the effective surface area for dissolution which may be the potential reason for the low 
dissolution rate of HME API-PVPVA 6:4 systems as seen in Figure 5.5. Similar events were also 
observed in previous works where the dissolution rate was reduced as a result of large particle 
formation (de Waard et al., 2008, Karavas et al., 2007). According to this literature, the reduced 
dissolution rate is due to the uncontrolled formation of large crystal particle following the 
saturation of drug concentration in the direct vicinity of the dissolving front. Hence, the overall 
dissolution rate is the net result of the solubilisation of the solid dispersion in its original form and 
the low specific area of the agglomerated particles.  
 
Particle size analysis 
In order to access the influence of the surface area changes in dissolution process of the HME 
APIs-PVPVA 6:4 systems, a light scattering particle size analyser was employed to track the 
particles size changes of the dissolving HME systems during their early dissolution process. Figure 
5.11 presents an example of the results obtained from particle size analyses of HME 30% KTP-
PVPVA 6:4 after 2 minutes of dissolution.  
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Figure 5.11: Examples of particle size analysis of HME 30% KTP-PVPVA in dissolution medium after 2 minutes 
of the dissolution experiment 
 
Based on Figure 5.11, particles with sizes up to 300 μm were noted, which was larger than the 
initial controlled size (63-106 μm). Besides, the all tested formulations showed almost bimodal 
particle size profiles except the HME NAP-PVPVA 6:4 system (data not shown). Figure 5.12 
summarises the 90 % of the cumulative undersize distribution of particles during the first 30 
minutes for the four studied HME API-PVPVA 6:4 systems. An increased in particle sizes upon 
dissolution process was noted that in all the HME API-PVPVA 6:4 systems which indicated the 
occurrence of agglomeration or precipitation.  
 
Figure 5.12: Particle size analysis: 90% of the cumulative undersize distribution of HME 30% APIs-PVPVA 6:4 in 
dissolution medium 
 
From Figure 5.12, larger particle size was noted after 2 minutes of dissolution. The trend of particle 
size of the HME API- PVPVA systems was INDO > KTP > NAP > OZP. This trend is noted to be 
in the same rank order with contact angle of HMEAPIs PVPVA 6:4 systems as presented in Figure 
5.9. Thus, the appearance of the big particles was attributed to the agglomeration of the dissolving 
particles due to the hydrophobic nature of their surfaces. 
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5.3.6.3. Recrystallization of APIs during dissolution 
In order to gain an understanding regarding the physical state of the HME API-PVPVA 6:4 
systems during the dissolution experiment, their behaviours on exposure to the dissolution medium 
were investigated by using polarized light microscope as described in Chapter 5.2.6.1. It is 
expected that birefringence of the crystalline materials will be revealed under the polarized light 
microscope observation if recrystallization of APIs occurs upon medium addition. Figure 5.13 
displays the images recorded over the time scale of the experiment. 
 
 
 
 
 
Figure 5.13: Images captured upon addition of dissolution media to HME 30% APIs-PVPVA 6:4. From top to 
bottom of the images a) KTP, b) NAP, c) INDO, d) OZP and from left to right:(i) t=0,  (ii) t=1, (iii) t=30, (iv) t=60 
minutes  
 
Base on Figure 5.13 (a) i, HME KTP-PVPVA 6:4 SD particles did not show any birefringence of 
crystalline material after 1 minute of the medium fluid addition.  Instead, an opaque appearance of 
the particles was observed. These opaque particles were noted to swell with time before complete 
dissolution of the particle took place (Figure 5.13 (a) ii to (a) iv). On the other hand, HME NAP-
PVPVA 6:4 SD revealed birefringence on the ground particles which became more intense with 
a) ii a) i a) iii a) iv 
b) ii b) i b) iii b) iv 
c) i c) ii c) iii c) iv 
d) i d) ii d) iii d) iv 
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time (Figure 5.13 (b) i to (b) iv) from left to right). This indicates the recrystallization of NAP on 
the surface of the ground extrudates after exposure to 0.1M HCl. For HME INDO-PVPVA 6:4 SD, 
no obvious changes such as birefringence of the wetted particles could be detected under 
microscopic investigation. Also, the particles of this system did not show an opaque appearance 
after the medium contact (Figure 5.13 (c) ii to (c) iv). However, the outer layer of the HME INDO-
PVPVA 6:4 SD particles was slightly depleted and the size of these particles remained largely 
constant up to one hour despite their contact with the dissolution medium.  
HME OZP-PVPVA 6:4 SD (Figure 5.13 (d) ii to (a) iv) revealed an opaque appearance similar to 
that of KTP upon contact with the dissolution medium. Unlike KTP, the opaque particles of HME 
OZP-PVPVA experienced apparent size reduction with time instead of particle swelling as noted in 
the HME KTP PVPVA 6:4 system (Figure 5.13 (a) ii to (a) iv). Besides, birefringence was also 
noted in the HME OZP-PVPVA 6:4 system similar to HME NAP PVPVA 6:4 system. However it 
took a relatively longer time in revealing the birefringence of crystalline material (i.e. after 30 
minutes of medium contact as shown in Figure 5.13 (d) iii) as compared to HME NAP PVPVA 6:4 
system (i.e. after 1 minutes of medium contact as shown in Figure 5.13 (b) ii). This suggested a 
slower recrystallization rate of OZP as compared to the HME NAP PVPVA 6:4 system.  
 
The observations deduced from microscopic investigation could be further supported by examining 
the surface morphologies of particles collected from the dissolution bath after 2 minutes dissolution 
were observed using scanning electron microscopy. Figure 5.14 shows the surface morphologies of 
the particles collected after 2 minutes of the dissolution experiment of HME API-PVPVA 6:4.  
According to Figure 5.14 (a), surface of HME 30% KTP-PVPVA 6:4 particle was shown to have 
some star shape cluster with the square-like crystal on its surface which is an indication of particle 
recrystallization during the dissolution process (Figure 5.14 (a)). Based on this observation, it is 
reasonable to suggest that the opaque appearance of HME KTP-PVPVA 6:4 in the HSM images 
(Figure 5.14 (a) ii) is a sign of early recrystallization of the KTP on the extrudate upon contact with 
dissolution medium. The covering of the recrystallized KTP at the surface dissolving may cause a 
reduction in dissolution of the surface, in which a continuation of medium ingression into the core 
of the particle resulted in polymer swelling inside the core of the particles as could be seen in 
Figure 5.14 (a) iii and iv.  
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Figure 5.14: SEM images of particle collected from dissolution of HME 30% APIs-PVPVA after 1 minute of 
dissolution process a) KTP, b) NAP, c) INDO and d) OZP 
 
Similarly, distinctive edges were also seen on the surface of HME 30% NAP-PVPVA 6:4 samples 
(Figure 5.14 (b)) which implying the appearance of crystalline material on the surface of these 
collected particles. On the other hand, particles of HME 30% INDO-PVPVA 6:4 in Figure 5.14 (c) 
indicate smooth surface of this system which suggesting the absence of crystalline material on its 
surfaces (Figure 5.14 (c)). This was in agreement with the observations of polarized light 
microscopy whereby the no recrystallization was expected from the HME 30% INDO-PVPVA 6:4 
system (Figure 5.13 (c) ii to (c) iv). However, some ‘flaky’ structures precipitated near the surface 
of particle collected from the dissolution vessel of HME 30% OZP-PVPVA 6:4 system was seen 
(Figure, 5.14 (d)). This might indicate a potential of early recrystallization of OZP on the surface of 
the HME OZP-PVPVA 6:4 system as complemented by the opaque appearance of these particles 
upon medium contact (Figure 5.13 (d) ii to (d) iv). 
Results obtained from both the polarized light microscope and SEM deduced that there were some 
extent of recrystallization occurred in all the investigated HME system upon media contact except 
the HME INDO-PVPVA 6:4 system. In summary, the recrystallization tendency were noted to be 
highest in HME NAP-PVPVA 6:4 system follow by HME OZP-PVPVA 6:4 > HME KTP-PVPVA 
6:4  > HME INDO-PVPVA 6:4 systems. This trend of recrystallization does not follow the same 
trend of dissolution rate difference between the HME different API-PVPVA 6:4 and their PM 
systems.  
a) b) 
d) c) 
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5.4. Discussion 
According to Figure 5.5 and Table 5.4, the production of poorly soluble APIs into an HME 
formulation did not show a consistent dissolution rate enhancement of the APIs as compared to 
their corresponding PM, despite the production of fully amorphous HME SDs as shown by the 
XRPD diffractograms (Figure 5.2). Hence, the production of a fully amorphous HME SD system 
may not necessarily be advantageous as compared to the product prepared by simple physical 
mixing procedure. Following this observation, the immediate question that arises is: what 
properties of the API are responsible for the different dissolution enhancement effects of the HME 
amorphous SD? This question can be answered by considering the factors determining the release 
rate enhancement of PM and amorphous system, as well as recognising the potential problems of 
dissolution process that have been observed during the dissolution process. 
 
5.4.1 Dissolution performance of APIs in comparison their PM API-PVPVA 6:4 
Dissolution enhancements of the investigated PM systems as compared to their pure API were seen 
for PM KTP, NAP and INDO PVPVA 6:4 system with the exception of OZP system which shows 
a superimposable dissolution profile to its pure API. The observed improvements may be due to the 
better wettability of the PM system as revealed by their reduced contact angles in comparison to the 
pure API.  
 
Based on Figure 5.5, the degrees of dissolution rate enhancement of the PM systems were different 
for different APIs. It was interesting to found that the rank order of the degree of dissolution 
enhancement were not correlated to the reduced contact angles of the PM system but instead 
correlated well to the degree of wettability increment of the tested APIs by dissolved PVPVA 6:4 
(Figure 5.7). In particular, the limited wettability enhancement of OZP by the dissolved PVPVA 
6:4 was in agreement with the limited dissolution rate enhancement in its PM system, hence it is 
reasonable to suggest that the PM enhancement in dissolution is directly related to the wetting of 
the drug by the dissolved polymer.  
 
It is worth mentioning that the wettability study of the API/PVPVA solution in Figure 5.8 was 
performed with high concentration of dissolved PVPVA, i.e 1% w/v PVPVA 6:4. Thus it is 
proposed that the dissolution enhancement of a PM system is highly dependent on the wettability 
enhancement of the API by the dissolved PVPVA 6:4 at early dissolution process as the high 
polymer concentration surrounding the API could only be formed at this early phase. A similar role 
of the PVP polymer has been reported previously as authors have recognized that a polymer rich 
layer is important for dissolution process of poorly soluble APIs (Chawla and Bansal, 2008).  
Dissolution performances of HME APIs PVPVA-based solid dispersions                         Chapter 5 
 
School of Pharmacy, University of East Anglia   204 
 
Besides, solubilisation of the API by its carrier may also contribute to the observed dissolution 
enhancement of the PM system based on the well-known Noyes Whitney equation that identifies 
solubility in driving a dissolution process (Noyes and Whitney, 1897). This can be seen for the 
dissolution of PM NAP PVPVA 6:4 system which shows its relatively high solubility in 10% w/v 
PVPVA 6:4 solution. In this case, dissolution rate enhancement of the PM NAP PVPVA 6:4 system 
was 2 fold as compared to the pure NAP alone. In contrast, the high solubilisation of OZP by 
PVPVA 6:4 solution did not give rise to dissolution enhancement of its PM OZP PVPVA 6:4 
system. This might be attributed to the strong crystal lattice of OZP which could be inferred by its 
high free energy difference of the crystalline material to its non-crystal state base on its Tm (as 
shown in Table 5.3) (Ivanov and Tsokeva, 2009). Therefore, apart from the limited wettability 
enhancement of OZP by PVPVA 6:4, the strong crystal lattice energy of the OZP  has also caused 
the limited dissolution enhancement of PM OZP PVPVA 6:4 (Reutzel-Edens et al., 2003, Gao and 
Olsen, 2013).  
The crystal strength of all the tested APIs as reflected from the free energy differences showed a 
trend of OZP > INDO > NAP > KTP (Table 5.3 and column 4). This is found to be in the reverse 
trend as seen in dissolution enhancement of PM as compared to its API, i.e. OZP < INDO < NAP < 
KTP, which implies that higher strength of a API crystal may cause ineffective dissolution 
enhancement of its PM prepared by simple mixing procedure. Hence, the role of crystal strength in 
dissolution enhancement of the PM API-PVPVA 6:4 as compared to its API alone was further 
confirmed. 
 
5.4.2 Dissolution performance of HME APIs-PVPVA 6:4 in comparison to PM 
It is interesting to note that different APIs behaved differently in term of wetting and dissolution 
performance in their PMs and HME SD systems. In this context, some APIs showed faster 
dissolution profiles in HME SD in comparison to the corresponding PM e.g. OZP and INDO-
PVPVA 6:4 and others, in contrast, showed slower dissolution rates for the HME systems e.g. KTP 
and NAP-PVPVA 6:4 despite the use of the same carrier system.  
 
Wettability of the HME formulations 
Wetting properties of the tested HME KTP, NAP, INDO systems were lower than their 
corresponding PM which was shown by the higher contact angle of the HME system as compared 
to the PM system. This might be the reason of the limited dissolution rate enhancement of HME 
systems as compared to their PM system. During the dissolution process of the PM system, the 
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hydrophilic polymer could be easily wetted due to the flexibility of the hydrophilic polymer system 
in its PM state. Then, the polymer can swell and form a layer of polymer rich continuum between 
the dissolving particle and the liquid bulk (Craig, 2002, Miller-Chou and Koenig, 2003). In this 
state, the drug could dissolve into the high concentration of the polymer prior to release into the 
bulk. However, this polymer rich layer is limitedly formed in HME system. This is mainly due to 
the reduced coordination of polymer chain as a result of drug-polymer interaction in the one phase 
system of HME (Dahlberg, 2010) as detailed in Chapter 5.3.6.1.2. The exception of OZP system 
which shows a similar wettability between the HME and its PM system might be due to the high 
solubility advantage of the amorphous form of OZP (Table 5.3 and column 7) that reflects its 
possibly low hydrophobicity properties at its amorphous state. Furthermore, the wetting effect of 
HME SD systems can be further deteriorated in by the intensive recrystallization of the amorphous 
API on the surface of dissolving particles during the dissolution process which will be further 
discussed in a later section.  
 
Agglomeration and precipitation 
The high tendency of particle agglomeration and precipitation of SD during the dissolution process 
could potentially reduce the drug release rates of the SD (Kapsi and Ayres, 2001, Karavas et al., 
2007). During dissolution experiment of HME formulations, pronounce agglomeration and 
precipitation was noted as indicated by the sizes of particles dispersed in the dissolution medium 
being larger than the initial controlled particles size range (63-106 μm). In this context, the extent 
of agglomeration was reflected by the particle size of the dissolving particle which showing the 
trend of particle as INDO > KTP > NAP > OZP. This may be ascribed to the high hydrophobicity 
of the surface system of the HME which could be correlated well to the value of contact angle 
found in HME system as highest values was seen in INDO followed by > KTP > NAP > OZP. 
Furthermore, the agglomeration of the dissolving solid during the dissolution process could also 
potentially lead to crystallization of the API depending on the crystallization tendency of the tested 
API which will be further discussed in the next paragraphs.  
 
Recrystallization 
In this study, microscopic observations confirmed recrystallization of all the tested formulations 
upon dissolution except HME INDO-PVPVA 6:4. For instance, HME NAP-PVPVA 6:4 showed 
intense recrystallization after agglomeration of particle upon medium addition as shown from the 
birefringence of crystalline material in Figure 5.13 (b). This was further supported by high 
magnification investigations using SEM where crystalline features was seen on the surface of the 
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particle collected while dissolution experiment (Figure 5.14). The recrystallization of API on the 
surface can lead to the lining of crystalline material at the dissolving front of particle which could 
hinder the movement of large molecular polymer from the core of particle to the outer layers of the 
particle. Consequently, this could hinder the formation of polymer rich layer at vicinity of the 
dissolving front in exerting its wetting effect which was shown to be important for dissolution 
enhancement of a poorly soluble API as shown in the contact angle measurement in Figure 5.8. 
Hence, it is proposed that the limited dissolution rate enhancement of HME KTP, NAP, and INDO 
PVPVA 6:4 in comparison to their PM systems could also be associated with the secondary 
phenomena of recrystallization which further reduces the wettability of the API.  
The previous chapter (Chapter 4) has shown the importance of drug polymer interaction in 
preventing physical recrystallization of HME PVP-based. Nevertheless, in this chapter, 
recrystallization trend of the dissolving systems as deduced from both the HSM and SEM images 
were not in coherent to the trend of hydrogen bond interaction between the API-PVPVA 6:4 as 
predicted by ATR-FTIR. This is attributed to the hydrodynamic dissolution process that causes 
different recrystallization trend of the HME system. During dissolution, the effect of drug polymer 
interaction in controlling the recrystallization of HME API-PVPVA 6:4 has been diluted as other 
events might come into play in the recrystallization of API while dissolution, such as ionization or 
solubilisation of the API in the dissolution medium. 
 
Theoretical solubility advantages of amorphous API and its phase solubility behaviour in PVPVA 
solution 
As mentioned in previous paragraph, the dissolution rate of an API has been long established to be 
associated to its solubility in which a high solubility of an API could drive the its dissolution rate 
(Noyes and Whitney, 1897). In amorphous systems, beside the absence strong crystal lattice bonds 
between the molecules which lead its readily dissolvable state, high apparent solubility of the 
amorphous API can also drive the dissolution rate. The apparent solubility of an amorphous API 
could be theoretically estimated by calculating the free energy difference between the crystalline 
and amorphous state as presented in Table 5.3. The rank order difference in free energy of 
amorphous and crystalline state of the tested API as shown in Table 5.3 was found to correlate well 
to the trend of extent in dissolution rate enhancement of the HME systems as compared to its PM, 
i.e. HME OZP-PVPVA 6:4  > HME INDO-PVPVA 6:4 > HME NAP-PVPVA 6:4 > HME KTP-
PVPVA 6:4. This suggested that the dissolution performance of a HME API-PVPVA 6:4 system is 
API specific where the free energy difference between the amorphous and crystalline form largely 
dictate the overall dissolution performance of a HME amorphous SD system. 
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The enhanced dissolution rate of the HME amorphous systems could be further driven by the 
enhanced phase solubility of the APIs in the concentrated polymer rich layer. For instance, the 
highest extent of solubility enhancement of OZP in the concentrated PVPVA 6:4 solution (Figure 
5.1) has promoted its high dissolution rate of HME OZP-PVPVA 6:4. This is due to the high 
concentration gradient of the dissolving system that fastens the dissolution rate of the system based 
on the classical Noyes-Whitney Equation (2.2). However, this solubilising effect can be potentially 
affected by the intense recrystallization of API which was clearly shown in dissolution process of 
HME NAP-PVPVA 6:4. In this system, the dissolution enhancement of NAP was not observed 
despite the apparent solubility enhancement of NAP in the presence of PVPVA 6:4. This is due to 
the high recrystallization tendency of the HME NAP PVPVA 6:4 system that has counter-balanced 
the positive effect anticipated from the solubility enhancement of NAP by PVPVA 6:4 solution.  
 
5.5. Conclusion 
This chapter have highlighted the issues arise in dissolution performance of HME PVP-based SD 
system. The limited wetting properties of HME poorly soluble API-PVPVA 6:4 system as 
compared to their PM may be a potential reason for the limited dissolution rate enhancement of the 
HME systems. The wettability alteration of the HME system has cause secondary dissolution 
limiting effect such as hydrophobic agglomeration which further promotes the recrystallization of 
the drug during dissolution process. Following the solid state changes of the HME API-PVPVA 6:4 
system upon dissolution, the subsequent dissolution dynamic is largely dictated by a combination 
of the total surface area for dissolution and the amorphous advantages of the APIs. The interactions 
between the different API and PVPVA 6:4 has shown to have minimal effect on the dissolution rate 
enhancement of the HME PVPVA 6:4 based system.  
Besides, the ‘solubility advantage’ of an amorphous API has shown to be an important parameter in 
determining the dissolution performance of solid dispersion of a poorly soluble API. In this study, 
it was found that an API candidate with its high ‘solubility advantage’ ratio is worth to be 
formulated into its solid dispersion form. This is clearly shown by the example of OZP system 
which reveals its high dissolution rate enhancement in its HME PVPVA system as compared to its 
PM system. On the other hand, a relatively low ‘solubility advantage’ of an API may not exert a 
big benefit in formulating into HME PVP-based SD. This is shown by the dissolution experiment 
of HME KTP and NAP systems where their HME systems revealed a similar dissolution profiles to 
their corresponding PM systems. The low ‘solubility advantages’ offered from the amorphous state 
of these APIs (KTP and NAP) could be easily counter-balanced by the secondary dissolution 
limiting processes of agglomeration and recrystallization which have been identified in this 
chapter.  
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Chapter 6. An investigation into factors governing the drug release 
mechanism of PVP-based hot melt extrusion 
formulations Part II: Dissolution performance of hot 
melt extruded naproxen-carrier systems 
 
6.1. Introduction 
Conventionally, transforming a poorly soluble crystalline API into amorphous form is beneficial to 
its dissolution performance as no additional bonds are necessary to be broken before complete 
dissolution of the system. However, previous chapter (Chapter 5) has found an inconsistent 
dissolution performance of HME amorphous SDs in comparison to their corresponding physical 
mixture (PM) system. In particular, the dissolution rate of the HME NAP-PVPVA 6:4 has shown a 
superimposable dissolution profiles to its corresponding PM system. This observation contradicts 
the general belief of ‘solubility advantages’ of amorphous pharmaceutical in the in-vitro dissolution 
performance of SD system (Hancock and Parks, 2000). Furthermore, the dissolution profile of the 
PM revealed a 2-fold increase in drug release rate as compared to the dissolution rate of the NAP 
alone. Therefore, PM NAP PVPVA 6:4 system seems to have reasonably increased the release rate 
of the poorly soluble NAP which makes its formulation into an HME system unnecessary. 
Thus, the purpose of this chapter is two-fold. On one hand, factors contributing to the dissolution 
enhancement of PM NAP-PVPs system will be explored. In this context, dissolution behaviour of a 
series of PVP homopolymers and a copolymer in PM will be studied. On the other hand, the root 
causes of the limited dissolution rate enhancement of HME API-PVPs system will be further 
investigated as an extension study from chapter 5, which has suggested an API dependency on 
dissolution performance of HME PVP-based SD systems. Here, other factors that affecting the 
dissolution performance of HME NAP PVP-based SD system will be explored. These factors 
include the effect of NAP loading, different molecular weight (MW) of PVP polymers and the 
effect of surfactant incorporation in the extrudate system on dissolution performance of HME NAP 
PVP-based SD. 
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6.2. Materials and Methods 
NAP was chosen as the API for the study on the effect of drug loading and carrier types in 
dissolution performances of PM and HME formulations. In this context, various grades of PVP 
were tested, which included PVP K12, PVP K17, PVP K29-32 and their copolymer, PVPVA 6:4. 
Therefore, the word ‘PVPs’ represents all the tested PVP carriers (PVP K12, PVP K17, PVP K29-
32 and PVPVA 6:4) and PVPVA 6:4 copolymer or otherwise specified. 
 
6.2.1. Preparation of PM 
PMs were prepared according to the same method as described in Chapter 5, section 5.2.3.  
 
6.2.2. Dissolution studies of pure NAP and its PMs 
Dissolution of the NAP systems was performed in 0.1M hydrochloric acid (0.1M HCl) at 37 
o
C and 
at 50 rpm.  The particle size of NAP and the polymers was maintained in the range of 63-106 μm 
prior to the dissolution experiments. Then, the samples equivalent to 10 mg of NAP (based on 
formulation composition) was transferred into the dissolution media for the NAP release 
measurement. At predetermined intervals, 10 ml of solution was withdrawn and filtered with a 
0.45μm polyvinylidene fluoride (PVDF) syringe filter. The filtrate solution was then scanned by 
UV spectrometer at 272 nm to determine the concentration of the released NAP.  
The release behaviour of NAP in the presence of PVPVA is evaluated in this study. The effect of 
PVPVA 6:4 on the release behaviour of NAP was measured in various conditions as shown in the 
dissolution experiments given in Table 6.1.  
Table 6.1: Dissolution experiments of NAP with the presence of PVPVA 6:4 in various conditions 
Sample Dissolution 
medium 
Explanation of experiment 
conditions 
Code 
Component 1 Component 2 
10 mg NAP - 0.1M HCl Pure NAP dissolution - 
10 mg NAP - 
0.1M HCl + 23.33 
mg PVPVA 6:4 
PVPVA 6:4 was pre-dissolved in the 
0.1 M HCl prior dissolution of NAP 
alone 
- 
10 mg NAP 
23.33 mg 
PVPVA 6:4 
0.1M HCl 
Addition of 23.33 mg PVPVA after 20 
minutes of NAP dissolution started 
Exp A 
PM30% NAP-
PVPVA 6:4 
 0.1M HCl Pre-mixing of NAP and PVPVA 6:4 as 
described in Chapter 6.2.1 
PM 
10 mg NAP 23.33 mg 
PVPVA 6:4 
0.1M HCl NAP and PVPVA were transferred into 
the dissolution vessel at opposite ends. 
Exp S 
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‘Exp S’ was carried out by transferring both the NAP and PVPVA 6:4 components from opposite 
ends of the dissolution vessel into the medium at the same time (also coded as ‘Exp S’ in Table 6.1) 
as illustrated in Figure 6.1. The dissolution profile of NAP in this experiment was used as a 
comparison to the dissolution profile of PM system in order to check the significance of the 
premixing step in dissolution enhancement of PM NAP PVPVA systems.  
 
 
 
 
 
 
6.2.2.1. Phase solubility of PVP and NAP 
Solubility of NAP in PVP solutions was determined by stirring excess of NAP powder in 10 ml 
0.1M HCl at 37 
o
C for 48 hours. The saturated solution was then filtered with a 0.45 µm PVDF 
syringe filter and the filtrate was measured for NAP content using a UV spectrophotometer at 272 
nm. Each sample was measured in triplicate. 
 
6.2.2.2. Surface tension of PVPs solutions 
Surface tension of the dissolution media and 1% w/v PVPVA 6:4 solution was determined by using 
a pendent drop measurement. A liquid dispenser holder with manual control was used to create the 
drops. OneAttension software was used to analyze the surface tension by Young-Laplace surface 
properties mode. The changes in the surface tension were recorded up to 120 seconds at 1 frame 
per second. 
 
Figure 6.1: Schematic to illustrate the dissolution experiment performed with addition of two components at 
different ends of the dissolution vessel, ‘Exp S’ 
Dissolution 
medium, 
0.1 M HCL 
Rotated paddle at 50rpm 
Polymer : PVPVA 6:4 Drug: Naproxen 
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6.2.3. Production of HME NAP PVP-based SDs 
HME NAP PVPs SD systems were prepared using co-rotating twin-screw extruders (Thermo 
HAAKE MiniLab Micro Compounder). NAP and polymers (total amount of 5g) were gently mixed 
in mortar and pestle for 2 minutes prior to extrusion. In the preparation of HME NAP-PVPVA 6:4-
Tween 80 system, Tween 80 (liquid surfactant) was premixing in the PM of NAP and PVPVA 6:4 
using a mortar and pestle prior extrusion. Please refer to Table 2.12 for the processing parameters 
used in the manufacturing of the HME systems. Table 6.2 lists the different compositions of HME 
SD system prepared in this study and the aims of each experiment.  
 
Table 6.2: HME formulations that were prepared and investigated in this study. All the HME formulations were 
prepared at 150 oC, 100rpm with a residence time of 10 minutes. 
HME formulation  Purpose of investigation 
HME 10% NAP PVPVA 6:4 To test the effect of NAP loading on dissolution performance 
HME PVPVA-based SD system HME 20% NAP PVPVA 6:4 
HME 30% NAP PVPVA 6:4 
HME 40% NAP PVPVA 6:4 
HME 30% NAP PVP K12 To test the effect of carriers on dissolution performance of 
HME PVP-based SD system HME 30% NAP PVP K17 
HME 30% NAP PVP K29-32 
HME 30% NAP PVPVA 6:4-2% Tween To test the effect of incorporation of surfactant into extrudates 
in dissolution performance of the HME PVP-based SD system  HME 30% NAP PVPVA 6:4-10% Tween 
 
 
6.2.4. Basic characterisation of HME NAP PVPs SD systems 
6.2.4.1. Differential scanning calorimetry 
Please refer to Chapter 5, section 5.2.5.1, as the experimental conditions used were the same. 
 
6.2.4.2. Attenuated total reflectance-fourier transform infrared 
Please refer to Chapter 5, section 5.2.5.2, as the experimental conditions used were the same. 
 
6.2.4.3. X-ray diffraction 
Please refer to Chapter 5, section 5.2.5.3, as the experimental conditions used were the same. 
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6.2.5. Dissolution studies of HME NAP PVP-based SD 
Dissolution behaviours of HME NAP-PVP based SDs were performed by using the same 
conditions as stated in Chapter 6.2.2.  
 
6.2.5.1. SEM  
Please refer to Chapter 5, section 5.2.6.3, as the experimental conditions used were the same. 
 
6.2.5.2. Hot stage microscope  
The appearance of the HME particles upon contact with dissolution medium was observed and 
recorded using a HSM as a function of time, where the freshly ground HME particles were loaded 
on a slide under a microscope with a pre-focused position of the lens. Two drops of the medium 
were added to the particles and appearance of the extrudates was immediately recorded with HSM 
after covering the samples with a cover slide.  
 
6.2.5.3. Particle size of residue 
Please refer to Chapter 5, section 5.2.6.2, as the experimental conditions used were the same. 
 
6.2.6. Contact angle measurement 
Previous chapter has concluded the potential of reduced wettability of HME as a cause of the low 
dissolution rate of HME as compared to their PM systems. Therefore in this study, contact angle 
measurements of both the PM and HME systems of NAP in different PVPs systems were also 
assessed. These contact angle measurements were performed on the surface of the compressed 
tablet with drop analysis, which have been described in a previous chapter (Chapter 5.2.6.4). Table 
6.3 summarises the contact angle experiments that have been carried out in this chapter.  
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Table 6.3: Experiments of contact angle measurement between the solid phase and liquid phase.  
Surfaces of the solid phase  Liquid phase 
 Distilled water (DW) 0.1M HCL saturated 
with NAP 
Diiodo-
methane 
NAP √ √ √ 
PM 30% NAP PVP K12 √ √ √ 
PM 30% NAP PVP K17 √ √ √ 
PM 30% NAP PVP K29-32 √ √ √ 
PM 30% NAP PVPVA 6:4 √ √ √ 
HME SD 30% NAP PVP K12 √ √ √ 
HME SD 30% NAP PVP K17 √ √ √ 
HME SD 30% NAP PVP K29-32 √ √ √ 
HME SD 30% NAP PVPVA 6:4 √ √ √ 
 
Determination of Interfacial tension 
The contact angle measurements of system/distilled water and system / diiodomethance are 
intended for the calculation of interfacial tension. Interfacial tension between the solid surface and 
the dissolution media could be calculated by using Fowkes Equation (6.1), (6.2) and (6.3) 
(Żenkiewicz, 2007). 
 
γs= γs
d+ γs
p
                                                                   (6.1) 
γs
d=0.25γl (1+cosθd)
2
                                                           (6.2) 
γs
p
=[0.5γl (1+cosθp)-( γs
d
 γl
p 
)
0.5
]
2
/ γl
p
                                                (6.3) 
 
where γs is the measured surface tension of the solid, γs
d
 is attributed to the dispersive component 
(determined from diiodomethane) of the solid surface tension and γs
p
 is attributed to the polar 
component of the solid surface tension which could be obtained from the polar medium i.e. water. 
γl is the surface tension of the liquid phase i.e. either the apolar liquid in Equation (6.2) or polar 
liquid in Equation (6.3). The θd or θp could be obtained from contact angle measurement. After 
obtaining the solid surface tension in Equation (6.1), the interfacial energy, γsl between the solid 
formulation and dissolution medium or solution of interest could then be calculated by using 
Young's equation, as described in Equation (6.4).  
γsl= γs- γl (0.1M HCl) cos θ                                                     (6.4) 
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where γs is the solid surface tension, γl is the liquid surface tension which is dissolution medium in 
this study and θ is the contact angle between the solid surface of the prepared formulation and the 
dissolution media which have been measured in the previous section. Table 6.4 displays the values 
used for the calculation of interfacial energy by using Equation (6.1) to (6.4). 
 
Table 6.4: Values used for the calculation of interfacial energy by using Fowkes Equation (6.1) to (6.4) 
Liquid phase Surface tension (mJ/m
2
) References 
γl of diiodomethance 51.84 ± 0.09 Experimental value 
γl of water  71.81 ± 0.39 Experimental value 
γl
d
 of water 21.8 (Żenkiewicz, 2007) 
γl
p
 of water 51 (Żenkiewicz, 2007) 
γl of 0.1MHCl saturated with NAP 70.34 ± 1.99 Experimental value  
 
 
6.3. Results 
The first part of the results (i.e. Chapter 6.3.1) will explore the reasons for dissolution enhancement 
of NAP in its PM NAP-PVPVA 6:4 system, whereby the effects of wetting and solubilising of 
polymer in the dissolution performance of the PM NAP PVPVA 6:4 system were investigated. 
Secondly, dissolution behaviour of HME NAP-PVP-based SDs (Chapter 6.3.2) with different 
combinations of NAP loading and PVPs carrier system will be presented in sections 6.3.2.1 and 
6.3.2.2, respectively. Then, an attempt was made to incorporate a non-ionic surfactant, i.e. Tween 
80 in the HME NAP-PVP based SD and their dissolution behaviours will be presented in Chapter 
6.3.2.3. The last part of the results will reveal whether amorphous nature of a SD system is 
essential for the dissolution enhancement of HME NAP PVP-based SD (Chapter 6.3.3). 
 
6.3.1. Investigation of dissolution behaviour of PM formulations 
Several factors have been suggested to cause dissolution enhancement of PM of a poorly soluble 
API with their API. Crystallinity changes of API upon physical mixing with polymer has been 
suggested as one of the causes in dissolution rate enhancement of PM API-polymer (Rawlinson et 
al., 2007). However, this effect was excluded in dissolution enhancement of the PM NAP PVPVA 
6:4, in this study, as there is no crystallinity change of NAP in its PM system which was confirmed 
by the XRPD diffractograms of PM NAP in PVPVA 6:4 (data not shown). Therefore, other 
possible factors were subsequently explored. 
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Previous chapter has shown the important wetting effect of PVPVA 6:4 in increasing dissolution 
rate of NAP in its PM NAP PVPVA 6:4 system. In that case, the extent of dissolution rate increase 
of the APIs in their PM systems was proved to be related to the degree of increase wettability by 
the hydrophilic PVPVA 6:4 in its dissolved state. This implies that the premixing of the drug and 
polymer might be insignificant in enhancing of the dissolution rate of a poorly soluble drug. 
Therefore, in order to explore the root cause of dissolution rate enhancement of NAP in its PM 
system, dissolution experiments of NAP in different conditions of the presence of PVPVA 6:4 was 
performed as described in Table 6.1 (Chapter 6.2.2). Figure 6.2 shows the dissolution profiles of 
NAP that were performed according to the dissolution experiments listed in Table 6.1.   
 
 
Figure 6.2: Dissolution profiles of NAP in the presence of PVPVA 6:4 at various ways as presented in Table 6.1. 
 
According to Figure 6.2, the release of NAP was slow, as only 50% of NAP was released after 1 
hour of dissolution (brown line). On the other hand, release rate of NAP in a pre-dissolved PVPVA 
6:4 0.1M HCl medium (pink line) was increased, implying a wetting effect by the dissolved 
PVPVA 6:4 in the 0.1M HCl medium. This wetting effect could be further indicated by the marked 
increase in the release rate of NAP in ‘Exp A’ after the addition of PVPVA 6:4 at 20 minutes of the 
NAP dissolution experiment (purple line). In this experiment (‘Exp A’), the initial dissolution rate 
of NAP without the presence of PVPVA 6:4 was 0.57 mg/min (in NAP alone in 0.1M HC); it was 
then increased to 2.39 mg/min upon the addition of polymer (an increase of approximately 4 - 
fold). This increased release rate of NAP was found comparable to the dissolution rate of NAP in 
the pre-dissolved PVPVA 6:4 0.1M HCl medium (pink line) which confirmed the essentiality of 
the presence of PVPVA 6:4 in dissolution rate enhancement of NAP. A further increase in the 
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initial dissolution rate of NAP was noted in its PM NAP PVPVA 6:4 system (light blue line in 
Figure 6.2). This might be attributed to the solubilising effect of PVPVA 6:4 on top of its wetting 
effect in the PM system. 
In ‘Exp S’ (navy blue line in Figure 6.2) where both the PVP polymers and NAP were added from 
different ends of the dissolution medium (Figure 6.2), the release NAP was surprisingly 
superimposed to the dissolution profile of PM NAP PVPVA (pre-mixing prior to dissolution 
experiment). This implies that the pre-mixing procedure of the NAP and PVPVA 6:4 does not exert 
beneficial effect on dissolution enhancement of PM NAP PVPVA 6:4 formulations.  
 
6.3.1.1. Dissolution behaviour of PM NAP in different carriers system: PVP K12, PVP K17, 
PVP K29-32, PVPVA 6:4 
The insignificance of premixing step in dissolution enhancement of a PM NAP-PVPVA 6:4 was 
not expected. To further understand these phenomena, the dissolution experiments of PM and “Exp 
S” of NAP-homopolymers with different MW of PVPs were also studied. Figure 6.3 compares the 
dissolution profiles of NAP among different MW of PVPs, whereby dissolution profiles of both the 
PM and ‘Exp S’ in each grade of PVPs were compared quantitatively by using similarity factors, f2 
values, a term that was described in Chapter 5.2.6.  
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Figure 6.3: Comparison of the dissolution profiles for PM (blue ◊) and ‘Exp S’ (pink □) of binary NAP PVPs systems a) PVP K12, b) PVP K17, c) PVP K29-32 and d) PVPVA 6:4.
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Unlike the NAP-PVPVA 6:4 system, significant differences between the release of NAP in PM and 
‘Exp S’ were noted in NAP-homopolymer PVP as indicated by the f2 factor, i.e. f2 < 50 (Figure 6.3 
(a) to (c)). The trend of dissolution profiles differences between the HME and PM system based on 
similarity factors as presented in Figure 6.3 is PVP K29-32 > PVP K17 > PVP K12.  This trend 
implies the effect of pre-mixing is in the rank order of PVP K12 > PVP K17 > PVP K29-32 which 
in turn implies the importance of the pre-mixing step in the dissolution of NAP in the PM NAP 
homopolymer systems, particularly in LMW PVP systems. The observed discrepancy in 
significance of the premixing step among the different PVPs carriers might be ascribed to their 
different degrees of wetting or solubilising effect onto the poorly soluble NAP, which will be 
further explored in the next section.  
 
6.3.1.2. Solubility tests of NAP in PVP solutions 
The solubility of NAP in PVP solutions were examined in order to establish the possible role of 
solubility enhancement in promoting dissolution of both PM NAP formulations and ‘Exp S’ as 
shown in Figure 6.3. Figure 6.4 represents the profiles of phase solubility of NAP in different 
concentrations of PVP polymers. 
  
Figure 6.4: Phase solubility relationships between different polymer concentrations and solubility of naproxen 
after stirring for 48 hours at 37 oC 
 
Based on the solubility results in Figure 6.4, PVP K29-32 was found to exert the highest increase in 
the apparent solubility of NAP. This trend was observed to increase linearly up to 7% w/v of 
polymer (with an approximately 10 fold increment in solubility of NAP at 37 
o
C). The solubilizing 
effect of the PVP polymer onto the poorly soluble NAP was then followed by PVP K17 > PVPVA 
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> PVP K12. The solubilizing effect of homopolymer was appeared to be directly related to the 
molecular weight of the PVP homopolymer used, i.e. PVP K29-32 > PVP K17 > PVP K12. This 
solubilizing trend was noted to be similar to the trend of ‘significance of the premixing step in 
dissolution’ that was compared between the PM and ‘Exp S’ (the significance was reflected by the 
similarity factor, f2 as shown in Figure 6.3). This suggested that dissolution enhancement of a 
physical mixture of NAP and homopolymer might be related to the solubilisation of NAP by its 
homopolymer carrier during the dissolution process.  
 
6.3.1.3. Surface tension properties 
Dissolution rate enhancement of both the PM NAP-PVPs and ‘Exp S’ have shown to be related to 
the solubilising effect of the PVP carrier on the solubilisation of the poorly soluble NAP. However, 
despite the relatively lower solubilising effect of PVP K12 carrier on the solubilisation of NAP, the 
PM of NAP in this polymer system showed a similar dissolution profile to those of other tested 
PVPs, i.e. PVP K17, PVP K29-32 and PVPVA 6:4. This might be due to the wetting effect of this 
polymer which was further investigated.  
The previous chapter (Chapter 5) has shown the significance of surface properties in dissolution 
behavior of poorly soluble API in its PM formulation. Hence, in this study, the surface tension of 
the dissolved PVP polymer solutions was also studied to understand the wetting effect of the 
polymer onto NAP. Table 6.5 lists the surface tension of the dissolution media and solution with 
the pre-dissolved polymer system.  
 
Table 6.5: Average surface tensions and average volume of drops during the 120 seconds of the experiment time 
frame. All the solutions were saturated with NAP which was denoted as ‘sat NAP’. 
Medium Average surface tension 
± STDEV (mN/m) 
Average Volume ± 
STDEV (μl) 
sat NAP 0.1M HCl 70.34 ± 1.98 14.90 ± 0.12 
sat NAP Distilled water 70.91 ± 1.40 13.74 ± 0.20 
0.1MHCl+1%w/v PVPVA 6:4 with sat NAP 55.66 ± 0.77 12.68 ± 0.11 
0.1MHCl+1%w/v PVP K12 with sat NAP 58.37 ± 0.35 12.79 ± 0.11 
0.1MHCl+1%w/v PVP K17 with sat NAP 62.91 ± 0.95 14.22 ± 1.99 
0.1MHCl+1%w/v PVP K29-32 with sat NAP 61.90 ± 1.15 13.49 ± 0.42 
 
According to Table 6.5, the surface tensions of distilled water and 0.1 M HCl that were pre-
saturated with NAP are similar. As anticipated, the surface tensions of the media were reduced 
slightly with the addition of PVP homopolymers which was reported earlier  (Huang and Wang, 
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1996, Bolten and Türk, 2011). The marginal reduction in surface tension of the PVP homopolymer 
is probably ascribed to the small tendency of the PVP migration to the interface, particularly at 
high concentration of PVP (Huang and Wang, 1996, Bolten and Türk, 2011). In this case, PVP K12 
was shown to have the lowest surface tension among the tested PVPs homopolymer solution which 
is in agreement with Huang and Wang (1996) whom have demonstrated the molecular weight 
dependence of surface tension at high (above 10
-4
 g/ml) polymer concentration (Huang and Wang, 
1996). This explained the high dissolution enhancement of NAP in PM NAP PVP K12 as 
compared to ‘Exp S’ system despite its relatively low solubilizing capacity as compared to other 
PVP homopolymer system.  
Furthermore, the surface tension of 0.1M HCl was found to be reduced greatly with the addition of 
1% w/v PVPVA 6:4 in the 0.1M HCl. This might be attributed to the 40% of the hydrophobic 
vinyl-acetate monomer in the PVPVA 6:4 that lead to the higher hydrophobic to hydrophilic 
balance which increases its surface active nature as compared to the PVP homopolymer. This 
might be the main reason for the superimposable dissolution profile of PM and ‘Exp S’ that 
suggested the insignificant pre-mixing step in the release rate of NAP.  
 
Summary of dissolution studies of PM  
To summarise, solubilizing and wetting effects of the concentrated PVPs polymer are the main 
reasons for the increase release rate of NAP in its PM system. Thus it is essential to have the 
hydrophilic PVP presence at vicinity of the poorly soluble NAP during its dissolution process. In 
this context, PVPVA 6:4 carrier system showed a more apparent wetting effect which leads to the 
insignificant of the premixing step in enhancing the dissolution of NAP in PVPVA 6:4 system.  
 
6.3.2. Dissolution performances of amorphous HME PVP-based SDs 
After detailed studies of the reason for dissolution rate enhancement of the PM NAP-PVPVA 6:4 
system, dissolution performances of the HME NAP-PVPVA 6:4 systems were also studied.  
The previous chapter (Chapter 5) has suggested that dissolution performance of the HME system as 
compared to their PM counterpart is highly API dependence. However, the effect of carrier system 
in dissolution performance of HME SD shall not be overlooked. Therefore, dissolution 
performances of HME SD systems were studied from the perspective of the drug loading and 
carrier system in the subsequent sections of this chapter. This is to complement the limited 
understanding of the release mechanism of HME SD system.  
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Basic characterisation of HME NAP SD extrudates 
The physical state of the freshly prepared HME NAP PVPs systems were confirmed prior to the 
detailed study on their dissolution performance. These physical states were characterised by using 
XRPD, ATR-FTIR and DSC measurements. Figure 6.5 display the DSC thermograms of the 
freshly prepared HME 10% to 40% NAP-PVPVA 6:4.  
 
Figure 6.5: MTDSC thermograms of HME NAP PVPVA 6:4 with different NAP loading (a) 10% NAP, (b) 20% 
NAP, (c) 30% NAP and (d) 40% NAP. Green lines of the thermograms are total heat flow profile whereas blue 
line represents reversing heat flow of the DSC thermograms. 
 
According to Figure 6.5, a single Tg was obtained for the HME 10 - 30% NAP-PVPVA 6:4 which 
indicated the production of homogenous HME systems. These Tg values were NAP loading 
dependent, whereby a higher content of PVPVA 6:4 increased the value of the Tg. Besides, no 
apparent melting point was detected in the HME NAP-PVPVA 6:4 SD except HME 40% NAP 
PVPVA 6:4. In HME 40% NAP-PVPVA 6:4 system, a minor melting endotherm at circa 141 
o
C 
was detected which was believed to be due to the depressed melting point of crystalline NAP.  
However, both XRPD and ATR-FTIR results of these formulations suggest the absence of 
detectable crystalline trace through the halo pattern and the disappearance of characteristic 
crystalline peak of NAP in both the XRPD and ATR-FTIR spectra, respectively.  
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To study the effect of different carrier types in dissolution performance of HME system, HME with 
different MW of PVP carriers (PVP K12, PVP K17, PVP K29-32, PVPVA 6:4) at 30% of NAP SD 
systems were produced. Basic characteristic of these systems were also studied. Figure 6.6 depicts 
the thermograms of the HME 30% NAP in different PVP carriers system.  
  
 
Figure 6.6: MTDSC profiles of HME 30% NAP-PVPs different carriers system, i.e. (a) PVPVA 6:4, (b) PVP K12, 
(c) PVP K17 and (d) PVP K29-32. Green lines of the thermograms are total heat flow profile whereas blue line 
represents reversing heat flow of the DSC thermograms. 
 
No apparent melting endotherm was detected in the DSC thermogram of HME 30%-different PVPs 
carrier, which implied complete amorphisizing of NAP-PVPs via HME process. These systems 
were homogenous as indicated by the single Tg (s) of HME NAP-PVPVA 6:4. The Tg (s) values 
were closely related to the Tg of the different MW of PVP carriers whereby the highest Tg was 
recorded for HME NAP-PVP K29-32 > HME NAP-PVP K12 > HME NAP-PVP K17 > HME 
NAP-PVPVA 6:4. Similarly, XRPD and ATR-FTIR spectra of these systems indicate halo patterns 
and absence of characteristic crystalline peak of NAP, respectively (data not shown), which 
suggests the absence of detectable crystalline NAP. 
 
To summarise, all the freshly prepared HME NAP-SD extrudates shows amorphous nature in 
XRPD (data not shown). However, DSC analysis of these systems also suggested the amorphous 
nature for all the prepared HME NAP SD system except HME 40% NAP-PVPVA 6:4 system as 
indicated by the minor melting endotherm in its DSC thermograms. 
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6.3.2.1. Dissolution studies of different NAP loading on HME NAP PVPVA 6:4 SDs 
After basic characterisation of the HME SD system, dissolution behaviours of these systems were 
studied. It is worth mentioning that the dissolution behaviours of the PM 10% up to 40% of NAP 
PVPVA 6:4 show superimposable dissolution profiles (data not shown). Therefore, in order to 
simplify the comparison of dissolution profiles between the different HME systems, Figure 6.7 
displays the dissolution profiles of only the PM 10% NAP-PVPVA 6:4 and all the different NAP 
loading, i.e. 10-40% of HME NAP-PVPVA in comparison with NAP alone.  
 
Figure 6.7: Dissolution of HME formulations of NAP-PVPVA 6:4 in 0.1M HCl pH 1.2.  
 
According to Figure 6.7, dissolution of NAP was markedly enhanced in the HME 10% and 20% 
NAP-PVPVA 6:4 systems in which 100% of NAP was released after 30 minutes of dissolution 
experiment. Whereas, the dissolution profile of NAP in HME 30% NAP-PVPVA 6:4 was 
superimposed with the PM NAP-PVPVA 6:4 system. However, dissolution of HME 40% NAP 
PVPVA 6:4 was slower than the PM NAP-PVPVA 6:4. This was not expected as there is some 
extend of amorphocity of the NAP in HME 40% NAP-PVPVA 6:4 formulation as compared to the 
full crystallinity of NAP in the PM system. Thus, the role of amorphicity in dissolution rate 
enhancement of a SD is questionable, which will be further addressed in a latter section Chapter 
6.3.3. 
Overall, dissolution of HME NAP-PVPVA 6:4 SD was found to be NAP-loading dependent where 
the enhancement effects were found to decrease with an increase in loading of the NAP.  Figure 6.8 
illustrates a comprehensive picture of the initial dissolution rate of PM and HME 10-40% NAP-
PVPVA 6:4.  
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Figure 6.8: The effect of NAP-PVPVA 6:4 compositions in HME and PM products on the initial dissolution rate 
(at first 5 minutes) of solid dispersion 
 
It is clear from Figure 6.8 that different loadings of NAP had little effect on initial dissolution rate 
of the PM systems. On the other hand, the initial dissolution rate of NAP in HME systems was 
noted to decrease with an increase of NAP loading (Figure 6.8). In this case, a critical loading of 
the NAP that leads to the effectiveness in dissolution performance of HME SD systems in 
comparison with their PM systems was found to be approximately 30% NAP loading. This critical 
loading of NAP in its dissolution performance of HME PVPVA 6:4 SD might be ascribed to the 
turning point of the drug release mechanism of SD, i.e from the carrier-controlled mechanism to 
drug controlled mechanism (Craig, 2002, Karavas et al., 2007). The different release rates of the 
NAP at different NAP loading of HME system were further investigated base on the identified 
limiting step such as agglomeration and recrystallization of the dissolving system that have been 
shown in Chapter 5.  
 
6.3.2.1.1. Agglomeration 
During the dissolution process, large particles were visible by eye in the dissolution medium 
possibly attributed to the extensive agglomeration of the dissolving system. This may cause a 
dramatic change in the effective surface area of dissolution which is essential in determining the 
dissolution rate of a system (Noyes and Whitney, 1897). Thus, particle size changes as a result of 
particles agglomeration during the dissolution processes of the HME SD were evaluated using a 
laser diffraction particle size analyser. Figure 6.9 shows the particle size distributions of HME 10% 
to 40% NAP PVP systems after 2 minutes of dissolution.  
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Figure 6.9: Particle size distribution of particles collected from the dissolution vessel at 2 minutes of dissolution of 
HME 10-40% NAP PVPVA 6:4 systems 
 
It should be remembered that the particle size of all formulations was initially controlled within the 
range of 63-106 μm. The pronounced particle size reduction of HME 10% NAP-PVPVA 6:4 after 2 
minutes of dissolution process indicated the fast dissolution of the particle in this system (Figure 
6.9), which was consistent with the dissolution profiles found in Figure 6.7. Besides, particle size 
of HME 20% NAP-PVPVA 6:4 was remained at around the initial controlled size range with some 
distribution of particle up to 200 μm. However, larger size particles were detected in HME 30% 
and 40% NAP-PVPVA 6:4 system which indicated the extensive agglomeration of these HME 
particles during the dissolution process. This result is in agreement with a previous work on 
dispersions of felodipine in PVP and PEG SD whereby a higher extent of agglomeration was seen 
in higher API loading systems (Karavas et al., 2007). 
 
Particle morphology by SEM 
The size and morphology of the dissolving particles during dissolution experiment could also be 
evaluated using SEM. Figure 6.10 presents the SEM micrographs of the collected particles at 
different time points from the dissolution vessel of HME 40% NAP-PVPVA 6:4 during the 
dissolution experiments.  
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According to Figure 6.10 (a), agglomerated particles with their size larger than the initially 
controlled size range (60-106 μm) were observed. Ordered features were also seen in these particles 
which imply the formation of crystalline material on their surfaces (Figure 6.10 (b) and (c)). This 
might be due to the uncontrolled agglomeration and recrystallization of the system upon dissolution 
process. After 1 hour of dissolution, the edges seen on the particle faded and became relatively 
round after continuous dissolution of the particles (Figure 6.10 (d)). 
  
 
Figure 6.10: SEM images of residues collected from a dissolution experiment of HME 40% NAP-PVPVA 6:4 
system at a) 1minute, b) high magnification for particles at 1 minutes, c) 2 minutes, and d) 1 hour 
 
6.3.2.1.2. Recrystallization 
Birefringence of crystalline NAP observed via polarise light microscope 
To further confirm the recrystallization of the HME NAP-PVPVA 6:4 powder while dissolution 
process, the change in particle appearance of HME 10-40% NAP-PVPVA 6:4 samples upon 
dissolution medium contact were analysed by using HSM as described in Chapter 6.2.5.2. 
Birefringence of the tested sample observed under HSM is an indication of recrystallization of the 
system upon contact with the dissolution medium. Figure 6.11 displays the captured screens of 
HSM for HME 10-40% NAP-PVPVA 6:4 upon medium contact as the function of time.  
(a) (b) 
(d) (c) 
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Figure 6.11: Hot stage microscopy examination of HME a) 10%, b) 20%, c) 30% and d) 40% of NAP PVPVA 6:4  
upon contact with 0.1M HCl at room temperature. Left to right of each row shows the change in appearance of 
the ground extrudates upon contact with dissolution medium at various time point, a) i =96s, a) ii=118s, a) iii = 
3min, a) iv = 5 min, b) i =60s, b) ii=79s, b) iii = 3min, b) iv = 5 min, c) i =45s, c) ii=48s, c) iii = 3min, c) iv = 5 min, d) 
i =10s, d) ii=55s, d) iii = 3min, d) iv = 5 min. All the captured images are under magnification of 20x (the white 
scale bar at right bottom corner indicates 150 µm) 
 
Based on Figure 6.11, birefringence of the recrystallized NAP was clearly noted in all the HME 10-
40% NAP-PVPVA 6:4 samples. The refracted birefringence of the wetted HME 10-40% NAP- 
PVPVA 6:4 particles became more intense with time due to the continuous recrystallization (from 
left to right in Figure 6.11). By comparing different NAP loadings, 10% loading of NAP revealed 
the smallest sizes and the least birefringence of the particles (Figure 6.11 (a) to (d)). The 
birefringence and size of the recrystallized particles increased accordingly with drug loading 40% ( 
≈ 300 μm) > 30% ( ≈ 100 μm) > 20% ( ≈ 50 μm) > 10% ( < 10 μm) of HME NAP-PVPVA 6:4 
which was consistent with the results from the laser diffraction technique with the exception of the 
10% formulation. This was due to the different hydrodynamic surrounding in the cuvette of the 
laser diffraction experiment.  
Table 6.6 summarises the onset time of birefringence when the HME 10-40% NAP-PVPVA 6:4 
were exposed to their dissolution medium. The onset time in revealing birefringence was in the 
trend of 40% < 30% < 20% and < 10% HME NAP-PVPVA 6:4 which implied the trend of 
a) i a) ii 
b) ii 
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d) ii d) i 
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recrystallization in the reverse, i.e. 40% > 30% > 20% and >10% upon contact with dissolution 
medium.  
Table 6.6: onset time of birefringence upon contact with dissolution medium as recorded via HSM 
HME NAP loading PVPVA 6:4 system (%) Onset time of birefringence (seconds) 
10 118 
20 79 
30 45 
40 10 
 
To summarise, higher NAP loading in HME PVPVA 6:4 indicated higher tendencies of 
agglomeration and recrystallization which could be a possible factor in reducing the dissolution 
rate of NAP in HME system, although these effects of NAP loading was hardly seen in PM 
systems. 
 
6.3.2.2. Dissolution study of HME 30% NAP using different MW of PVPs carriers 
There is some contradiction regarding the impact of MW on dissolution performance of SD in the 
available literature. On one hand, dissolution rate of SD was shown to inversely proportional to the 
MW of carrier (Tantishaiyakul et al., 1999, Doherty and York, 1987). On the other hand, other 
studies have shown that dissolution rate of SD of poorly soluble drug was directly proportional to 
the MW of the carrier (Kapsi and Ayres, 2001). Therefore, the effect of different MW of PVPs 
carriers in dissolution performance of SD was further investigated in this chapter. Figure 6.12 
shows the dissolution profiles of HME 30% NAP in different PVPs carriers.  
 
Figure 6.12: Dissolution profiles of HME 30% NAP with different PVPs carriers (PVP K12, PVP K17, PVP K29-
32, PVPVA 6:4) in 0.1M HCl at 37 oC.  
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According to Figure 6.12, it was found that high MW PVP homopolymer carriers, i.e. PVP K29-32 
give rise to higher dissolution rate of HME NAP as compared to the low MW PVP, i.e. PVP K12. 
In dissolution profile of HME NAP-PVP K12, only 45% of the NAP was released after 60 minutes 
of the dissolution process. The result shows the higher dissolution rate of HME NAP SD in higher 
MW carrier systems, which was in agreement with Kapsi et al., 2001 where the author found a 
considerably improved in dissolution of drug with increasing MW of PEG. However, this result is 
in contrast to the better wetting of PVP K12 than the PVP K17 and PVP K29-32 system that was 
deduced from Table 6.5. Thus, the low release rate of NAP in the low MW PVPs of HME system 
may be associated to the low viscous hindrance of the low MW PVPs in their solution, which 
causes an inability to prevent the agglomeration and recrystallization during the dissolution 
process.  
Furthermore, the similar K-values of PVPVA and PVP K29-32 indicate their similar viscosities, 
which might imply their similar ability in hindering the possible limiting steps of agglomeration 
and recrystallization during the dissolution process. However, this is not the case, because HME 
30% NAP-PVPVA 6:4 system revealed a higher dissolution rate than the HME 30% NAP-PVP 
K29-32. 100% NAP release was achieved after 60 minutes of dissolution of HME 30% NAP-
PVPVA 6:4 system. Thus, the viscous hindrance of the polymer carriers might not be the sole 
governing factor in the dissolution performance of HME NAP-PVPs. This phenomenon will be 
further investigated in the coming sections. 
 
6.3.2.2.1. Surface properties of HME and PM of NAP in different PVP polymers 
It is worth paying attention to the dissolution profiles difference between the HME and their PM 
systems. To simplify the comparison, Figure 6.13 relates the initial dissolution rate of HME 30% 
NAP-PVPs and PM 30% NAP-PVPs according to their different MW of PVPs.  
 
Figure 6.13: The comparison of initial dissolution rate (at linear release of NAP in the first 10 minutes) between 
HME and PM system of NAP in different PVPs carriers system 
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There are gaps to dissolution performance between the PM and HME systems of different PVPs as 
shown by the arrow in Figure 6.13 which were noted to decrease with the increase in MW of the 
PVPs carrier. These gaps of dissolution performances may be related to the potential drawback of 
reduced wetting in HME systems as compared to their corresponding PM system which has been 
concluded in Chapter 5. Hence, the comparison of surface properties between the PM and HME 
systems were investigated by interfacial tension of the solid phase to the 0.1M HCl (abbreviated as 
solid system / 0.1M HCl) calculated from the contact angle data (not shown) as described in 
Chapter 6.2.6. Table 6.7 lists the values of interfacial tension for the HME NAP-PVPs / 0.1M HCl 
and the difference of interfacial energies between the PM / 0.1M HCl and HME / 0.1M HCl.  
 
Table 6.7: Interfacial tensions of different HME NAP-PVPs system between their solid phase and 0.1 M HCl 
 Interfacial tension between the formulation systems and 0.1M HCl, γsl (mJ/m2) 
NAP 26.98740738 - - 
Binary system PM HME Δ γsl  
NAP PVPVA 6:4 9.46 13.40 3.94 
NAP PVP K12 8.29 20.28 11.99 
NAP PVP K17 10.36 15.40 5.04 
NAP PVP K29-32 14.52 15.22 0.7 
 
It is worth emphasizing the interfacial energy presented in Table 6.7 might not be the exact 
interfacial energy of the powder solid with its dissolution medium as these values were calculated 
from the contact angle experiments that were performed on surface of compressed tablets. 
However, relative values of these systems are useful to understand the relative wettability of these 
systems upon dissolution. 
Based on interfacial tension values, γsl in Table 6.7, PM NAP-PVP K12 / 0.1M HCl exhibited the 
highest extent of interfacial tension reduction as compared to NAP / 0.1M HCl. This means that the 
PM of NAP-PVP K12 system possessed the highest increase in wettability among the different 
polymer types. However, the same binary NAP-PVP K12 system in its HME / medium showed the 
lowest reduction in interfacial tension among the HME different carrier / 0.1 M HCl. This indicated 
the highest wettability deterioration in the binary NAP-PVP K12 system after formulating into the 
HME system (Chibowski and Perea-Carpio, 2002). The differences of interfacial tension between 
the PM and HME was in the rank of PVP K12 > PVP K17 > PVPVA 6:4 and > PVP K29-32 which 
indicates the rank of wettability reduction of the HME systems.  
Polymer orientation with its hydrophilic moieties facing the surface of the solid might responsible 
to the reduced contact angle of the PM in comparison to the HME system which has its polymer 
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coordination restricted due to API-polymer interaction (Dahlberg, 2010). Following this 
hypothesis, the highest interfacial tension in HME NAP-low MW PVP system shall indicate the 
highest interaction between the NAP and the lower MW PVP of HME system as compared to other 
carrier system. However, the intensity of interaction between the NAP and different MW PVPs 
polymers in the ATR-FTIR study was not convincing in drawing this conclusion (data not shown). 
Thus, this might serve as a ramification for future study. 
 
6.3.2.2.2. Agglomeration 
During the dissolution process of HME NAP different MW PVPs, big particles were also noted in 
dissolution medium. The changes in the sizes of these particles were analysed by using laser 
diffraction particle size analyser. Figure 6.14 displays the changes of particle sizes during 
dissolution experiments of HME 30% NAP of different MW PVPs for up to 1 hour detected by 
laser diffraction analysis.  
 
 
Figure 6.14: Particle size changes of formulation during dissolution experiment. 
 
A dramatic increase in particle size of HME NAP-carriers was noted in all the dissolution 
experiment of HME system (Figure 6.14). Bigger size of particles were detected in the dissolution 
medium of HME 30% NAP with lower MW carrier which showing the trend of PVP K12 > PVP 
K17 > PVP K29-32 and > PVPVA 6:4. This might be due to their higher surface energy of HME 
30% NAP with lower MW carrier systems that lead to the agglomeration via hydrophobic forces in 
order to reduce their energy level (Sievens-Figueroa et al., 2012). 
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6.3.2.2.3. Recrystallization 
The recrystallization of NAP in HME NAP-different PVPs systems upon contact with the 
dissolution medium was also studied by using HSM. Figure 6.15 shows the images of the ground 
extrudates after 48 seconds of medium contact. 
 
 
Figure 6.15: Microscopic images of HME 30%NAP with a) PVP K12, b) PVP K17, c) PVP K29-32, and d) PVPVA 
6:4 after addition of 0.1M HCl at 48 seconds. All the captured images are under magnification of 20x (white 
horizontal line at right bottom corner indicated 150 µm) 
 
Based on Figure 6.15, PVP K12 reflected the highest intensity of birefringence after 48 seconds of 
medium contact (Figure 6.15 (a)). This is followed by PVP K17, K29-32 and PVPVA 6:4. The 
times taken in reflecting their birefringence were tabulated in Table 6.8.  
 
Table 6.8: Onset time of birefringence base on HSM studies of HME 30% NAP-PVPs systems 
HME NAP-carrier system (63-106μm) Time revealing birefringence (seconds) 
PVP K12 22 
PVP K17 32 
PVP K29-32 34 
PVPVA 6:4 45 
 
Based on Table 6.8, the earliest onset of birefringence was recorded for HME NAP-PVP K12 
carriers system, i.e. at 22 seconds, followed by PVP K17 > PVP K29-32 > PVPVA 6:4 (Table 6.8). 
Thus, the recrystallization trend of HME NAP different carriers is PVP K12 > PVP K17 > PVP 
K29-32 and > PVPVA 6:4. This trend is inversely related to the dissolution rate of HME NAP 
PVPs SD system as shown in Figure 6.12. Therefore, it is suggested that the slow dissolution rate 
of HME NAP-PVPs SD could also be ascribed to the fast recrystallization of NAP. This is 
particularly occurred in the low MW PVPs carrier due to their limited ability in recrystallization 
inhibition of the particles during the dissolution process. 
 
a) b) c) d) 
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6.3.2.3. Dissolution studies of HME 30% NAP-PVPVA 6:4-2% and 10% Tween 80 
Previous sections have identified the agglomeration and recrystallization of HME formulations 
during dissolution process as being the limiting steps in dissolution enhancement of HME NAP 
PVP formulations. To counterbalance these limiting steps, incorporation of a surfactant into the 
extrudate was attempted. This was performed in order to reduce the driving force of agglomeration 
and recrystallization of the particles (de Waard et al., 2008) as well as to increase the wetting effect 
of the HME system during dissolution process.  
The freshly prepared HME 30% NAP-PVPVA 6:4-surfactant shows halo pattern in XRPD and no 
detected melting peak associated with the melting point of crystalline NAP in their DSC 
thermograms (Appendix V). This suggested the amorphous nature of the HME 30% NAP-PVPVA 
6:4-surfactant samples. To test the dissolution behaviour of HME 30% NAP-PVPVA 6:4-Tween 
80 system, dissolution experiment in the 0.1M HCl was performed. Figure 6.16 compares the 
dissolution profiles among PM binary 30% NAP-PVPVA 6:4, PM ternary system (NAP-PVPVA 
6:4-Tween 80), HME 30% NAP-PVPVA 6:4 and HME 30% NAP-PVPVA 6:4 -Tween 80 system.  
According to Figure 6.16, dissolution profiles of HME 30% NAP-PVPVA 6:4 -10% Tween 80 and 
HME 30% NAP-PVPVA 6:4 -2% Tween 80 have shown an improved the dissolution rates of NAP 
as compared to the HME NAP-PVPVA 6:4 system without surfactant. 100% and 90% of NAP 
were released after 30 minutes dissolution of HME 30% NAP-PVPVA 6:4 -10% Tween 80 and 
HME 30% NAP-PVPVA 6:4 -2% Tween 80, respectively (blue and red lines, respectively in 
Figure 6.16). 
 
Figure 6.16: Dissolution profiles of PM NAP PVPVA 6:4, PM NAP PVPVA 6:4-Tween 80, HME NAP-PVPVA 
6:4, and HME NAP-PVPVA 6:4 -Tween 80 in 0.1M HCl at 37 oC.  
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The increase dissolution rate of the HME NAP-PVPVA 6:4- surfactant system as a result of 
micelle solubilisation effect of the NAP by the Tween 80 was excluded as the concentration of 
tween 80 was lower than its CMC in the dissolution medium (Sjokvist et al., 1992, Ghebremeskel 
et al., 2007). This can be further confirmed by the limited increase in dissolution rate of the PM 
NAP-PVPVA 6:4-Tween 80 ternary systems (green line in Figure 6.16). Therefore, the increased 
dissolution rate of NAP in the HME-surfactant extrudate might be mainly attributed to the reduced 
agglomeration and recrystallization of particles in the presence of Tween 80 during the dissolution 
process. These agglomeration and recrystallization of particles will be further confirmed in Chapter 
6.3.2.3.1 and 6.3.2.3.2, respectively. 
 
6.3.2.3.1. Agglomeration 
The effect of Tween 80 in the agglomeration of the HME-Tween 80 particles during the dissolution 
process was accessed using laser diffraction. Figure 6.17 and Table 6.9 compare the cumulative 
curves of particle size distribution of the aggregates within the dissolution bath.  
 
Figure 6.17: Cumulative curves of particle size analysis of PM and HME SD of NAP PVPVA 6:4 and HME NAP-
PVPVA 6:4 –Tween 80 systems after 2 minutes of dissolution 
 
Table 6.9: Particle size distribution of formulation after 2 minutes of dissolution experiment 
Formulations D10% D50% D90% Span 
PM 30% NAP-PVPVA 6:4 6.31± 0.147 20.01± 0.168 54.51± 2.372 2.409 
HME 30% NAP-PVPVA 6:4 34.57± 0.730 101.03 ± 3.539 170.1± 14.427 1.342 
HME 30% NAP-PVPVA 6:4 +2%Tw 30.26 ± 0.044 72.71 ± 0.399 128.78 ± 3.553 1.355 
HME 30% NAP-PVPVA 6:4 +10%Tw 20.87 ± 0.704 40.86 ± 1.240 65.01± 3.129 1.080 
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Larger particles were also noted in the dissolution experiment HME NAP-PVPVA 6:4-surfactant 
systems which indicating agglomeration of the particles to a certain extent in these systems. After 2 
minutes of dissolution process, the average particle size noted in the dissolution vessel was 101.03 
± 3.539 μm for the HME system without surfactant. This number was reduced to 72.71 ± 0.399 μm 
and 40.86 ± 1.240 μm, respectively, when 2% and 10% of Tween 80 were incorporated into the 
HME NAP-PVPVA 6:4 systems. Thus it is deduced that the addition of surfactant in the extrudate 
formulation has effectively reduced the agglomeration of the dissolving particle.  
It is worth paying attention to the comparison of particle size between the PM and the HME system 
without surfactant (Figure 6.17). Although, HME system displayed a much bigger particle size than 
its corresponding PM system, however both systems revealed superimposable dissolution profiles 
as shown in Figure 6.16. This infers the possible dissolution advantages of amorphous in HME 
NAP PVPVA 6:4 during the dissolution process of which will be further examined in Chapter 
6.3.3. 
 
6.3.2.3.2. Recrystallization 
Since addition of surfactant was reported to potentially reduce recrystallization of API (de Waard et 
al., 2008). In this section, the onset of recrystallization of NAP was accessed using HSM. Figure 
6.18 indicates images captured from the HME 30% NAP-PVPVA 6:4-Tween 80 upon medium 
contact.  
 
 
 
Figure 6.18: Hot stage microscopic observations of a) HME 30%NAP PVPVA +2% Tween 80 , b) HME 30%NAP 
PVPVA +10% Tween 80 upon contact with 2 drops of 0.1M HCl. Images in the corresponding row from left to 
right indicated the time increase of the sample contact with 0.1 M HCl up to 5 minutes. All the captured images 
are under magnification of 20x (white horizontal line at right bottom corner indicated 150 µm) 
 
a) 
b) 
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HME formulation of 30% w/w NAP-PVPVA 6:4 without surfactant shows birefringence of NAP 
crystal after 45 seconds of medium contact (images not shown). Similarly, HME 30% NAP-
PVPVA 6:4-2% Tween 80 formulation revealed birefringence of the particle after 45 seconds of 
medium contact (Figure 6.18 (a)). Given the similar onset time of birefringence (based on HSM) 
were seen between HME 30% NAP-PVPVA 6:4-2% Tween 80 and HME 30% NAP-PVPVA 6:4 
without surfactant, the former system revealed a faster dissolution rate of NAP (Figure 6.16). Thus, 
it is suggested that the faster release of NAP in HME 30% NAP-PVPVA 6:4-2% Tween 80 is 
mainly ascribed to the reduced agglomeration of this system during the dissolution process (as 
indicated from the particle size analysis of Figure 6.17 and Table 6.9).  
Based on HSM images in Figure 6.18, a prolonged onset time of birefringence (≈ 85 seconds) was 
recorded for HME 30% NAP-PVPVA 6:4-10% Tween 80 formulations (Figure 6.18 (b)). This 
observation supports the enhanced dissolution rate of NAP in the HME 30% NAP-PVPVA 6:4-
10% Tween 80 as shown in Figure 6.16, which suggested that the increase dissolution rate of NAP 
is also attributed to the slower recrystallization of NAP during dissolution. 
To summarise, the addition of Tween 80 to the HME extrudates of NAP-PVPVA 6:4 has improved 
the dissolution rate of the HME NAP-PVPVA 6:4 system by reduce the recrystallization, 
agglomeration and increase dispersibility of the system while dissolution process. 
 
6.3.3. Dissolution study of partially crystalline NAP-PVPVA 6:4 system  
Previous sections (Figure 6.7 and 6.12) show the dissolution profile of fully amorphous HME 
NAP-PVPs system being slower than its crystalline counterpart, particularly for HME 30% NAP-
PVP K12 system. Thus, the dissolution advantage of amorphous system is questionable. To further 
investigate this, the dissolution advantages of amorphous state of the HME NAP-PVPVA 6:4 
system right after processing was explored.  
To do this, dissolution behaviour of a control system which possess a partially crystalline NAP in 
PVPVA 6:4 was assessed and compared its dissolution performance to the HME fully amorphous 
system. The partially crystalline formulation (IM 30% NAP-PVPVA 6:4) was prepared by 
injection moulding with temperature lower than the melting of NAP i.e. at 130 
o
C. Figure 6.19 
compares the dissolution profiles of the freshly prepared HME fully amorphous NAP-PVPVA 6:4 
and partially amorphous NAP-PVPVA 6:4 systems as compared to their corresponding PM system.  
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Figure 6.19: Dissolution profiles of the freshly prepared fully amorphous HME NAP PVPVA 6:4, partially 
amorphous NAP PVPVA 6:4 systems and the corresponding PM systems in 0.1 M HCl at 37 oC.   
 
From Figure 6.19, a decreased in dissolution rate of NAP was noted in the partially crystalline NAP 
PVPVA 6:4 (black line) as compare to the fully amorphous HME NAP-PVPVA 6:4 (red line). This 
data clearly showed that the presence of crystalline material did slow down the release rate of NAP 
which confirmed the importance of the amorphous nature of poorly soluble drugs in a freshly 
prepared HME SD. However, when the dissolution profile of the partially crystalline NAP-PVPVA 
6:4 was compared to the PM, a reduced rate of NAP release was also observed despite the higher 
crystallinity of NAP in the PM NAP-PVPVA 6:4 system (pink line). This might be attributed to a 
more extensive agglomeration and recrystallization of the partially crystalline system as compared 
to the PM and the fully amorphous HME system. Furthermore, the pre-existing NAP crystalline 
material in the partially crystalline systemt may serve as the crystal seeds that drive the 
agglomeration and recrystallization of the highly energetic amorphous fraction of the particles.  
To summarise, the amorphous form of an API did play a significant role in dissolution 
enhancement of poorly soluble drug. However, dissolution advantages of the amorphous state 
could be potentially affected by agglomeration and recrystallization process of the amorphous 
particles, which might be extensive in a partially crystalline system.  
 
6.4. Discussion 
As shown in Chapter 5, dissolution performance of the HME PVP-based systems is highly 
dependent on type of API as the amorphous form of the API determines its amorphous advantage 
in SD while dissolution process. However, detail understanding on the other possible factors in 
affecting the dissolution performance of a SD is also essential for the production of a successful SD 
as far as immediate release dosage form is concerned.  
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In this study, several factors of influencing the dissolution performance of SD have been identified. 
These include the solubilizing and wetting effects of the polymer carrier, amorphous dispersed 
systems, and solution mediated process such as agglomeration and recrystallization. Among all the 
previously mentioned factors, there is no sole determinant for dissolution of a particular substance. 
Often the resultant dissolution profiles reveal the interplay of several mechanisms.  
 
6.4.1. Dissolution process of PM 
Based on the dissolution studies of PM NAP-PVPVA 6:4 system, dissolution rate of the crystalline 
NAP could be enhanced via increase wetting, solubilising of NAP by the addition of hydrophilic 
polymers. In this context, the wetting effect of polymer onto NAP is more prominent in PVPVA 
6:4 and PVP K12 than in PVP K17 and PVP K29-32 carriers due to the reduced surface tension of 
the polymer solutions of the former. On the other hand, the solubilising effect on NAP was shown 
to be pronounced in PVP K17 and PVP K29-32 which have led to the similar dissolution profiles 
of NAP in all the PM NAP-different PVP polymers. Dissolution of the PM system will be further 
discussed in comparison to the dissolution behaviour of its HME system. At the end of this 
discussion, a comparison between the dissolution mechanism of PM and HME will be provided. 
 
6.4.2. Different drug loadings of HME NAP-PVPVA 6:4 
The study of different NAP loading has shown that low loading of NAP lead to higher dissolution 
rate of NAP. This is due to the higher proportion of the polymer with its higher viscosity that were 
created surrounding NAP particles which could reduce the recrystallization and agglomeration of 
NAP during the dissolution process.  
Besides, 30% of NAP was found to be the critical loading of API that leads to a faster dissolution 
rate of HME system in comparison to the corresponding PM. This observation has also been 
reported in a study of SD with alkyl p-aminobenzoates (PABA) using polyethylene glycol as the 
carrier, where 50% of PABA was the critical API loading that led to no additional advantages in 
the dissolution increment of the SD system (Saers and Craig, 1992). In this study, the critical 
loading of NAP was found to be highly dependent to the extent of solution mediated phase 
transformation such as agglomeration and recrystallization of API during dissolution. The 
agglomeration tendency is mainly attributed to the hydrophobic force which increases with the 
higher loading of NAP. As a result, intense recrystallization of NAP in the highly agglomerated 
particle could also occur. This may be pronounced especially in API with high crystallization 
tendency such as NAP in this study (Baird et al., 2010). 
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6.4.3. Different carriers 
In this study, PM of NAP in different PVPs showed similar dissolution profiles. However, HME of 
NAP in different PVPs revealed a trend of NAP release rate. The dissolution rate was highest in 
NAP-PVPVA 6:4 > followed by NAP-PVP K2932 > NAP-PVP K17 > NAP-PVP K12. This trend 
is closely related to the viscosity (indicated by K-values) of the carriers used. Higher MW of PVPs 
develops a higher resistance against recrystallization and agglomeration which was shown by the 
lower birefringence and particle size in HME NAP high MW carrier systems (Yagi et al., 1996, 
Mokarram et al., 2010b). Hence, in HME system, high dissolution rate of the homopolymer PVP is 
not favourable for the dissolution process of HME NAP SD, as the highly soluble polymer will 
dissolve quickly and leave the poorly soluble NAP dispersed in the dissolution medium for its 
solution mediated phase transformation such as extensive agglomeration and recrystallization.  
Besides, the hydrophobic vinyl-acetate group in PVPVA 6:4 has rendered the more surface active 
properties of PVPVA 6:4 as compared to the homopolymer PVPs. This is evidenced by the lower 
surface tension of PVPVA 6:4 solution as compared to the homopolymer solutions. Thus, HME 
systems of PVPVA 6:4 was shown to have lowest interfacial tension between the solid phase 
(HME) and the PVPVA 6:4 medium phase, thereby gave rise to the highest dissolution rate of 
HME NAP PVPVA 6:4 amongst all the HME NAP SDs. This result was in contrast to a published 
paper in comparing the dissolution performance of HME ketoconazole-PVP K17 and 
ketoconazole-PVPVA 6:4. In that paper, the PVP K17 was showed to be better than PVPVA 6:4 in 
stabilizing the supersaturated ketoconazole created from the SD (Kanaujia et al., 2010). This might 
be due to the low crystallization tendency of the ketoconazole as compared to the high 
recrystallization tendency of NAP that was employed in the current investigation (Baird et al., 
2010, Tajarobi et al., 2011a). 
Furthermore, the hydrophobicity of vinyl acetate group in PVPVA 6:4 polymer could also enables 
its adsorption on the hydrophobic surfaces and sites of newly recrystallized growing unit of the 
poorly soluble API, which subsequently delayed the potential of nucleation and recrystallization 
process (Ilevbare et al., 2012b). Thus, it is suggested that certain extent of hydrophobicity in the 
polymer carrier such as PVPVA 6:4 is beneficial for crystallization inhibition and optimal 
dissolution rate enhancement of an amorphous SD. 
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6.4.4. The effect of Tween 80 in the HME extrudates on dissolution behaviour of HME 
NAP-PVPVA 6:4-surfactant system 
To reduce the solution mediated phase transformation (agglomeration and recrystallization) during 
the dissolution of the SD system, surfactant was incorporated into the HME extrudate. It was found 
that the incorporation of surfactant into the HME SD did not only ease the processing condition 
(Fernandez et al., 1989, Ghebremeskel et al., 2007, Ghebremeskel et al., 2006, Soontravanich and 
Scamehorn, 2010), but also maintain the dissolution performance of SD. In this context, instead of 
having the superimposable dissolution profiles between the PM and HME, dissolution rate of NAP 
in HME 30% NAP-PVPVA 6:4-Tween 80 was found to be faster than its PM system (Figure 6.16). 
According to Fernandez et al.(1989) the incorporation of Tween 20 or 80 can allow the higher 
loading of API in a SD for a carrier controlled dissolution mechanism (Fernandez et al., 1989). 
This agreed to our results as the increased dissolution rate of NAP in HME 30% NAP-PVPVA 6:4-
Tween 80 implying that the critical loading of NAP has shifted to a higher loading, at least > 30% 
loading of NAP after the addition of Tween 80 in the HME extrudate SD.  
Besides, the increased dissolution rate of NAP after incorporation of Tween 80 in the HME 
extrudates of this study shows agreement to the studies carried out by Ghebremeskel et al., 2007 
and Ghebremeskel et al., 2008. In those studies, increased dissolution rate of poorly soluble API 
after the incorporation of Tween 80 into its SD was also noted as long as the concentration of the 
surfactant is below its CMC value during dissolution process. The author suggested that surfactant 
acts via microenvironment modulation by enhancing the apparent solubility of the API molecules 
at dissolving front of the particle which in turn reduce the degree of supersaturation of the API and 
the driving force for nucleation and crystallization process. Similar observations of increased 
dissolution rate were also noted in a study of fenofibrate sugar-based SD after the addition of SLS 
(de Waard et al., 2008). In that study, the author suggested that effective prevention of API 
crystallization during dissolution process was noted with the incorporation of SLS in the SD 
formulation. Conversely, the prevention of API crystallization during dissolution was not 
significant when the SLS was added physically (de Waard et al., 2008). This observation is in 
parallel to the result obtained from this study as PM ternary NAP-PVPVA 6:4-Tween 80 did not 
reveal a similar dissolution advantages as could be seen in HME NAP-PVPVA 6:4-Tween 80 
(Figure 6.16) when these profile were compared to the dissolution performance of the 
corresponding HME system without Tween 80.  
The surfactant is also playing a role in the prevention of aggregation and agglomeration of drug 
particles (Swanepoel et al., 2000) as could be seen by the increase dissolution rate of HME NAP-
PVPVA 6:4-2% Tween 80 despite the similar onset of recrystallization with HME NAP-PVPVA 
6:4 without surfactant (Chapter 6.3.2.3.2 and Figure 6.18). Besides, the increase dissolution of 
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HME NAP-PVPVA 6:4-2% Tween 80 as compared to HME NAP-PVPVA 6:4 without surfactant 
could also be due to the change of crystal defect density by surfactant while recrystallization of 
particles during the dissolution process (Kumar et al., 2008). In this case, surfactant act via step 
pinning the recrystallization of the API during dissolution process which alter the growth kinetic 
and dislocate the API molecule in crystal growing process (Qiu et al., 2004). This could cause a 
change in hillock and crystal shapes which may potentially give rise to better dissolution properties 
as shown in the dissolution study of the HME NAP-PVPVA 6:4-surfactant formulations despite the 
detection of crystal traces in these systems during dissolution process (Qiu et al., 2004). 
 
6.4.5. Pathway of dissolution mechanisms in a physical mixture and HME solid dispersion 
Combining the results obtained from the dissolution studies of PM and HME NAP-PVP carriers 
system, it was found that hydrophilic PVPs carrier play a different roles in dissolution process of 
PM and HME SD systems. Figure 6.20 shows the different pathways taken by a PVP-based PM 
and HME of a poorly soluble system.  
 
 
Figure 6.20: Dissolution mechanisms of PM and HME of PVP-based poorly soluble APIs 
 
According to Figure 6.20 a (i), the role of the hydrophilic PVP polymer in PM is merely a wetting 
and solubilizing agent. However, these roles of the PVP were weakened in HME SD system 
(Figure 6.20 b (i)) as compared to their PM system. This is due to reduced wettability of this 
system as could be seen by the higher interfacial energy of the HME system as compare to its PM 
system (Table 6.7).  
Physical mixture 
 
a (i) wetting and solubilisng of API by of 
polymer  
 
a (ii) dissolve via  crystalline API 
Hot melt extrusion 
b (i) ↓wetting/ ↓solubilisation 
b (ii) Solution mediated phase tranformation 
•agglomeration (big mass) 
•modulation of medium 
•precipitation (chemical seperation) 
•crystallization 
b (iii) dissolve via amorphous /crystalline 
•Δ surface area of dissolution 
•amorphous advantages 
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Based on the dissolution mechanism as presented in Figure 6.20, there is a distinct step of 
dissolution (Figure 6.20 b (ii)) involving only the dissolution mechanism of HME PVP-based 
system but not in the PM, i.e. the step of solution mediated phase transformation. This is the 
limiting step of dissolution performance of SD, as additional roles of the polymer is required if an 
immediate release of API is desired. The role of polymer in this step is associated to the effective 
interruption of the solution mediated phase transformations, i.e. ability in reduce agglomeration, 
precipitation and recrystallization of the dissolving system. Therefore, the key of dissolution 
enhancement in SD as compared to its PM is laid in the effective prevention of the solution 
mediated phase transformations in step (b) ii (Figure 6.20). 
The subsequent stages (Figure 6.20 (a (ii)) and (b (iii)) of the dissolution process are highly 
dependent on the previous steps. Based on the dissolution pathway of HME in Figure 6.20, if an 
API remains amorphous state devoid any solid state transformation, the enhanced dissolution rate 
could be retained. In contrast, if the API recrystallize and agglomerate, the resulting dissolution 
profile would be highly depend on the total surface area of the dissolving surface which could be 
either dissolve in a similar rate to its PM or slower than that when its total surface area has reduced 
dramatically due to extensive agglomeration. 
 
6.5. Conclusion 
The results obtained in this study suggested that dissolution performance of HME NAP-PVP-based 
is highly drug loading dependent whereby higher loading of NAP revealed a higher agglomeration 
and recrystallization tendency. Besides, recrystallization of the poorly soluble NAP during 
dissolution of the HME NAP-PVPs systems is also closely related to the hydrophobic-
hydrophilicity balance, proportion and MW of the polymeric carrier used.  
PM and HME NAP PVPs-based systems underwent different pathways of dissolution. The extra 
solution mediated phase transformations step involving the dissolution of HME NAP products 
requires the prudent selection of carrier incorporated in this system. Among the tested PVP carriers 
in this study, PVPVA 6:4 was recognised to be the best carrier for dissolution performance of SD 
as it revealed lowest extent of solution mediated phase transformations of the studied SD system. In 
this respect, the solution mediated phase transformations (agglomeration and recrystallization) 
could be also reduced via incorporation of non-ionic surfactant into the HME formulation which 
could subsequently maintain the solubility advantage of the amorphous API system. This is an 
important step in maintaining the effectiveness of solid dispersion for dissolution enhancement. 
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Chapter 7. Concluding Remarks and Recommendations for Future 
Work 
7.1.   Conclusion 
 
Overall, this thesis provides an understanding of the development of PVP-based amorphous solid 
dispersions prepared using HME processing method, with three main focuses, i.e. manufacturing, 
physical stability, and performance of formulations.  
 
Chapter 3 investigated the feasibility of using PVP in the HME manufacturing of an interacting 
API (i.e. PCM) and non-interacting API (i.e. CAF). The first objective of the thesis was addressed 
in this chapter, where the use of PVP in HME was described to be feasible by applying the 
phenomenon of ‘melting point depression’. The melting temperatures of the tested APIs were 
reduced in the presence of PVP polymers which allowed the extrusion process to be carried out at a 
temperature below the Tg of PVP or Tm of the API. This is particularly useful for API that has a 
relatively high melting temperature when the extrusion temperature could not be raised above its 
melting point in the production of the amorphous dispersion, due to the concern over PVP 
degradation. This lowering of the softening point not only resolves the issues of PVP degradation, 
but also reduces the risk of the decomposition of the thermolabile API. In addition, the presence of 
the API plasticised the PVP and hence eases the extrusion process.  
Miscibility of API and PVP has reported to be important in the production of amorphous solid 
dispersions. This could be predicted by using Hansen solubility parameter. In this study, 
differences in the Hansen solubility parameters (Δδ) between drug and polymer were found to be 
useful in predicting the miscibility of the drug and polymer, in turn leading to a homogeneous 
amorphous dispersion. In this respect, Δδ of less than 7 MPa1/2 indicates miscibility of the two 
components, whereas the components are not miscible when the Δδ is more than 10 MPa1/2 (Forster 
et al., 2001c). As shown in Chapter 3, extruding the interacting PCM and PVP (which showing a 
Δδ of less than 7 MPa1/2, miscible) produced fully amorphous dispersion up to 40% and 50% 
loading of the PCM in  PVPVA 6:4 and PVP K29-32 carrier system, respectively. Conversely, 
extrusion of the non-interacting API, i.e. CAF with PVP (Δδ > 8 MPa1/2, limited miscibility) led to 
the production of a partially crystalline SD. Therefore, in order to produce a fully amorphous HME 
PVP-based solid dispersion at temperatures lower than the Tm of an API, a miscible API, which 
was interacting one with respect to PVP carrier, is preferred.  
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Nonetheless, as shown in Chapter 3, the extrusion of interacting API with PVP polymers at 
temperatures lower than the Tg of the PVP polymers showed an increase in the torque value over 
the extrusion time. This implies rheopectic behaviour, i.e non-Newtonian fluid flow of the molten 
extrudate. In contrast, shear thinning was observed in the extrusion of non-interacting API with 
PVP where torque value reduced with time. This parameter is expected to impact on the physical 
stability of HME SD system which will be further explained in the next paragraphs.  
The second area of investigation in thesis is to understand the physical stability of HME PVP-based 
solid dispersions. Chapter 4 presented the physical stabilities of the interacting API i.e. PCM in 
HME PVP-based solid dispersions. All extrudated systems were found to be highly humidity 
dependent. The moisture absorbed in the sample has plasticised the SD and caused a certain degree 
of phase separation in the HME SD system which is the cause of physical instability.  
As shown in Chapter 4, hydrogen bonding between the drug and polymer is a critical factor in 
physical stabilisation of PVP-based dispersion prepared using HME. This is evident in the 
comparison of recrystallization behaviour between homo-polymer PVP K29-32 and copolymer 
PVPVA 6:4 carriers for the aged HME PCM extrudates at different PCM loadings. At 50% drug 
loading, PCM dispersion in PVPVA 6:4 recrystallized faster than in PVP K29-32 SD despite lower 
water content in the former. This is caused by the insufficiency of proton acceptors that form 
hydrogen bonds with PCM molecules in the copolymer PVPVA 6:4 as compared to that in the 
homopolymer PVP. However, at low PCM loadings, i.e. 30%, PVPVA 6:4 carrier systems attained 
a superior stabilization effect. This was attributed to the optimum drug-polymer interaction as there 
are sufficient proton acceptors in PVPVA 6:4 that interact with PCM molecule, giving no surplus 
of free PCM available for the recrystallization process. Hence, it is suggested that the drug loading 
of an API should be kept below the theoretical limit of its hydrogen interaction with the PVP 
polymer in order to produce a physically stable HME SD system. 
HME systems with a high molecular weight PVP appeared to recrystallize faster than its 
corresponding composition prepared with lower molecular weights of PVP. This difference 
correlated well to the torque profiles recorded during the HME preparation process (Chapter 3). 
The torque value recorded during HME process is a measure of viscosity of the extruded molten. A 
high torque value implies difficulty in mixing between the drug and polymer. This may minimise 
the drug-polymer interactions which have been identified to be one of the main factors in 
maintaining the physical stability of HME PVP-based SDs. However, in order to establish a clearer 
relationship between the torque and drug-polymer interaction, more extensive studies are needed. 
Another specific objective of Chapter 4 is the determination of the critical storage conditions 
associated with stabilising the HME PVP-based SD. The result of this study suggested that HME 
PVP-based SD achieved a better stability profile in storage condition with elevated temperature 
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(i.e. 40 
o
C) than that with higher humidity (22% RH to 75% RH). Under very humid storage 
conditions ( > 53% RH), the aged extudates underwent physical transformation, changing from 
solid state (at room temperature) to the rubbery state due to extensive moisture sorption as 
presented in Chapter 4. This transformation is not favoured as it can affect the performance, 
particularly in terms of dissolution. Thus, packaging may be a critical step in maintaining a good 
physical stability of an HME PVP-based solid dispersion.  
 
As discussed in Chapter 1.6, a number of papers have demonstrated the unpredictable trend of 
dissolution performance for SD system by showing a slower release rate than their corresponding 
PM systems (Moneghini et al., 1998, Verheyen et al., 2002, van Drooge et al., 2004, Margarit et al., 
1994). It was also found in this study that not all the amorphous solid dispersion systems could 
guarantee a higher dissolution rate of the BCS Class II API as compared to their PM. This is highly 
dependent on properties of both the API and carrier which were identified in Chapters 5 and 6, 
respectively.  
Chapter 5 of this thesis presented the dissolution behaviours of poorly soluble APIs after the 
formulation of HME PVPVA based SD which include, ketoprofen (KTP), naproxen (NAP), 
indomethacin (INDO) and olanzapine (OZP). Based on these studies, factors contributing to the 
production of an effective SD were identified. These factors include, theoretical ‘solubility 
advantages’ of amorphous APIs, solubilising capacity of the polymer carrier and wettability of the 
SD system which promote agglomeration and recrystallization of the SD system during dissolution. 
These factors are discussed in more details in the subsequent sections.  
 
‘Solubility advantages’ of amorphous APIs 
The dissolution performance of a SD is highly drug dependent. Results in Chapter 5 showed that 
‘solubility advantages’ ratio of amorphous API calculated from Hoffman equation (Equation 5.1) is 
the best indicator in formulating a successful solid dispersion, as far as the dissolution enhancement 
of the poorly soluble API is concerned. This ratio reflects the Gibbs free energy difference between 
the two solid forms i.e. amorphous form and its crystalline state which dictates whether formulating 
a solid dispersion is worthwhile. As presented in Chapter 5, a higher ‘solubility advantages’ of 
OZP gave rise to a dissolution enhancement in its HME OZP PVPVA system. However, lower 
‘solubility advantages’ of KTP and NAP lead to only a limited increment in dissolution rates of 
NAP-PVPVA and KTP-PVPVA systems respectively.  
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Solubilisation of API in its carrier solution 
Based on the classical Noyes Whitney Equation (2.2), the solubility of an API in a dissolution 
medium can affect its dissolution process. In this study, the solubilisation effect of the carrier on 
the API (using concentrated PVPVA 6:4 solutions) was found to be more significant to the 
dissolution performance of the HME system rather than PM system.  
As shown in Chapter 5, the high degree of solubility enhancement of OZP in the 10% w/v PVPVA 
6:4 polymer solution is one of the contributing factors of the dissolution rate enhancement of HME 
systems. During the early phase of the dissolution process, a high PVPVA 6:4 concentration is 
expected to be at the dissolving front of the HME particle. At this early phase, the readily 
dissolvable amorphous form of API in its HME SD system can immediately initiate the carrier 
solubilisation effect upon dissolution process which subsequently drives the dissolution of the 
HME system. This is provided that no other confounding events (such as recrystallization of API) 
come into play during the dissolution process. However, the increase of dissolution rate was not 
observed in the PM system. This was largely due to the need for crystal bond breakage of the 
crystalline OZP in the PM before the effect of carrier solubilisation could exert its influence on the 
dissolution process. Consequently, it is reasonable to suggest that the strength of a crystalline 
structure of poorly soluble API is a limiting factor for the dissolution process of its PM system.  
 
Wetting and agglomeration of SD 
In this study, the dissolution process was also found to be surface based phenomenon. Often, the 
presence of a hydrophilic polymer is expected to increase wettability of a system. This was verified 
for both PM and HME of the API-polymer systems in comparison to their pure API system as 
presented in Chapter 5.  
However, when the wettability was compared between the PM and HME of 30% APIs-PVPVA 6:4 
system, the wettability of the HME systems was lower than their corresponding PM systems as 
indicated by the increase in the contact angle. When a PM system is introduced into a dissolution 
medium, the polymer carriers can orientate and dissolve into the medium easily. This subsequently 
increases the wettability of poorly soluble API in by its dissolved carrier. On the other hand, drug-
polymer interactions in the HME 30% API-PVPVA 6:4 SD system reduced conformation of the 
polymer carrier. This has weakened the interaction of the hydrophilic polymer with the dissolution 
medium which eventually lowered its wettability. Nevertheless, the extruded OZP-PVPVA 6:4 
system was an exception which revealed a similar wettability to its PM system, reflecting the 
originally low wettability enhancement of OZP on contact with the PVPVA 6:4 solution. Thus, any 
wettability effects of the polymer in the HME system might not be significant.  
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Low wettability in the HME system suggested strong hydrophobicity with high free energy on its 
surface. During the hydrodynamic dissolution process, particle collision with their high surface free 
energy may cause particle aggregation owing to the reduction of their surface-to-volume ratio in 
reaching the more stable state. This eventually causes agglomeration of the dissolved particles due 
to the hydrophobic forces on their surfaces as shown in the dissolution process of extruded APIs-
PVPVA 6:4 (Chapter 5). This is evident by the growing of particle to a size larger than the initial 
controlled size range as presented in Chapter 5. Following agglomeration of the dissolving system, 
its effective surface area exposed to the dissolution medium is reduced hence slowing down the 
overall dissolution rate.  
 
Recrystallization of API during dissolution 
In Chapter 5, recrystallization was clearly observed on the surface of HME particles collected from 
the dissolution vessel during dissolution. The relative recrystallization tendency of different HME 
API-PVPVA 6:4 systems did not show a clear trend in dictating their degree of dissolution 
enhancement in comparison to their PM systems. This was due to the different sensitivity of the 
amorphous APIs to under the exposure to the dissolution medium and hence different 
recrystallization behaviours of the APIs that cause their different influences on dissolution 
enhancement of their HME as compare to their PM systems. However, the recrystallization effect 
of the API during dissolution process was apparent when focusing on a single API in different 
carriers or compositions as shown in Chapter 6 which will be further discussed in the subsequent 
paragraphs.  
 
Chapter 6 of this thesis focused on the dissolution study of formulations with a single API, i.e. 
NAP. The influences of NAP loading, molecular weight (MW) of PVP carriers and surfactant on 
the identified dissolution rate limiting processes (i.e. agglomeration and recrystallization of APIs, 
which were identified in Chapter 5) were studied.  
 
Effect of drug loading  
In Chapter 6, the effect of different NAP loadings on dissolution process of HME NAP-PVPVA 
6:4 system was investigated. During dissolution process, the dissolution rate limiting processes, i.e. 
agglomeration and recrystallization were significant especially at high drug loadings. This was due 
to the higher loading of the hydrophobic API on the surface of the dissolved systems at this 
loading. The intensity in occurrence of the observed dissolution rate limiting processes causes a 
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critical drug loading limit of NAP in the HME system that leads to its dissolution advantages over 
the corresponding PM system. When this critical drug loading limit is exceeded, such as for 30% 
NAP-PVPVA 6:4, there will be no dissolution enhancement of the HME SD as compared to its 
PM.  
As shown in in Chapter 5, naproxen is considered to be a poorly soluble drug with a relatively low 
‘solubility advantages’ of its amorphous state. Thus, these advantages may easily overcome by the 
minor extent of the dissolution rate limiting process, i.e. agglomeration and recrystallization of 
HME NAP-PVPVA 6:4 system as shown in its dissolution performances in Chapter 6.  
 
Effect of PVP carrier systems 
In the same chapter (chapter 6), the influence of carrier system on dissolution performance of the 
HME 30% NAP-PVPs-based dispersions was also investigated. In different PVP carrier systems, 
the relative wettability difference between the PM and HME system might also be different. This 
was shown in Chapter 6 through examining the interfacial properties of PM and HME of 30% 
NAP-PVPs in different carrier systems. In this case, a low MW PVP carrier showed a high 
wettability in the PM system but a low wettability in its HME system. However, this difference in 
wettability was relatively small in the system with high MW carriers. The reasons behind these 
differences require further investigations.  
Among the tested polymer carriers, PVPVA 6:4 copolymer was proposed as the best candidate for 
the dissolution performance of HME PVP-based solid dispersion, despite the relatively lower 
hydrophilic nature of PVPVA 6:4 as compared to the tested homopolymers. The less hydrophilic 
nature of PVPVA 6:4 (as compared to PVP) has led to its slower dissolution rate which remained 
its presence at the vicinity of the dissolving amorphous API for a longer period. This promotes the 
carrier solubilising capacity and ability of PVPVA 6:4 in minimising the extensive agglomeration 
and recrystallization of the amorphous API via a physical hindrance effect. In addition, the 
hydrophilic-hydrophobic balance of PVPVA 6:4 has led to its surface active nature, which lowers 
the agglomeration and recrystallization of its HME system during dissolution. This is another 
contributing factor for the better dissolution performance of PVPVA 6:4-based HME system as 
compared to the homopolymeric carriers.  
On the other hand, the hydrophilic homopolymer PVP of HME system dissolved quickly. 
Consequently, the API molecules were isolated which caused extensive agglomeration and 
recrystallization during dissolution. This is particularly pronounced in low MW carriers of PVP as 
compared to the high MW PVP. The physical hindrance effect in low MW PVP of HME systems is 
relatively low, thus the agglomeration and recrystallization may not be effectively reduced as 
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compared to that of high MW PVP. It is evident in Chapter 6 that the dissolution rate of HME NAP 
system is lower in the low MW PVP carrier alongside to their higher extent of agglomeration and 
recrystallization.  
 
Addition of surfactant to the extrudate composition 
De Waard et al. (2008) has suggested the addition of a non-ionic surfactant into composition of SD 
at a concentration below the CMC in order to increase dissolution rate of a SD system (de Waard et 
al., 2008). In Chapter 6, incorporation of Tween 80 (a non-ionic surfactant) into the composition of 
NAP PVPVA 6:4 extrudates significantly enhanced the dissolution rate. This could be explained by 
the reduction of agglomeration and recrystallization during the dissolution process of the PVPVA 
6:4-surfactant extrudates. The concentration of surfactant added was below its CMC in the 
dissolution medium, thus the solubilising effect of the surfactant is expected to be low. However, a 
transient solubilising effect might be apparent at dissolving front of the HME system which reduces 
the hydrophobic forces of agglomeration; consequently, this may lead to the reduction in extent of 
recrystallization and agglomeration as presented in Chapter 6.  
 
Role of amorphous or crystalline states 
Chapter 6 also highlighted the roles of amorphicity and crystallinity of NAP in dissolution 
performance of an immediate release solid dispersion. The importance of amorphicity was 
confirmed by a reduction in dissolution rate of a partially crystalline NAP-PVPVA system.  
Surprisingly, the release of the partially amorphous NAP PVPVA was slower than the PM system 
with NAP in the fully crystalline form. This implies that the advantage of amorphicity in both the 
fully and partially amorphous system is not fully apparent as would have been anticipated. This 
may be due to secondary processes such as agglomeration and recrystallization that negate the 
advantages of amorphicity during the dissolution process. Therefore, one can conclude that the loss 
in crystallinity of NAP might be beneficial in aiming for the dissolution enhancement of HME 
solid dispersion as compared to its PM system but it is not always the case. 
 
The last objective of this thesis was to propose a possible framework of dissolution mechanisms for 
HME PVP based SD in accordance with the observations in Chapter 5 and 6. In order to visualise 
the dissolution process, Figure 7.1 illustrates a wetted HME SD particle once it has contacted the 
dissolution medium. As seen in Figure 7.1, three phases of the particle are identified, i.e. dissolving 
phase, rubbery phase and un-wetted glassy phase.  
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When HME SD particles are introduced into a dissolution medium, hydrophilic polymer in the 
system absorbs a considerable amount of water. At the core, the un-wetted area remains in glassy 
state. Between the wetted surface and the core of particle, there is an area of rubbery state of the 
dissolving system as a result of water ingression and exert its plasticization effect. In this area, 
polymer reptation (thermal motion of a long macromolecule (Dahlberg, 2010)) occurs which 
increases the local mobility of the SD system. Thus, if the trapped domains of API (from solid 
dispersion system) obtain sufficient mobility and are close to each other, phase separation can 
occur. Recrystallization can potentially happen depending on the crystallization tendency and 
solubility of API in the polymer carrier. 
 
 
 
At the dissolving front, polymer will dissolve at a rate depending on its hydrophilicity. Figure 7.2 is 
a schematic of a proposed dissolution mechanism of HME PVP-based solid dispersion system at its 
dissolving front (dashed box in Figure 7.1) according to the results and observations in Chapter 5 
and 6.  
 
 
 
 
 
 
  
 
Rubbery phase 
 
 Reptation of polymerincrease 
mobilityphase 
separation/recrystallization of drug 
molecules 
 High [polymer]dissolve drugs 
 Disentanglement reduce protection 
Glassy phase 
Dissolving front 
 
 Agglomeration reduce surface area 
 Recrystallization reduce further 
penetration  of dissolution medium 
Dissolution 
medium 
Figure 7.1: Schematic of a wetted particle of HME poorly soluble drug PVP-based solid dispersion when it is in 
contact with dissolution medium 
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Figure 7.2: A schematic of the proposed dissolution mechanism of HME PVP-based solid dispersion system 
based on this study. The spheres represent drug domains and the curved lines represent the polymer. 
Pathway (a) on the left indicates dissolution process of a system with low ‘solubility advantages’ of its 
amorphous API: 2a shows the occurrence of agglomeration or phase separation, 3a shows the decrease in the 
effective surface area for dissolution as a result of agglomeration and 4a shows a new barrier formed as a 
result of continuous recrystallization and agglomeration process which give rise to a hydrophobic layer at the 
dissolving front of the solid dispersion. Pathway (b) on the right illustrates the dissolution process of a system 
with high ‘solubility advantage’ of its amorphous API: 2b shows that the drug domains are ready to dissolve 
once the carrier is dissolved, 3b shows the stable drug molecule in the midst of medium and polymer without 
agglomeration or crystallization and at 4b, system has completely dissolved. 
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Assuming the amorphous API is molecularly dispersed in the HME PVP-based solid dispersion, 
Figure 7.2 shows the homogenously dispersed of the drug molecules in the polymer carrier. During 
the dissolution process, the surface of the solid dispersion particle is wetted by the dissolution 
medium. The wetting of the SD causes polymer swelling and reptation as mentioned in Figure 7.2 
(1). Following reptation and swelling, two possible pathways could be taken, i.e. pathway (a) or 
pathway (b). 
 
Pathway (a) 
Pathway (a) will be taken if the hydrophobic API of interest possesses a low ‘solubility advantage’ 
in its amorphous state. Due to high energy state and hydrophobicity of amorphous API, there is a 
high tendency in drug agglomeration and phase separation as shown in Figure 7.2, pathway 2 (a). 
Besides, this pathway may be also promoted by a high loading of hydrophobic API.  
After attaining a certain extent of the polymer dissolution, drug molecules are mostly stranded 
alone and agglomeration occurs as shown in pathway 3 (a). Agglomeration of the drug domain will 
lead to recrystallization of the API. At this point, the role of carrier is of utmost importance in 
solubilising the existing crystalline API and inhibiting further recrystallization of the API.  
Pathway 4 (a) in Figure 7.2 shows the continuous crystallization process at the outer surface or the 
dissolving front of the SD. After a period of dissolution, the properties of dissolving front are 
altered where it is predominately covered with the hydrophobic recrystallized drug. This newly 
formed layer can prevent further penetration of the dissolution medium into the core of the SD 
particle and thus slow down the overall API release. Besides, the highly hydrophobic nature of the 
recrystallized API may promote further agglomeration of the dissolving particles via its 
hydrophobic forces and lead to a reduction in effective surface area for dissolution In this context, a 
dissolution enhancement effect could be achieved if ‘solubility advantage’ of the amorphous API 
predominate over the reduced effective surface area for dissolution process. Otherwise, a reduction 
in dissolution would be noted due to the agglomeration and recrystallization of API, generating a 
less soluble solid form. This effect is significant in API with a high crystallization tendency. 
 
Pathway (b) 
Pathway (b) mainly occurs in API with high ‘solubility advantage’ of its amorphous state and low 
crystallization tendency. A high ‘solubility advantage’ of an API implies a relatively low 
hydrophobicity of its amorphous state which reduces the agglomeration as indicated in Figure 7.2 
pathway 2 (b), hence, the domains of drug are separated from each other. For a drug with low 
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crystallization tendency, once the carrier has disentangled, the amorphous drug domains are ready 
to dissolve again as seen in Figure 7.2 pathway 3 (b). Thus, a fast dissolving polymer which is 
usually a hydrophilic and low MW polymer will lead to a faster API release of this system.  
 
Application of the dissolution mechanisms 
Dissolution mechanism presented in Figure 7.2 has revealed the reasons for an inconsistent benefit 
observed in solid dispersion system of different APIs in comparison to their corresponding PM. 
The mechanism infers the significance of ‘solubility advantages’ and recrystallization tendency of 
amorphous API in determining the dissolution enhancement of HME SD system as compared to the 
PM system.  
Furthermore, the two possible dissolution pathways proposed in Figure 7.2 have resolved the doubt 
of inconsistent influence of polymer MW on the dissolution rate of solid dispersion as discussed in 
section 1.6.1.3 of Chapter 1. For a relatively stable amorphous API with its low tendency to 
crystallise, low MW polymer would promote drug release profoundly due to a higher 
disentanglement concentration (polymer concentration at which individual or small clusters of the 
matrix are dissociated from the system (Tajarobi et al., 2011b)) of the matrix system as compared 
to high MW polymers. In addition to wetting or solubilisation, no other role of the carrier was 
required in performing the enhanced dissolution of amorphous API. Conversely, for a highly 
unstable amorphous API (i.e. NAP in this study), high MW polymer is preferred due to its ability to 
exert steric hindrance in inhibiting molecular mobility that leads to recrystallization. As mentioned 
before, if amorphous API possesses only a very minor ‘solubility advantages’ its dissolution 
enhancement effect will be easily compromised by a minor extent of recrystallization and 
agglomeration.  
According to the proposed mechanism in Figure 7.2, pathway (a), polymer carrier in HME PVP-
based SD is found to have an additional role in dissolution process of API as compared to its PM. 
Unlike PM, carrier in solid dispersion is expected to maintain the high solubility state and 
dispersion of API molecules, limiting agglomeration and recrystallization. But only wetting and 
solubilising effects are anticipated as main factors affecting carrier in PM as far as an immediate 
release dosage form is concerned. This explains the unexpected dissolution performances of SD in 
comparison to their corresponding PM system as previously reviewed in the literature in Chapter 
1.6.1.1. 
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To conclude, the use of PVP and PVPVA 6:4 polymers is feasible in HME application in which 
interacting API is preferred for the extrudability and production of fully amorphous solid 
dispersion. Physical stability of these HME PVP-based SD is highly dependent on the hydrogen 
bond interactions between the drug and polymer. Besides, HME PVPs-based SD should be kept dry 
at a temperature lower than the Tg of product in order to maintain a good long term stability. A 
proposal has been suggested for better understanding the dissolution performance of HME PVP-
based which outlines an underlying dissolution mechanism of HME PVP-based solid dispersions, 
based on the properties of both the API and polymer carrier.  
 
7.2.   Recommendations for future works  
Based on the results obtained in this project, it would be interesting to explore the following 
research areas in the future. 
As processing parameter of torque was found to have an impact on the physical stability of solid 
dispersion, the relationship between the processing torque of HME SD, physical stability and its 
final dissolution performance should be further analysed. Investigation of the other processing 
parameters may contribute to the optimisation of the formulation design. For instance, the 
relationship of molten residence time in the hot barrel and the physical stability of the product 
could be investigated.  
The characterisation of the PVP-based extrudates in Chapter 3 suggested the existence of trapped 
moisture in the extrudates. This may well have some impact on the physical stability of the 
corresponding products. A study of different moisture contents of the same polymer before feeding 
may serve as good approach to further understanding the physical stabilisation of HME based 
dispersion. Furthermore, many APIs have shown polymorphism in their crystalline state, thus the 
extrusion of these APIs at temperatures near to the polymorphic transformation temperature might 
potentially affect the physical stabilisation of the drugs. 
Hydrogen bond interaction between the drug and polymer was shown to be a critical factor in 
preventing the recrystallization process of HME PVP-based SD. This interaction is suggested to be 
pertinent to the dissolution performance of HME PVP-based systems which were shown to reduce 
with an increase in recrystallization of API during the dissolution process. Thus, a further study in 
this area is required to complement the hypothesis of drug-polymer interactions in modifying the 
dissolution performance of HME PVP-based SD systems.  
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In this study, dissolution performance of the HME system is shown to be a surface based 
phenomenon. In this regards, PVPVA 6:4 was revealed to be a better carrier in dissolution rate 
enhancement of solid dispersion due to its surface active properties with the presence of the 
hydrophobic portion of vinyl-acetate. Thus the investigation of different ratio of the pyrrolidone 
and the vinyl-acetate might be able to further confirm this hypothesis. Besides, the addition of 
surfactant was found to assist in dissolution performance of HME SD by reducing the extent of 
recrystallization. However, according to literature (Kumar et al., 2008, Swanepoel et al., 2000), the 
incorporation of surfactant was reported to increase recrystallization as well as inhibit 
recrystallization. Thus more study could be concentrated on the use of difference surfactants its 
effect on the mode of recrystallization and dissolution performance of HME SD system.  
Moreover, it would be interesting to study the alteration in dissolution performance of the aged 
HME PVP-based systems after storing under extreme storage conditions such as high humidity and 
elevated temperature. In particular, the change in the secondary rate limiting process (as explained 
in Chapter 5), i.e. agglomeration and recrystallization during dissolution process of the aged HME 
PVP-based system should be investigated. It may be hypothesized that relaxation of the SD system 
under these storage conditions leads to different tendencies of recrystallization and agglomeration.  
Overall, the ‘solubility advantage’ of amorphous API was found to be a critical factor in 
determining dissolution performance of solid dispersion. This parameter should be further 
investigated to extended number of APIs in assessing a clear relationship to their dissolution 
performance. By studying this aspect, a cut-off point of the ‘solubility advantage’ of amorphous 
APIs in relation to their secondary dissolution rate limiting step such as agglomeration (due to 
hydrophobicity) and recrystallization tendency could be established. This could provide a guide to 
the formulator in API and carrier selection so as to secure the investment of formulating a solid 
dispersion for commercial use. 
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Appendices 
 
Appendix I: Calibration curve of PCM crystallinity based on diffracted peak of XRPD  
Calibration curves were constructed according to the intensity of the two sharp peaks at 23.4 and 
24.5
o
 2θ Bragg diffraction peaks from XRPD diffractograms of physical mixture of PCM and 
polymer with known crystalline percentage as suggested in a previous literature (de Villiers et al., 
1998). Detail of the parameter could be found in Chapter 2.4.5.  Figure (i) shows the obtained 
calibration curves with R
2
= 0.9817 and  R
2
= 0.9898, respectively for PCM-PVP and PCM-PVPVA 
6:4 systems ranged from 10 -100% w/w of PCM loading.   
 
Figure (i): Calibration curves based on physical mixture of 10-80% w/w PCM-carriers system a) PVP K29-32, b) 
PVPVA 6:4  
 
Appendix II: Validation of ATR-FTIR method in tracking crystalline content of PCM in 
HME PCM PVPs-based solid dispersions 
To validate the use of ATR-FTIR as an analytical tool for the quantification of Form I PCM as 
developed in Chapter 4, section 4.3.1, crystallinity estimation of partially crystalline HME PVP-
based products measured by different analytical methods were compared with the crystallinity 
detected from the developed ATR-FITR method.   
To do this, hot melt extruded products with excess of crystalline content were prepared, in order to 
enable the crystal detection by using all the employed methods (XRPD, DSC and ATR-FTIR). 
With that, HME extrudates with 55% to 70% of PCM in PVP K29-32 and 45% to 60% of PCM in 
PVPVA were extruded at 120 
o
C 5 minutes residence time. Crystallinity of these products was 
accessed by ATR-FTIR using Equation 4.6 (Chapter 4, section 4.3.1), XRPD, and DSC.  
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Verification by XRPD 
The partially crystalline HME products were scanned by using XRPD and their degree of 
crystallinity was approximated using the calibration curves presented in Figure (i). Figure (ii) 
demonstrated the XRPD diffraction spectra of the partially crystalline HME products of 45 to 60% 
PCM loading of HME PCM PVPVA 6:4 and 55 to 70% PCM loading of HME PCM PVP K29-32 
systems. These results indicated the consistent increment of diffraction peaks intensity with higher 
loading of PCM. The percentage of crystallinity in each formulation could be found in Table (i), 
which will be further discussed in the later section for overall comparison.   
 
Figure (ii): Verification of crystallinity of partially crystalline HME products a) 45% - 60% PVPVA carriers 
system, b) 55% -70% PVP K29-32 carrier systems 
 
Verification by DSC 
Besides, the partially crystalline HME products were also scanned in DSC. The issue of crystalline 
material dissolution into the polymer carrier during heating scan of DSC was reported. On this 
basis, standard DSC melting enthalpy method (10 
o
C per minute) was employed to minimise the 
dissolution effect. The ratio of the enthalpy melting of the partially crystalline HME product to the 
melting enthalpy of pure PCM was taken as the degree of crystallinity. 
Alternatively, the heat capacity method could also be used to estimate crystallinity of product (Qi et 
al., 2010). In this method, amorphous content was assumed to be linearly proportional to the heat 
capacity value. The reversing heat capacity signal was used to remove the effects of the 
endothermic relaxation processes occurring simultaneously. The changes in Cp values before and 
after complete melting were taken to calculate the content of crystalline material (Figure iii). 
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Figure (iii):  MTDSC traces of reversing heat capacity of HME 55% PCM PVP K29-32. Green lines represent the 
first cycle of the heating scan and blue line representing the second cycle of the heating scan after complete 
melting of the existing crystalline material during the first heating cycle. 
 
Generally, the Cp value of an amorphous material is higher than the crystalline counterpart at 
temperature above Tg. If the fresh samples are totally amorphous, there should be no changes in Cp 
value in first heating cycle, cooling cycle and reheating cycle. Instead, if crystals exist in the fresh 
samples; Cp value of the first cycle should be lower than the Cp in cooling and reheating cycle. It is 
attributed to the melted crystal above melting point that contributed to the higher heat capacity at 
cooling and reheating scans (Qi et al., 2010).  
The total heat capacity of the sample can be expressed as Equation II-I, 
  
             
               
                                        (II-I) 
Heat capacity contributed by the drug component could be detailed in Equation (II-II): 
  
        
                    
                                                   
By combining the Equation 4.7 and 4.8, heat capacity of the samples can be expressed using 
Equation (II-III): 
  
          [   
                    
              ]         
                (II-III) 
Heating upon melting, all the initial crystal content disappears. Thus, the heat capacity during the 
cooling cycle could be expressed as Equation (II-IV): 
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Therefore, the changes of heat capacity between the first and cooling / reheating cycles can be 
solved into Equation (II-V) by using equations above: 
   
                   [  
               
              ]                         
where   
     ,  
    ,  
        are total heat capacity, heat capacity of the drug and polymer 
respectively at temperature T, and   
          and   
            are the heat capacity of the 
amorphous and crystalline of the drug at temperature, T;   is the weight fraction of the drug in the 
extrudate and   is the weight fraction of amorphous drug in the total amount of drug in extrudate.  
In the current studies, partially crystalline HME PCM PVPs systems were scanned in MT DSC at 
2
o
C per minutes with modulation of ± 0.318 
o
C, 60 seconds. To avoid the influence of water 
content  in Cp values of the scanned extrudate, Cp value at temperature 110 
o
C (higher than 100 
o
C) 
was chosen for the calclulation of crystallinity using heat capacity method. The quantified 
crystalline content were tabulated in Table (i) for overall comparison. 
Table (i) summarises the percentage of crystalline material in the partially crystalline HME PCM 
PVP K29-32 or PVPVA 6:4 products using different analytical methods. According to the obtained 
crystallinity, there are good agreements among the percentage of crystallinity detected from these 
methods.  
Table (i): Comparison of crystallinity (the average of n=3) of PCM in partially HME PCM PVPs-based SD 
systems estimated by using different methods 
HME Drug 
Loading (%) 
XRPD 
(%crystal) 
ATR-FTIR 
(%crystal) 
DSC Cp 
 (% crystal) 
DSC Tm  
(% crystal) 
PVP K29-32      
55% 2.75 3.71 4.75 4.7 
60% 13.72 15.44 15.19 14.33 
65% 21.96 27.48 24.41 21.3 
70% 29.25 33.42 29.34 24.82 
PVPVA 6:4       
45% 0 2.09 2.33 2.59 
50% 10.528 10.86 10.86 8.25 
55% 13.149 19.77 20.63 13.59 
60% 20.973 28.05 28.08 19.64 
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Figure (iv) compares the percentage of crystallinity in HME 55 to 70 % PCM PVP K29-32 and 
HME 45%- 60% PCM PVPVA 6:4 estimated using ATR-FTIR, XRPD, DSC heat capacity and 
melting methods. XRPD and DSC melting methods consistently revealed a lower crystallinity 
content as compared to ATR-FTIR methods and DSC heat capacity method. However, cross 
validation indicated that the results showed less than 5% deviation from each method. This result is 
in agreement with Grisedale et al., 2011.  
   
Figure (iv) : Comparison of crystallinity of (a) HME PCM-PVP K29-32 and (b) HME PCM-PVPVA 6:4 estimated 
using different methods 
XRPD was reported to be much less sensitive in comparison with DSC (Nagapudi and Jona, 2008), 
in which crystals are undetectable if the amount of crystals was < 10% (Saleki-Gerhardt et al., 
1994). In the current study, it was found that the sensitivity for XRPD for Form I PCM detection 
was ≥ 3% w/w via scanning the low crystal content of PM PCM-PVP. Based on the results in Table 
(i), crystal contents detected by using DSC heat capacity method and ATR-FTIR are generally 
higher than that by using XRPD method. Thus, in this study, XRPD was found to be less sensitive 
in detecting the HME PCM-PVP based SD systems. In DSC, there is a high potential of 
interference of different thermal events in the DSC heating scans, hence, data interpretation using 
this method may be complex.   
On the other hand, ATR-FTIR method is a sensitive method where lower detection limit of PCM in 
PM was found to be < 1% via scanning the PMs of low PCM loading. Thus, ATR-FTIR is an 
appropriate method for tracking the recrystallization process of SD due to the reliable crystallinity 
prediction, good sensitivity, fast data acquisition and simple sample preparation of this approach. 
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Appendix III :  Dissolution of crystalline PCM during heating scan of DSC 
As presented in Chapter 4, the result of ATR-FTIR was not coherent to the DSC data as the former 
indicated the presence of crystalline material and the later did not show any detectable crystalline 
material even in the sample that was stored in an accelerated humidity conditions, 75% RH. This 
could be arisen dissolution of the existing crystalline materials into the polymer during the DSC 
heating scan.  
To further confirm the dissolution of PCM in polymer upon heating in DSC, an aged HME samples 
with high percentage of crystal was taken to scan in ATR-FTIR with variation by controlling the 
temperature of the ATR accessory at 2 
o
C per minutes from 30 - 200 
o
C. Upon gradual heating of 
the aged sample in ATR-FTIR scanning, relative intensity change of 807 cm
-1
 (the characteristic 
peak) in its spectrum may indicates the change in amount of Form I crystal in the scanned sample. 
In this measurement, the aged HME 40% PCM PVPVA 6:4 after 3 months in 75%RH was 
selected. Figure (v) shows the temperature variation (at 2
o
C per minutes from 30-200
o
C) of ATR-
FTIR spectra for aged HME PCM PVPVA 6:4 after 3 months storage in 75% RH  
 
Figure (v) : FTIR-ATR spectra of aged HME PCM PVPVA 6:4  (after 3 months storage in 75% RH) scanning at 
2oC per minutes from 30-200oC which corresponded to the ATR-FTIR spectra from top to bottom. 
According to Figure (v), the intensity of the diagnostic wavenumber of 807 cm
-1
 was decreasing 
with the increase of heating temperature. This indicated the gradual disappearance of the Form I 
PCM upon heating. This relative intensity change may be closely correlated to the undetectable 
crystalline material upon heating in DSC measurement.  
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Figure (vi) display the overlay profiles of DSC thermograms and the profile of relative intensity of 
807 cm
-1
/ 797 cm
-1
of the aged HME PCM PVPVA 6:4 in the same heating scan rate. 
 
Figure (vi) The Overlay profiles of DSC thermograms and the profile of relative intensity of 807cm-1/797cm-1  for 
aged HME 50% PCM PVPVA 6:4 in the same heating scan rate 
 
Base on Figure (v), relative intensity of the characteristic peak of the aged sample were decreasing 
with heating. Approaching 100 
o
C, relative intensity of the characteristic peak was approaching to 
zero, which indicated the disappearance of the crystalline material upon heating. This might be 
ascribed to the dissolution process of the crystalline into the polymer system while heating. The 
disappearance of the characteristic peaks were apparent in between the temperature of 50 
o
C to 100 
o
C which is coincide to the temperature of moisture evaporation as indicated from the 
corresponding DSC thermogram. Thus, it is suggested that the water detachment from the sample 
has leads to a high solubilisation of the existing crystal in the polymer via drug polymer interaction. 
From Figure (vi), relative peak intensity of the characteristic peak was zero at any possible melting 
temperature of the crystalline PCM (circa 148 
o
C for depressed melting of Form I PCM in the 
presence of PVPVA 6:4 based on Chapter 3, circa 158 
o
C and 169 
o
C for Form II and Form I PCM, 
respectively) which indicated complete dissolution of the crystalline material at this temperature. 
Therefore, the dissolution of the existing crystal while heating is the main reason for the 
undetectable melting endotherm in DSC thermogram of the aged samples.  
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Appendix IV:  Analysis of surface of HME API-PVPVA systems for contact angle 
measurement 
 
In order to effectively compare the surface roughness of the compacted tablets that were used for 
the contact angle measurement in Chapter 5.2.6.4, Atomic Force Microscope (AFM) was used to 
map the surfaces. Figures (vii) reveals the example topography of the examined surfaces for both 
the compacted physical mixture and hot melt extruded product. In this case, the z variations of the 
piezoelectric scanner were deemed in providing the roughness information.  These magnitudes 
were presented in Table (ii). According to Table (ii) the generated surfaces were comparable with 
standard deviation of < 0.86 μm. This suggested the validity of the results in reflecting wetting 
properties of the solid dispersion. 
 
 
Figures (vii) : AFM images of sruface roughness of compacted tablet of PM and HME formulations 
 
Table (ii): Z is the Surface roughness information of the generated flat surface by IR press.  
API Physical mixture Hot melt extrusion 
 Zmax (μm)  Zmin (μm) Zmax (μm)  Zmin (μm) 
Ketoprofen 3.13 -1.33 3.44 -2.08 
Naproxen 4.12 -2.76 4.55 -0.40 
Indomethacin 3.50 -2.13 4.33 -1.69 
Olanzapine 3.50 -1.55 3.70 -3.04 
 
 
 
 
 
 
Appendices 
 
School of Pharmacy, University of East Anglia   290 
 
Appendix V :  Amorphous nature of HME NAP-PVPVA-Tween 80 systems  
 
DSC thermograms of HME NAP-PVPVA-Tween 80 revealed apparent reduction in glass transition 
temperatures. Tg was lowered slightly in formulation with 2% added Tween 80, more intense 
reduction is noted in formulation with 10% w/w added of Tween 80 (Figure (x)). No apparent 
melting endotherm was detected which indicated the absent of detectable crystalline naproxen.  
 
Figure (x) : DSC thermogram of HME 30% NAP PVPVA, HME 30% NAP PVPVA+2% Tween 80 and HME 
30% NAP PVPVA + 10% Tween 80 
The amorphous nature of HME 30% NAP-PVPVA-Tween 80 was further confirmed by the XRPD 
diffractograms as presented below.  
 
Figure (xi) : XRPD diffractograms of HME 30% NAP-PVPVA-Tween 80 in comparison to PM 30 NAP-PVPVA 
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